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To explore trial participants' and non-participants' perspectives of a randomised 
controlled trial. Principally these patients' understanding of randomisation, their 
recall and understanding of information about the trial, plus an examination of 
their expectations and preferences. 
Design 
This exploratory study is concerned with re-focusing onto the patients' 
experience, therefore qualitative in-depth, semi-structured interviews were 
carried out with 22 participants and 11 non-participants who were eligible to 
participate in the ClasP randomised controlled trial. Interviews were recorded on 
audio tape and fully transcribed. Data were analysed by comparing transcripts 
and describing emergent themes, using a grounded theory approach. Case 
studies were also carried out for each respondent. 
Setting 
The CLasP study comprises three linked pragmatic RCTs to evaluate the 
effectiveness and cost effectiveness of a new technology (laser therapy - ELAP) 
compared with standard surgery (transurethral resection of the prostate - TURP) 
for men with evidence of acute or chronic retention of urine who require active 
intervention, and laser, TURP and conservative management (monitoring 
without active intervention) for men with lower urinary tract symptoms related 
to benign prostatic disease. 
Subjects 
The study reported here sets out to elicit the perspectives of 'ordinary' middle-
aged and elderly men who require elective treatment for a common condition, 
and have either agreed or refused to participate in a pragmatic randomised 
controlled trial. 
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Purposeful sampling was used to include eligible patients who had decided not 
to participate in the trial from each of the main reasons as reported in the trial 
records. Trial participants were also interviewed from both trial centres, and 
included a number who had been allocated to each of the treatment arms at 
different stages of trial participation and receiving different treatments within 
the trial. 
Interventions and outcome measures 
Interviews used a checklist of topics to encourage participants to describe their 
experiences. Narratives concerning their their recall and understanding of 
information about the trial, their expectations and preferences were compared to 
identify common themes, retaining the context of the discussion to allow detailed 
interpretation. Case studies were used to examine the dialogue that participants 
engaged in a to try and make sense of the trial design, their lay beliefs and their 
actual experiences of participation or non-participation. 
Results 
It was found that the majority of the participants were aware of some aspects of 
randomisation and most (15/22) acknowledged the involvement of chance in 
their allocation. A large number of the non-participants were also aware of some 
aspects of randomisation and almost all (9) could recall that the trial was some 
sort of experiment. However, their recall was at a lower level than that of the 
participants and only a small number (4/11) were aware of the involvement of 
chance. 
All but one (Mr Taylor) of the trial participants also held other co-existing ideas 
about non-randomised methods of allocation such as rationing and 
individualised treatment, which they used to understand and explain their 
treatment allocation. For a small number, altruism (7) and an expectation of 
personal benefits (7) were motivations for taking part. However, trust (10), 
distrust (11) and their beliefs about fate and destiny (13) developed as they tried 
to make sense of their treatment allocation in relation to their treatment 
preferences. 
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Surprisingly, the non-participants made sense of their experience of being asked 
to participate in similar ways. Some placed their trust in the clinician, believing 
they received the best treatment by receiving individualised care (see Mr Young). 
For some this was thought to be within the trial and thus cynically believed that 
they had been excluded from the trial and that the most effective treatment was 
being rationed and denied them (see Mr McCarthy). 
Three main types of refusal were identified: those who made an active decision 
not to take part in the trial (5), those who believed that they had agreed to 
participate (3), and those having no recall of being invited to participate in the 
trial (3). Surprisingly a small number of non-participants also appeared willing to 
participate in the trial, citing trust (7), personal benefits (4) and altruism (2) as 
motivations. Half of these patients (6) expressed anxiety about their treatment 
and may be why they are 'refusers'. 
The key to understanding peoples' experiences of RCTs lies in the basic 
inconsistencies of trial design, as shown in these mens' struggle to piece together 
what paricipation means. Each individual's narrative about trial participation 
was analysed as a case study and this showed that most participants engaged in 
a dialogue to try and make sense of the trial design, their lay beliefs and their 
actual experiences of participation. 
Conclusions 
This study confirms the importance of providing clear and accurate patient 
information, but also shows that this in itself is unlikely to ensure consistent 
interpretation of concepts such as randomisation by participants. The patient 
information in this study was well received and largely accurately recalled, but 
patients still struggled with the concepts underlying the design and developed 
sometimes competing accounts. It may be that participants need to discuss the 
reasons for particular methods of trial design (such as randomisation) with 
researchers and reflect on these in order to understand them fully enough to give 
true informed consent. 
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Summary of the research findings 
Patients' expectations of and experiences of participating in randomised 
controlled trials 
There is an increasing reliance on the randomised controlled trial - often 
regarded as the I gold standard' in clinical research. The ethical and 
methodological issues of clinical trials continue to be debated. However the 
patients' perspective of the process has received little attention, except in trials of 
rare conditions, or attitudes towards hypothetical trials. This research has 
focused on thirty middle aged and elderly men involved in a randomised 
controlled trial of treatments for benign prostatic disease. Twenty participants, 
purposefully sampled in each of the clinical centres, different treatment arms and 
at different time points in the trial, were interviewed. In addition, 10 men who 
refused to participate in the trial were also interviewed. These data were 
supplemented by participant observation of recruitment. 
Data were collected by in-depth interviews carried out by KF using a semi-
structured checklist of topics, covering the same basic issues, including initial 
symptoms; recall, understanding and experience of recruitment; feelings about 
participation; experiences of treatment and outcome. The aim was to encourage 
the men to relate stories about their experiences and to explore their 
understandings of what had happened. Interviews were conducted in the men's 
homes, audio-tape recorded and lasted from half-an-hour to one-and-a-half-
hours. The data were analysed to allow the development of grounded theory. 
Among refusers, differences were observed between the reason for not taking 
part as recorded in notes and the respondents' explanation/ interpretation of 
what took place. It was apparent that for many respondents, the lack of direction 
from the clinician about the treatments and trial participation was problematic. 
Among participants, it was clear that while the majority were able to recall 
aspects of randomisation, many struggled with the concept and developed co-
existing alternative accounts to explain treatment allocation. Common terms 
Vll 
used by trialists were often interpreted differently by patients - even apparently 
simple terms such as 'random' and I trial.' 
It is not clear, however, whether this greater understanding would lead to higher 
or lower levels of accrual to trials, but such an investigation could be linked with 
research attempting to incorporate patient preferences into RCTs. 
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The History and Ethics of the randomised 
controlled trial 
Introduction 
This chapter will summarise the history of the RCT to examine its ascendancy as 
the I gold standard' and to place it within the context of other developments in 
the evaluation of treatments. Considerable debate has focussed on the ethics 
involved in RCTs and these issues are also considered within this chapter. 
The history of the randomised controlled trial 
Just over fifty years ago the first randomised controlled trial, the MRC 
streptomycin trial of pulmonary tuberculosis1 was reported. By comparing 
streptomycin (a new antibiotic) plus bed rest with bed rest alone for the 
treatment of pulmonary tuberculosis, the trial found that streptomycin was 
effective.1 Prior to this trial, there had been a long practice within medical 
research of comparing treatment groups, where alternate cases were allocated to 
a treatment at accrual, one of which would receive the intervention and the other 
acting as a contro1.2 The editorial published to coincide with the streptomycin 
trial report distinguished the method used from such previous practice and 
emphasised that random allocation, through the" ingenious system of sealed 
envelopes" (p.792), would ensure that this "removed personal responsibility 
from the clinician" (p.792) while also eliminating bias in recruiting patients.3 
Randomisation was used within this trial for two main reasons. First, in response 
to the limited supplies of streptomycin, randomisation meant that only one half 
of patients received the active drug. Second, Bradford Hill had been strongly 
promoting the methodological benefits of randomisation.2 He argued that the 
aim of the experimental design must be to "ensure that, as far as possible, the 
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control and treated groups are the same in all relevant respects" (p.42).4 As 
Yoshioka points out, the justification for this initial use of randomisation has 
changed over time. Most contemporary accounts refer to the shortage of 
streptomycin as the impetus because it meant it was ethically permissible for 
some patients not to receive this new treatment.2 More recently, the 
methodological benefits of randomisation have been advocated. 
The MRC trial was not the first to consider new approaches to the elimination of 
bias and the field of tuberculosis research has played an important role in the 
methodological development of the randomised controlled trial. 2 Because 
pulmonary tuberculosis was a varied and unpredictable condition, with bed rest 
alone leading to recovery in some cases, the assessment of treatments for this 
condition was difficult. Four years before the MRC trial, in 1944, Hinshaw and 
Feldman, tuberculosis researchers in the US, set out a number of methodological 
techniques that could reduce bias, such as setting clear eligibility criteria in order 
to obtain a comparable group of patients, blinded evaluation and patient 
allocation to a treatment based on 'some procedure of chance'.s In 1931, 
Amberson et al had similarly advocated the use of controls in the evaluation of 
the effectiveness of a popular treatment, sanocrysin, which was a gold 
compound for pulmonary tuberculosis. Twenty-four patients were paired 
according to age and severity of disease and divided between two groups, with 
the 1/ flip of the coin" (p.404) allocating the groups to either injections of 
sanocrysin or distilled water. The researchers found that the control group had a 
better outcome.6 
The MRC streptomycin trial of pulmonary tuberculosis is not as novel an 
approach as it has been portrayed. As Doll points out, the MRC Whooping-
cough vaccination triaF was the first trial to randomly allocate patients to an 
intervention, although it was reported later than the streptomycin trial.s 
Moreover, Hrobjartsson et al9 in a recent paper argue that Fibiger carried out the 
first clinical trial using randomisation in 1898 in Denmark. Fibiger10 allocated 
patients with diphtheria to receive standard treatment or standard treatment 
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plus injections of diphtheria serum twice daily. Treatment allocation was 
dependent upon day of admittance using alternate days, thus creating two 
comparable groups,10 using a 1/ quasirandomised trial" (p.1245) design.9 Fibiger 
was aware of the need to control for selection biases and is noted for the clarity of 
the reporting of his methods.9,ll 
Nevertheless, the MRC streptomycin trial was the first to describe the method of 
random allocation explicitly,2, 11 even though, as Yoshioka points out, random 
allocation was scarcely mentioned within the MRC documents relating to the 
trial at the time.2 Random allocation was carried out by Bradford Hill, who drew 
up random sampling numbers for each gender within each centre, the details of 
which were unknown to any of the investigators or to the co-ordinator. The 
central office allocated eligible patients by opening the appropriate numbered 
envelope that assigned them to either streptomycin and bed rest or bed rest 
alone. The clinician at the treatment centre was then notified.1 The accompanying 
editorial highlights the fact that this method attained similar levels of disease 
between the two groups at baseline.3 
The streptomycin trial also employed a rigorous approach to other aspects of the 
trial protocol to avoid bias.2 The participants and assessors were blinded and the 
patients were not informed that they would be receiving a different treatment. 
The trial examined one type of tuberculosis, using narrow eligibility criteria. To 
ensure standardisation of data collection, each of the participating hospitals 
recorded patient details on standard forms and carried out examinations at fixed 
intervals. The data were examined centrally and to avoid bias, the radiological 
pictures, one of the main outcome measures, were assessed blind by an 
independent panel of two radiographers and a clinician.1 
The number of randomised controlled trials since then has mushroomed, 
becoming a global institution within health care. This development can be seen 
in the context of other significant scientific advances which are a culmination of 
processes that occur over a number of years.8 Yoshioka similarly concludes that 
"the innovation of centrally controlled randomisation can be attributed to a 
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combination of scientific logic and political and social pressures on the medical 
bureaucracy" (p.1223).2 However, the adoption of randomisation was not 
straightforward and as Doll points out it was a number of years before 
randomisation was an accepted element of clinical research.8 
The RCT is now widely recognised as the I gold standard' within clinical research, 
the most effective method to minimise bias and provide valid answers to 
important clinical questions.12 The RCT sets out to measure and compare 
outcomes, that is, the events that are present or absent after trial participants 
have received an intervention,13 A trial usually includes an active intervention 
and a control treatment as part of the experiment. The experimental treatment 
can, for example be a new drug or procedure, whilst the control is the 
intervention which is regarded as the standard for comparison, for example the 
standard practice, a placebo or no intervention.13 The results of such trials are 
then used to make inferences about the effectiveness of interventions within the 
whole population. Cochrane predicted that the implementation of such research 
could lead to 1/ an increased effectiveness and efficiency. There will be a marked 
reduction in the use of ineffective remedies and of effective remedies used 
inefficiently" (p.84),14 
Since this first trial, the development of the RCT has developed into many 
different designs and in recent years there has been a proliferation of 'how to' 
publications.13, 15-18 The choice of trial design is dependent upon a number of 
factors, including the aspect of an intervention trialists wish to examine, the 
method of providing the intervention, patient preferences, sample size and 
whether the trial should be blinded.13 Explanatory and pragmatic trials, efficacy 
and effectiveness trials and phase I, II and III trials all evaluate different aspects 
of an intervention. The parallel, crossover and factoral trial designs are related to 
the method of exposure of participants to the trial intervention. Trials also differ 
in size, from N=l up to mega-trials which can be fixed or flexible (sequential 
trials).13 Future developments include the move towards such 'mega trials',12,13 
simple, pragmatic trials which examine large samples of patients and employ a 
limited number of outcome measures.13 
However, there is also an increasing awareness of the problems associated with 
the RCT,19 including attaining the required level of precision, validity and 
interpretation. Some suggest that the focus on this method has led to 
'randomised trialomania' that has limited clinical research.20 Other approaches 
have been suggested, for example the use of retrospective controls and 
'computrials'.19 Future challenges include the examination of disease from the 
patient's perspective,21 detecting small but important effects, for example where 
outcome is qualitative rather than quantitative, and the development of trial 
designs which take patient preferences into account.22-24 Trial methods will be 
considered further in chapter 2. 
Considerable debate has also focussed on the ethics involved in RCTs, and these 
issues are considered in the section that follows. 
The ethics of the randomised controlled trial 
Introduction 
Clinical research is regulated to protect participants from any potential physical 
harm. It is possible for patients' rights to be violated and in the past, some have 
received actual physical harm as a result of taking part in clinical research, for 
example the Holmesburg prisoners.25,26 Here, inmates in the Holmesburg prison 
were paid to take part in dermatology experiments. Although these treatments 
often appeared to be benign such as shampoo, they often involved painful 
biopsies. Retin-A was developed in this way. Other experiments involved 
psychoactive drugs, radioactive isotopes and dioxin. The experiments ended in 
1974, however, this remains a contemporary issue. There are on-going exposes of 
past and current breeches of ethical guidelines, as highlighted by the recent 
inquiry into the North Staffordshire paediatric ventilation trial. This was set up 
in response to parents' claims that they were unaware of the experimental nature 
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of the treatment and had been misled into signing the consent form for a trial 
comparing a new type of ventilator with conventional treatment for premature 
babies.27,28 
In response to the Nuremburg trial of Second World War medical atrocities, the 
Nuremberg Code of 1947 sets out a number of principles to protect research 
participants. This states that consent must be voluntary and free from" constraint 
or coercion" and that participants must be able to choose not to continue with the 
experiment. The researcher has a personal duty to ensure the quality of such 
consent and that participants have" sufficient knowledge and comprehension of 
the elements of the subject matter involved as to enable him (sic) to make an 
understanding and enlightened decision". 29 
The Nuremberg Code also indicated that experiments must not be "random or 
unnecessary" with the design based either on the results of animal experiments 
or knowledge of the natural history of the condition. There is a duty to produce 
findings that will benefit society and are unobtainable by other means, with the 
expected results justifying the study. "Unnecessary physical and mental 
suffering and injury" must be avoided and experiments must not take place if 
there is any prior reason to believe that participation may result in death or 
disability. The Code declares that the necessary degree of risk should never be 
greater than the humanitarian importance of the research question and there 
must be adequate provision to protect subjects from any risk of injury, disability 
or death.29 
The Code demands that highly qualified people using the highest level of skill 
and care must carry out all experiments. Those in charge must be willing to 
terminate the study if there is "probable cause to believe, in the exercise of the 
good faith, superior skill, and careful judgement required of him (sic), that a 
continuation of the experiment is likely to result in injury, disability, or death of 
the experimental subject" .29 
The Declaration of Helsinki of 1964 and revised in 1975,1983,1989 and 1996,30 
modified the Nuremberg Code in a number of ways. This makes an important 
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distinction between therapeutic and non-therapeutic experimentation and 
includes rules to protect vulnerable subjects. The Declaration states that any risks 
must be in proportion to the benefit of an experiment and it also classifies a 
wider range of benefits, risks and harms than those stated within the Nuremburg 
code. It also asserts that all publications resulting from experiments must be 
accurate, and that reports that do not meet these guidelines must not be 
published. 
Research is also governed by civil and criminal law and in addition, the majority 
of professional bodies,31,32 the NHS and other funding bodies such as the 
Medical Research CounciP3 have guidelines governing research. However, these 
are mainly concerned with setting appropriate scientific rather than ethical 
standards. Such guidelines usually state that ethical committee approval is 
required, leaving detailed considerations to the individual committees 
themselves. The Declaration of Helsinki declares that the experimental protocol 
must be "transmitted for consideration, comment and guidance" for an ethical 
review by an independent committee.3D 
Every trial within the UK must obtain Multicentre or Local Research Ethics 
Committee (MREC or LREC) approval. RECs provide independent advice about 
the ethical status of clinical research within their geographic area and are 
independent of health authorities and NHS trusts. However, this does not 
guarantee that a trial will be I ethical' or that there are uniform standards of 
acceptability. Kodish et aP4 point out that the various US Institutional Review 
Boards, set up to ensure the scientific and ethical standards within trials (similar 
to the role of ethics committees in the UK), have different standards of 
acceptability. A protocol may be accepted by one but be rejected by another. 
They believe that such variability in decision making may be the result of some 
boards focusing on protecting patients while others may be more concerned with 
the scientific standard of a trial, suggesting that patient autonomy is not always 
guaranteed by such approval. 
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The main ethical issue within the randomised controlled trial is that it must not 
exploit participants, who must also not be used purely for the benefit of others. 
The main focus of this debate is whether it is ethical for patients to receive 
experimental treatment that may be detrimental, ineffective or not as effective as 
the standard treatment. The trial may also benefit other future patients and any 
possible risks resulting from participation must be outweighed by the benefits to 
future patients. It is also argued by some that it would be unethical to give 
patients a treatment which has not been tested when a standard treatment is 
available.35 
The exploitation of trial participants does not have to be intentional and may 
occur when patients are exposed to risks that could be avoided by using 
adequate technology or introducing appropriate safeguards.36 The trial must be 
well designed (see chapter 2). Any randomised trial that does not use the best 
available methodology, from the design and planning through to the 
administration and statistical methods employed could be considered to be 
unethical.18 If the poor quality of a trial's design leads to problematic results, then 
this is both unfair to participants and also a waste of resources.37 The clinicians 
participating in research may be inefficient or incompetent and trialists must 
have the appropriate level of knowledge and training. De Castro suggests that 
trialists could be screened or regulated in some way to ensure competence.36 
The research question must be valid and necessary. It would be unethical to run 
a trial where the question had already been answered. To ensure this does not 
occur, Herxheimer38 suggests that all trial proposals must include a systematic 
review of previous studies examining the research question. Publication bias (the 
under-reporting of negative trials), can however, distort the available evidence. 
The Cochrane Controlled Trials Register within the Cochrane Library was set up 
in an attempt to ensure the availability of the results of all trials and to create a 
source of data on which to base systematic reviews which can be used to 
determine the validity of research questions. This register is a bibliography of 
controlled clinical trials that have been identified by contributors and includes 
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reports published in conference proceedings and other sources not covered by 
bibliographic databases.39 
Design issues 
The ethics of trial design focus on whether there is equipoise, the 
appropriateness of randomisation, blinding and placebos and the dilemma of 
which groups should be included or excluded from trial participation. 
a) Equipoise 
A trial must only be carried out when there is clinical equipoise, which exists 
when the evidence for treatments is balanced, and the clinician has no treatment 
preference. Fried first introduced the term" equipoise" (p.51)40 and although this 
is often referred to as 'uncertainty' as to which is the best treatment, as Lilford 
and Jackson41 point out, equipoise exists when there is no preference between the 
treatments being compared, a state where clinicians are" on the fulcrum of a 
decision" (p.552). Thus when there is clinical equipoise, personal care is not 
abandoned, rather chance is used to determine treatment assignment, each 
thought to be of equal benefit to patients.42 Once evidence indicates the greater 
effectiveness of one of the treatments then equipoise no longer exists and a trial 
should not be mounted.35 
However, as Freedman points out, such theoretical equipoise is 
"overwhelmingly fragile" (p.143) and can be disturbed by any slight change in 
the evidence which can be obtained from" the literature, uncontrolled 
experience, considerations of basic science and fundamental physiologic 
processes, and perhaps a 'gut feeling' or 'instinct''' (p.143).43 Levine similarly 
argues that perfect equipoise rarely exists and that when it does, this state cannot 
be maintained for long.44 As Fried notes, "is it ever likely to be the case that in a 
complex medical situation, the balance of harms and benefits discounted by their 
appropriate probabilities really does appear on the then available evidence to be 
in equipoise?" (p.52) . .to For a trial to be ethical, then, the research hypothesis must 
be simple enough to allow such a balance to exist. 
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The practical aspect of the dilemma of equipoise means that clinicians often have 
difficulty accruing patients. A number of studies indicate that the requirement of 
an open discussion of clinical equipoise with patients is an obstacle for many 
recruiting clinicians.43, 45-48 The justification for many appeared to be that any 
discussion of uncertainty is not in the patient's best interests. For example, many 
recruiting oncologists believed that such disclosure undermined patient 
confidence,48 reduced patient morale47,49 and could lead to an increase in patient 
morbidity.48 
Many clinicians appear to prefer to trust their own experience, even if this is in 
conflict with the available evidence. For example, the majority (67%) of an 
international sample of breast cancer oncologists (n=484) regarded clinical 
experience as the most important part of decision making where there was such 
uncertainty, with only 33% preferring published evidence.45 In an examination of 
US oncologists' patient logs, Hunter et al found that the recruiting clinician's 
preference for a treatment was the main reason for the non-participation of half 
the eligible patients, especially amongst those eligible for phase II trials.50 
Even where those running a trial hold clinical equipoise, those recruiting patients 
onto a trial, often nurses or junior staff, may not be in equipoise.49 For example, 
Alderson found high levels of ignorance about equipoise among breast cancer 
clinicians (n=40). Although there were high levels of concern about the 
uncertainty of breast cancer treatment and the associated high levels of mortality 
within the wider profession and the press, only 23% were similarly 'very 
concerned' about current knowledge.49 Such issues can have consequences for 
trials51 (see chapter 2). 
In response to the problems of traditional individual or 'theoretical' equipoise, 
Freedman suggests the use of" clinical" or community equipoise, which only 
calls for uncertainty within the medical community as to the efficacy of the 
treatments.43 The argument here is that community equipoise is a preferable 
requirement because the aim of all trials is to answer disputes within the wider 
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medical community where there is a lack of consensus as to which are the most 
effective treatments.44, 52 
Using this approach, recruiting clinicians with a treatment preference must 
recognise that other respected colleagues hold different preferences. Freedman 
suggests that even where the recruiting clinician's personal equipoise is in 
conflict with the community equipoise, a trial is still valid and ethical because 
"progress in medicine relies on progressive consensus within the medical and 
research communities" (p.144). Community equipoise can also be maintained 
even when interim results from a study suggest that one treatment may be 
preferable, because it can be preserved until the evidence is strong enough to 
influence the whole community of clinicians as to the effectiveness of the 
treatments.43 
However, Gifford52 does "not believe that community equipoise can do what it 
was hoped it could" (p.148). Both Gifford and Lilford and Jackson suggest this is 
a problem of definition and that it is hard to establish the extent of such 
equipoise.41,52 For example, how is the community opinion reached, and should 
this be based on the opinion of a small group of experts or all clinicians? There is 
also the difficulty of the level of uncertainty that is required and what proportion 
must be uncertain. 52 Johnson et al53 point out that opinion within the medical 
community will rarely be equally divided. To establish the extent of 
disagreement within the medical community necessary for community equipoise 
to exist and for a trial to remain ethical, they carried out a trade-off survey of a 
sample of the public, nurses and medical students (n=113). Half the participants 
believed equipoise would be disturbed in situations where 70% or more of the 
clinical community were in favour of one of the treatment options.53 
In cases where collective and personal equipoise differ or where both are 
required, this may have an important and often negative effect on trial 
recruitment. However, if only one is required, then there is the question about 
how to decide which takes precedence.5cl Chard and Lilford suggest that rather 
than impose a I point' where equipoise is achieved, I zones of equivalence' or 
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"equiphase" (p.5) would be more appropriate. Such equiphase would allow 
equipoise to exist within a range of probability estimates that are less restrictive 
than traditional equipoise. They argue that this approach would allow a more 
robust system of informed consent within trials. 54 
Personal equipoise, when an individual clinician has no treatment preferences, is 
also believed to be an important element of patient-centred ethics within 
medicine. If recruiting clinicians, based on their previous experience or patient 
history, suspect that one treatment may be more likely to benefit a particular 
patient, the use of randomisation within trials represents a compromise in 
individual care.42 Levine maintains that clinicians have a duty to recommend 
what they believe to be the most beneficial treatment for a patient.44 Similarly, 
Lilford and Jackson suggest that following collective equipoise, and entering a 
patient onto a trial when the clinician does not have personal equipoise and does 
not state this preference, may be a violation of doctor-patient trust. They propose 
that personal equipoise is less important, however, where the preferred 
treatment is only available within the tria1.41 
Peto and Baigent believe that trial accrual should use the uncertainty principle in 
order to bring the process of informed consent closer to standard medical 
practice.12 Using this approach, patients are only entered into a trial if the 
recruiting clinician is uncertain as to which treatment is best for each individual 
patient. If the clinician or patient believe that there are any medical or other 
reasons why one of the trial interventions may be unsuitable for that individual 
patient then they should not be recruited onto the trial.12 Similarly, Kodish et a134 
argue that clinicians should only enrol patients onto a trial if they do not have a 
preferred treatment for that particular patient. While accepting the clinician's 
right to base their decision on their personal belief about the acceptability of 
treatment within a trial, Segelov suggests that such decisions should be 




However, equipoise can be disturbed by such things as interim data and thus 
there is the additional ethical problem of what should be done if the result of a 
trial become apparent before the trial has been completed. Although clinical 
equipoise may have been achieved at the start of the trial, this may be altered by 
preliminary information from data monitoring, which may indicate that one of 
the interventions is more effective. 
There is no agreement on the ethics of having a predetermined endpoint for 
trials. The main argument against its use is that to continue a trial until a certain 
point of significance is deceptive. In using this approach, trialists must pretend 
that they have no access to data because they have agreed not to examine it. 
Others argue that the use of a pre-agreed endpoint is ethical as long as patients 
are informed of this prior to enrollment.56 It has also been suggested that interim 
data should be withheld from recruiting clinicians or that new trial designs be 
developed that can avoid any violation of the therapeutic obligation. 57 
b) Randomisation 
Randomisation is considered in detail in chapter 2. Here, only the ethical issues 
relating to randomisation are discussed. 
In their recent review, Ashcroft et aP5 point out that randomisation" divides the 
medical research community rather sharply" (p.7). The basis for this conflict is 
both methodological and ethical. Those in favour of random allocation suggest 
that this method does not abandon personal care, because randomisation is only 
ethical if there is clinical equipoise. Chance is used to determine assignment to a 
treatment, so that each participant is equally likely to benefit from the new or 
existing treatment. Other non-randomised research methods, particularly studies 
using historical controls, as Altman18 shows, may be intrinsically unethical 
because their results are untrustworthy and support the use of ineffective 
treatments. As previously stated, any randomised trial that does not use the best 
available methodology is also unethical by exposing patients to unnecessary risk. 
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However, there is evidence to suggest that both recruiting clinicians and 
participants find randomisation problematic. Randomisation can be viewed as a 
compromise in individual care and as McPherson indicates, the issue of 
preferences (clinician or patient) is also important, with random allocation 
depriving patients of the benefit of treatment choice, preference and control 
which may have a therapeutic benefit.22 Even though from the clinician's 
perspective, a trial may have achieved equipoise, a patient's personal 
circumstances may mean that they have a preference for one of the treatments.34 
c) Representativeness 
Representativeness is a key ethical issue for trials. If those who take part in the 
trial are not representative of the future population of patients whose treatment 
may be affected by the trial's outcome, it is difficult to interpret the subsequent 
findings and assess the generalis ability of their results. 
The under-representation of racial and ethnic groups participating in clinical 
trials needs to be addressed by trialists.58,59 Without their participation, the 
results of trials may not be applicable to these populations.58 This may be 
particularly important for example, in trials of malignancies such as myeloma, 
cervical and oesophageal cancers, where there are substantial epidemiological 
and clinical differences between Black and White populations.59 Ashcroft et al 
similarly conclude that trials must not focus their eligibility criteria on certain 
sub-groups within the population unless there is clear justification for doing SO.35 
In a contrasting view, Peto and Baigent emphasise that that some findings are 
generalisable to wide population groups and that it is not possible or ethical to 
carry out trials on every population and every sub-group, because with small 
samples the resulting selection bias will produce greater errors, and inevitably it 
would mean withholding effective treatment from some participants.12 
The ethics of excluding eligible patients 
The ethics of not entering eligible patients into a trial must also be examined. 
Segelov et al55 argue that it is unethical not to enter eligible patients onto a trial 
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because this contradicts clinical equipoise and assumes that the recruiting 
clinician knows which is the most effective treatment. They suggest that once the 
ethics committee within an institution has agreed to the trial, they are 
acknowledging that there is equipoise and that trial entry should be the standard 
treatment in such circumstances.55 
d) The use of placebos 
A placebo is an inert substance used to ensure that neither the individual 
clinician nor the patient knows the allocation within a double-blind drug trial. 
The ethical principle of equipoise means that unless the placebo is believed to be 
as good as the existing treatment, it is unethical to assign patients to a placebo.60-
62 However, advice on the use of placebos is inconsistent.61 It has been found that 
many recent trials have used placebos in circumstances where an effective 
therapy is available but has been denied to participants. They highlight that trials 
of rheumatoid arthritis, Ivermectin (to treat river blindness), Ondansetron (to 
control chemotherapy-induced emesis) antidepressant, congestive heart failure 
and antihypertensive drugs have been particular areas where this has occurred.62 
The Declaration of Helsinki states that "in any medical study, every patient-
including those of a control group, if any, should be assured of the best proven 
diagnostic and therapeutic method".30 On this basis, the use of placebos and 
'active' experimental treatments could be considered unethical. 61 The Helsinki 
Declaration has been criticised for this position, with many arguing that such 
statements must be revised.60, 61 
Trials of new drugs are held to be scientifically strongest when there is a placebo 
control.13,15-18,62 One of the main arguments for the use of placebo is that it 
provides a clear benchmark as to whether a new treatment is better than nothing. 
However, there are considerable 'placebo' effects (improvements are commonly 
found with the use of an identical but inactive intervention) and as Bradford Hill 
points out, the aim of trials is to establish the effectiveness of treatments against 
the standard treatment, not whether it is better than nothing.63 
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Determining the effectiveness of treatments is not always clear. For example, 
although a treatment may be therapeutically inferior to the standard treatment, it 
may be beneficial in other ways, for example by providing better quality of life. 
Hence it can be argued that for some patients, the adverse effects of a treatment 
may balance the therapeutic benefits sufficiently to ethically justify the use of 
placebo. However it is not ethical to use a placebo as a means of avoiding making 
the often complex decision as to which is the standard treatment.62 Placebos are 
often preferred for scientific reasons because it is easier to demonstrate a 
statistically significant difference between an active treatment and placebo, even 
within small trials. However even in situations where the use of active controls 
are difficult, "scientific considerations should not take precedence over ethical 
ones" (p.396).62 
The use of placebos is often justified because in some cases withholding a 
standard treatment will not cause serious harm, for example in the treatment of 
nausea, which will result in no long-term effects for patients. However, although 
this may seem acceptable, this is in conflict with the fundamental ethical 
principle that patients should receive the best available treatment or a new 
treatment believed to be of equal or better effectiveness.62 It is also argued that 
placebo trials are ethical where patients are fully informed that they may not 
receive an active treatment and are aware as to the risks of participation. 
However, this passes the ethical burden onto the individual patient who, even if 
they accept, must not be placed in the position where their well-being could be 
compromised.35t62 This is linked to the problems of providing informed consent62 
which are considered in more detail in the section that follows. 
Informed consent 
The first principle of the Nuremberg Code states that "the voluntary consent of 
the human subject is absolutely essential" .29 A fundamental ethical requirement 
of the randomised controlled trial is that patients must give their informed 
consent to participate. Changes in medical knowledge and the development of 
research in medicine have led to an increasing respect for patient autonomy as a 
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central moral imperative, even though this was unheard of until relatively 
recently.64 The clinicians who provide informed consent are expected to ensure 
that patients receive all relevant information to make that decision.36 
Exploitation of trial participants can occur when some form of deception has 
taken place during their recruitment. Patients must not agree to take part in a 
trial because they have false hopes or expectations of an intervention achieving a 
favourable outcome which is "less than reasonably likely" (p.261)36 to happen. 
Such false expectations may be the result of receiving inaccurate information 
about a treatment's possible benefits and associated risks. This may not be 
deliberate, as recruiting clinicians may believe that some information is not 
necessary and this can occur particularly if there are cultural or socio-economic 
differences between the recruiting clinicians and participants.36 
Although the use of guidelines and regulations governing research can minimise 
the potential for exploitation, they must be able to take into account differences 
within society, such as the position of vulnerable groups. There is potential for 
exploitation through an imbalance of power between the researcher and the 
researched, which may lead patients to participate in research which in other 
circumstances they may not have agreed to.36 
Some take the position that such a violation of the doctor-patient relationship can 
be justified, for example by the use of informed consent and the minimisation of 
potential harm.57 A stronger position states that the RCT must be abandoned 
because it is inconsistent with the doctor-patient relationship and the doctor's 
therapeutic obligation to treat a patient in a manner that will ensure the best 
chance of recovery. This latter perspective suggests that new scientific 
methodologies must be developed which are consistent with the doctor-patient 
relationship. Concurrent matched-pair analysis has been suggested as one 
method of achieving this, where clinicians in favour of one of the treatment 
options, prescribe to their patients accordingly.65 However, this approach can 
introduce bias and we do know that RCTs generally provide the most reliable 
and unbiased evidence.57 
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A Lancet editorial suggests that potential trial participants should be informed 
specifically about the components of research that constitutes a change from the 
standard doctor-patient relationship. These central differences are randomisation 
and blinding, plus any additional clinical examinations and therapies.66 Edwards 
et al similarly conclude in their review that abstract concepts such as 
randomisation should receive particular attention, 1/ since it is the conceptual 
scientific basis of trials rather than details of the treatments themselves which 
patients find hard to grasp" (p.53). It is also important that participants 
understand equipoise and thus have realistic expectations of the benefits of trial 
participation.67 
The main tool used to avoid exploitation of subjects is the consent form, which is 
a legal document. This and the procedure of providing informed consent should 
ensure that participants receive all the relevant information about the trial and 
that the perspectives of all interest groups within the trial are adequately 
represented.36 Interestingly, the consent form is generally perceived by trial 
participants, to be a legal document protecting those running the trial rather than 
educationa1.68-7o Harth and Thong found that 14.5% of parents (64) thought 
informed consent was unnecessary because they trusted the clinician to give their 
child the best treatment.69 
The UK General Medical Council has recent! y issued new guidelines to doctors 
obtaining consent. This recognises that the information provided to patients will 
be variable and should be based on the individual's needs and priorities.71 
Information should not be withheld unless it is believed that such information 
would cause serious harm to the patient. It goes on to state that doctors should 
not make assumptions about patients' views and also cautions that patient 
compliance with procedures should not be interpreted as consent.71 
However, the quality of the informed consent procedure and subsequent 
reporting is highly variable.72 Research examining informed consent has found 
that even when trials adhere to strict informed consent procedures and ensure 
that I simple language' is used, this does not guarantee that subjects will fully 
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understand the implications of participation and that they may still have 
unrealistic treatment expectations. Harth and Thong, for example, found that 
trust in the medical system, the tendency of patients to lessen the potential risks 
of participation and the psychological need to volunteer were 'significant 
attitudinal barriers' to the informed consent process and hence the 
understanding of trial participation.69 When participants do not understand what 
they have consented to participate in, then this does not constitute truly 
informed consent. 
Edwards et al suggest that ensuring that all patients achieve fully informed 
consent is "an unobtainable ideal" (p.vi).67 Their recent review suggested three 
approaches to dealing with this issue. One option would be to conclude that all 
trials are unethical unless the participants are medical experts or alternatively, 
waive all requirements for obtaining informed consent and instead use other 
safeguards such as ethics committees to protect participants. The approach 
preferred by Edwards et al would be to retain the essence of the informed 
consent principle by ensuring that all practical measures are taken to increase 
participants' understanding with the additional protection of ethics committee 
safeguards.67 
Recruiting clinicians commonly find obtaining informed consent a barrier to 
recruitment.45, 47, 48,73,74 For many this is based on a dissatisfaction with the rigid 
format of the consent form48, 73 or because it highlights their dual role as 
physician and investigator.48 Such barriers can affect the development and 
uptake of trials. For example, the introduction of explicit regulations for a clearly 
defined process of informed consent describing both the risks and benefits to 
potential participants, led to a subsequent drop in the number of breast cancer 
trials being carried OUt.49 Alderson concluded that providing such explicit 
information to patients may be problematic for clinicians.49 Clinicians have also 
been found to screen patients by trying to predict who would have difficulty 
with the informed consent process and thus enrol only some of their patients 
onto trials . .t7, 75, 76 Kee believes that paternalism is still prevalent within medicine, 
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with clinicians still believing that they can make the best therapeutic decisions 
for their patients. It is highly questionable as to whether clinicians are better able 
to interpret medical evidence than patients themselves.77 Given the importance 
of the clinician in recruiting patients onto trials, it is surprising that little research 
has investigated their role?8 
Edwards et aF2 in a recent (1998) systematic review of the ethics of the ReT from 
the perspective of patients, the public, and healthcare professionals concluded 
that a surprising number of recruiting clinicians were aware that their patients 
did not fully understand what trial participation involved, "For many, informed 
consent seemed little more than a ritual" (p1212). This will be explored in more 
detail in chapter 3. Edwards et al conclude that there may be significant 
differences between trialists and ethicists as to what is ethically acceptable and 
suggest that there should be a greater public debate about ethics and medical 
research. Zwitter and Tobias similarly acknowledge that there may be a wide gap 
between the investigator's beliefs about informed consent and patients' actual 
understanding of the tria1.79 
Information provision 
The ethics of providing greater information has also been debated. It has been 
argued that greater provision of information to patients is "needlessly cruel" 
(p.1199)80 by promoting greater anxiety among patients and thus a negative 
effect on the doctor-patient relationship. Taylor and Kelner similarly found that 
the majority of North American and European oncologists (n=170) believed that 
the admission of uncertainty undermined patient confidence (91 %) and could 
increase patient morbidity (73% ).48 However, it has been suggested that the open 
discussion of clinical uncertainty may actually encourage trust and improve the 
doctor-patient relationship.81 Recruiting clinicians may need more support and 
training to deal with providing informed consent and acknowledging such 
uncertainty.82 
From the perspective of participants, Jensen et al found that the majority of 
women within a breast cancer trial (26) believed that the detailed information 
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they received had reduced their uncertainty and anxiety.83 Although they found 
decision making difficult, this gave them responsibility for their own treatment 
and most felt that this helped them to face their prognosis. Only two believed 
that this information had increased their anxiety, preferring their treatment to be 
chosen by the doctor or to be randomised without their knowledge. Jensen et al 
concluded that because these doctors were open about their uncertainty, this 
preserved patient trust. 83 
In contrast, Olver et al found that patients experienced differing levels of anxiety 
from the information they received. Although 21 % of participants in an oncology 
trial felt that detailed information reduced their anxiety, a similar number (19%) 
believed it increased their anxiety.7o White et al also found that even though the 
majority of breast cancer patients (65 %) preferred to receive detailed information, 
20% preferred a consent form which merely stated that they had been selected by 
the clinician to receive a specific treatment which was beneficial for most 
patients.84 
Kent suggests caution is necessary because it is not known whether information 
will actually decrease or increase anxiety among patients.85 In a recent review of 
the literature on patient participation in decision-making, Guadagnoli and Ward 
conclude that patients do want to be involved in decision-making and be 
informed of the alternative treatments. They suggest that the first step in this 
process must be to establish the level of decision making patients believe is 
appropriate.86 
Voluntary consent 
An important principle of the ReT is that participation must be voluntary. 
However, there is some debate surrounding the true voluntary nature of trial 
participation. For example, Kodish et al point out that willingness to participate 
in trials may be affected by patients' preferences for a treatment, especially when 
that preference is only available within the trial. They suggest that the frequency 
of unwillingness to be randomised could be used as an indicator of such 
inequality between the treatment options from the patient's perspective.3-l 
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Minogue et al87 argue that patients with a terminal condition should not be 
recruited onto trials because the seriousness of their condition precludes genuine 
volunteering. They suggest that trials should only randomise patients who are 
motivated by a wish to contribute to medical knowledge or those who are not 
/ desperate/.87 They believe / desperate volunteers' who want to receive the 
experimental treatment should be given the option of either participating in the 
trial or receiving the experimental treatment outside of the trial. However, in 
response to Minogue, Logue and Wear88 argue that such an approach hinders 
medical progress and fails to provide an appropriate clinical response to such 
patients. Thornton in a personal account, believes that asking patients to 
participate in a trial when they have just received a cancer diagnosis is ethically 
unacceptable, damaging the doctor-patient relationship and leaving patients 
feeling isolated at a time when support is vital.89 
Providing financial compensation may also hinder voluntary participation 
because this may impede a patient's ability to realistically weigh up the benefits 
and disadvantages of participation.9o This is the case even though not 
compensating patients for any risk or inconvenience caused by participation may 
also appear to be exploitative.36 
Informed consent in clinical trials 
A far more stringent standard of providing informed consent is required for 
clinical trials, which are considered to possess a higher risk than standard 
treatment, even when the same treatment is prescribed outside of a trial. The 
issue of experimentation is the main reason for this, because of the way research 
changes the doctor-patient relationship and because research is also for the 
benefit of future patients.64 
However, as an editorial in The Lancet points out, "clinical decisions are often 
made randomly in a haphazard way. Why are we so concerned when the 
randomness is formalised in a controlled tria!?" (p.806).66 Chalmers91 refers to 
this as a "malignant double standard" (p.337) and argues that the informed 
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consent requirements should be equivalent for all patients, whether they receive 
standard treatment or participate in a trial.91 
Trialists believe that the evaluation of therapies is not in conflict with patients 
receiving the best care because participation in such trials is the most effective 
way for patients to receive the best available treatments.64 Trials that meet clear 
criteria, are well designed, set out to answer a clinically important question and 
where there is a belief that the treatments are equal on the evidence so far, offer 
patients treatment which is at least comparable to treatment outside the trial and 
thus constitutes good medical practice.92 Trial participation will result in some 
loss of freedom in their allocation to a treatment and this must be weighed 
against the benefit to future patients and the benefits of trial participation, 
regardless of the treatment allocation they receive. 
It is often assumed that trial participants who are found to have received the less 
effective treatment at the end of the trial have been deprived of better treatment. 
However, as Lilford and Jackson41 point out, this group may not have received 
better treatment outside of the trial and may be privileged patients who 
benefited from the extensive monitoring of the condition within the trial. Trial 
participants will receive one of the best therapies available and are likely to 
receive their treatment within a major institution with highly qualified staff 
where they are likely to increase the chances of a positive outcome.44 
Although the regulations for experiments were originally from the perspective of 
protecting subjects from harm, since the mid 1980's and the rise of AIDS 
activism, trials have been increasingly perceived as offering patients a chance to 
gain access to the best available treatments.44 There is evidence to suggest that 
patients receive better treatment within a trial. Stiller in a review of cancer 
survival rates found that treatment within a clinical trial was associated with 
improved outcome.93 Davis et al similarly found that participants in lung cancer 
trials had an improved outcome over matched controls. They suggest that this 
may be due to differences in the evaluation, staging and follow-up of 
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participants, the quality of the surgery, a placebo effect or differences in patient 
motivation. 94 
The use of improved treatment protocols within trials can lead to improved 
outcome. Reiser and Warner95 found improvement in the condition of 
participants within three paediatric asthma trials who did not receive active 
treatment. Although they recognise that this may be a placebo effect, they 
suggest that this may be due to the improved management of their condition. 
Trial participants had regular, lengthy consultations with a specialist, received 
training on how to control their symptoms which increased participants' 
motivation and compliance.95 Karjalainen and PaIva similarly found that patients 
within the same geographic area as three trials of chemotherapy in Finland had 
an improved survival compared to patients living in other areas.96 
However, any such benefit of participation should not be part of the decision to 
take part and should not be used by recruiting clinicians as an inducement to 
participate.67 This would violate the Helsinki principle that non-participation will 
not affect the patient's standard of care.3D 
Inequalities in informed consent 
It is often stated that obtaining informed consent to participate in a trial from 
poorly educated patients is a 'sham'.66 However, the data examining inequalities 
in the comprehension of informed consent is contradictory. Some studies have 
found socio-economic differences in comprehension. For example, Harth and 
Thong found that parents who volunteered their children were "significantly 
more socially disadvantaged and emotionally vulnerable" (p.1375) than those 
who did not. 97 Higher levels of understanding amongst participants with a 
college education have been found98 and similarly, Howard et al found that 
education, ethnicity and age were all associated with participants' awareness of 
fundamental aspects of the Beta-Blocker Heart Attack Trial (BHAT).98 In contrast, 
Flanery et al found that a well educated population of mathematics and medical 
undergraduates also had problems understanding consent forms.99 
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The DCCT Research Group evaluating the informed consent procedure within a 
US diabetes treatments trial found no relationship between IQ and 
comprehension.100 Sussman et al,lOl Goodmanl02 and Gallet et a1103 similarly 
found no evidence to suggest that age influenced understanding. 
International differences in providing information 
There are international differences in the requirement of informed consent and 
the guidelines within trial protocols for obtaining informed consent vary widely 
between countries. Zwitter and Tobias found for example, that over half the 
principal investigators of 47 international lung cancer trials (1993-1995) reported 
that patients were often not told about their diagnosis and prognosis (40%) and 
that written informed consent was only required within half of these trials 
(55.8%). Patient information about diagnosis and prognosis (96.2%) and the 
requirement of written and signed informed consent (100%) was highest within 
the North American studies. Within other countries surveyed, patient 
information about diagnosis and prognosis (49%) and the requirement of written 
and signed informed consent (41.8%) was less than half that level and often 
provided only verbally (54 %). However, this study relies on the reporting of the 
principal investigator and the authors speculate that there may be a wide gap 
between the investigators' beliefs about their informed consent procedure and its 
implementation.79 
Prior to 1980, clinical researchers in Canada were not required by ethical 
guidelines to inform trial participants that they had been randomly allocated to 
the treatment they received. Similarly, obtaining informed consent from patients 
before entering them onto a clinical trial was not mandatory in Spain until the 
early 1990'S.104 In Sweden, although it was recommended that the informed 
consent procedure should involve both oral and written provision of 




The debate on the ethics involved in RCTs has focussed on whether there is 
equipoise, the appropriateness of randomisation, blinding and placebos and the 
dilemma of which groups should be included or excluded from trial 
participation. These debates have influenced the design of the RCT and this will 
be discussed further in the following chapter. 
Much of the attention has been placed on the importance of the informed consent 
procedure. However, the quality of the informed consent procedure and 
subsequent reporting is still highly variable72 and there appears to be a wide gap 
between investigators' beliefs about informed consent and patients' actual 
understanding of the tria1.79 There is little from the patient's perspective. 
Ashcroft et al in their review conclude that there must be "a shift in research 
emphasis away from ethics from the professional viewpoint and toward the lay 
point of view" (p.45).35 This will be discussed in more detail in chapter 3, after a 
consideration of the methods of RCTs. 
26 
Methods of the randomised controlled trial 
This chapter considers the methods of the randomised controlled trial. In the 
section that follows, general aspects of RCTs are described, followed by an 
examination of issues specific to the design, organisation and planning of an 
RCT. Randomisation, concealed allocation, blinding, placebos, bias, validity, 
outcome measures, compliance, and preferences are each covered. 
Introduction 
There is an increasing reliance on the RCT, often regarded as the I gold standard' 
within clinical research. The basic rationalisation behind the clinical trial is that it 
is comparative rather than representative.I06 The RCT sets out to measure and 
compare outcomes, that is, the events that are present or absent after participants 
have received the trial intervention.13 This outcome measure may be "death, a 
nonfatal clinical event or a laboratory test" (p.3)16 and can take the form of 
survival, disappearance of symptoms, reduction of symptom severity, speed of 
recovery and/ or the prevention of symptom recurrence.IS The results of such 
trials are then used to make inferences about the effectiveness of the 
interventions within a relevant patient population. 
A trial usually involves one or more experimental interventions and a control. 
The experimental treatment can, for example, be a new drug or procedure, whilst 
the control is the intervention that is regarded as the standard for comparison, 
usually routine practice, or where none exists a placebo or no intervention. The 
quantity and type of such interventions and the subsequent treatment regimen 
are decided upon by the trial investigators.13 
The RCT is ideally suited to examine, as Jadad points out, "the effects of health 
care interventions which are small to moderate" (p.8).13 However, the RCT is not 
appropriate to explore questions associated with the aetiology or natural history 
of diseases. Here cohort or case controll studies are more appropriate. 
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In the section that follows, general aspects of RCTs are described, followed by an 
examination of design issues specific to RCTs. 
Traditional trial methods 
Decisions about the design of a trial are dependent upon a number of factors: the 
type of intervention trialists wish to examine, the method of providing patients 
with the intervention, whether patient preferences are being taken into account 
and sample size required.13 Explanatory and pragmatic trials and phase I, II and 
III trials all evaluate different aspects of an intervention. Parallel, crossover and 
factoral trials are related to the method of exposure of participants to the trial 
intervention. Trials also differ in size, from n=l up to mega-trials which can be 
fixed or flexible (sequential trials).13 
Explanatory and pragmatic trials 
RCTs are often distinguished by whether they evaluate the efficacy or 
effectiveness of an intervention. Efficacy trials are designed to produce a basic 
evaluation of an intervention and are therefore explanatory trials. Effectiveness 
trials are designed to establish whether an intervention is effective within the 
population who have received it and are pragmatic.13 Thus the two main 
approaches to the design of a clinical trial are the pragmatic and explanatoryl07 
and in general it can be said that lithe first approach (pragmatic) regards the 
patients as an end, the second (explanatory) as a means" (pp.58-59).17 
An explanatory trial examines the efficacy of an intervention, for example, 
whether a drug or treatment is effective under certain conditions.13 This type of 
trial usually employs strict inclusion criteria to ensure patients reflect a specific 
definition of the disease under investigation. Analysis is confined to compliers 
only- that is, patients who received the treatment according to the protocol,15 
with the focus on clinical outcomes such as death, flow rates and blood tests.13 
However, protagonists of pragmatic trials believe that limiting the analysis to 
patients who adhered to the treatment protocol can distort the comparison of 
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treatments by its inability to demonstrate the effectiveness of an intervention in 
real clinical practice.15 
The pragmatic approach is increasingly preferred because "it provides a more 
valid assessment of treatment efficacy as it relates to actual clinical practice" 
(p.182).15 The aim of a trial using this approach is to determine the effectiveness 
of the intervention in circumstances that attempt to imitate clinical practice.13 To 
achieve this, pragmatic trials have wider inclusion criteria than explanatory trials 
with the aim of reflecting the patient population, usually use active treatments as 
controls, and provide flexible treatment regimens. Pragmatic trials often use a 
wider range of outcome measures that attempt to assess quality of life and take 
into account factors such as side-effects, cost and complexity.13 Randomisation 
determines how patient data are analysed as well as their treatment allocation, 
hence within this type of trial, patient randomisation should be carried out as late 
as possible.10B Data analysis is by intention to treat and all patients randomly 
allocated to an intervention are analysed as one randomised group, regardless of 
whether they completed or actually received that intervention.17, lOB The 
advantage of this approach is that it aims to reflect the effectiveness of 
interventions under the conditions of normal clinical practice. Hence, Brewin and 
Bradley suggest that pragmatic trials are most suitable for testing interventions 
that require patient participation: an explanatory design may underestimate the 
effectiveness of such interventions because they are unable to take such factors 
into account.109 
The main objection to the pragmatic approach is that it includes in the analysis of 
an intervention, participants who did not actually receive this treatment. Using 
this approach, however, does allow for data to be analysed as for an explanatory 
trial. Proponents of this method argue that all patient outcomes after 
randomisation must be included in the analysis of an intervention because this 
reflects the normal pattern of practice where there are often inherent delays or 
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allows the sequence of treatments to be considered in the evaluation, including 
adverse outcomes or switching to an alternative treatment.10B 
Different interventions 
Within RCTs, the method of participants' exposure to the trial intervention may 
differ. The principal methods are parallel, crossover and factorial trials. The 
parallel design is used in the majority of RCTs and provides between-group 
comparisons. Here, each patient group receives only one of the treatments 
available within the trial.13 
Within crossover trials, patients receive a sequence of interventions at different 
points within the study and these treatments are evaluated using within and 
between-patient comparison. Using this approach, patients act as their own 
control. Smaller samples can be used and bias can be avoided through the 
random allocation of the initial treatment.15 The two-period crossover trial 
involves two treatment sequences. Respondents are randomised into two groups: 
the first group are given treatment A and after a wash-out period are given 
treatment B, while the second group are given treatment B, then a wash-out 
period followed by treatment A. More complex designs can also be carried out; 
for example, multi-period crossover designs include more than two treatments 
and examine the short-term response to treatments, with patients acting as their 
own control. 
In theory, crossover trials allow the precise comparison of treatments, but this 
method is only appropriate for examining stable, chronic or incurable diseases 
with relatively rapid outcomes. Problems associated with this design include low 
statistical power, time effects and possible carry-over effects of each treatment. 
Factorial trials are employed when it is necessary to evaluate an intervention 
both separately and combined in order to assess the interaction between 
therapies and compared to a control treatment.13 
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Different types of sample sizes 
Sample sizes within RCTs can be fixed or flexible and can vary from n=l up to 
mega-trials with thousands of participants. N-of-l trials are used to provide 
information on whether a treatment will help a particular patient (usually with a 
rare condition), rather than provide generalis able results. They are similar in 
design to the crossover trial, with one patient given the trial interventions either 
combined, randomised or on a number of occasions.13 At the other end of the 
scale, "mega-trials" (p.19) are increasingly being advocated12 and used. These are 
simple, pragmatic trials which examine large samples of patients and employ a 
limited number of outcome measures.12, 13 However, Charlton argues that mega 
trials are not hypothesis testing but are in fact inductive, using a level of analysis 
at population level to assess representativeness and as such should be regarded 
as a form of epidemiology. 51 
Sequential trials are based on the parallel trial design, although in this case the 
sample size is not fixed, and participants are recruited until a difference between 
the interventions is established. Jadad believes that although this type of trial can 
be more efficient than fixed sample trials, for this design to be effective, the main 
outcome measure must be obtained as soon as possible after participants have 
entered the trial.13 
To obtain a realistic calculation of the size of trial it is important to estimate the 
accrual rate necessary and assess the subsequent resources needed. Pocock 
emphasises that this calculation must be realistic, and take into account that the 
number actually recruited to a study is often less than half the original estimate.15 
Some clinical trials are terminated because such estimates fail to take into 
account the proportion of patients who will be ineligible or may refuse to 
participate.11o As a general rule Pocock states that the accrual period should be 
no more than two to three years.15 
To ensure that a trial has a strong chance of detecting a statistically significant 
difference between the interventions, if such a difference exists, sample size 
calculations are used. To obtain this, the minimal degree of benefit that a new 
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treatment would have to achieve in order for it to be preferable to the standard 
treatment is estimated. Sample size calculations should be based on the primary 
outcome measure(s) and the power of the hypothesis test. A power calculation of 
80-90% is commonly used and the greater power achieved, the greater the 
possibility of detecting such differences, although to obtain this, larger sample 
sizes are required.18 
Types of trials 
Clinical trials are funded by pharmaceutical companies, research councils such as 
the MRC, the NHS through the Health Technology Assessment (HT A) 
programme and regional R&D directorates and other nationally based health 
organisations. 
There are four phases of experimentation, which in general are part of the 
research programme for the development of a new drug, treatment or 
technology. Phase I trials take place once the safety and possible efficacy of a 
drug have been tested on animals. Trials at this stage are usually a series of cases 
and are mainly concerned with safety and the identification of the optimum 
dosage of the drug without causing serious side effects. Participants within this 
type of trial often have conditions for which there is no other effective treatment, 
such as HIV and some cancers. The next stage, Phase II trials, involves small-
scale studies (usually approximately 20 patients) examining the efficacy and 
safety of different doses of a drug. This stage is effectively a screening process to 
identify whether a drug has potential benefits.13 Phase I and II trials are usually 
explanatory. 
The full-scale evaluation of a treatment is obtained from Phase III trials. For 
example, once a drug has successfully completed phase II, it is then compared to 
the standard treatment(s) or placebo and at this stage, patients are usually 
assigned randomly to the different treatments.15 These are generally pragmatic 
(effectiveness) trials.13 Phase IV trials use longitudinal methods to examine 
morbidity and mortality to identify any adverse effects of the drug. In drug trials, 
this stage is often linked to the post-marketing surveillance of a drug. 
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Specific design issues of trials 
A number of specific issues are involved in the design, organisation and 
planning of a randomised controlled trial. Randomisation, concealed allocation, 
blinding, placebos, bias, validity, outcome measures, compliance, and 
preferences are each covered below. 
Randomisation 
Randomisation is one of the central precepts of experimental methodology and is 
generally accepted as the most efficient and preferred method of patient 
allocation within the ReT. As Pocock, states, "such plans to eliminate bias are the 
key to a successful trial" (p.9).15 The alternatives to randomisation, such as 
systematic assignment and judgement assignment are likely to lead to biased and 
overoptimistic results for new treatments (see further below). 
Randomisation, as Altman points out, does not mean that allocation is 
"haphazard" (p.86), but that patients have an equal (or known) chance of being 
allocated to any of the trial interventions.18 Random allocation is used to address 
within-trial variation, by distributing any known and unknown factors between 
the treatment groupsl06 and thereby reducing the risk of serious imbalance of 
factors between groups which could affect outcome.13 By ensuring that the 
intervention groups are similar, it is hoped that the trialists will be more likely to 
identify and measure the effect of the intervention, with minimal influence of 
other factors which could affect the results.13 
However, even if randomisation is used, bias may still be present13 and it does 
not necessarily balance the distribution of known or important factors that may 
influence the outcome of the trial.106 Randomisation does allow, however, the 
clear comparison of groups at baseline and differences can then usually be 
accommodated within the statistical analysis. 
Surprisingly, few studies have examined recruiting clinicians' attitudes to 
randomisation. The few studies that do, indicate that recruiting clinicians may 
find randomisation problematic. For example, Alderson found that although 39% 
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of breast cancer specialists approved of randomisation in principle, they 
preferred the limited certainty of personal care. Randomisation was the main 
reason this group did not recruit their patients onto trials.49 McLean found that 
many Canadian trialists were uncomfortable with the disclosure of information 
about the random allocation to patients, believing it would lead to a fall in 
patients' willingness to participate.1l1 In contrast, the majority (73%) of 
oncologists and haematologists within one US state (Maine) believed that 
randomisation was not an obstacle to recruitment, although this may reflect the 
lack of anonymity of this sample.78 
Because of such attitudes there are concerns that recruiting clinicians may in 
some instances, attempt to distort randomisation. Schulz relates that during the 
course of 20 epidemiology workshops with clinicians over 8 years, over half of 
the participants admitted that they had deciphered or witnessed someone else 
deciphering the assignment sequence. Although anecdotal, this does indicate 
that this problem cannot be treated as just a rare occurrence. He suggests that 
such behaviour may occur because fundamentally, "RCTs are anathema to the 
human spirit" (p.1457). Even if recruiting clinicians understand the need for 
trials, once they are participating they may experience conflicting interests. "Trial 
procedures attempt to impede human inclinations" (p.1457), and although 
deciphering may be a deliberate attempt to alter the trial findings, more 
generally it may be "an innocent reflection of human inquisitiveness and 
ingenuity rather than scientific malevolence" (p1457).1l2 Yet such failure to 
adequately conceal randomisation can lead to the distortion of the treatment 
effects.113 
Concealed allocation 
Most clinical trials use a list of consecutive random treatment assignments that 
have been prepared in advance to allocate participants. Clinicians must not know 
the order of these lists and patients should be formally identified and registered 
before the treatment assignment is revealed. Common methods of concealment 
are sealed envelopes or drug packages with identical intervention or placebo 
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prepared by a pharmacist in the case of double-blind trials. For multi-centred 
trials with a central registration office, treatments can be assigned over the 
telephone. For all trials 'independent' trial personnel should be responsible for 
patient registration and randomisation. IS 
There are various methods of randomisation. Stratified randomisation is used to 
ensure that treatment groups are comparable and contain equal numbers of 
patients with certain characteristics that may affect outcome such as age or 
functional status. Crucially, any variable used for such stratification must be 
"prognostically important" (p.89).18 As Altman points out, although many 
studies stratify by age and gender, only age is a known prognostic and gender 
should not be used to determine allocation in this way.18 Stratification based on 
patient characteristics is a useful tool for small scale trials that are well organised 
and where factors known to affect response have been identified. IS 
When necessary, minimisation can be used to ensure that several variables are 
distributed as evenly as possible between groups.18 Using minimisation, the next 
patient is assessed using the stratification variables to establish which treatment 
allocation would reduce the overall disparity between the groups at that point in 
patient accrual. Randomisation is then weighted in favour of this allocation. This 
method ensures that there is a balance of various prognostic factors, even within 
small samples and is mainly suitable for small trials or where small groups of 
patients are accrued from a limited number of recruitment centres.18 
Although usually it is individuals who are randomised, cluster randomisation 
can allow allocation in groups. This is often used when it is not possible to 
randomise individuals, for example, within institutions (such as hospitals or GP 
practices), families or locations.18 Individuals can also be a cluster, with repeated 
measurements taken from the individual. Cluster randomisation may be 
appropriate when an intervention may affect more than one person within the 
group or when the effect of an intervention on an individual may affect other 
participants (contamination).13 This method is thought likely to become 
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increasingly utilised as the need to evaluate the delivery of health services 
grows.114 
Restricted randomisation is commonly used to ensure that there are roughly 
equal numbers within the intervention groups by creating 'blocks' of random 
sequences.13 It is standard practice to have roughly equal numbers of patients' 
randomised into each treatment group. However, weighted or unequal 
randomisation, which allows unequal numbers within groups while maintaining 
a distribution of characteristics across groups can be used for a number of 
reasons13. Trialists may wish to allocate fewer participants to the experimental 
treatment for a number of reasons. For example, if there are concerns about 
possible adverse reactions to an intervention; to monitor the learning curve of a 
new treatment; when the expected drop-out or crossover rate is likely to be 
greater for one of the interventions; when unequal variances are expected 
between interventions or for rare conditions. This may also be appropriate where 
it is possible to include historical controls within the standard treatment group, 
so that a greater proportion of patients can be allocated to the experimental 
intervention. This approach may also have economic benefits by providing the 
maximum statistical power for the minimum resources.115 Unequal 
randomisation is useful, but if the differences in sample size between groups are 
great, then this can diminish the statistical power of the trial.15 
Concealed random allocation is important to avoid bias116 (see further below). 
Kunz and Oxman, in their review, found that failure to conceal adequately can 
lead to the distortion of the treatment effects in either direction, leading to either 
larger or smaller effects than is actually the case.113 For example, Schulz et al 
found that inadequately concealed randomisation led to estimates of effect which 
were 30-40% larger than trials which were believed to have adequately concealed 
allocation.117 Schulz points out that although sequentially numbered, opaque, 
sealed envelopes or pharmacy allocation, centralised or telephone randomisation 
methods are generally seen to represent the minimal standards required for 
concealed randomisation, they are met by only a quarter of current trials. There 
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is anecdotal evidence that some of these methods, for example, the use of 
envelopes, may still be open to subversion.112 The description of randomisation 
and the methods employed are often poorly reported in published trials, even 
within principal journals, making it difficult to establish whether these studies 
have employed a truly random method of allocation.13, 118 Kunz and Oxman 
conclude that the adequacy of concealment may be a more sensitive measure of 
bias within a trial than current quality assessment scales.113 
Blinding 
Blinding (or masking) is a methodological device to ensure that participants and 
sometimes clinicians are unaware which intervention has been allocated. The aim 
is to reduce" ascertainment or observation" (p.20) bias13 (see below, pp.) which 
may occur if anyone involved in the trial knows which treatments patients are 
receiving. For example, if a patient knows their treatment allocation this may 
have a psychological effect: "one should not underestimate the importance of 
psychology in other non-psychiatric diseases: whether it be asthma, cancer or 
heart disease the manner in which patients are informed of therapy can have a 
sizeable effect on subsequent performance" (p.91).15 Similarly, the clinicians 
involved in the treatment and management of a patient may be influenced by 
their knowledge of the patient's treatment. In an attempt to ensure unbiased 
evaluation, the evaluator should also remain unaware of which treatment 
patients are receiving (blinded evaluation). As Pocock states, "One key issue is to 
ensure that those responsible for assessing patient outcome are as objective as 
possible" (p.91).15 
A double-blind trial refers to an ReT where both the patients and those 
responsible for outcome assessment do not know the treatment assignment.13 
Within a double-blind, double dummy trial, participants receive one of the active 
interventions or a placebo that is identical to the other active intervention. This is 
often employed when the interventions being compared are administered using 
different methods, for example, a trial comparing tablets with injections.13 
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Trials that are not blinded are referred to as open RCTs and are used where it is 
not possible to blind participants to the intervention, for example, comparing 
surgery with a drug. A single-blind trial is where one group, usually the 
participants or the investigators assessing outcome, have no knowledge of the 
intervention allocation. Senn suggests that such partially blinded designs should 
be referred to as 'veiled' trials.106 
It is often argued that the inability of trials of surgery to be blinded is a major 
methodological problem. Single blind surgical trials have been carried out where 
a surgical intervention has been compared to a 'sham' procedure, however, there 
are ethical problems with such an approach. Russell argues that such problems 
can be overcome by the implementation of pragmatic trial designs and ensuring 
that the assessment of outcome is blinded. Those trials specifically comparing 
new procedures with standard ones should also take into account the experience 
of the surgeons performing the new technique and also randomise patients as 
soon as possible in order to evaluate the learning curve and short term costs 
involved.119 
Placebos 
To achieve blinding, the treatments being compared must be presented in an 
identical format. In a double blind drug trial, a placebo, an inactive substance 
which looks and tastes the same as the active treatment can be used.13 However 
there are a number of problems with the use of an 'inactive' rather than an 
'active' placebo because of the differences in side effects that can occur. 
Greenberg and Fisher120 looking at the effect of RCT design on outcome within 
psychotropic drug trials, point out that "the typical drug trial is transparent 
because of the use of inactive placebos. The side effect profile associated with 
virtually every psychiatric medication unmasks both the patients and the 
research personnel as to who is receiving drug vs. placebo" (p.245).120 This may 
not be limited to studies of psychiatric medication but extends to other fields, 
particularly when outcome is evaluated using subjective factors which may 
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introduce bias (see further below). Some placebos can also have harmless side 
effects, such as blackening stools, which are easily detected. 
Because the placebo and active treatment usually have different effects, a 
significant difference between the treatments can be found even in small trials. 
This means that although the placebo trial can state that the treatment is better 
than placebo it cannot necessarily evaluate the effectiveness of that treatment in 
relation to the standard treatment for a condition.6o 
A further issue is the 'placebo effect'. "Placebos are not totally inactive, they are 
pharmacologically inactive" (Vere p.8)121 and improvements are commonly 
found with placebos. In benign prostatic disease, for example, symptom 
improvements of 32% are not uncommon on placebo, compared to Alpha 
blockers (48%) and Finasteride (37%).122 
It is argued by some that the placebo should no longer be part of the' gold 
standard' trial. Although placebos have been commonly used because there has 
often been no effective treatment with which to compare the new treatment, as 
medical knowledge increases the use of placebos should fall. When a standard 
treatment is available, it is preferable and ethical to compare this to new 
treatments.60 However, placebos are still utilised even when a standard treatment 
is available. Aspinall and Goodman in a review of published trials of 
ondansetron for postoperative nausea and vomiting, found that over 2000 
patients had been denied effective prophylaxis and over 400 patients who were 
experiencing symptoms had also been denied effective treatment within the 18 
trials.123 Patients may also be less willing to participate in trials that include a 
placebo arm.124 
Bias 
Bias includes any aspect or practice within a trial which systematically affects the 
results leading to an underestimation or an inflation of the efficacy of an 
intervention.13 Bias can occur at any stage of a trial from planning, sample 
selection, execution of the interventions, and analysis, through to the 
interpretation, reporting and publication of the subsequent results. Although it is 
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not possible to identify conclusively whether the findings of a study are truly 
unbiased, certain sources of bias have been identified, as have methods for 
red ucing their effect.13 
The selection, care and evaluation of patients taking part must not differ between 
treatments.15 Selection bias may occur if there are systematic differences in the 
way in which participants are chosen or subsequently assigned to an 
intervention within the trial. Randomisation should ensure that the recruiting 
clinicians and the patients are unable to influence the allocation, however, if 
eligible patients are excluded because their allocation is known, then selection 
bias will be introduced. This can also occur when clinicians decide to treat 
patients with a particular intervention, regardless of random allocation. To 
prevent such bias, concealed allocation should be included in the design of any 
trial,13 ideally by telephone randomisation. Selection bias should not occur if 
there is true clinical equipoise, where participants are informed of, and consent 
to, the trial, and when it represents best clinical practice. 
Poor management of patients who withdraw, drop out or do not comply with the 
treatment protocol can also introduce bias. Intention-to-treat analysis can be used 
to avoid this type of bias.13 Such problems can also be caused by structural faults 
in the design of a tria118 or introduced by the inappropriate use of different ReT 
designs such as the cross-over trial.13 The use of a registry or log book to record 
data on participants and non-participants, giving reasons for non-participation of 
eligible patients, may increase external validity.l25 
The exclusion criteria for trial entry can be a major source of bias, affecting the 
validity and generalisability of the results. For example, Schwartz and Fox found 
that the criteria used in a trial of two psychosocial interventions for multiple 
sclerosis resulted in only 3% of the initial registry of 1500 patients actually being 
randomised, with an additional over-representation of patients with the chronic 
progressive stage of the disease.126 Similarly, Hunter et alSO found that of newly 
diagnosed US oncology patients (44,156), only 9508 were clinically eligible to 
participate, and of these, only a small proportion (19%) were actually entered 
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into a tria1.5o McCusker et al found that the results of two lung cancer 
chemotherapy trials applied only to the 42% of patients who were eligible, 
because participants were more likely to attend specialist hospital units and have 
a higher socioeconomic status.l25 The selection criteria used within a trial must be 
described in detail to allow an assessment of the representativeness and 
generalisability of the results.127, 128 
Ascertainment bias can occur when the findings of a study are systematically 
distorted because treatment allocation is known. To avoid this type of bias, the 
double-blind trial design can be used to ensure that these groups are unaware 
which intervention has been allocated13 (see further below). 
McPherson suggests that treatment choice, preference and control may have a 
therapeutic benefit and because random allocation deprives patients of this 
benefit, this may lead to a negative estimate of treatment effectiveness.22 
Leventhal et al illustrate how a number of psychosocial and behavioural factors 
between treatment groups can introduce bias.129 They found that women in the 
active treatment arm of a breast cancer prevention trial were more likely to 
maintain breast self-examination a year after trial participation, while this 
decreased in the placebo arm. They hypothesise that those in the active treatment 
group may feel less vulnerable to breast cancer, seeing this task as confirming 
their healthy status rather than a means of detecting disease.129 
Failure to standardise the informed consent procedure may also introduce bias, 
which could in turn change or modify the outcome of a trial.130 Dahan et al 
compared the effects of written informed consent on the responses of patients 
with insomnia to a placebo and found that patients given detailed information 
about possible side effects experienced more side effects than the control group 
who received no information.130 Similarly, a sixfold increase in the number of 
participants withdrawing from an angina trial occurred within centres which 
informed patients of a gastrointestinal side effect.131 
Bias can also occur at the dissemination stage of a trial (publication bias). Studies 
reporting positive results are more likely to be published in English-language 
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journals if the findings are statistically significant, whilst negative papers are 
more likely to be published in German and Japanese journals.132 Trials with 
positive results are also published sooner than those with negative results, as is 
the case for I potential breakthrough' studies. 
A systematic review, that is the evaluation of the evidence from published trials, 
can be useful, allowing clinicians access to combined results from many trials 
and up-to-date research. This method is based on the reviewer's personal 
evaluation and dependent upon access to, and inclusion of, all relevant trials.1s 
Meta analysis (where the results of a number of studies are combined to get an 
overall answer to the research question) is the major quantitative method used. 
However, any attempt to summarise the findings from a number of trials is 
problematic and consistency is necessary as trials are likely to differ.ls 
Jadad et all33 and Moher et all34 have both developed guidelines to assess the 
quality of reporting of clinical trials. Broadly, they suggest that the relevance of 
the research question to clinical practice, the internal and external validity of the 
trial, the suitability of the analysis and data presentation and the ethical 
implications of the intervention must all be assessed to establish the quality of 
reporting. However, one problem with such assessment is that it is based on the 
quality of the published report, and as J adad13 acknowledges, poorly designed 
but well reported trials may receive a high score, while a well conducted, but 
badly reported study may receive a low quality score. Kunz and Oxman in their 
review, conclude that concealed allocation may be a more sensitive measure of 
bias than current quality assessment scales.!13 
Standards have been developed to improve the level of reporting trials. 
CONSORT (Consolidation of the Standards of Reporting Trials) provides 
guidelines to improve the standards of trial publication, both at the submission 
and final publication stage.127, 128 Submitted papers must be supplemented with a 
21-point checklist to aid reviewers, describing key aspects of the trial necessary to 
evaluate its validity, for example, details of the methods of allocation and 
conceahnent employed. To assist readers, the published report must also include 
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details of the protocol, assignment, blinding, participant profile and follow-up, 
flowchart, and details of the data analysis.127,128 This statement has been adopted 
by many high quality journals including the BM}, The Lancet, Annals of Internal 
Medicine and }AMA. However, a number of reviews79, 118, 135 have found that the 
information provided in many of the trial reports is still inadequate, although 
this may increase over time as the CONSORT guidelines are increasingly 
applied. 
Validity 
Ideally, patients recruited to a trial should be representative of the disease 
population under investigation. To ensure this, all clinicians involved in the 
selection process must see a representative group of patients, be willing to 
randomise a substantial proportion of their suitable patients and agree to accept 
the random assignments of treatments. Only if a patient does not meet the 
eligibility criteria should they be excluded from the trial.15 The generalisability of 
the trial findings to the target population is referred to as external validity. The 
internal validity of a trial is dealt with by the use of concealed and random 
allocation (see further below). 
However there are problems associated with achieving external validity. Many 
recruiting clinicians do not enter all their eligible patients onto trials and this has 
implications for the realistic estimation of accrual rates and the 
representativeness and generalis ability of trial findings. For example, many were 
found to overestimate their patient accruaF3,75 and half of the recruiting 
clinicians within a number of large scale trials were found not to have entered 
any of their eligible patients.47, 75 Similarly, 29% of a sample of Nordic 
oncologists136 and 52 % of breast cancer oncologists47 admitted that they had 
excluded some of their eligible patients from trials. 15% of the recruiting 
oncologists within one US centre also admitted that they sometimes discouraged 
participation.73 
There are a number of reasons for this. It has been suggested that the inherent 
conflict of taking on the dual role of investigator and physician committed to an 
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individual patient's health is a barrier for many.46-48,136-138 Clinicians may fall into 
two groups: I experimenters' who are primarily interested in contributing to 
scientific information and therapists, for whom the patient is the main focus.-±5 
Recruiting oncologists have often been found to have such a I therapist' 
orientation to their practice45, 46,75 and appeared to be deterred because they 
believed helping individual patients was more important than contributing to 
research.46,75 This ethical dilemma may be one of the main reasons for such 
excl usions50 (see further in chapter 1). 
Trial design may also be a barrier and it is important to incorporate the recruiting 
clinician's perspective when designing trials. For example, the design of some 
oncology trials were often believed to be too rigid and for many recruiters within 
one US centre, this was their rationale for excluding patients.73 Many breast 
cancer clinicians have also been found to have objections to trial design,45,49 
believing that they would enter more of their patients if trial participation was 
closer to normal practice.45 Surprisingly, only a small number were deterred by 
the practical barriers to recruitment such as difficulty collecting data,5o,73, 74,78 the 
time involved,73, 74 staff shortages,74 cost,73 traveF8 and side effects.78 However, 
the majority of these studies have examined those recruiting patients onto 
oncology trials and it is not known to what extent these barriers are present 
within trials for non-life threatening conditions. 
A number of practical interventions can be employed by trialists or incorporated 
into the trial protocol to improve the external validity of a trial. For example, 
Schwartz and Fox suggest targeting potential recruiting clinicians with 
information and obtaining their prior endorsement of the study may be one way 
to increase their willingness to allow their patients to participate. Farrell propose 
that trial campaigns to encourage recruitment should reflect the clinical practice 
at a local level by translating the recruitment rate so that it has practical meaning 
for the recruiting clinicians. It must also /I offer some sort of kudos or recognition 
to those willing to participate" (p.1237).139 
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Taylor et al suggest that the recruiting clinicians could be asked to set their own 
realistic levels of accrual, with a system to support and reward clinicians who 
meet their targets, or hold accountable those who do not.75 However, despite the 
clinicians' right to base their decision on their personal belief about the 
acceptability of a trial, Segelov argues that such decisions should be documented 
to ensure that they are not just based on II nonscientific, whimsical feelings" 
(p.l04}.55 
Trialists must become aware of the unique barriers to participation of some 
groups if they are to achieve an unbiased sample. There is evidence that accrual 
of women140 and participants from low income,141 racial and ethnic groups is 
lower than for the majority.59 It has been suggested that to improve the accrual of 
such groups, the design and recruitment of trials must take into account the 
social and behavioural aspects of participation.142 McCabe et al suggest that 
recruitment strategies should identify the specific cultural needs and barriers to 
participation of ethnic minority groups. Staff should receive specific training, 
with nurses having a key role in the identification, education and recruitment of 
participants from minority groupS.141 Only two studies have examined the 
attitudes of minority groups to trial participation. These also conclude that trials 
must be tailored to meet the needs of their target group58,143 and recommend that 
professional and lay representatives of the communities should be involved in 
the planning of future trials.143 HIV trial pilot studies similarly suggest that at the 
design stage, trials should take into account the needs of the target population by 
understanding individual and community issues.144-146 
To improve the accrual of those on low incomes, outreach work within the 
community has similarly been suggested as a way to increase trust and 
communication, for example by giving public presentations and the setting up of 
an advisory group that includes representatives from the target population. 
Collaboration with clinics providing medical care at reduced rates for these 
populations, improving access and availability of services and employing staff 
from these population groups has also been suggested to improve accrual.H1 
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Providing participants with transportation to clinic appointments may also be 
effective. Thirty-eight patients in one such study cited travel as their main reason 
for non-participation and this intervention had the potential to increase accrual 
rates by 25%.126 
Information may also be an issue. For example, a small number (34) of the 
sample of injecting drug users were eligible, but did not enrol onto a phase II 
clinical trial. Asked for their reasons, many (54 %) stated that they were interested 
in participation but had lost the study information.147 Many studies suggest that 
the provision of information before recruitment may increase participation.142,148-
150 Turner and Sheon in their review, conclude that this must focus on the 
communication of clinical uncertainty and the potential risks of participation.151 
Others suggesting that trialists must deal with patients' anxieties about taking 
part150 by ensuring they have realistic expectations of participation, especially in 
relation to the benefits of standard therapy.152 
Outcome measures 
To evaluate change, outcome measures are used. Outcome measures can be 
clinical (impairment), patient based (activities), or use social, demographic and 
health care utilisation data (participation). An important aspect of the 
appropriateness of outcome measures is that they must measure change 
effectively.153 Measures obtainable from clinical practice can include mortality, 
case severity, diagnostic tests (e.g. x-rays) and laboratory investigations (e.g. 
blood tests). Rates of re-treatment, hospital readmission, complications and 
adverse reactions following the intervention are also used. A common measure 
to assess the resource implications of an intervention is length of stay.153 
Patient based outcome measures include questionnaires examining condition 
specific symptoms and/ or bother, quality of life and generic health status. Trials 
commonly use both a general and a disease-specific health status measure.1S-! 
Qualitative research methods can also be used to evaluate an intervention from 
the patient's perspective. These can involve in-depth interviews and participant 
observations within the clinical setting. There are also social, demographic and 
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utilisation measures, which include mortality, hospital readmission, length of 
stay, time off work, utilisation of primary care and social/voluntary services. 
Depending on their relevance to the design of a particular trial, all or a number of 
these measures can be used to evaluate an intervention in order to build up a 
picture of outcome. Primary or secondary outcome measures should be 
established at the planning stage of a trial. Primary outcomes are those of central 
interest to the trialists. The number should be limited and although this may 
vary, it is standard practice to have no more than three primary outcome 
measures, although in some trials this may be as high as six. Secondary outcomes 
are the other measures taken within the trial which are not part of the main focus 
of the trial.15 Large scale trials that use a small number of simple outcome 
measures are also being increasingly advocated.12 
One challenge for future RCTs is to examine disease from the patient's 
perspective. Patients' views have been neglected in the evaluation of treatments 
and this methodologically important yet poorly investigated area is the main 
focus of this thesis. Although clinical outcome can be measured with few 
problems, the issue of what quality of life questionnaires actually measure is 
problematic. Thus the validity and reliability of quality of life measures looking 
at social and psychological well-being are much debated. Quality of life 
assessment typically involves standardised measures and these can miss issues 
important for the individual. Although patients are often given the opportunity 
to indicate the size of the problem they are rarely given the opportunity to rate its 
actual importance to them.22 
The evaluation of quality of life is becoming recognised as an increasingly 
important outcome measure. However, Sanders et al found that less than 5% of 
all RCTs (1980-97) reported using quality of life measures. Even within cancer 
trials, where there are expectations of higher levels due to the nature of the 
condition and the increasing demands of many funding bodies to examine such 
issues, this was less than 10%.155 They also found that the quality of reporting 
quality of life measures is often poor and conclude that standards must be 
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established to improve the measurement and reporting of quality of life within 
RCTs.155 
Wynne suggests that the assumptions made in the evaluation of a therapy and 
the definition of therapeutic benefit within trial methodology often impose an 
artificial framework onto the trial findings which may be very different from the 
trial participants' own beliefs about outcome.21 The aim should be to give 
prominence to the characteristics most important to the individual and it has 
been suggested that an evaluation of quality of life which takes into account 
individual preferences and values may be more appropriate than standardised 
measurement.156 McPherson similarly proposes that quality of life and physical 
functioning must be assessed from the patient's perspective.22 
Compliance 
From a clinical perspective, patient compliance is a crucial aspect of the success 
and validity of a clinical trial. Each patient who takes part in a clinical trial is 
expected to comply with a non-individualised treatment regimen, often not 
knowing to which treatment they have been randomised in blinded clinical trials. 
There are also repeated laboratory tests, examinations and interviews and the 
demands placed upon the individual may be protracted, with many clinical trials 
lasting for over 2 years. However, there are relatively few studies examining 
compliance within the RCT.157, 158 
Patient preferences 
Few classically designed trials attempt to take patients' preferences or views into 
account. Chapter 3 discusses attempts to include patient views. In the section 
that follows, the rationales for the designs of trials that accommodate patients' 
preferences are described. 
Many eligible patients have a preference for, or do not want to receive one of the 
treatment options available within a trial. Some refuse to participate in trials for 
this reason, while others may take part despite such preferences. The outcomes 
of these groups of patients are rarely examined, although potential participants' 
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perceptions of the condition, treatment and the trial can affect the internal and 
external validity of an RCT.159 As Silverman and Altman acknowledge, the 
placebo effect suggests that other possible psychosocial influences such as 
preferences should be examined.160 
Patients who have strong preferences for a treatment may differ from those 
without a preference and this may affect the outcome of the trial. For example, 
those who are allocated to their preference may have a better outcome than 
others who are unhappy with the treatment they receive.13 Similarly, patients 
who prefer one treatment may differ from other participants which may 
introduce bias into the trial.24 
Although preferences may be based on a belief that a treatment will be the most 
effective, quality of life is also an important factor in patients' decision making24 
and may be important for trials where the treatment options have different 
degrees of impact on patients' lives. For example, in a breast cancer trial with the 
treatment options of a lumpectomy or mastectomy, preferences are likely to vary 
considerably between individuals. Such treatment options may only seem 
comparable to relatively few patients eligible to participate in the trial.159 
Thus, preferences may affect accrual. Although the recruiting clinician may 
believe that the treatment options available within a trial are equally effective on 
the evidence so far, the decision to participate is left to the patient and this may 
depend on their preferences for one treatment over another.159 Barofsky and 
Sugarbaker found that willingness to participate in three skin cancer trials was 
dependent upon patient perceptions of the trial treatment options. They suggest 
that differing rates of trial accrual may be due to the disparity between patients' 
prior experiences and expectations and the treatments available, concluding that 
the influence of these factors on patient accrual and retention should be 
addressed in the design and implementation stage of trials.161 
Preferences can also have implications for the trial findings. For example, Berry 
et al found a range of treatment preferences among a sample of rheumatology 
patients (n=60) taking part in a crossover double-blind drug trial. The greatest 
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difference between the two experimental groups occurred in patients who 
wanted improved mobility from the treatment, despite any side effects they 
experienced.162 Patients' motivations for following a treatment may also be 
influenced by their initial preferences, for example, when an intervention 
involves self monitoring or dietary changes.109 It has been argued that where at 
least one of the trial interventions are participative, motivation will be equally 
distributed across intervention groups because only patients who receive 
informed consent and agree to be randomised are included.109 However, such 
patients may still have strong preferences, agreeing to participate only because 
there is a chance they will be allocated to their preference or because it is their 
only chance of receiving the experimental treatment. If such patients are not 
allocated to their preference, this may reduce their motivation and lead to biased 
estimates of treatment effectiveness.109 
Kassirer identifies seven circumstances where preferences are likely to vary 
widely or are 'utility-sensitive': where the potential outcomes of treatments are 
very different; where possible complications and repercussions resulting from 
the treatments are very different; when decision-making involves choosing 
between short and long-term outcomes; when one of the treatments has a small 
chance of resulting in a grave outcome; where the differences between treatments 
are minimal; when a patient is averse to risk taking; or when a patient places 
their hopes on one possible outcome.163 
It has been argued that in such cases randomisation is not always appropriate 
and may itself lead to bias. Trials do not replicate what usually happens in 
everyday life, where treatment is individualised,l64 and specifically the process of 
random allocation means that patients are deprived of choice, preference and 
control over treatment which may have a therapeutic benefit. In theory then, 
randomisation itself may lead to a biased estimate of a treatment's 
effectiveness. 22 
Alternative designs could be considered for trials which will be demanding for 
participants or where patients are likely to have strong preferences for one of the 
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treatments.109 Zelen's design, the comprehensive cohort and Wennberg's design, 
all take patients' preferences into account. These trial designs include at least one 
group of participants who have been allocated to their preferred treatment and 
are referred to as preference trials.13 
Zelen model of randomisation 
Within a Zelen designed trial, patients who are eligible to participate are initially 
randomised to one of two groups. The first group are a 'do not seek consent' 
(control) group and are allocated to the standard treatment. Patients within the 
second group are asked to give informed consent to participate in the trial and 
receive the experimental treatment. If they agree, then they receive this 
treatment, or they can decline this and receive the standard treatment. In a 
modification of this design, Zelen suggests that patients in this second group can 
be given the opportunity to receive their preferred treatment. The analysis of 
such a trial compares the outcome of patients allocated to the control group who 
received the standard treatment with the second group, regardless of whether 
they received the standard or experimental treatment.23 
The double randomised consent design is a modification of the Zelen design, 
which attempts to deal with the ethical problem of not informing participants 
that they have been randomised to the standard treatment. Here participants are 
told to which group they have been allocated and given the chance to change to 
the alternative treatment groUp.13 
Zelen believes the main benefit of this design is that it does not compromise the 
doctor-patient relationship, as the recruiting clinicians only need to discuss one 
of the treatment options and do not have to mention random allocation. From the 
patient's perspective, this method simplifies the decision making process since 
patients know which treatment they are agreeing to receive.23 This approach also 
ensures the participation of the majority of eligible patients, allowing the 
evaluated effect of the experimental treatments to be generalised.13 This design 
was used within the National Surgical Adjuvant Project for Breast and Bowel 
Cancer Trial.159 By randomising before they obtained patients' informed consent 
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to participate in the trial, accrual increased sixfold. However, this introduces the 
ethical problem of not giving such patients informed consent prior to 
randomisation (this has been discussed in more detail in the previous chapter). 
However, Zelen also points out that the analysis of such trials may not be able to 
detect possible treatment effects and patient characteristics if these are related to 
patient preferences.23 It has also been argued that where participation is based on 
preferences the sample will not be representative of the target population. 
Comparing the outcomes of randomised and non-randomised groups is also 
likely to introduce uncontrolled confounders and hence problems of validity.160 
Comprehensive cohort design 
The comprehensive cohort design is effective where a large number of eligible 
patients refuse to participate because they have strong preferences for one of the 
treatments available within the trial.13 Using this design, patients are initially 
asked to give their consent to be randomised and those who agree are 
randomised to one of the trial interventions. Patients who do not agree to be 
randomised, receive their preference and are followed as if they were within a 
cohort study. All participants are followed-up, regardless of whether they were 
randomised or not and the outcomes of the trial and cohort participants are then 
compared. The main limitations of this approach is the difficulty of determining 
whether the results from a small number of randomised patients can be applied 
to the target popuiation160 and in establishing whether any outcome differences 
between the groups are real or due to differences in baseline characteristics 
between the two grou ps.13 
Wennberg's design 
Here eligible patients agree to be randomised to either an 'RCT group' or a 
'preference group'. Those randomised to the preference group are given the 
option of choosing which intervention they receive, while the RCT group are 
randomly allocated to one of the interventions. The outcomes of the two groups 




It is often difficult to achieve a consensus among clinicians as to the appropriate 
eligibility criteria for certain trials, hence many clinicians are often reluctant to 
randomise and enter their patients onto trials.164 In response to this problem, the 
clinician-preferred treatment trial design has been proposed. Using this method, 
eligible patients are assessed using fixed criteria to establish whether clinicians 
would be likely to have a treatment preference and if this is the case, these 
patients are excluded. A panel of 2-4 clinicians then individually assesses those 
remaining, and only if there is disagreement within the panel is informed 
consent sought and the patient randomised. They are subsequently assigned to 
the clinician preferring this treatment allocation during the patient's screening 
process. However, because this design restricts participants to a specific group of 
patients, the applicability of the trial to the patient population is problematic.164 
Other approaches 
Other approaches have also been suggested to address this issue. Widder's 
solution would be to ask patients to consider why they want treatment and what 
they want or expect their treatment to achieve before entering a study. Only 
when patients' aims are in concordance with the aims of the trial should they 
take part.165 Alternatively, Thornton suggests that one way to address patients' 
preferences within trials is for patients to be involved at the design and planning 
of trials and for their preferences to be integrated at this stage.166 
Preference trials are seldom used, although with the growth of consumer 
participation in decision making this method is likely to be increasingly used.13 A 
number of preference trials have been carried out,167-171 although relatively few 
involving surgical procedures. An exception is the trial by Henshaw et a1167 to 
evaluate the acceptability of medical abortion and vacuum aspiration. Just over 
half (54 %) of the eligible women willing to participate (n=363) had no preference 
and agreed to be randomised. Those who did not want to be randomised were 
allocated to their preference: medical abortion (20%) and vacuum aspiration 
(26%). A self-completion questionnaire assessing the acceptability of the 
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treatment found that 22 % of those randomised to a medical abortion would 
choose a different procedure in the future compared to only two of the women 
allocated to vacuum aspiration. Henshaw et al suggest that it would not be 
possible to obtain this type of information without a trial design that took 
preferences into account.167 
However, there are problems associated with the use of preference trials. King et 
aP70, carried out a pilot preference trial to evaluate counselling in general 
practice. Overall, the majority of patients (particularly those with higher 
psychiatric scores), were allocated to the counselling intervention. The authors 
speculate that the recruiting GPs may have been influenced by the severity of the 
patients' illness and directed their preferences. This was confirmed by many of 
the GPs who remarked that they may have influenced patients' choices by 
suggesting that counselling may be beneficial.I7o Angell similarly notes that 
although the Zelen method may increase accrual, this maybe the result of 
clinicians' withholding or colouring information in favour of the treatment to 
which the patient had been allocated.159 
Preference trials have been considered and rejected for a number of controversial 
studies. In a breast conservation trial where patients would be randomised to one 
of two types of surgery, mastectomy or lumpectomy (which may provoke strong 
preferences), the working party rejected the Zelen method of randomisation. 
They believed it would be unethical to seek informed consent from only one 
group of patients. Legal action was also a consideration. If a patient who received 
a mastectomy later finds out that they had taken part in a clinical trial and 
discovered that they had been denied the more conservative treatment 
(lumpectomy), they would be in a position to sue.172 The Zelen approach was 
also suggested for a number of paediatric trials. However, this was seen as only a 
partial solution for a trial of critically ill babies with acute respiratory failure 
because participants would receive less information, when qualitative research 
had concluded that clearer information was required prior to randomisation.173 
Similarly, Levene et al concluded that the trial design proposed by Zelen is no 
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alternative in trials of premature infants because of the legal requirement to 
obtain parental consent. They believe that where early entry is required, 
informed consent should be a continuous process, with parents provided with 
further written and oral information after randomisation. They recognise that in 
these trials consent is obtained before parents are fully informed.174 
A dominant feature of medicine is choice and the need to communicate the 
associated probabilities. Silverman and Altman suggest that misconceptions 
about probability may be an important aspect of preferences and thus patients 
must be protected from exaggerated claims about new treatments.160 The 
importance of patient preferences varies with the condition, but may be 
particularly important for conditions such as benign hyperplasia of the prostate, 
where there is not only a choice between treatments, but a decision about 
whether treatment is necessary.22 
So far trialists have been reluctant to involve patient groups in the design of 
trials. However, patients may prefer different outcomes from those imposed by 
trialists. For example, in the development of a trial for young people with sickle 
cell disease, Prestifilippo et al56 found that although morbidity was the main 
clinical outcome, patients did not see this as the most important criteria for 
assessing trial outcome.56 Naylor and Llewellyn-Thomas175 suggest that patients 
and the public should be involved in trial planning and be able to indicate the 
level of benefit they want from a 'new' treatment, given the known side effects 
from this treatment that may occur.175 They believe that the probability trade-off 
technique could be used to ensure that patient autonomy and the principles of 
informed consent are incorporated, even though this approach means adding 
another stage onto the design of a trial.175 
Conclusion 
The focus on the ReT as the only unbiased method to evaluate a medical 
intervention has led to an increasing awareness of the problems of attaining the 
required level of precision, validity, and the feasibility of this approach. 
However, textbooks and reports in journals focus on the design, methods and 
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results of trials,ls, 106, 176 suggesting that each decision in the planning and design 
of a trial, from selecting the intervention, the population, and the aims of the 
trial, occurs in isolation and according to standard rules. The possible impact of 
these decisions on patients is often ignored and such decisions may influence the 
behavioural dynamics and thus affect the internal and external validity of a 
trial.129 The following chapter examines the experience of trial participation. 
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Trial Participation: patient perspectives 
Introduction 
In this chapter, research relating to the publics' and patients' perspectives of 
being involved in RCTs will be considered. Studies have primarily been 
undertaken from the perspective of trialists, often using hypothetical trial 
scenarios with a variety of lay or potential trial populations with the ultimate aim 
of improving accrual within future trials. Studies that explore the experience of 
participation have predominantly used structured questionnaires to examine 
motivation, satisfaction and barriers to recruitment. The assessment of the 
informed consent procedure within trials has also been the subject of many 
studies, often evaluating effectiveness using recall and recruitment rates. Only 
recently and in a few studies has there been an assessment of the perspective of 
actual participants: their attitudes towards, their experience of and motivation 
for taking part in a clinical trial. 
Attitudes to participation 
Hypothetical participation 
Many studies have used hypothetical scenarios to determine willingness to 
participate in trials. These often attempted to assess general attitudes to trial 
participation by examining the attitudes of the public.99, 177-180 Others have 
focused on potential trial populations of patients49, 124, 142, 181, 182 and specific 
treatment groups, for example, paediatric and psychiatric populations148, 149 or 
racial and ethnic groups often underrepresented within trials.58, 143 Many have 
been used to assess the feasibility of trials for particular conditions which 
potentially present specific ethical, methodological or accrual difficulties. From 
the perspective of the trialists, these studies aim to gather information to improve 
the feasibility of, and accrual rates to, these proposed trials by presenting 
hypothetical scenarios to their respective populations, particularly in the areas of 
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HIVl44-147,183-185 and oncology.49, 142, 150, 186 A summary of these studies can be 
found in tables 1 and 2 below. 
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Table 1: Surveys, structured and unstructured schedules used to explore 
hypothetical participation 
Author Population Sample size Purpose of the study Outcome Main results 
assessed measurements 
Kemp et all78 UK Lay (1022) General attitudes - Structured survey Participation -63% 
population oncology trial Trust-88% 
scenarios 
Mackillop et Lay (400) General attitudes- Structured survey Participation -50% 
aP79 population oncology trial Altruism-63% 
(Canadian) scenarios 
Millon- US African- (220) General attitudes to Structured survey Participation-75% 
Underwood American oncology trials Trust-20% 
et all43 population 
Saurbreyl82 Danish in- (114) General attitudes- a Structured Participation- 98% 
patients range of trial interviews Trust-86% 
scenarios 
Bevan et all81 UK (119) General attitudes-a Structured Participation- 70% 
outpatients range of trial interviews Altruism-57% 
scenarios Personal benefits-42% 
Cassileth et US Patients Patients (186) General attitudes to Self-completion Participation- 71 % 
all77 and the public Public (107) trial participation questionnaire Altruism-55 % 
Personal benefits-52% 
Gerrard et French (609) To evaluate the Postal questionnaire Participation- 50% 
a1149 community potential impact of 
psychiatric informed consent 
population regulations 
Mettlinl42 US population (576) A feasibility study Postal questionnaire Participation- 77% 
who had been for an oncology trial 
screened for 
cancer 
Slevin et alISO UK oncology (75) General attitudes- Self-completion Participation- 42% 
patients oncology trial questionnaire Personal benefits-83% 
scenario Altruism-75% 
Llewellyn- US colorectal (60) Presented with an Self-completion Participation- 25 
Thomas et cancer patients actual clinical trial questionnaire 
al186 protocol 
Autretl48 French parents (541) To evaluate the Self-completion Participation- 21 % 
potential impact of questionnaire Personal benefits-44% 
informed consent Altruism-67% 
regulations- Trust- 52% 
paediatric scenario 
Flanery et al99 US students Medical (57) Presented with a Structured Personal benefits-49% 
Mathematics 'typical' consent questionnaire- Al truism-88 % 
(67) form to multiple choice 
(hypothetically) 
partici pa te 
Alderson49 UK clinicians Clinicians (40) Ethics Interviews with Altruism, personal 
and breast Patients (50) clinicians and benefits important 
cancer patients Screened patients. motivations within all 
and screened women (93) Postal survey of groups 
women those screened 
Corbett et allllO UK lay and Public (50) Informed consent Comparison of Non-participation due 
medical Medical- different way of to adverse etfl'ds of 
population secretaries (25) prOViding informed treatment-25°;, 
Students (25) consent 
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Welton et al124 UK general Post- Recruitment Interviews Altruism-26% 
practice menopausal 
women (436) 
Roberson58 Minority (28) General attitudes to Qualitative Altruism 
groups in trial participation telephone interviews 
Mistrust New York 
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Table 2: Surveys and structured schedules used to explore hypothetical 
participation within target populations for HIV vaccine trials 
Author Population Sample Purpose of Outcome Trial 
assessed size the study measurements information 
McQueenet (US) Gay and (1071) Feasibility Structured A brief 
allS3 bisexual men study-HIV interviews and self- statement 
vaccine completion explaining the 
trial questionnaires vaccine and 
Ranked scales 
the trial 
BartholowH-l Men who have (1267) As above As above A brief 
sex with men statement 






Douglas146 Men who have (1660) As above As above No details 
sex with men 
(US) 
Jenkinsl84 Thai health care (255) As above Survey and open- No details 
workers ended responses to a 
questionnaire and 
focus groups 
Wiley et al185 Men who have (371) As above Structured self- No details 
sex with men completion 
(US) questionnaires 
Vlahov147 (US) mainly (375) As above Structured A fuller 
Black (94%) interviews and self- disclosure of 
population of completion possible risks 
HIV questionnaires - of 
seronegative willingness to participation 
injecting drug participate rank on a 
users scale 
Gross et all45 (US) Gay and (630) As above Structured self- No details 







81 %, dropping to 
21% 
Altruism-94 % 





(later dropped by 
half) 
Initial participation-




Overall, these studies found favourable attitudes towards hypothetical trial 
participation among the general public, ranging from 48%-75% agreeing to 
participate. 143, 177-179 Many (70%) would still contribute, even if this meant 
undertaking dietary changes (77%) or taking vitamin supplements (73% ).142 
Perhaps surprisingly, 40% would participate even when one of the treatment 
options involved amputation.178 These studies suggest, then, that a large 
proportion of the public is willing to participate in clinical trials- in theory at 
least. 
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Three studies suggest that patient groups, with rates of 50%,149 70%,181 and up to 
98%,182 were also willing (hypothetically) to take part in trials relevant to their 
condition. 
However, lower levels of willingness to participate were found in response to 
two oncology trials150, 186 a gynaecology trial,124 and a paediatric trial.148 Less than 
half of two samples of oncology patients would agree to participate.150, 186 
Similarly only 21 % of French parents (541) surveyed would agree to participate, 
but the majority (74%) would not allow their children to take part.148 However, 
these findings are not surprising, given the potentially life threatening (cancer) 
and emotive (paediatric) trials these studies examine. 
Willingness to participate varied amongst the target populations for HIV vaccine 
trials. McQueen et al found 37% of gay and bisexual men were 'definitely' 
willing to participate,183 although Gross et al found only 17% very interested in 
taking part.l45 Willingness to participate was often related to the amount of 
information these men received about such trials. Three studies initially found 
high levels of willingness, ranging from 62%,185 up to 85%.144,147 However, after 
receiving additional detailed information about what participation in such a trial 
would involve, this dropped by almost half (no figure given)185 and to as low as 
21 % in one study.l44 For example, once injecting drug users were informed that 
the vaccine might lead to a false positive HIV test result, willingness to 
participate dropped by almost half to 47%, and to 27% when they were told that 
the vaccine might contain a piece of the virus.147 Such trials clearly contain a 
number of particularly difficult issues for patients to deal with. 
Actual participation 
A fundamental problem with many of the studies above is their reliance on 
attitudes to hypothetical (not real) trial participation. As Gerard et al acknowledge, 
although 50% of their sample were willing to participate in clinical trials, 
intention may be different from actual participation rates.149 Those who have 
taken part in a trial may have a real and distinct difference of opinion compared 
to those whose responses are based on speculation.178, 182 
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Much of the literature evaluating patient participation in clinical trials is 
concerned with improving recruitment, by examining the 'mechanics of the 
process' and identifying methods for achieving a low refusal rate in future trials. 
Little is known about why patients decide or refuse to participate in clinical 
trials. "Do they see themselves as willing volunteers entering clinical trials to 
help both themselves and humanity or do they feel that they are victims, being 
used as guinea pigs in an experiment over which they have little 
control?"{pp.1270).150 Only recently and in a few studies has this been seen from 
the perspective of actual participants: their attitudes and motivation for taking 
part in a clinical trial. 
Surveys and structured schedules have been used to explore participation within 
large-scale heart disease trials/187-189 phase I oncology trials,190, 191 paediatric 
trials/97 UK out-patients,181 a gynaecological trial105 and an arthritis trial.192 These 
studies have been summarised below within table 3. 
Table 3: Surveys and structured schedules used to explore participation 
Author Population assessed Sample size Purpose of the Outcome Main results 
study measurements 
Daugherty et US oncology (27) Motivation and Structured interview Personal benefits-
al,191 patients prior to perceptions of schedules with 100% 
participation in a participation additional open-ended Trust-75% 
range of phase I questions 
cancer trials 
Hudmonet US oncology (64) Motivation and Postal survey AItruism- 95% 
al190 patients who had perceptions of Multiple choice Personal benefits-
completed a phase I partici pa tion questions 95% 
colon cancer trial 
Mattson et (US) Asprin (398) Retrospective Structured Personal benefits-
al187 Myocardial study of questionnaire 84% 
Infarction Study participation interviews with Problems with (AMIS) trials additional open ended transport- 11 % 
Beta-blocker Heart (1503) questions 
Attack Trial (BHAT) Postal questionnaire 
Henzlova et (US) chronically ill (3522) Perceptions of Survey- structured Trust-31 % 
aP88 middle aged and participation questionnaire Personal benefits-
elderly participants 25% 
in a long-term heart Not anonymous AI truism-32 % 
failure trial Problems with 
transport- 21 % 
DeLuca et (US) participants (172) To identify Structured interviews Personal benefits-
aP89 within 12 sociodemograph 88% 
cardiovascular trials ic predictors of Altruism-79% 
informed Pressure to 
consent participate-63% 
Harth and Parents who had (68) To identify Structured interviews Personal benefits-
volunteered their sociodemograph with additional open- 90% 
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Thong97 child onto an asthma (42 non- ic predictors of ended questions Altruism-100% 
drug trials participants) informed Trust- 48% (Australia) consent 
Lynoe et alIOS Women after (43) To assess recall Postal survey based on Altruism-56 % 
participation in a of informed the Declaration of Personal benefits-
Swedish consent Helsinki 35% 
gynaecological trial 
Bevan et al181 UK out-patients (66) General Structured interviews Altruism-62% 
who were current or attitudes-a range Personal benefits-
previous trial of trial scenarios 38% 
participants 
Hassarand Participants in an (17) Knowledge of Structured self- Personal benefits-
WeintraubI92 arthritis trial the trial and completion 94% 
reasons for questionnaires Altruism-88 % 
partici pa ting 
Qualitative in-depth interviews were carried out with participants 
predominantly within breast cancer trials,83, 193 oncology trials,194-197 HIV drug 
trials,198, 199 a paediatric trial,173 a prostate tria1200 cystic fibrosis201 and a herpes 
tria1.68 Longitudinal studies have been carried out by three of these studies.196, 197, 
201 Additionally, Jayne Harrison describes her personal motivation to participate 
in a breast cancer tria1.202 These studies have been summarised below within 
table 4. 
Table 4: Qualitative and semi-structured schedules used to explore participation 
Author Population assessed Sample Purpose of the Outcome measurements Main results 
size study 
Charles et Canadian women in breast (20) Decision making Qualitative in-depth Personal 
al193 cancer trials interviews benefits Trust 
Jensen et al83 Danish women in breast (34) Evaluation of Qualitative in-depth Altruism -26% 
cancer trials informed consent interviews Personal 
benefits-24% 
Cox and UK participants in phase I (7) The psychosocial Longitudinal semi- Personal 
Avis1% and II oncology trials aspects of structured interviews benefits-hope 
participa tion before and after Trust 
completion Some altruism 
Blair et al201 UK participants in a phase (16) The psychosocial Longitudinal semi- Personal 
I safety trial of gene aspects of structured interview benefi ts-56 % 
therapy for cystic fibrosis participation before and after Trust-25% 
completion. Health 
measurement scales 
Stetzl97 Participants with (24) The experience of Longitudinal semi- Personal 
advanced liver cancer - partici pa tion structured interview benefits-
Their partners- (16) before and after survival, hope 
completion 
Tabakl94 (Israel) oncology and Oncology To assess decision Structured interviews Trust 
vascular patients (23) making before participation 
vascular 
(20) 
Rodenhuis et Participants within a (10) Motivation to Interviews Hope 
64 
al,195 Dutch Phase I oncology participate Trust 
trial 
Snowdonet UK study of parents who 37 Understanding of In-depth interviews In only half of 
al173 had agreed to the (21 randomisation the interviews 
participation of their couples) (12) did one 
newborn child with acute parent believe 
respiratory failure in a their allocation 
clinical trial was based on 
chance 
Featherstone Participants in the ClasP (20) Understanding of In-depth, semi- Many recalled 
and prostate trial randomisation structured interviews randomisation 
Donovan2OO Lay 
in terpreta tions 
of the concept 
Tindall et al198 HIV positive men one (113) To examine Self -completion Trust- 88% 
week before taking part in informed consent structured 
an HIV drug trial questionnaires 
(Australia) 
Ryanl99 HIV positive men (16) The experience of In-depth semi- Confidentiality 
participating in AIDS participation structured interviews ' wa tching sick 
clinical trials and HIV Participant observation people' 
phase I trial (Australia) The clinic 
setting 
Searight and Patients after participation (14) From the Semi-structured Altruism 
Miller68 in a herpes trial. perspective of interviews Personal 
All White, well educated informed consent benefits 
and predominantly 
female. 
The majority of studies have examined participation within oncology trials.83, 190, 
191,193-197 paediatric trials97, 173 and HIV trials198, 199 It can be seen in tables 3 and 4 
that the main focus, as with the hypothetical studies, has been an examination of 
participation within trials that present trialists with specific ethical problems. For 
example, five such studies have considered Phase I trialsl90, 191, 195, 196, 201 where the 
aim is to determine the maximum dose tolerated and the toxicity of new drugs. 
Traditionally, a drug is administered at low levels, followed by a succession of 
dose increases. Hence, the chances of receiving any personal medical benefits 
from participation is small while the toxicity of the treatment may be high.191 
Similarly, because of their inability to provide fully informed consent,30 the use of 
children in medical research is a much debated ethical area.69,97 Parents are 
expected to make important, complex and possibly life-changing decisions about 
their unborn or newborn child.173 
A number of studies examined participation within Phase I trials. Two US 
studies used structured schedules, Hudmon et al in a postal survey,190 while 
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Daugherty et al included additional open-ended questions within the interview 
schedule.191 Daugherty et al interviewed patients (27) before participation in a 
range of cancer trials,191 while Hudmon et al examined perceptions after 
completion (64) of a colon cancer trial.190 Two UK studies were longitudinal in 
design. Blair et al examined a phase I safety trial of gene therapy for patients (16) 
with cystic fibrosis,201 while Cox and Avis examined participants (7) within 
phase I and II cancer drug trials. Both used semi-structured interview schedules 
before and after completion of the trial and in addition, Blair et al employed a 
number of health measurement scales.201 
Oncology trials were also explored by a further four studies. Participants in 
breast cancer trials were interviewed by Charles et a1193 (Canadian women) and 
Jensen et al (Danish women).83 Additionally, Jayne Harrison describes her 
personal motivation to participate in a breast cancer tria1.202 A longitudinal 
qualitative study of trial participants (24) with advanced liver cancer and their 
partners (16) was carried out by Stetz,197 while Tabak (Israel) interviewed 
oncology (23) and vascular patients (20) who had been offered experimental 
treatment.194 
Four US studies explored the motivation and satisfaction of participation in 
large-scale heart disease trials. Mattson et al examined survivors of a myocardial 
infarction taking part in two randomised, double-blind, placebo-controlled trials. 
Within the Aspirin Myocardial Infarction Study (AMIS), participants (398) were 
interviewed using a structured questionnaire with additional open-ended 
questions. These results were then used to inform a postal questionnaire sent to 
patients (n=1503) within the Beta-blocker Heart Attack Trial (BHAT).187 The 
focus for Henzlova et al was a survey of chronically ill middle aged and elderly 
heart patients (3522) participating in a long-term heart failure tria1188 and Deluca 
et al also interviewed participants (172) within a range (12) of cardiovascular 
trials.189 
Paediatric trials were examined by three studies. Harth and Thong examined the 
attitudes of parents (68) who had volunteered or had decided not to volunteer 
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(42) their child in a randomised, double blind, placebo controlled asthma drug 
trial in their 1990 study.97 Their 1995 study examined a similar group of parents 
(62), although this study was mainly concerned with issues of informed 
consent. 69 Both samples were interviewed using a structured questionnaire 
containing additional open-ended questions.69, 97 Snowdon et al in a UK study, 
carried out qualitative interviews with thirty seven parents (21 couples) who 
agreed to the participation of their newborn child with acute respiratory 
failure. 173 
A range of other trials has also been examined. Two Australian studies examined 
participation in HIV drug trials.198, 199 Tindall et al interviewed HIV positive men 
(113) one week before taking part in an HIV drug tria1198 and Ryan similarly 
carried out in-depth interviews with current or recent participants in AIDS 
clinical trials (16). Additionally, trial nurses (12) were interviewed and a 
participant observation of one HIV phase I trial was carried OUt.199 Qualitative 
methods were also used by Searight and Miller who interviewed participants 
(14) after their completion of a herpes trial.68 Lynoe et al in a Swedish study 
carried out a postal survey of women (43) after participation in a multi-centre 
gynaecological trial.105 Bevan et a1181 carried out structured interviews with 66 
UK out-patients who were current or past trial participants,181 while Hassar and 
Weintraub employed structured self-completion questionnaires which included 
true/false and multiple choice questions with participants (17) in an arthritis 
trial.192 
Motivation to participate 
Both the quantitative, structured studies (see table 3) and those employing 
qualitative research methods (see table 4) have examined participants' 
motivation to take part in a trial. The studies examining the hypothetical 
motivation to participate are also reported here (see tables 1 and 2). They identify 
altruism, trust in recruiting clinicians and an expectation of receiving personal 
benefit as the main personal motivations for taking part in a trial. There was 
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often an overlap, with most patients motivated by a combination of these 
reasons. 
Altruism 
A feeling of altruism, that is, the desire to help others and the progress of science, 
was an important motivation among participants. Within Phase 1 trials, almost 
all the colon cancer patients (95 %) believed that altruism was a very or extremely 
important aspect of their participation.190 This was reflected to a lesser extent in 
the qualitative findings of Cox and Avis196 and Similarly, over half of the 
participants (56 %) in the gene therapy trial believed they would not benefit 
personally.201 Helping others was cited by almost all parents (98%),97 arthritis 
patients (88%),192 out-patients (62% ),181 and over half of the participants in a 
gynaecological trial (56% ).105 Many were motivated by the belief that their 
participation would contribute to medical research. This included all the 
parents,97 the majority in a range of cardiovascular trials,189 just over a quarter of 
breast cancer trial participants83 and the majority of the 14 participants within a 
herpes tria1.68 Within a trial of social support in pregnancy, altruism was 
reported to be the main reason women agreed to participate. 203 
The high level of altruism displayed by participants within Phase 1 trials may 
also be linked to the nature of the trials and the seriousness of their condition. 
When the drug did not work or only worked for a short time, anger and 
resignation often replaced the (UK) oncology patients' initial hope. These 
participants were left to face death and in an attempt to find a positive meaning 
for taking part, they hoped they had helped the clinicians and future patients.196 
Similarly, Jayne Harrison in her personal account, cites altruism and wanting to 
contribute to the clinical understanding of breast cancer treatment as her main 
motivation.202 
Altruism was also the main (hypothetical) motivation among UK out-patients 
generally (57%),181 a UK general practice sample of women (26%)124 UK oncology 
patients (75% )150 and the Canadian public (42-63% )179 in response to a range of 
oncology trials. Qualitative telephone interviews with minority groups in the US 
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also identified altruism as the main incentive for participation. 58 Among women 
with breast cancer (92 %), and screened women (50 %), the main motivation for 
(hypothetical) participation would be to help others. This was also the case for 
breast cancer clinicians, whose main motivation was to help others (82%) and to 
increase knowledge about this condition (92% ).49 
A specific desire to help future patients was the main reason cited by US 
cardiology and cancer patients and the public (77%),177 French parents (67% ),148 
and almost half (40%)183 and nearly all (94%)146 of two similar populations of 
men asked to participate in HIV vaccine trials. Macqueen et a}183 observed that 
those who were definitely willing to participate in HIV vaccine trials tended to 
use language reminiscent of a war effort, describing AIDS as an I epidemic' and 
the 'virus'. Thus, willingness to participate was often in response to the loss or 
possible loss of loved ones to AIDS (12%), and out of a sense of duty to the 
community (11 %).183 
Increasing scientific knowledge was a significant motivation for French parents 
(53% )148 and for US patients and the general public (69%).177 To a lesser extent 
this was also a motivation among UK out-patients,181 UK oncology patients,150 
the Canadian public179 and gay and bisexual men.183 
A small number of studies question the importance of altruism. For example, 
Kemp et al found that few (5-10%) of their UK population sample who were 
willing to participate in a range of oncology trials would do so for altruistic 
reasons, with the majority placing their trust in the clinicians.178 Similarly, only 
22% of the sample of African-Americans cited altruism as their motivation.143 
Both studies examined attitudes to cancer trials and it may be that the primary 
motivation for participating in this type of trial would be to benefit personally. 
Within actual trials, only 32 % of participants within one heart failure trial 
(although this was still the main motivation amongst this groUp)188 and none of 
the respondents within a range of US oncology trials referred to altruism as their 
main reason for participating.191 They suggest that the chronic or life threatening 
illnesses of such groups may mean that personal benefits are more important. 
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However, altruism was a common motivation to take part in a number of similar 
oncology trials. 
The importance of altruism as a motivation to participate is variable. This may be 
associated with the different methodologies employed by these studies. Surveys 
and structured schedules used to examine both actual and hypothetical 
participation found high levels of altruism ranging from over half (56%) up to 
100%. Hypothetical studies using qualitative methods also found high levels of 
altruism; however, such motivations are perhaps to be expected from what were 
predominantly lay groups where their responses are based on speculation. In 
contrast, this was a weak motivation within only a few studies examining actual 
participation using qualitative methodologies to examine the experience of 
participation.83, 193, 196,201 
Trust 
For patients with a life threatening condition, trust in the clinician often 
constitutes an integral part of their decision making.194 Two thirds of participants 
in US oncology trials191 placed their trust in the research oncologist, the referring 
clinician or the institution, and the majority (89%) of colon cancer patients 
similarly believed that there was no better option than to participate in the 
tria1.19o Qualitative interviews with oncology trial participants also found this to 
be an important motivation for the majority.193, 196 They expected their clinicians 
to be responsible for decision-making, in the belief that they did not have the 
knowledge to make such decisions.193, 196 
Tabak suggests that for cancer patients, the life threatening nature of their 
condition may create a special behaviour pattern that overcomes any reluctance 
to agree to experimental treatment. These cancer patients were under significant 
pressure to participate in experimental treatments and their recruiting clinicians 
confirmed that few made independent decisions, participating either from lack of 
choice or based on trust in the recruiting clinician.194 
This may also be the case for other groups of patients with life-threatening 
conditions, for example, HIV, cystic fibrosis, heart disease and paediatric trials. 
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The majority of HIV positive trial participants (88%),198 and a quarter (4) of 
patients within the gene therapy trial for cystic fibrosis,201 believed that their 
clinician always acted in their best interest. Any concerns were mitigated by the 
general belief that the clinicians would not put them at risk.201 Within two heart 
disease trials, trust in their clinician (63%),189 and the recommendation of the 
primary physician (31 % ),188 were the main motivations. The majority of parents 
also placed their 'trust in the hospital' (48%), frequently volunteering their 
children because they 'liked the people conducting the trial' (72 % ). 97 
Trust in their clinician or clinicians generally, was an important factor for many 
who were willing (hypothetically) to participate. The majority of a UK 
population survey (88%),178 Danish patients (86%),182 and half of French parents 
(52 % )148 had high levels of confidence in their clinicians. A UK lay sample often 
believed that the' doctor knows best' in response to a range of hypothetical 
oncology trials (69-70%).178 Similarly, Macqueen et al found that those definitely 
willing to participate in HIV vaccine trials appeared willing to place their trust in 
the researchers.183 However, only a small number within an African-American 
sample (20%)143 and a Canadian general population sample (5.2%) would 
participate for such reasons.179 The African-American sample were sceptical of 
the effectiveness of cancer treatments143 and the Canadian sample179 were 
predominantly motivated by altruism. 
An association between socio-economic status and willingness to trust the 
recruiting clinician has been identified. Kemp et aI, in a large scale survey of a 
UK lay population, found that those who were older (60-70yrs) and from lower 
socio-economic groups were more likely to agree, while younger groups (25-
34yrs) or with a higher socio-economic status were more likely to refuse, 
preferring to choose their own treatment.178 
The perceived expertise of the recruiting clinicians may also play an important 
role in recruitment. Half (51 %) of the UK oncology patients wanted the clinician 
to allocate them to a treatment150 and 70% of US patients and the public, similarly 
believed or were unsure if 'doctors know privately which one of the 
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investigative treatments is best'.l77 Over half (58%) of Danish patients believed 
that ethics committee approval conferred extra protection.182 Thus, when 
participation is motivated by the chance to receive the best treatment, the 
clinicians' recommendation of the trial may be interpreted by patients as 
equivalent to the clinician recommending the best treatment.178 
Personal benefits 
Physical improvement as a result of receiving the new experimental treatment 
was a widespread expectation. This was an important motivation for all (100% )191 
and almost all (95% )190 of the participants in a range of Phase 1 trials, even 
though the actual chances of receiving any personal medical benefits from such 
trials was small.191 This is confirmed by two qualitative studies which also found 
that the majority of participants within a range of Phase I trials had 
unrealistically high expectations of the experimental therapy.196,201. 
Few participants and only within two US heart disease trials were motivated by 
access to free medical care, ranging from 1.4188 to 11 %.187 An expectation of 
receiving better health care was an important motivation to hypothetically 
participate among UK out-patients (42% )/181 a sample of US patients and public 
(52% )177 and for up to 62% of the Canadian public.179 Such personal benefits as 
receiving treatment from a specialist (83%)/ increased monitoring (80%) and 
receiving greater information about their condition (75 % ) were also important for 
UK oncology patients. ISO To increase their chances of obtaining the best care was 
an important motivation for women with breast cancer (43 %) and screened 
women 40%. Interestingly, a sample of breast cancer oncologists similarly 
believed that trial participation would improve their access to the best care 
(67% ).49 
After participation, improved outcome was often attributed to the trial and the 
experimental treatment. The majority of parents whose babies had received the 
'new' treatment for acute respiratory failure believed that this was responsible 
for their child's survival and they were 'lucky' to receive this treatment.173 Of 
those recruited to heart disease trials, many believed that they had received 
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emotional (62%) and physical (56%) benefits188 and often ascribed their 
improvement to their allocated medication (43 %), with the trial benefiting their 
general (24%) and cardiac health (36%).187. Participation may also have a wider 
role in improving health. A significant number within a long-term heart failure 
trial reported changes in smoking (15 % ), alcohol consumption (15 %) and diet 
(38%), although there were no interventions attempting to influence such health 
behaviours.188 
Within some types of trials there may be specific benefits from participation. For 
example, in her personal account of breast cancer, Harrison believes trial 
participation will provide her with the greatest chance of receiving the best 
treatment. She is aware that the trial would be based within a specialist oncology 
unit and that there is evidence indicating trial participants may achieve a better 
outcome.202 Hudmon et al similarly found that the expectation of receiving 
increased information, medical follow-up and being part of new research were 
very or extremely important benefits for 80% of the colon cancer patients.190 The 
expectation of receiving treatment and information from specialists, increased 
monitoring and reassurance were also important for the majority of heart disease 
trial participants.187 
Access to the most effective treatment was also an important incentive for 
participation in a range of cardiovascular (88% ),189 UK out-patient (38% ),181 and 
breast cancer (24 % )83 trials. This was also the case for all but one of the 
participants (16) in an arthritis trial.192 The majority of parents agreed to take part 
out of a concern for their child's health (90%) and a I dissatisfaction with current 
treatment' (82%).97 Almost a quarter hoped to 'feel better' and 'live longer' as a 
result of their participation in heart disease trials.188 Nearly all (14) within a 
herpes trial similarly hoped to receive better care within the trial. However, such 
a hope within this group is surprising, the trial required some to refrain from 
taking their medication for a condition that has no known cure.68 
This belief in the experimental treatment was linked to hope for participants in 
oncology and Phase 1 trials. Three qualitative studies identified this as the main 
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motivation among a range of oncology,196 breast cancerl93 and advanced liver 
cancer
197 patients. Such patients often felt they had no choice: non-participation 
was equated with death and hence they felt they had to do everything possible to 
increase their chances of survival.193, 196, 197 70% of those taking part in a range of 
cancer trials believed that they would at least gain psychologically.l91 For some, 
continuing medical treatment enabled them to postpone or deny that their 
condition was terminal.l95, 197 
The hope of obtaining the 'new' or 'experimental' treatment was also cited by 
many willing hypothetically to participate as their main motivation.143,145, 148,179, 
183 This applied to parents (44%),148 a lay population (12.7%),179 an African-
American population (28 % ),143 and gay and bisexual men asked to participate in 
HIV vaccine trials.145,183 Macqueen observed that many (37%) who were willing 
to participate in an HIV vaccine trial saw the vaccine itself as a possible way of 
reducing their personal risk.183 Similarly, 72% of UK oncology patients welcomed 
the' greater chance of receiving new treatments', although many (27%) also 
indicated that the least appealing aspect of participation was the 'chance of 
obtaining experimental treatments' .150 
The enthusiasm and hopes of family and friends were often the driving force 
behind participation. Within a range of phase 1,191,195,196,201 oncology197 and 
cardiovascular trials,189 respondents received pressure from their families to take 
part. The opinion of family and friends was a powerful motivation for all the 
participants (10) in a Phase I oncology trial. For example, three women who had 
no interest in participating did so because they were urged by their husbands "to 
grab their last chance" (p.460).195 Approval of the trial by the patient's partner 
was a significant predictor of consent, with 97% of patients whose partners 
approved participating in a cardiovascular trial and 96% declining when 
partners objected.189 Similarly, for a quarter of those who decided not to 
participate in a UK out-patient trial, their relatives were opposed to their 
participation.181 Partners often assumed shared responsibility for finding 
treatment, sometimes in a more forceful manner than the patients themselves.197 
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Such beliefs highlight the vulnerability of some groups and the risks they are 
willing to take if there is a chance of survival. l96 Expectations of benefiting 
personally from participation are unrealistic for many of these trials and 
indicates poor communication about the trial. For example, many women (35%) 
believed they had received better care within a gynaecological trial that involved 
keyhole surgery performed under a general anaesthetic. However, this 
procedure was purely for research purposes and Lynoe et al speculate that these 
patients may have mistakenly assumed that this was a beneficial procedure only 
available within the trial.105 
The low refusal rate within many trials, often with highly toxic treatment 
regimens, may be a further indication of participants' unrealistic expectations. 
Zwitter and Tobias found that overall only 5% of patients refused to participate 
in lung cancer trials due to side effects. This was consistent, even within 
chemotherapy trials, where higher levels of side-effects would be expected.79 
Similarly, the refusal rate was very low (6%) within the paediatric trial for acute 
respiratory failure. Snowdon et al found that parents did not believe there was 
uncertainty about the 'new' treatment and few were concerned about the 
possible risks. As their child's condition deteriorated, most parents believed they 
had nothing to loose and that the chance of a new treatment was a powerful 
incentive.173 
Edwards et al in a recent (1998) systematic review also concluded that gaining 
personally from participation was the main motivation.72 They suggest that such 
expectations, especially within trials where participants will not gain, should be 
explored in more detail.72 
Satisfaction with participation 
Satisfaction was high within heart disease trials, despite the fact that these 
patients had often taken part in these trials for several years187 and up to four 
years in some cases.188 Almost all (97%) within a long-term heart failure trial 
were satisfied, would repeat the experience (87%) and would recommend 
participation to a friend (96% ).188. Similarly, Bevan et aP81 found that just over 
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half (54 %) of the UK out-patients believed that there was no aspect of the trial or 
participation with which they were unhappy.181 
Within a Phase 1 gene therapy tria1,201 almost all believed there had been no risk 
and 75 % (12) did not think they had been affected by participation in what was a 
safety trial. Their expectations about the therapy were slightly higher after the 
trial, although overall they remained realistic about how much personally they 
would benefit. Follow-up interviews revealed that none believed that the trial 
had contributed to an improvement or deterioration in their condition. Those 
who were worried about taking part remained worried after the tria1.201 
The majority of patients within two myocardial infarction (51-87% )187 and two 
Phase 1 (75-100%)190,201 trials would participate in future trials if asked. 
However, for colon cancer patients this was related to the benefits of 
participation. Just over half (52 %) were willing to participate in a placebo trial, 
although this dropped to 35% if the trial did not reimburse expenses.190 
Problems with participating 
Few practical problems with trial participation were reported. Participants 
within heart disease trials cited travelling to the clinic (10-187 21 % ),188 time 
waiting at the clinic (3-10% )187 and changes in clinic staff (4_187 7% ).188 Patients 
within oncology and HIV trials were the only groups to report significant 
problems with participation. The focus was often on issues that would affect 
them personally. For example, the risk of infection from the wards and the 
general disruption to their lives of participation in the gene therapy trial were 
more important than the wider issues of safety and ethics associated with such 
treatment.201 Qualitative studies similarly found that the demands of attending 
the clinic caused problems for participants in a Phase 1 trial.196 
Information was an important issue within a phase I oncology trial. Most of these 
participants (7) were not told what to expect or of the procedures involved in the 
trial and often found this distressing.196 The end of the trial left some oncology 
patients with a sense of loss. Participants often entered these trials with high 
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expectations, even though their condition was serious. At the end of the trial they 
lost contact with the research staff.196, 197 As the treatment often does not work or 
only works for a short time, their hope can be replaced by anger and 
resignation.196 Stetz suggests that recruiting clinicians should establish patients' 
reasons for participation to ensure that they have realistic expectations of the 
trial.197 
Patients within an HIV phase I trial often experienced anxiety seeing others 
attending the trial clinic at later stages of the same disease. This may have a 
negative psychological impact on patients, especially those who are 
asymptomatic.199 When patients initially agree to participate they may not be 
aware of such aspects of participation, which may force them to confront issues 
about their condition such as their future illness trajectory and mortality.199 Ryan 
suggests that the health care setting itself had a significant impact on the 
experience of these participants and this may extend to other clinical trials. The 
clinic setting is an under-researched, I seen but unnoticed background feature' of 
participa tion.199 
Recruitment 
The experience of being asked to participate in a trial was variable. Many 
patients felt that they experienced pressure to participate in cardiovascular 
(63%),189 cancer and vascular (58%),194 anaesthesia (34%),102 and HIV (15%)198 
trials. Similarly, many UK out-patient (38%)181 and gynaecology (9%)105 trial 
participants felt obliged to comply with the recruiting clinician's request. 40% of 
oncology patients who had agreed to take part in a range of phase I trials 
believed that they had no option but to participate in the trial, no other treatment 
had been discussed.191 
Patient reactions to being asked to participate in a trial differ. The point in their 
diagnosis at which patients are asked to take part in a trial may be significant. 
For example, two patients give very different personal accounts of their 
recruitment onto breast cancer trials. Hazel Thornton experienced feelings of 
isolation at being asked to participate in a trial and believes that recruiting 
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patients who have just received a cancer diagnosis is ethically unacceptable, 
damaging to the doctor/ patient relationship and isolates patients at a time when 
support is vita1.89 In contrast, after receiving her breast cancer diagnosis, Jayne 
Harrison actively sought trial participation based on her prior knowledge of both 
ReT methodology and the uncertainties surrounding breast cancer treatment. 
However, she was told by her consultant that he knew which was the best 
treatment for her and that she 1/ mustn't let academic niceties get in the way of the 
best treatment" .202 
Patient expectations and preferences 
Patients' expectations of the potential benefits of the standard and experimental 
treatments available may be central to their decision to participate or not in a 
trial.152 An examination of patients' (282) willingness to participate in a breast 
cancer clinical trial, for example, found that many had inaccurate expectations, 
often based on incorrect assumptions about the effectiveness of the standard 
treatment. It is suggested that participants in such trials who have high 
expectations of treatment may be attempting to deny the life threatening aspect 
of their cancer, or alternatively may not have been informed of the benefits of 
conventional therapy.152 
The term I preferences' describes 1/ the level of satisfaction or desirability that a 
person associates with a particular health state (e.g. chronic angina), treatment 
process (e.g. hemodialysis, duration of treatment or illness), or level of 
participation" (pp.859). A distinction must be made between patients' informed 
choice where they are aware of risks and benefits of treatments and uninformed 
preferences.204 A central but debatable assumption is that such preferences are 
measurable.205 
Preferences can influence patients' willingness to participate. This was the main 
reason for refusal (23) among those eligible to participate in a breast cancer trial 
(147)206 and also influenced participation within three sarcoma trials.161 All 
agreed to participate in a trial comparing immunotherapy with no therapy. In 
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contrast, fewer were willing to be randomised when amputation was one of the 
treatment options. Almost all of the patients who withdrew received other 
treatments which caused less disruption to their lives.161 Barofsky and 
Sugarbaker believe that these different rates of trial participation were due to the 
disparity between patients' prior experiences and expectations and the actual 
treatments available within the tria1.161 
A number of studies have found that participants often have strong treatment 
preferences. Snowdon et al found that the majority of parents preferred the 'new' 
experimental treatment. Most did not believe that there was uncertainty about 
this treatment and few were concerned about the possible risks. They were aware 
that the' new' treatment was being used in other countries and thus assumed 
that this treatment had been proven and was safe. Treatment preferences were 
often based on information from the recruiting clinician, who sometimes 
'inadvertently promoted a preference' (p.1349) for the 'new' treatment.173 
Characteristics of participants 
Only a small proportion of eligible patients asked to participate are actually 
recruited into trials (see chapter 2). Thus in an attempt to improve accrual in 
future trials, many studies have attempted to identify demographic predictors of 
participation. While there appear to be some predictors of accrual, sample sizes 
and accrual rates for studies vary considerably. 
Education and socioeconomic status were indicators of participation within some 
studies. High school (p<O.Ol)142 and college (p<O.Ol)148, 152 education were both 
predictors of (hypothetical) willingness to participate in cancer trials. 
Psychiatric149 and multiple sclerosis (p<O.OOl)126 patients from higher socio-
economic groups were also more likely to actually participate, as were women at 
high risk of breast cancer who had a high school education (p<O.OOl).207 
Correspondingly, patients with lower education levels were less likely to agree to 
participate in US cardiovascular trials than those who had received a higher 
education (p<O.02).189 
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In contrast, lower educational achievement was related to participation in HIV 
(p<0.0003)144 and paediatric97 trials. Harth and Thong suggest that "vulnerable 
parents may be volunteering their vulnerable children for clinical research" 
(p.1375). Those who volunteered their children were also significantly more 
likely to seek medical advice at least once a month (p<O.OOl), have fewer close 
friends and confidants (p<O.OOl), smoke more cigarettes (p<O.OOl) and take 
analgesics (p<O.OOl) and tranquillisers (p<0.Ol).97 Similarly, psychiatric patients 
who were the most 'medicalised' were more likely to agree to participation.149 In 
a subsequent study, Harth and Thong conclude that the informed consent 
process functioned as a social filter, as parents who volunteered their children for 
research were more likely to be from an economically and emotionally 
disadvantaged groUp.69 
Willingness to participate was also associated with age, although this evidence is 
confusing. People screened for cancer (p<0.01),142 and women with cancer 
(p<0.001),152 were more likely to be willing (hypothetically) to participate if they 
were younger. However, those who were older were more likely to agree to 
participate (hypothetically) in HIV (p<O.0002)144 and paediatric (p<O.Ol)148 trials. 
Health beliefs have also been identified as a predictor of participation. In a US 
postal survey, Mettlin et al found that those willing (hypothetically) to 
participate were more likely to be concerned about getting cancer, and be 
positive about the preventative effects of dietary interventions (p<O.Ol).142 
Similarly, Rimer et al found that participants (987) in a US breast cancer trial 
were more likely to have had a recent breast examination and to have a higher 
subjective and objective (p<0.002) risk of developing breast cancer.207 
The timing of recruitment can also influence participation. Women within one 
breast cancer trial were more likely to agree if they were approached within two 
months of a relative's diagnosis of cancer. Those approached later were more 
likely to participate if they were non-smokers.207 
No demographic differences were found between those hypothetically willing 
and unwilling to participate among African-Americans who attended two 
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community agencies,143 and those eligible to participate in one breast cancer208 
and two sarcoma,161 trials. Family composition, socioeconomic group209 race, 
gender, religion and marital status189 were similarly found to have no association 
with willingness to participate. 
Non-participants 
Few studies have examined non-participation. Those that do examine why 
people refuse to take part in clinical trials are predominantly set within the 
context of how to improve the response rate for future studies. 
Although there was often an expectation that design issues would be an 
important reason for refusal,209 only a small number within a few studies cited a 
dislike of being randomised to a treatment (4 %_148 6 % ),126 experimentation 
(10% ),50 the research methods or trial results (1 % )210 or gave religious or ethical 
reasons (3 % )210 for their refusal. 
Trial design was problematic for a number of those asked to participate in 
hypothetical HIV vaccine trials. However, the aim of these studies was to assess 
the acceptability of the design of such trials. They found that many were less 
interested in participation if the treatment assignment was not revealed for 
'months or years after the study began' (19%) or if the trial involved a placebo 
(11 % )145 and many would attempt to uncover their treatment assignment 
(15% ).146 Colorectal cancer patients who 'refused' were less willing to experience 
short term toxicity for a possible increase in survival and wanted greater benefits 
from participation and a greater say in the decision making process.186. Similarly, 
a study specifically examining patients' and clinicians' views of trial design 
found that design issues (97%) and randomisation (39%) were the main reason 
for refusals among oncology clinicians. Their patients reflected this. Objection to 
randomisation was the main reason for refusals among breast cancer patients 
(58%) and screened women (56%).49 
Logistical problems such as transportation were mentioned as reasons for non-
participation in diabetes (19%)209 and multiple sclerosis (38)126 trials. 
Inconvenience was also cited for paediatric97 and cardiovascular (10%)210 trial 
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non-participation. Similarly, the number of visits to the clinic was an important 
factor (42%) within a diabetes tria1.209 In contrast, time was only mentioned by a 
few non-participants in the multiple sclerosis (4)126 and UK out-patient (3)181 
trials. 
A distrust of modern medicine (52%) and the hospital (19%) was cited by non-
participants in a paediatric trial97 and this was also a barrier amongst ethnic 
minority and low income groups.141 Concerns about side effects97 and toxicity 
(4%)50 of the new drug were similarly mentioned. Cultural sensitivity was also a 
factor. Trial information may not be available in the patients' first language.141 
Qualitative telephone interviews revealed that some distrust was also apparent 
among African Americans, Hispanics, and Native Americans. Although specific 
cultural and religious beliefs, moral values and folk medicine were barriers, a 
'mistrust of being treated like a guinea pig' and a 'mistrust of white people' was 
mentioned by all groups as an important reason for their unwillingness 
(hypothetical) to participate.58 
The issue of mistrust, however, mainly arose amongst those who would refuse to 
participate in HIV vaccine trials, who often indicated that they also had an 
aversion to becoming a 'guinea pig' .145. Many were unsure if they could trust the 
government (58%),146 the institutions running the trials (15%),183 and were 
uncertain of the researchers' motivations (17% ).146 There were also concerns 
about confidentiality (23% ),146,147 social discriminationl84 and insurability 
(26%).146 Unsurprisingly, within the HIV pilot studies, many were concerned 
about safety issues184 such as HIV infection being caused by the vaccine (27-183 
37% ),145 testing HIV positive (24 %), the experimental nature of the vaccine and 
possible side effects (23 % ).183 
Concerns about safety were also prevalent among those asked hypothetically to 
participate in a range of trials. Apprehension about possible side effects was a 
common reason for refusal among UK out-patients. Many believed they were too 
ill (22%) and would not want to change their current treatment.181 The majority 
of parents (75%) would also refuse and this group's main concern was that the 
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treatment was unproven (49%).148 Corbett et al found a quarter of the UK public, 
medical secretaries and medical students believed that their treatment could be 
adversely affected by trial participation.18o 
The number of refusals varied according to the type of trial and the severity of 
treatment. Four parents would not enrol their critically ill child onto a trial 
because of the uncertainty and risk of adverse events, not wanting their child 
'used as a guinea pig' and being unable to make the decision while her child was 
critically ill.211 In contrast, all the parents consented to their child's participation 
in a similar, although non-life threatening tria1.211 
Ryan in a qualitative study identified three barriers to participation in HIV trials: 
confidentiality, being identified as part of a specific social group or sexual 
identity and to avoid 'watching sick people'.199 'Watching sick people' refers to 
the anxiety they experienced on seeing others at later disease stages attending the 
clinic which may have a negative psychological impact on patients. 
Confidentiality was also an important consideration with patients concerned that 
although staff were bound by rules of confidentiality, others attending the clinic 
were not and could disclose their HIV status outside the trial setting.199 Taking 
part in an HIV trial may also lead to their identification as HIV positive and 
having a specific social and sexual identity. Hence' going public' in this way may 
also be a barrier to participation.199 
Recall and understanding of trial participation 
Three types of studies have examined recall and understanding of trial 
information. The majority of studies have focussed on patient recall rather than 
comprehension, often failing to disclose their criteria (see below in table 5), or 
based on participants' own rating of their understanding of the trial (see below in 
table 6). Participation rates, both hypothetical and actual have also been used to 
indicate the effectiveness of the informed consent procedure (see below in table 
7). A smaller number of studies have defined the criteria used to evaluate 
participants' understanding (see below in table 8) or have asked participants to 
describe the trial in their own terms (see below in table 9). 
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Table 5: No criteria used to evaluate recall 
Author Population assessed Sample Purpose of the Outcome measurements Main results 
size study 
Blair et al201 UK participants in a (16) The Longitudinal semi- Only 2 
phase I safety trial of psychosocial structured interview participants 'well 
gene therapy for aspects of before and after informed' 
cystic fibrosis participation completion. Additional 
health measurement scales 
Jensen et a183 Danish women in (34) Evaluation of Qualitative in-depth 'good recall' 
breast cancer trials informed interviews 
consent 
Rodenhuis et Dutch Phase I cancer (10) Assess both Interviews 'adequately 
al195 trial participants recall and informed' 
understanding 
Tindall et aP98 Participants in an (113) Recall Two groups received the 44% (both groups) 
Australian HIV trial consent form plus did not 
summary. The second understand' all' 
group could also discuss the information 
participation 
A true! false self-
completion questionnaire 
Cox and UK participants in (7) The Longitudinal se'mi- 'poor' recall 
Avisl96 phase I and II psychosocial structured interviews 
oncology trials aspects of before and after 
participation completion 
A number of studies have failed to define their criteria for evaluating recall and 
understanding (see table 5 above). Such studies often conclude that participants 
'understand', even though some do not comprehend important aspects of trial 
participation, while other studies have failed to examine participants' 
understanding of key aspects of participation. For example, Rodenhuis et al 
concluded that 8 of the 10 participants within a Phase I oncology trial were 
'adequately informed', even though half (4) believed that participating in an 
experiment and 'being used like a guinea pig' was unacceptable. A further two 
believed they were receiving the standard treatment that had unpredictable 
results.195 Rodenhuis et al classified four participants as 'vulnerable'. For two, 
their lack of understanding was attributed to their 'limited intelligence' (p.460), 
the cognitive abilities of one was believed to have been impaired by cancer and a 
fourth was convinced the experimental treatment would cure her, despite 
attempts by the recruiting clinicians to modify these expectations.195 
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Four studies similarly failed to define their assessment of patients' knowledge of 
the trial or the therapy. The majority of participants in a breast cancer trial were 
believed to have' good' reca1l83 and in contrast, Cox and Avis found that overall, 
participants had 'poor' recall.196 Blair et al in a qualitative study, judged only two 
participants in the gene therapy trial to be 'well informed' .201 Tindall et al found 
no differences in recall between participants in an Australian HIV trial receiving 
written consent and those who received additional verbal information.198 
However, many (44%) of these HIV drug trial participants stated that they did 
not understand 'all' of the information.198 
Recall was often used as a measure of effectiveness (see table 6 below). Such 
studies frequently tested participants' recall of the trial using structured 
questionnaires, often incorporating scales,212 multiple choice1oo, 212 and true/ false 
questions213. 
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Table 6: Recall as a measure of effectiveness 
Author Population Sample Purpose of Outcome Main results 
assessed size the study measurements 
Daugherty et all91 US oncology (27) Recall Structured interview Believed they understood-
patients prior to schedules with 93% 
participation in a additional open-ended 
range of phase I questions Only 33 % knew the aim of 
cancer trials the trial 
Miller et al212 Patients after (168) Recall Structured survey 98 % could recall the 
participation in a 
Multiple choice, likert 
informed consent procedure 
US drug trial 
scales and believed that they 
understood the information 
provided. 
The DCCT US diabetes trial Recall 14 item multiple- Mean score of 97% 
Research GrouplOO choice questionnaire 
Harrison et al2l3 US intravenous (39) Recall A 17 item true/ false Median score of 16 out of 17 
drug users asked questionnaire 
to enrol onto a 
Phase II HIV 
vaccine trial 
Olver etaFO Participants in a (100) Recall Structured interviews 60% believed they 
range of understood the consent form 
Australian Phase I, 52% recall their treatment 
II and III oncology 4 % recalled side effects 
trials 
Oddens et al214 Participants (81) Recall Telephone interviews Better recall of diagnosis 
within a Nordic than trial design 
(unspecified) trial 
Immediately after informed consent had been obtained, participants in a US 
diabetes trial achieved a mean score of 97% for a multiple-choice questionnaire 
based on the informed consent procedure. A year later this was still high 
(91 % ).100 Knowledge was correspondingly high among HIV vaccine trial 
volunteers. Two key questions: the belief that the vaccine would infect them with 
HIV or that the vaccine would protect them from HIV infection, were used to 
exclude potential participants. Harrison et al report that only three patients were 
excluded from the trial on this basis.213 
However, recall does not necessarily reflect understanding. Almost all (98%) of 
participants in a US analgesics trial could recall the informed consent procedure 
and believed that they understood the information provided. However, over half 
(52%) could not recall possible side effects and over a quarter (29%) were unable 
to recollect the experimental treatments.212 The majority (93%) within a range of 
US Phase I cancer trials also believed that they understood all (33 %) or most 
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(60%) of what they had been told about the trial. However, only 33% knew the 
aim of the trial was to determine the maximum drug dose or the toxicity. Almost 
half (42%) believed that the trial was to ascertain the response of their tumour to 
treatment and 15% could not explain its purpose.191 Olver et al similarly found 
that although 60% believed they understood the consent form, only half (52%) of 
these oncology trial participants could remember the name of the drug they 
received, and only 4 % could recall potential side effects.70 
Miller et al conclude that although participants were able to recall information 
about the wider issues such as the purpose of the trial, specific information about 
the drugs and possible side-effects was poorer.212 In contrast, Oddens et al found 
that participants had better recall of the disease and therapy than the design of 
the tria1.214 
Many studies have evaluated the effectiveness of different methods of providing 
informed consent by examining participation rates. These evaluation studies 
examine both hypothetical84, 215, 216 and actual111, 174, 189 trial participation (see 
table 7 below). 
Table 7: Studies evaluating the effectiveness of informed consent by the 
recruitment rates achieved 
Author Population Sample size Purpose of the study Outcome Main results 
assessed measureme 
nts 
Levene et A comparison (52) The first trial sought Participation Early entry-71 % 
al174 of two UK parental consent before or rate Additional time-43% 
trials of soon after delivery, the participation rate 
premature second prOVided parents 
infants with more time and an 
additional discussion 
McLean111 Participants Informed Participants informed or Participation All agreed to participate 
within a (104) not of random allocation rate 
psychiatric to their treatment 
not informed trial. (22) 
Dal-Re215 Spanish Minimal (160) Compared two Participation Willingness to 
university hypothetical consent rate participate Minimal-4 % 
students detailed forms containing different Detailed- 11 % 
information levels of information (146) 
Ubel et a1216 US (165) Two hypothetical trials Participation Initial willingness-75% 
prospective with different preliminary rate Information indicating 
jurors results. differences in treatment 
outcome- 49% 
DeLuca et (US) (172) To identify Structured No differences in 
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a1189 participants sociodemographic interviews consent between those 
within 12 predictors of informed given verbal and written 
cardiovascular consent consent and those who 
trials only had verbal 
information 
Siminoff et US oncology 47 eligible Half provided with Interviews Those provided with 
al76 patients patients information on the risks more information were 
and benefits. Half received more likely to agree to 
less information participate. 
Corbett et UK lay and Public (50) Comparison of different Written information was 
alISO medical Medical- way of providing preferred by 91 % 
population secretaries (25) informed consent 
students (25) 
Kempet UK Lay (1022) Group A- random Structured No apparent differences 
al178 population allocation Group B- survey 
additional information 
Appelbaum Patients (16) Informed consent Interviews 8 understood the 
et al42 within four US after consent concept of 
trials of randomisation 
psychiatry 
White et alM US study of (75) A long consent form Preferences Preference for the 
women with giving detailed detailed consent form 
breast cancer information. 
A similar 'medium' form 
omitted randomisation 
Fewer (43 %) parents agreed to their child's participation when they were given 
additional time to consider their decision. In contrast, the majority (71 %) of 
parents within the early entry trial agreed to their child's participation.174 Levene 
et al conclude that informed consent is unlikely to be 'educated consent' or 
'understanding consent' where early entry is required.174 
Information on the effectiveness of the treatments available within a trial may 
effect recruitment. Initially, the majority (75%) of US jurors were hypothetically 
willing to participate. However, when preliminary data indicated that one 
treatment achieved better results, this fell to 49% .216 Similarly, only 4 % of the 
Spanish university students who received greater information about possible 
side effects compared to those presented with less information (11 % ) were 
willing hypothetically to participate. This suggested that providing more 
information about possible side effects can lead to lower levels of hypothetical 
recruitment.215 Many participants preferred to receive detailed information.84,180 
In contrast, McLean found that all agreed to participate in an actual psychiatric 
trial, despite receiving different levels of information about random allocation.ll1 
No differences in willingness to participate were found between those given 
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verbal and written information and those who only received verbal information 
to participate in one of 12 cardiovascular trials.189 
However, Siminoff et al concluded that providing detailed information 
encouraged agreement with the clinician, rather than improving patient 
comprehension.76 Half of the patients (51.6%) who received information about 
the benefits and risks of therapy agreed with the clinician's recommendation, 
compared with only 34.8 % of those who received less information. 
Three studies have attempted to ascertain ways to improve participants' 
understanding of the concept of randomisation.42, 178, 180 It has been suggested 
that a focus on improving patients' understanding of the scientific method may 
reduce confusion and the stress experienced by those involved.42, 173 
Appelbaum et al provided trial participants with a supplementary discussion 
with a neutral person trained to explain trial methodology. On follow-up, half (8) 
understood the concept of randomisation, suggesting that trial participants can 
be helped to understand the ways in which research differs from standard 
treatment.42 Kemp et al similarly attempted to explain the concept of 
randomisation to a large scale stratified sample of UK adults. They were 
informed that" doctors did not influence the results by choosing, the patients 
would be randomly allocated to Group A and Group B and the randomisation 
would be a matter of chance 'rather like tossing a coin"'(p.157). However they 
suggest that the inconsistent results (although no details are given) indicate that 
few understood this concept.178 
The preferred explanation of randomisation among members of the UK public 
(50), medical secretaries (25) and medical students (25) was one that made no 
explicit attempt to explain the role of chance. The descriptions of treatment 
allocation that mentioned 'the tossing of a coin' and 'names pulled from a hat' 
were the least popular, while the public most disliked the explicit statement of 
the role of the clinician.18o 
Hence, explicit details of the process of randomisation may be problematic for 
many people and Corbett et a}180 conclude that trialists must balance the need to 
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provide independent and open information against the subsequent benefit to the 
individual. Appelbaum et al propose a simpler consent process which does not 
focus on the details of the trial routinely included in consent forms such as 
information on minor risks and procedures.42 
A smaller number of studies have defined the criteria used to evaluate 
participants' understanding (see below in table 8) or have asked participants to 
describe the trial in their own terms (see below in table 9). 
Only six studies have defined their criteria for evaluating participants' 
understanding of the trial (see table 8 below). These have predominantly used 
structured questionnaires to assess recall of the information presented to 
participants as part of the informed consent procedure68, 98, 103, 217 with a smaller 
number using international guidelines.10l, 105 These studies appear to be 
attempting to examine understanding against some objective criteria, however, 
such criteria are not defined by these studies and are predominantly used to 
inform the questionnaire design. These studies still fail to unpack the meaning of 
trial concepts, although a number do demonstrate that patient recall does not 
reflect understanding.10l, 103, lOS, 217 
Table 8: Defined their criteria for evaluating participants' understanding of the 
trial 
Author Population assessed Sample Purpose of the Outcome Main results 
size study measurements 
Postlethwaite After recruitment Parents The recruiting Semi- 80% had a 'good' or Ivery 
et al217 onto a UK growth (30) clinicians checklist structured good' recall 
hormone trial. Patient of information interviews (14) 
Searigh t and Participants in two (14) Based on informed Declaration of Aware they were I guinea 
Miller68 US herpes trials consent procedure Helsinki pigs I 
White, well educated Understood they had been 
and predominantly randomly asSigned 
women. 
Gallet et al103 Participants of a (77) "understanding of A short item On average recalled 60% 
French myocardial the most self- of the informed consent 
infarction trial important details completion form 
of the consent questionnaire 
form" (p.44) 
Howard et US Beta-blocker Participan The informed Interviews Knew they were taking 
al98 Heart Attack Trial ts (53) consent procedure part in research-61 % 
(BHAT) Spouses 
That they could receive (42) 
the experimental 
trea tment or a ..£lacebo-
90 
55% 
Lynoe et allos Women participating (43) Declaration of Postal 81 % recall of consent in a Swedish Helsinki questionnaire procedure gynaecological trial 
Susmanet Participants in a (44) 7-20 US federal Informed 64 % believed they allol cancer (20) or obesity yrs old guidelines consent understood (24) trial (US) Only 15% knew of trial 
procedures/ risks 
The highest level of recall was found amongst a White, well educated and 
predominantly female population taking part in a herpes trial. All of these 
participants (14) were aware that they were taking part in research, had been 
randomly assigned to their treatment, that allocation was blinded, that there 
were risks associated with participation and could also describe why a placebo 
was being used.68 Gallet et al concluded that on average, myocardial infarction 
patients recalled a large proportion (60%) of the information within the trial 
consent form.l03 However, only 40-50% could recall the aims of the trial, knew 
that some patients received a placebo and others received an active treatment, 
the concept of double-blinding and the possible side effects and 10-25% were 
unaware that they could withdraw from a drug trial.103 
Patient recall varied among women (43) who had participated in a Swedish 
gynaecological trial. Although the majority (81 %) could recall giving their 
consent, 16% had no recollection of this and one participant believed she had not 
given her consent. Similarly,16% did not know what participation involved and 
many (39%) were unaware that they could withdraw from the trial.10S 
Although 64 % of young people participating in an oncology or obesity trial 
believed they 'knew the benefits to themselves of participation', less than half 
understood the purpose of the research, how it benefited others, alternative 
treatment options or their ability to withdraw from the trial, and less than 15% 
knew the procedures or risks involved.101 Similarly, although Postlethwaite et al 
judged the majority (80%) to have a 'good' or 'very good' understanding of the 
trial, 36 % of these young people were unable to recall or understand any details 
of the trial. Poor understanding among six young people was associated with 
unrealistic treatment expectations and having no knowledge of possible side 
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effects.217 Sussman et al speculate that patients deny the risks involved because 
this allows them to justify the unpleasant aspects of participation.101 
Only half (27) of the cardiac trial participants were aware of the involvement of 
chance in their treatment allocation. Most of this group did not know how they 
had been allocated (25) and two believed that their treatment allocation was 
based on clinical information. Overall, only a third (18) were aware that they had 
been randomly allocated and that this involved a 50/50 distribution between the 
treatments.98 However, five participants and their families believed that they 
were receiving a I special' treatment and four believed the placebo was the 
standard treatment. 98 
However, there are both conceptual and methodological problems with such 
studies examining informed consent. One of the central problems is the difficulty 
of determining when informed consent has actually been achieved.85 The 
majority of these studies are not from the patients' perspective and are based on 
recall rather than understanding. Often these studies fail to examine or define 
how these participants, clinicians and researchers understand these trial 
concepts. 
There is a need for studies that do more than point out the flaws in current 
practice. The provision of information occurs within a social context, with trust 
and the quality of the doctor/patient relationship important.85 Attitudinal and 
psychological barriers such as trust and the impulse to disregard potential risk, 
mean that even strict informed consent procedures do not guarantee 
understanding among these groupS.97 
Only three studies asked participants to describe the trial in their own terms 
using qualitative research methods (see table 9 below).42, 173,200 
Table 9:Participants asked to describe the trial in their OIvn terms 
Author Population assessed Sample Purpose of the Outcome Main results 
size study measuremen 
ts 
Snowdon et UK study of parents 37 Understandin In-depth Only half of the interviews (12) did 
al173 who had agreed to the g of interviews one of the parents believe their 
participation of their (21 randomisa tion allocation was based on chance. 
newborn child with couples) Many believed they had been 
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acute respiratory 
allocated on the basis of their failure in a clinical individual therapeutic needs. 
trial Confusion and a ' distortion of the 
aims of randomisation' 
Appelbaum Patients within four (88) Informed Observed Understanding of randomisation-25% 
et al42 US trials of treatment consent the A third believed they had been 
for psychiatric illness informed allocated on the basis of their 
consent, individual therapeutic needs. 
interviews 
after consent 
Feathersone Participants in the (20) Understandin In-depth, The involvement of chance-14 
and ClasP prostate trial gof semi-
Donovan2OO randomisation structured Lay interpretations of the concept 
interviews 
Around half of the psychiatric trial participants did not understand central 
aspects of the trial design. For example, many did not realise that the use of a 
placebo meant that some patients would not receive active treatment (42 %), or 
that the purpose of the double-blind procedure was to ensure that the clinician 
would not know their treatment allocation (34 % ).42 Similarly, 50% of participants 
in two trials where treatment dosage was restricted, expected their treatment to 
be adjusted to meet their individual needs and few (9%) were aware that the trial 
would limit their treatment in some way.42 
The terminology used by trialists was problematic for some. The word 'trial' had 
different meanings for parents. Many believed that the 'new' treatment was 
available for a 'trial period' or on a 'trial basis', rather than a trial to evaluate the 
treatment's effectiveness.173 An article based on preliminary findings from this 
thesis showed that trial terms used by trialists had other meanings outside the 
confines of randomised controlled trial. Terms such as 'trial' and I random', for 
example, were understood differently by participants. In lay language, the word 
trial meant something that is I tried out', while' at random' related to things being 
done without purpose.200 Roberson in a study of hypothetical trial participation 
(see table 1) also found that respondents from minority groups in the US were 
familiar with the term 'experimental study' and could describe what this meant. 
For example' a study to help people' and I an experiment where people are used 
as guinea pigs'. However, two thirds had not heard of the term I clinical trial' .58 
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Randomisation 
Only a small number of the studies looking at either actual or hypothetical 
participation have examined randomisation. However, these have 
predominantly assessed recall using structured instruments. Randomisation was 
cited as a reason for refusal within only a small number of the hypothetical trials. 
A general dislike of randomisation (they were given a detailed description), was 
the main reason colorectal cancer patients refused (63%)186 and over half (57%) of 
a lay UK population sample would want to choose their own treatment, an 
inferred rejection of the principal of randomisation.178 Gallet et al found that 40-
50% of participants in a heart disease trial recalled randomisation103 and this was 
the impetus for a small number of refusals within a paediatric (4 % )148 and a 
multiple sclerosis (6%)126 trial. However, no details were given as to how these 
studies defined this question, although they appeared to be assessing recall using 
a series of closed questions. 
Participants within studies of informed consent often had difficulty 
distinguishing research from receiving treatment within a standard therapeutic 
setting. This implies a failure to recognise the involvement of chance in their 
treatment allocation. Searight and Miller68 found that almost all believed that 
they received better care within the herpes trial, although only two had a clear 
understanding of the difference between personal care and research procedures. 
Howard et al98 also found that participants and their families believed that they 
were receiving a special treatment, with many believing that the trial was a 
therapeutic rather than experimental program. Similarly, even among 'well 
informed' patients within a Phase I cancer trial, Rodenhuis et al identified a clash 
between recall and interpretation of the treatment objectives.195 However, only 
Searight and Miller68 examined randomisation. They found that the majority of a 
young, well educated and predominantly female sample participating in a 
herpes trial were found to have a I good' understanding of randomisation, with 
their descriptions often taking a I concrete' form, for example I they roll the dice' 
(pp.18-19). However, no further details were given.68 Interestingly, recruiting 
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clinicians may also be unaware of this distinction between RCTs and 
personalised care. Flanery et al found that half of a sample of medical students 
believed they would benefit personally from trial participation.99 
Only Snowdon et al,173 Appelbaum et a142, and Feathersone and Donovan2oo have 
used in-depth semi-structured interviews to examine participants' 
understanding of randomisation. Snowdon et al in a UK study carried out 
qualitative interviews with thirty seven parents (21 couples) who agreed to the 
participation of their newborn child with acute respiratory failure in a clinical 
trial.173 Appelbaum et al observed the informed consent process, conducting 
interviews with patients (88) immediately after this had been obtained within 
four US trials of treatment for psychiatric illness.42 
Both of these studies examine vulnerable populations asked to participate in 
trials and hence it was important to address their understanding of treatment 
allocation and how this differs from personalised care. Only Feathersone and 
Donovan reporting preliminary findings from this research have elicited the 
perspectives of participants taking part in a pragmatic trial for a common 
condition.2°O These findings will be considered in more detail in chapter 5. 
Both Snowdon et aP73 and Appelbaum et al42 found that many trial participants 
did not believe chance was involved in their treatment allocation. A large 
proportion of the psychiatric patients (69%) had no understanding of the basis 
for their treatment allocation and only a quarter (22) were considered to have a 
complete understanding of randomisation. Appelbaum et al suggest that patients 
misinterpret the aims of a trial because they are unable to differentiate between 
research and standard care. However, they give no indication as to how they 
defined such understanding, only that detailed enquiry was necessary to reveal 
such I distortions' (p.22) within their accounts.42 
Snowdon et al examined randomisation in terms of whether parents believed this 
was actually carried out, their understanding of why it was used and through an 
examination of parental reactions to their child's allocation. Parents were divided 
into two main categories, those who did or did not believe that their treatment 
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allocation was based on chance. Many had no understanding of the basis for 
their allocation to a treatment. In only half of the interviews (12) did one of the 
parents believe their allocation was based on chance. This group often used 
terms such as 'lottery', 'tossing a coin', 'drawing a name from a hat' and 'potluck' 
to describe this. However, Snowdon et al found that the recognition of the 
involvement of chance did not mean that these parents held a coherent model of 
the trial or randomisation. They concluded that only two parents totally accepted 
the use of randomisation.173 
The majority of the parents rationalised randomisation and the implied 
uncertainty in a number of ways. Randomisation was predominantly seen as a 
'gateway to the desired treatment' (p.1343), with the baby often believed to be 
the focus of this decision. For example, three parents used the information on the 
limited availability of the 'new' treatment to conclude that randomisation was 
used to resolve the ethical problem of deciding between two treatments when a 
child's life is at stake. Many parents whose babies received the standard 
treatment focused on the idea that risks were possibly averted by the use of 
randomisation. Some believed that their treatment allocation had been affected 
'by beneficial or almost supernatural forces' (p.1347) or predestination.173 
Snowdon et al and Appelbaum et al conclude that trial participants may 
systematically misinterpret the underlying scientific methodology and hence 
participate in the trial because of their belief in personalised care.42, 173 A third of 
the psychiatric patients42 and many parents173 believed they had been allocated 
on the basis of their individual therapeutic needs. Appelbaum et al referred to 
this denial of random allocation as the' therapeutic misconception' (p.20) and 
they suggest that patients filled such 'vacuums of knowledge' by constructing 
'elaborate but entirely fictional' (p.21) accounts of their treatment assignment.42 
Snowdon et al and Appelbaum et al both suggest that although participants' 
descriptions of the trial seemed correct, further scrutiny often revealed 
'distortions' of the aims of randomisation. Snowdon et al additionally concluded 
that most parents were 'confused' (p.1348) about randomisation and the 
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methodology of the trial.173 A recent systematic review of informed consent 
similarly suggested that "patients do not always grasp what information is 
disclosed to them" (p.44), resulting in "defects in reasoning" (p.44).67 This was 
not the finding of the preliminary analysis of data from this thesis,2oo and this 
will be persued further in chapter 5. 
Conclusion 
The majority of studies examining trial participation are problematic in that they 
have tended to reflect the perspective of trialists with the aim often to improve 
accrual and by their focus on informed consent as opposed to patients' views. 
The reliance of some studies on hypothetical vignettes is also problematic and 
possibly misleading, because the perspectives of considering issues 
hypothetically may be different from those actually undergoing treatment or 
participating in research.8s 
The majority of studies have employed structured, closed questions to examine 
the motivation for, and satisfaction with, trial participation.2l8 Edwards et al in a 
recent (1998) systematic review also point out that the methods employed in 
accessing participants' motivation vary greatly between studies. Some only 
provide closed, forced choice questions, few allow open responses, whilst others 
do not outline their rationale and hence these studies may not be comparable.72 
The main criticism of such studies is that they" only give a weak clue as to what 
patients had understood of the questions and hence what they meant by their 
responses" (p.1210).72 Snowdon et al emphasise the need to look beyond 
participants' recall of information and terminology to their understanding of the 
underlying scientific method.173 For example, there is little detailed information 
on patients' understanding of key concepts such as randomisation.2l8 
Comparative studies of those who take part, drop out or refuse to participate in 
trials have been suggested but have not yet been undertaken.180,187,196 Turner and 
Sheon acknowledge that there may be resistance to the use of these additional 
methodologies.151 However, Snowdon et al,173 Appelbaum et al,-12 and 
Featherstone and Donovan200 have shown the value of using these methods to 
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investigate the randomised controlled trial from the participants' perspective. It 
is to the methods of this latter study that I now turn. 
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Methodology, Design and Implementation 
Introduction 
In the sections that follow, the ReT within which this study is set will be 
described, followed by a detailed explanation of the qualitative research methods 
used. Included within this are details of how the qualitative study was 
undertaken, including methods of sampling for both participants and those who 
decided not to take part, the data collection and analysis. 
Aims and objectives of the study 
The participants' perspective of clinical trials has received little attention. The 
existing research record has tended to focus on hypothetical questions, or 
participation within trials of rare conditions or (in Snowdon et aI's case) parents 
of critically ill babies.173 The study reported here uses qualitative research 
methods to elicit the perspectives of 'ordinary' middle-aged and elderly men 
who require elective treatment for a common condition, and have either agreed 
or refused to participate in a pragmatic randomised controlled trial. The 
objectives were to examine these men's understanding of randomisation, their 
recall and understanding of information about the trial, plus an exploration of 
their expectations and preferences. 
The research strategy was exploratory in nature and concerned with re-focusing 
onto the patients' experience, and so in-depth interviews were most 
appropriate.219 Rather than using survey methods or structured interviews which 
can provide only broad classifications of people's behaviour, this approach 
attempts to look beneath the surface of a subject in order to examine in detail 
what people say and explore these trial participants' own interpretation of their 
experience and their search for meaning. 
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The context: the ClasP RCT 
This study involved patients eligible for recruitment to the CLasP study. CLasP, 
funded by two regional NHS R&D Directorates, comprises three linked 
pragmatic RCTs to evaluate the effectiveness and cost effectiveness of a new 
technology (laser therapy - ELAP) compared with standard surgery 
(transurethral resection of the prostate - TURP) for men with evidence of acute or 
chronic retention of urine who require active intervention, and laser, TURP and 
conservative management (monitoring without active intervention) for men with 
lower urinary tract symptoms related to benign prostatic disease.22o 
Lower urinary tract symptoms are commonly found in middle aged and older 
men and usually occur in association with benign prostatic enlargement because 
of hyperplasia of the prostate gland and! or benign prostatic obstruction. Patients 
were included according to the severity of their lower urinary tract symptoms 
and low flow rates. Urodynamic tests were also used to group these men 
according to whether they were obstructed, equivocal or unobstructed. Patients 
were excluded if they were diagnosed with prostate cancer, had previous 
prostatic surgery, a life-expectancy of less than six months, or symptoms that 
meant TURP or laser therapy were unsuitable.221 
Patients randomised to laser therapy or TURP were listed for surgery within 
three months of randomisation. Patients randomised to conservative 
management were given general advice and bladder training as deemed 
clinically appropriate. All patients were followed up 7.5 months after 
randomisation. 
The allocation of treatment in the CLasP study followed a protocol which 
consisted of a process of written informed consent, completion of questionnaires 
and clinical tests with eligible patients informed of their treatment allocation by 
clinical researchers who opened consecutive opaque envelopes. Before giving 
consent, patients were given an information sheet which included details about 
the treatments and described the study design in terms of it being called a 
randomised controlled trial, that it involved comparing treatments, that one of 
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the treatments was new (laser therapy), that there was uncertainty about which 
treatment was best, that allocation would be by chance and by means of the 
clinician opening a sealed envelope (see appendix 1). The clinicians recruiting 
patients were asked to explain the study in similar terms during recruitment. 
Figure 1 below provides a trial profile summarising participant flow and the 
numbers assigned to each of the interventions. Within the group of symptomatic 
patients (340): 117 (34%) were randomised to laser therapy, 117 (34%) to TURP, 
and 106 (31 %) to conservative management; 142 were recruited from Centre 1, 
178 from Centre 2, and 20 from Centre 3. Acute patients (148) were randomised 
to TURP (74) and laser (74) and chronic patients (82) were randomised to TURP 
(44) and laser (38). I had access to basic information about all the men within this 
study and the non-participants via the clinical staff within the two recruitment 
centres. Before describing the characteristics of the sample and this study, the 
background and details of the research methods employed will be described. 
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Figure 1: CLasP study and symptomatic trial profile 
Acute patients 
N=148 
TURP n=74 Laser n=74 CMn=106 
Considered for recruitment 
n= 1073 
[not eligible for trials n=318] 












TURP=44 Laser n= 38 
Research methods 
There is no one doctrine underlying the term I qualitative research', rather there 
are a number of ideologies and methods.222 As Denzin and Lincoln point out 
qualitative research does not belong to one discipline, but is employed by many 
differing theoretical approaches, from the constructivist perspective through to 
cultural studies and Marxist and feminist perspectives. It is applied within many 
social science disciplines, such as anthropology, cultural studies and within 
sociology.223 
Qualitative research is a collection of interpretive methods, within which no 
single methodology is held as superior. The overall aim is to make sense of 
phenomena from the perspective of the individuals within the social world, 
emphasising the importance of the socially constructed nature of reality by 
examining the social world from an interpretivist, naturalistic perspective using a 
variety of empirical approaches such as observation, interviews, and case 
studies.223 Hence the method of choice within this study was in-depth interviews 
within the setting of one randomised controlled trial because it allowed an 
exploration of the trial participants' own interpretation of their experience and 
their search for meaning. 
Interpretivist perspectives 
The foundation of the interpretivist perspective is the 18th Century German 
intellectual tradition of hermenuetics which focused on 1/ trying to understand, 
take meaning from, or make intelligible that which is not yet understood" 
(p.110)224 and the work of Hussurl who argued that the relationship between 
perception and objects was not passive, but that people actively developed the 
objects of their experience. 
The interpretivist school developed particularly in reaction to the positivist 
perspective of the natural sciences and its influence within the social sciences 
which attempted to reduce social life to universal laws and the interaction of a 
number of variables.225 In contrast, the interpretivists emphasised verstehen 
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(understanding), and the need for an interperative understanding of human 
ti· 226 Th· . b 1· h ac on. IS perspectIve e leves t at for social analysis to be valid, this must 
relate to the meaning people give to their actions and environment which lie at 
the core of social interaction. 'Verstehen' provides a theory for studying social 
phenomena without distorting the social world of the subjects. 
The interpretive approach differs from the scientific model of rational action, by 
focusing on how individuals make sense of the world and investigating the 
meanings of social phenomena.225 Thus from the perspective of the interpretivist 
school, people interpret stimuli, with such interpretation continuously being 
revised as events take place with these in turn shaping their actions. Thus it can 
be seen that the same stimuli can mean differing things to different people and to 
the same individual at different points in time.227 There are several sub-schools 
with particular approaches within the interpretivist perspective that have been 
influential within this study: phenomenology and symbolic interactionism. 
Phenomenology 
Weber, drawing upon the work of Hussurl, maintained that the individual was 
of more importance than 'the system'.226 This approach sees the individual as the 
main unit for investigation and capable of social action. Weber defined social 
action as taking place when an individual gives behaviour a meaning which is 
related to the behaviour of others.226 A key aspect of this approach is 'meaning' 
and the relationship to the type of information necessary to understand and 
explain social phenomena.225 Weber believed the aim of interpretive sociology 
was to "interpret the actions of individuals in the social world and the ways in 
which individuals give meaning to social phenomena" (p.6 in Schutz).228 
Weber introduced two principles of social science methodology: value neutrality 
and the use of ideal types. Value neutrality referred to the principle that social 
scientists must not pass off value judgements as scientific truths, because to do so 
would be an abuse of their scientific status. He also suggested the use of the ideal 
type as a method of accessing, in a more objective way, subjective meaning. Such 
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'models' can be developed by investigators to compare and evaluate empirical 
data.225 
Schutz, in 'The Phenomenology of the social world', developed Weber's work 
and believed the role of sociology was to examine the" phenomenon of meaning 
in everyday social life" (p.44). Schutz argued that Weber failed to recognise the 
complexities within this or make a distinction between the way in which an 
interpreter modifies meaning. He believed the social world was not 
homogeneous, but a "complex system of perspectives" (p.8) with the' act of 
attention' leading to various modifications which constitute the meaning of 
experiences. This creation and structure of life experiences must, he believed, be 
examined because this is what gives meaning to actions.228 "Meaning is a certain 
way of directing one's gaze at an item of one's own experience" (p.42), thus the 
social world is seen as a complex system of perceptions, some shared, some 
unique to individuals.228 Schutz also introduced the idea that experience can only 
be accessed reflectively, not when it actually occurs. The meanings of our actions 
are reconstructed retrospectively on the basis of memory, they are not given in 
an immediate way.228 
This has important implications for interpretation, because it suggests that social 
scientists cannot access directly the experiences of others, but only through the 
interpretation of their reasons and motives. Schutz believed that the role of 
interpretive sociology was to "describe the processes of meaning-establishment 
and meaning-interpretation as these are carried out by individuals living in the 
social world" (p.248) in order to understand the deeper layers of understanding 
beyond our ordinary perception. This acknowledges the existence of multiple 
realities; there is no one 'truth' but lots of different and some shared truths.228 
Within the present study, this theoretical approach advocates an exploration of 
trial participants' own interpretation of their experience, their search for meaning 
and the importance of context in understanding their perspective. For example 
this allowed an examination of participants' understanding of randomisation 
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that look beyond the standard definition to explore their perspective and their 
process of rationalisation, after they have had time to reflect on the actual events. 
Symbolic Interactionism 
Symbolic interactionism is based on the work of G.H. Mead (1934), although the 
term was coined by Blumer229 and is part of the interpretivist perspective. 
Blumer used the term symbolic interactionism to refer to the approach developed 
by the Chicago school of sociologists in the 20' sand 3~' s. Symbolic interactionism 
stresses the importance of the human capacity to create the social world by 
attaching meaning to things, with such meaning arising from the process of 
human interaction. These meanings are also established and modified within the 
process of interpretation.23o 
The aim of this approach is to take into account how people being studied 
interpret the situation they are faced with, because this will influence their 
action. Blumer argued that this constructive element of human behaviour must 
be taken into account.231 These meanings are the result of social interaction with 
others, the emphasis here being that human behaviour is constructed and can 
change at any point through an interperative mechanism which people use to 
make sense of the things they encounter. Communication is symbolic because 
language and other symbols are used by social actors to communicate meaning, 
with the process of communication also producing such symbols.230 
This perspective places importance on the social scientist actively entering the 
social world of those being studied to "see the situation as it is seen by the actor, 
observing what the actor takes into account, observing how he (sic) interprets 
what is taken into account" (p.56).229 
The main criticism of this approach is that the focus on the processes of 
interaction is based on a concept of social action that emphasises the symbolic 
aspects of social action. It therefore has limited usefulness in relation to 
'phenomena of interpersonal immediacy' (p.84) and also ignores issues of 
power.232 A further critique is that this descriptive approach, which privileges the 
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views of social actors, cannot be used to critically appraise any subsequent 
evaluation of the social reality they are attempting to depict. 230 
Interpretive interactionism developed from Denzin's criticism of Blumer. He 
believed that symbolic interactionism must become more interpretive, suggesting 
that it should take on board some of the developments of post-structural 
philosophy, such as cultural and feminist approaches in order to facilitate a 
closer connection between the study of meaning and interpretation. Denzin 
suggests that such an approach would allow the critical examination of "how 
interacting individuals connect their lived experiences to the cultural 
representations of those experiences" (p.74).233 
Grounded Theory 
These theoretical schools place little emphasis on empirical methods. With the 
introduction in 1967 of 'The Discovery of Grounded Theory',234 Glaser and 
Strauss set out to close lithe embarrassing gap between theory and empirical 
research" (p.vii) while also legitimating qualitative research, which at that time 
was not thought capable of providing satisfactory verification.234 
Grounded theory is derived from phenomenology and is situated within the 
modernist, postpositivist perspective235 and is currently the interpretive strategy 
most widely used by social scientists. This approach is a methodology, "a way of 
thinking about and conceptualising data" (p.275) and provides a specific method 
for theory development and verification.235 
Glaser and Strauss stated that theory should be generated and developed, 
'grounded' (p.3) through the close connection between data collection and 
analysis.234 This approach involves the interpretation and understanding of the 
actions of those being studied from the perspectives of the participants 
themselves235 and provides a systematic set of procedures in order to develop 
inductively derived theory about phenomena.236 The main elements of this 
method are constant comparison, analysis of deviant cases and theoretical 
sampling. 
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This approach is often called the' constant comparative' method, with 
verification of the main themes emerging from the research carried out through 
the close connection of data collection and analysis throughout the research 
process.235 Grounded theory is inductive and is" discovered, developed and 
provisionally verified through systematic data collection and analysis of data 
pertaining to that phenomenon" (p.23).236 
Theoretical sampling is the process of using the data collection as part of the 
generation and development of theory. The initial data collection aims to obtain a 
general examination of the subject area, with the objective of further data 
collection to develop the concepts within the analysis, for example, examining 
variation will add to the conceptual richness of the analysis.235 Theoretical 
coding, the systematic interrogation of data to identify emerging categories or to 
refine existing codes, must also be carried out in conjunction with theoretical 
sampling and constant comparison. Such an approach allows the researcher to 
"conceptualize how the substantive codes may relate to each other as hypotheses 
to be integrated into a theory" (p.72)237 
An important part of this approach it the 'fitness' of a theory. Deviant cases are 
used to test and refine theory, "a grounded theory that is faithful to the everyday 
realities of a substantive area is one that has been carefully induced from diverse 
data ..... Only in this way will the theory be closely related to the daily realities 
(what is going on) of substantive areas, and so be highly applicable to dealing 
with them" (pp.238-239).234 
The main difference between this approach and others is the focus on the 
development of theory, with most studies using this approach to develop 
substantive rather than grand theory.235 Theory "consists of plausible 
relationships proposed among concepts and sets of concepts" (p.278). They are not 
"the formulation of some discovered aspect of a preexisting reality 'out there'" 
(p.279), rather they are 'fluid', taking into account process and change through 
the interrogation of theories to determine whether new situations fit or not.235 In 
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this thesis, I employed grounded theory, and the specific methods of this 
research project are detailed below. 
Design and methods 
The aim of the research strategy was to elicit participants' experiences, therefore 
in-depth interviews using a semi-structured checklist of topics, were 
employed.219, 227, 238, 239 This approach attempts to look beneath the surface of a 
subject in order to examine in detail what people say and explore trial 
participants' own interpretation of their experience and their search for meaning. 
The dominant quantitative methodologies employed within previous studies had 
led to a proliferation of the use of structured surveys and interview schedules to 
examine trial participation. Rather than using survey methods or structured 
interviews which rely upon assumptions about people's behaviour, this has the 
additional potential of revealing new areas that may not initially be 
anticipated.240 One possible source of validity error is asking the wrong 
question,241 and because a qualitative approach allows the continual testing of 
emergent theories, this can be avoided. This was important within the context of 
this study, for example, by allowing me to uncover participants' actual 
understanding of trial terminology rather than assume such comprehension. 
However, the widespread use of the open-ended interview within qualitative 
research has been called into question.242 As Dingwall points out, lithe essential 
feature of interviews is that people are put on notice to talk about something" 
(p.58).242 All experience, including private as well as public accounts are 
expressed through language. This in turn is evaluated for its appropriateness 
within a range of forms of the I self' that are thought to be permitted within that 
setting.242 Interview data are not just a series of objective facts, but active social 
interactions.243 Thus interview data are social constructs developed through the 
participants' self-presentation and the cues the interviewer has transferred 
within this interaction. 242 
However, as Silverman244 points out, although non-verbal elements of social 
interaction are recorded, observational data also includes a large proportion of 
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conversational data. Such an approach also assumes participants respond to the 
setting in a similar way and does not deal with the distinction between what 
people say and what they actually do. Thus although such an approach may 
reveal how people react to a specific environment, it fails to deal with how they 
make sense of that verbally. 
The possibility of observing recruitment consultations was considered. However, 
at the inception of this project there was an absence of studies within the 
literature that provided a detailed examination of the perspectives of participants 
and non-participants. For example, the literature examining recall and 
understanding of trial information, the majority had predominantly focussed on 
patient recall rather than comprehension, often failing to disclose their criteria, 
based on participation rates, or participants' own rating of their understanding of 
the trial (see previously in chapter 3). Thus semi-structured interviews were 
thought to be a more appropriate method given the exploratory nature of this 
study and to facilitate the discovery of other areas not anticipated. It was 
believed to be important to consider these mens perspectives in detail and to 
examine how they reflected on the actual events of their recruitment and 
subsequent experience of being a trial participant or non-participant. 
Sampling 
Sampling in qualitative research uses non-probability methods,219 with the 
sampling strategy determined by the research question and the needs of the 
study rather than according to external criteria. It is driven by the aim of 
illuminating the research question and to uncover 'multiple realities' {p.33)245 by 
ensuring that the individuals included cover a range of characteristics that might 
have an influence on the findings and thus should include extreme or deviant 
cases to clarify the areas of importance.246 
Theoretical sampling is a key aspect of grounded theory,234 and here the aim of 
sampling is theoretical development rather than representativeness.247 Hence in 
this study the subsequent sampling method used was stratified purposeful 
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sampling strategy,245 in which individuals with particular characteristics were 
deliberately and systematically selected to explore emerging analytical themes. 
First, data were extracted from patients' notes and this included demographic 
information such as age, marital status and diagnosis. If they were trial 
participants, information on when they were enrolled onto the trial, which 
procedure they were allocated to and when they received this treatment was 
included. For non-participants, I identified when they had been asked to 
participate, the reasons for refusal as recorded in the notes, which treatment (if 
any) they received and when they had received this treatment. 
This informed the initial sampling, by allowing me to identify patients with a 
range of ages, treatment allocation and time since they had been approached to 
participate in the trial. The initial analysis led to the development of preliminary 
theoretical explanations, such as patients' understanding and rationalisation of 
their treatment allocation. This was then used to inform the next stage of data 
collection with the emphasis on testing and developing these initial theoretical 
explanations, with this in turn leading to further sampling and analysis.247 For 
example, those who experienced poor outcome and participants recruited in the 
other clinical centre were included at later stages of sampling in order to test the 
preliminary findings. These men were identified with the help of the recruitment 
centres rather than based on trial outcome data, due to the timing of the data 
collection. 
Thus, within this study men who chose not to participate for the range of reasons 
(n=ll) and participants (n=22) in the CLasP study were interviewed. The 
experience of non-participants has rarely been explored and in this study I 
wanted to examine the experiences of both refusers and participants and their 
reasons for their decision to participate or not in the trial. The sample included 
men who were participating in each of the two major clinical centres, in the 
different arms of the trial, and at different time points. 
Men who chose not to participate were the first group interviewed (11). This 
group was predominantly from one centre (9 from centre B) and had given a 
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range of reasons (according to their notes) for not participating. I did originally 
intend to interview more 'refusers' from centre A, however, at that stage I did 
not feel that further interviews with this group would assist with the 
development of the analysis. I thus widened my focus and interviewed twenty-
two participants in the CLasP study who had been recruited within both centres. 
The detailed analysis of these men's accounts took a long time to develop. These 
were perplexing and often contradictory accounts of participation in what is an 
unusual event involving a number of highly complex concepts: the randomised 
controlled trial. The aim of this study was to explore these men's accounts of 
their experiences and understanding of participation rather than to produce 
more general findings about the experience of trial participation. 
Participants 
In total, 1073 patients were considered for inclusion into the trials. However, 318 
were ineligible according to the study criteria (see figure 1).570 patients in total 
were entered into the three trials, with 340 to the symptomatic trial and 148 into 
the acute and 82 in the chronic trial. Within this study twenty two CLasP 
participants were interviewed: eleven from centre A and eleven from centre B. 
Seven were allocated to conservative management, seven to laser therapy, and 
eight to TURP. 
The aim of the sampling was initially to talk to men from both trial centres, and 
included a number who had been allocated to each of the treatment arms (see 
table 10 within chapter 5). It was also considered important to interview men at 
different stages of trial participation. Thus eight men were interviewed within 
three months of being randomised, six within five months, and eight after they 
had received treatment/ follow-up. Eight participants were randomised to TURP, 
seven to laser and seven to conservative management. At later stages of the 
sampling, participants who experienced poor outcome were included in order to 
test the preliminary findings. The majority of the participants interviewed at that 
time were found to have extremely successful outcome and I was concerned that 
these men did not represent the range of possible outcomes found more widely 
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within this trial. It was thought that such different outcomes may affect these 
mens' accounts of trial participation. 
Refusers 
Within the trial, 185 men were recorded as refusing to participate. Figure 1 states 
that eight of these were omitted in error. Of the remaining 177 eligible patients, 
the main reasons for non-participation as stated in their trial records were 
patients who did not want surgery (54), those wanting surgery (39), travel 
problems (19) and no reason (65). Using purposeful sampling I attempted to 
obtain a number of patients from each of these groups (see table 14 within 
chapter 6): treatment preference (5), randomisation/research (3), tests (I), travel 
(1) and no reason given (1). 
Identification proved problematic. Originally participants were selected via the 
recruiting clinicians. However during some interviews it became apparent that 
some patients, for example, believed that they were participants even though 
they had been identified as non-participants. To confirm their status, I checked 
the trial database. Two 'non-participants' (Mr Cullum and Mr Stone) were 
actually participants. These patients are included within the analysis of 
participants within chapter 5. There were eleven confirmed non-participants. 
Data collection 
Contacting respondents 
Gatekeepers are crucial to access the sample223 and within this study, access to 
the research setting was gained via the main grant holders for the trial. I was able 
to sample directly from the trial database at the start of the sampling procedure 
and for the sampling at later stages in the project, and the registrars collecting 
clinical data within each centre also provided assistance. These registrars 
provided lists of participants from which I selected my sample. Initially this was 
based on the characteristics I had identified, ensuring that the sample I had 
selected included a number who had received each of the treatments available 
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within the trial. Because the treatments available within the trial were so 
different, patients allocated to different treatments are likely to have different 
experiences of trial participation. I later specifically identified participants who 
had a poor outcome as well as those who had improved symptoms as a result of 
participation. I was concerned that these men did not represent the range of 
possible outcomes found more widely within this trial. It was thought that such 
different outcomes may affect these mens' accounts of trial participation. 
However, because of the timing of the interviews, this was based on information 
provided by the trial centres, rather than trial outcome data. 
There was a possibility that the gatekeepers could covertly influence my 
sampling by directing me towards certain types of participants. The trial staff 
may have found my presence threatening; I was identified as working with one 
of the grant holders of the trial (my supervisor), even though my primary role 
(student) was non-threatening. I took this into consideration in the development 
of my sampling strategy by specifically ensuring that the sample included a 
range of participants and sampled from the list of those eligible to participate. 
Interview procedure 
Once I obtained ethics committee approval, participants were sent an initial letter 
and information sheet [see appendix 2]. This described what the interview would 
involve, what I was interested in talking to them about, the length of the 
interview and assured them of confidentiality.24o It is important that participants 
are provided with clear information about what the researchers want to find out 
about and discuss.248 
The author (KF) carried out all of the in-depth, semi-structured interviews. Each 
interview began with 'breaking the ice' types of questions,249 for example, 
'Looking back, could you tell me about your prostate condition and your initial 
referral to the clinic?". Each interview covered the same basic issues from their 
initial symptoms and referral, through to recall of their recruitment onto the trial. 
The interviews then progressed to more focussed questions to explore their 
understanding and experience of the process of recruitment to the trial; feelings 
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about participation; experiences of treatment and outcome. The aim within the 
interviews was to encourage the men to relate stories about their experiences and 
to explore their understandings of what had happened to them. Using a topic 
guide (see appendix 2), the interviews were based on themes with the narrative 
following a sequential (chronological) order of events from their symptoms and 
referral to the centre with prostate problems, through to being asked to 
participate in the trial and ending (in some cases) with the patients' post-trial 
experIences. 
Initially, I used the topic guide based on a format of open-ended questions that 
broadly covered the area I was interested in exploring. This approach allowed 
both the interviewer and the interviewee to deviate from this open framework at 
any point.24o After the initial interviews this process became more relaxed and 
'natural'219 and during later interviews become more focused as the analysis 
developed.219 New questions were introduced within some interviews, either to 
follow up new areas, or to test emerging theoretical insights.240 The question 
order varied between interviews, following the direction of the discussion. The 
questions used to probe and illicit further information from the participants was 
also flexible, allowing the interviewer to be sensitive to the respondents' 
language by reflecting their wording in framing additional follow-up or probing 
questions.240 
To elicit these mens' understanding of the trial and what this involved, I 
considered that it was important not to ask directly about their knowledge. This 
was significant in the light of much of the previous work within the literature at 
that time, some of which had asked participants if they 'understand' the 
information they had received about the trial or used acceptance as a proxy for 
understanding. Within the interviews I developed broad questions that would 
initiate a discussion of what happened to them that would indirectly touch on 
aspects of the trial and the concepts involved. Following on from that, these 
men's understanding could then be explored in more detail. For example, 
although I did not ask these men directly about their knowledge of 
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randomisation, this concept was discussed within the majority of the interviews. 
To elicit these accounts, I asked these men to tell me about how they had 
obtained the treatment they had received. I also reflected the terms they used 
within the interview to describe randOmisation, such as 'the envelopes' and 
'lottery'. The results of the trial were not known at the time of the interviews and 
both centres and informants are anonymised. 
Interviews were conducted in the men's homes, at their convenience and lasted 
from half and hour to one and a half hours. All the respondents agreed for their 
interview to be audio-tape recorded, and this was the preferred method because 
writing notes can interfere with the flow of the interview.24o Each interview was 
transcribed as fully as possible, including descriptions of non-verbal factors 
where appropriate. Brief field notes were also taken. These notes recorded 
reflections on fieldwork, the analysis, methodological issues and the research 
process. 
Data analysis 
As Hammersley and Atkinson note, analysis is not a discrete phase within the 
research process, rather "it begins in the pre-fieldwork phase, in the formulation 
and clarification of research problems, and continues through to the process of 
writing reports, articles and books. Formally, it starts to take shape in analytic 
notes and memoranda; informally it is embodied in the ethnographer's ideas and 
hunches" (p.205).227 
Within this study, data collection (semi-structured interviews) and data analysis 
continued concurrently, according to the constant comparison methods of 
grounded theory (pp.101-115).234 Qualitative data were collected and at the same 
time concepts and hypotheses were developed in relation to that data. Further 
qualitative data were then collected in relation to these emerging concepts. This 
approach verifies theory primarily through the relationship it has with the data, 
rather than through the quantity of that data. 
Analysis of the data proceeded by a detailed scrutiny of the transcripts to 
facilitate a familiarisation with the data, in this case the interview transcripts and 
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listening to the tapes.227 This 'raw' data (in this case text) was then broken down 
and each idea or event given a conceptual label to represent that phenonenon.236 
The first stage was to identify common themes which were coded. Coding is the 
initial process of data analysis and" represents the operations by which data are 
broken down, conceptualized, and put back together in new ways. It is the 
central process by which theories are built from data." (p.57)236 The initial 
conceptual names were written directly onto the interview transcripts236 and 
these coded segments of text were grouped, given conceptuallabels236 and 
included in separate word processing files.250 These files were expanded as new 
transcripts were completed and were refined, focused or altered as new themes 
emerged. Each individual's narrative was also examined independently to 
establish the context and to verify the emerging themes. 
Thus the initial process of coding the transcripts ensured that all the relevant 
data were brought together in relation to a particular category/theme. This is a 
form of sign posting, with data stored together under general codes with 
identifiers for each segment of text so that the original and subsequent locations 
can be traced. 
Coding of the transcripts was a recurrent process. As new transcripts were 
coded, new categories emerged and previous transcripts were then re-examined 
in light of these new categories. The data were interrogated until there was an 
established framework of categories with which to code all the transcripts.236 As 
the categories were developed and refined, so the themes become more 
defined.227 The next stage was' axial coding' (p.96), the process of developing 
connections and giving statements of relationships between categories and sub-
categories.236 However, this process of both open and axial coding was 
interchangeable and an ongoing process.236 A number of the transcripts were also 
coded by my supervisor (JD), our coding was compared and discussed, leading 
to further development of the concepts. 
The development of categories also facilitated the next step within the analysis, 
which was to examine the relationships between themes and categories.236 Data 
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were examined for similarities and differences within themes, retaining the 
context of the discussion and characteristics of the individuals to aid 
understanding and to allow the interpretation and development of 
explanations.234 Detailed descriptive accounts of groups of men were produced 
and these were also examined by my supervisor (JD). At this stage the data were 
also interrogated to check for patterns between the themes, initially by 
contrasting and comparison, noting where there is anything surprising or 
puzzling. The process of questioning such as who, what, where, how, why, is 
central to the development and refinement of these categories236 and is part of the 
'constant comparative method of analysis' (pp.101-106).234 
I also looked for negative cases and examined how the data related to common-
sense expectations and to what was previously known and described within 
others' accounts.227 Within this study, this occurred at the sampling stage where I 
examined negative cases through the interviewing of non-participants and 
participants, selecting patients from the two main trial settings (A and B). During 
the analysis, I sought respondents who had or had not experienced some of the 
trial protocol procedures, for example the use of envelopes to reveal their 
allocation (see chapters 5 and 6). 
An important stage in the analysis was the production of a detailed case study 
for each respondent (these were also checked by JD). These were detailed 
descriptive accounts charting each man's narrative. Typologies were also used to 
examine why certain strategies were adopted by some subjects227 by tracing 
conditional paths to track the process of an event.236 For example, this approach, 
together with the development of case studies, was used to examine the various 
strategies employed by each trial participant and non-participant to explain their 
treatment allocation. This also allowed the development of the different 
pathways to refusal. During this stage I often returned to the transcripts to verify 
categories by interrogating it for evidence to support or refute queries. This 
constant interplay between questioning and verification is what makes such 
theory' grounded' .236 
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In light of these case studies, and the development of these strategies to explain 
their treatment allocation and the different pathways to refusal, all the original 
transcripts were once again re-examined and re-coded to check and verify the 
concepts as they became more defined and also to substantiate the context of the 
data. Sometimes I listened to the tapes themselves to check participants' 
emphasis on words/phrases and to re-familiarise myself with the original 
interviews. This led to the refinement and development of a number of themes 
within the analysis. 
In this study, to achieve the constant comparative approach, a level of formal 
analysis was always achieved at least to the level of developing categories which 
facilitated a reflection on the fieldwork and what this was providing, before 
further fieldwork was carried OUt.227 However the timing and timetable of the 
trial and its recruitment schedule led to occasional practical constraints in 
achieving the ideal model of close connection and interaction between the 
analysis and data collection at all times. 
Effective data management was important. The word processing package Word 
for Windows was used as a way of managing the qualitative data.251,252 All 
transcripts were cross-referenced and linked to the original source,219 facilitating 
the development of categories through the storage and retrieval of text during 
the analysis using the split screen facilities. Word for Windows allowed the 
sorting of transcripts, copying and pasting quotes from the original transcripts to 
create files with general codes such as 'treatment allocation' that emerged from 
the initial coding from the transcripts. These sub-category files were expanded or 
became focused as new categories emerged or were refined. For example, new 
categories such as 'the role of the clinician' and' chance' emerged from within the 
general code' treatment allocation'. 
The above description of the process of analysis seems very 'clean'. However 
throughout this process there were periods of confusion preceding each stage of 
the process of analysis. This confusion is central to the development of the 
analysis. Through a mechanism of questioning and scepticism of categories that 
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emerge, ideas about relationships start as vague, tentative conjecture and 
speculation and develop through a process of clarification and modification. 
Theories are' grounded' (p.3)234 because they develop from the data. 
Rigour 
An increasing number of papers236,247,253 and professional research 
organisations254 provide guidelines for the assessment of the rigour of qualitative 
research. 
There are many debates as to what criteria are appropriate. There are two main 
perspectives: realism, which states that there is one truth, and relativism which 
assumes multiple realities.255 Some argue that the criteria developed for 
quantitative research should be applied, while others believe that it is 
inappropriate because such criteria are fundamentally incompatible with the 
social world and how we understand it. However, the most common assertion is 
that different criteria should be applied to qualitative research, although there is 
much debate as to what these criteria should be.255 Silverman argues that too 
often qualitative researchers reject the application of validity, and argues that "it 
simply will not do to accept any account simply on the basis of the researcher's 
claims to I an intensive personal involvement'. Immediacy and authenticity may 
be a good basis for certain kinds of journalism but ethnography must make 
different claims if we are to take it seriously" (p.153).256 The grounded theory 
approach similarly states that such standards should be modified "in order to fit 
the realities of qualitative research, and the complexities of social phenomena" 
(p.250).236 
An examination of the validity and reliability of the analysis are the main 
methods used to assess the rigour of qualitative research.219 Here, validity refers 
to the description, the explanation and the subsequent fit between the two and 
the credibility of the explanation,257 "whether the researcher sees what he or she 
thinks he or she sees" (p.21).241 Hammersley defines validity within qualitative 
research as selective representation rather than the reproduction of reality, which 
is linked to judgements of plausibility, credibility and centrality.255 An account 
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must be plausible when seen against our existing knowledge about the 
phenomenon. It should be credible, that is, that we reasonably believe the 
findings to be accurate, given the methods used. The centrality of the arguments 
must also be taken into account and the key findings within the research must be 
supported by greater evidence than that required for more marginal 
arguments.255 Reliability is "the degree of consistency with which instances are 
assigned to the same category by different observers or by the same observer on 
different occasions" (p.67) and provides evidence of the usefulness of the 
research strategy employed.255 
The use of such measures of validity is dependent upon the researcher's 
philosophical approach. Hence, the use of validity, reliability and generalis ability 
within qualitative research has been criticised, with many researchers arguing 
that standards for judging quantitative studies are not appropriate for qualitative 
studies.236. For example, Woolcott258 rejects validity on the grounds that there is 
no one I correct' interpretation. Donmoyer259 similarly believes that traditional 
notions of generalis ability are inadequate because they fail to take into account 
research that focuses on the meaning of events for the individual. There is no 
objectivity; rather observations of the social world are situated within the worlds 
of the researcher and the researched.223 
Theoretical validity is the main focus of the grounded theory approach, with 
verification of the main themes emerging from the research carried out through 
the close connection of data collection and analysis throughout the research 
process, rather than through the quantity of data collected. Theory is verified 
through its relationship with the data.235 Such procedures must be explicit.236 
Plausibility or 'member checks' can also be carried out and can take the form of 
asking participants to review the findings, although this is dependent upon the 
researcher's approach.247,26o However, such respondent validation has also been 
criticised as inappropriate/55, 256 as participants may not be aware of the 
appropriateness of the findings when they are implicit within the setting.219 
Hammersley argues that" to assume that respondents can validate or even falsify 
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accounts in some definitive way is to forget the social character of the 
relationships between researcher and participants and to assume that they have 
privileged access to the truth. Neither of these assumptions is sustainable" 
(p.65).255 An additional problem is that the research findings may be in conflict 
with respondents' self image.256 In an example of using this approach, Bloor 
found that although this yielded some useful modifications within his research, 
they were not a test of those accounts and thus were not validation.261 
Verification of the findings using secondary informants can also be used to test 
the accuracy and validity of the research findings. This approach must take into 
account the fact that some groups may have different perspectives from others.247 
Hammersley similarly points out that there is no one 'true' account of social 
phenomenon, but that convincing evidence can always be produced to support 
differing interpretations. 255 
One method often used within sociology and anthropology is I confirmability'260 
or 'investigator triangulation',235 where a second researcher examines the data 
and evaluates the categories that have emerged.260 Within this study some 
transcripts were coded and detailed descriptive accounts were also checked by 
my supervisor (JD) and any differences were then discussed, leading to further 
development of the concepts. However, it is also argued that this process violates 
the inductive process of research that often relies on insights gained from the 
process of data collection. It is important that the interpretation of the principal 
researcher are paramount as she has the additional stock of knowledge gained 
from conducting the interviews.219 Lincoln and Guba argue that such secondary 
researchers should be familiar with the inquiry,260 which is the case within this 
study. 
Triangulation can also be carried out in an attempt to safeguard validity in 
qualitative research, and this can be by data source, method of data collection, 
researcher and type of data.262. Data triangulation is a common method whereby 
a range of sources and types of data are sought.235,247 Within this study, although 
only one trial was examined, the sample included non-participants as well as 
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participants, participants at different stages, with' successful' and' unsuccessful' 
outcome and at different trial centres. Source triangulation was also carried out, 
with quotes from several respondents within the sample necessary for a category 
to exist. 
However, the use of triangulation can prove problematic, for example it may 
produce contradictions within the analysis and the researcher then has to decide 
which account has primacy.262 Triangulation emphasises the need to overcome 
the context of the data and Silverman argues that it does so to the detriment of 
the analysis. It is important not to ignore the context-bound nature of social 
interaction, and hence it may be inappropriate to develop theory based on data 
from different contexts.256 
The audit trail is an important procedure for ensuring validity, and each stage 
within the research must be explicit so that it can be tested.227 Hence the integrity 
of the research must be maintained at all stages,247 from the sampling and data 
collection, to the coding and subsequent stages of the analysis and report writing. 
This must be a 'transparent'263 process, such that someone unfamiliar with the 
research could reconstruct the procedures that took place to reach the subsequent 
research findings.247, 260 This enables the reader to verify and thus have 
confidence in the findings, and provides the opportunity for secondary analysis 
of the data or replication of the study to be carried out.236,263 
To ensure that the research process within this study achieves such transparency, 
each stage of the analysis has been preserved so that all quotes can be traced back 
to the original transcripts and data sections are clearly labelled for retrieval and 
links.263 All quotes have been tidied for public consumption, by removing 
anything that does not add to the meaning of a quote, such as 'urn', I er' and 
'yknow'. The rationale for using the quotes presented is to illustrate the meaning 
of a concept and allowing the reader to judge their reaction, while balancing this 
with the need for all voices to be heard. Where possible within the analysis I have 
presented large pieces of data in the natural sequence it occurs, although this was 
not always practicable due to the limitations of space. 
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Silverman264 points out that in the presentation of qualitative data, the reader is 
often left to trust the findings on the basis of a few extracts from the qualitative 
data set. This allows the opportunity for favoured extracts to be selected and the 
presentation of analysis, which although rhetorically persuasive is not 
theoretically convincing. To prevent this from occurring within this study, 
counting has been used selectively to illustrate how often phenomena or patterns 
occur within the data. This can be used as a way of summarising the findings to 
make them easier for the reader to follow,247 qualitative research" does not imply 
a commitment to innumeracy" (p.10).241 
Silverman suggests that counting techniques can provide the reader with a 
feeling for the data as a whole, rather than having no choice but to take the 
researchers' word that such findings exist. It also provides the researchers with 
an opportunity to test and revise their generalisations about the data.256 An 
example of this approach is Silverman's analysis of clinical consultations with 
mothers of Down Syndrome babies. These encounters were compared to non-
Down's cases by counting the number of times types of questions were asked or 
omitted.264 This approach "remains qualitative since naturally occurring events 
on theoretical grounds are being counted" (p.112).247 However, he cautions that 
counting can produce findings that are as meaningless as qualitative analysis 
based on selective data, "the researcher must resist the temptation to count 
everything" (p.165).256 Within this study numbers have been used selectively to 
illustrate how often phenomena, such as the examination of their recall of trial 
terms, occur within the data and also to illustrate patterns, for example in the 
examination of the participants' beliefs about how they had been allocated to the 
treatment they received (see chapter 5 and 6). 
The adequacy and appropriateness of the data are also crucial. Qualitative 
research must ensure that sufficient data are collected to achieve saturation of the 
categories so that any variations within them can be recognised. Within 
qualitative research, sampling is purposeful, continuing until there are sufficient 
data to confirm or refute the analysis.219 As Mays and Pope state, qualitative 
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researchers must produce a "plausible and coherent explanation of the 
phenomenon under scrutiny" (p.llO).247 It is equally important within the 
presentation of the results to make a distinction between the data and the 
subsequent analytic interpretation of these data.265 
This is linked to representativeness. Miles and Huberman suggest that 
researchers should start off with the assumption that their sample is biased and 
attempt to refute this statement. They suggest this could be achieved by 
increasing the sample, purposefully sampling for negative or extreme cases, 
increasing the types of cases which are poorly represented and include a random 
sample (not appropriate within grounded theory).262 Evidence can also be 
weighted in terms of whether they are based on 'strong' or 'weak' evidence. 
Although their criteria for evaluating such evidence is based on participant 
observation methods, this can be used to indicate the strength of the conclusions 
reached.262 Miles and Huberman also point out that although there is the 
temptation to gloss over or explain away negative cases, I the outlier is your 
friend' (p.269). An examination of such cases can test and strengthen the analysis. 
Such negative cases can take the form of individuals, differing settings, unusual 
events.262 Within this study, this occurred at the sampling stage and during the 
analysis. 
Hammersley argues that the stark choice between relativism and realist 
perspectives does not have to be made, rather he suggests adopting the approach 
of I subtle realism' (p.69). This approach allows an acknowledgement that there is 
no access to 'reality', and assumes that an account can be valid if it can accurately 
represent the phenomena, although this will be in the form of a 'selective 
representation than a reproduction of reality' (p.69).255 
Many social scientists have provided personal statements concerning their 
experiences I in the field'. Behind the research process is the 'biographically 
situated researcher' (p.ll) who is informed by their gender, class, ethnicity and 
culture and from within" an interpretive community that incorporates its own 
historical research traditions into a distinct point of view" (p.ll) and thus leading 
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the researcher to adopt a certain perspective of those being studied.223 However, 
as Kirk and Miller241 argue, such statements do not illuminate the research, rather 
they are often uncritical, providing only the 'party line' or 'rehearsed 
information', since it is hard not to present partial or 'laundered' biographies. It 
is often a criticism of qualitative research, that researchers bring their own biases 
into their work, but it is argued that such bias can be used as a resource. 
Reflexivity (see chapter 7) is an important part of this, allowing the researcher to 
understand their own behaviour and interpretations of their research.266 The 
search for negative cases to refute or amend interpretations is a key feature of 
this process.266 Miles and Huberman suggest that one way to avoid the 
researcher effect is to ensure that participants are aware of what the purpose of 
the research is, why you are there, what you are studying, how you will be 
collecting information and what you will do with this information.262 The impact 
of these factors on the research is reported in chapter 7. 
Conclusion 
The empirical research carried out for this thesis, can, therefore, be described as 
qualitative. In-depth interviews were carried out with both participants and non-
participants in a randomised controlled trial comparing surgical and 
conservative treatments for a common disorder in older men: lower urinary tract 
symptoms related to benign prostatic disease. The results are presented below 
within a general descriptive overview and arranged according to the themes236 
that emerged from the interview data. Non-participants were also examined in 
terms of their pathways to refusal. The experience of participants and non-
participants are examined separately. It is to the results of the empirical research 
tha t I now turn. 
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The experience of trial participation 
Introduction 
This chapter examines participants' motivations for taking part and their 
perceptions of participation, including their recall of what the trial involved and 
how they made sense of their treatment allocation and participation. The men's 
symptoms, knowledge of the treatment available within the trial and outcome 
are also examined. A number of case studies are also described to demonstrate 
the dialogue that most participants engaged in to try and make sense of the trial 
design, set within their lay beliefs and their actual experiences of participation. 
Characteristics of participants 
Men (n=22) who were participating in each of the major clinical centres, in the 
different arms of the trial, and at different time points within the CLasP study 
were interviewed (see table 10 below). The sample included men aged 56-80 
years old who were predominantly retired (Mr Grange, Mr Cullum, Mr Symonds 
were employed). Previous or present occupation and the area in which they lived 
were used to broadly indicate these men's social class. The majority of these men 
were categorised as 'working class' and four (Mr Bowler, Mr Murray, Mr Grange 
and Mr Bullock) as 'middle class'. 
During some interviews it became apparent that some patients, for example, 
believed that they were participants even though they had been identified as 
non-participants. To confirm their status, I checked the trial database. Two 'non-
participants' (Mr Cullum and Mr Stone) were actually participants and are 
included here. 
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Table 10: Participants 
Name Age Occupation Arm of the trial lnteroiew time Location 
randomised to after (Centre) 
randomisation 
MrJamison 64 Driver CM* 3 months B 
MrBrown 77 Builder TURP* 3 months B 
MrStone 68 Cafe owner Laser 3 months B 
MrHall 66 Civil servant CM 3 months B 
MrWatson 78 Retail TURP 3 months B 
MrBowler 75 Accountancy Laser 3 months B 
MrCooper 65 Electrician TURP 3 months B 
MrTaylor 73 Lorry driver TURP 3 months B 
MrMurray 66 Teacher TURP 5 months B 
MrWebster 66 Post office TURP 5 months B 
worker 
MrGrange 56 Manager Laser 5 months A 
Mr Pierce 63 Printing firm Laser 5 months A 
MrFormby 72 Foreman- CM 5 months A 
warehouse 
MrCullum 56 Salesman CM 5 months B 
MrMott 66 Driving Laser 8 months A 
instructor 
Mr Booth 80 Gardener TURP 8 months A 
Mr Mills 67 Local council CM 8 months A 
worker 
MrHoughton 70 Betting shop TURP 8 months A 
Mr Bullock 78 Engineering Laser 8 months A 
MrSymonds 59 Manufacturing CM 8 months A 
Mr Flint 68 Brewery worker Laser 8 months A 
MrDaw 70 Washing CM 8 months A 
machine repair 
man 
*CM = Conservative management 
* TURP= Transurethral resection of the prostate (standard surgery) 
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Reasons for attending the urology clinic 
Symptoms 
The majority of these men discussed the urinary symptoms they were currently 
or had previously experienced that had prompted them to seek treatment (see 
below in table 11). The main symptoms were hesitancy, nocturia and frequency. 
Many described how these symptoms had impacted on their lives. Two (Mr 
Webster, Mr Symonds) gave only a vague indication of their condition: 
Through the doctor. He came, I was having trouble with the 
water, and he said that prostate trouble [Mr Webster: allocated to 
TURP, preferred laser] 
I was having trouble with the water works you know. [Mr 
Symonds: allocated to CM, preferred active treatment] 
A small number of these men sought treatment initially because they had been 
prompted to do so by their wives: 
It was sort of er it was the wife really, she said I should go and 
see someone about that like and that was it like you know [Mr 
Cullum: allocated to CM, no preference] 
Wife: I was pushing because it was a case of he wouldn't go 
anywhere. He was getting to be a stay-at-home because he 
wouldn't even go up to the shops because of the toilet 'oh I can't 
go there' and to do a three, four mile journey [Mr Pierce: allocated 
to and preferred laser] 
Table 11: Participants' reported symptoms 
Name Frequency Hesitancy Nocturia Affecting Acute Other 
social life retention 
MrJamison ./ ./ 
MrBrown 
MrStone ./ ./ 
MrHall ./ 
MrWatson ./ ./ 
Mr Bowler ./ 
Mr Cooper 
Mr Taylor ./ ./ ./ 
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MrMurray ./ ./ 
MrWebster ./ 
MrGrange ./ ./ 
Mr Pierce ./ ./ ./ 




Mr Mills ./ 
MrHoughton ./ ./ 
Mr Bullock 
MrSymonds ./ 
MrFlint ./ ./ 
MrDaw ./ 
TOTAL: 4 (18 %) 4 (18%) 11(50 %) 7 (32 %) 1 (5%) 5 (23% 
%) 
A tick signifies that these men discussed this symptom within the interview. 
Nocturia 
Nocturia, that is, the need to urinate often during the night, was a common 
symptom among these participants. For a number of the men, this prompted 
them to seek medical advice: 
Well no, it's the same like, more or less the same but it's annoying 
like to you know get out of bed, and when you go out somewhere, 
if you see a drop if water you've got to rush to the toilet like, you 
know. This is it, how I feel about it. [Mr Jamison: allocated to eM 
but preferred active treatment] 
I had no sooner got into bed but I felt I wanted to go again and I 
was up eight times that night and that prompted me to go to the 
doctors, I thought I'm fed up with this, I think I'm going to go to 
the doctors. [Mr Murray: allocated to and preference for TURP) 
I'd gone with the problem of not getting a good night sleep 
basically. [Mr Grange: allocated to and preferred laser] 
Oh yes, I would say yes because it was bad. I was getting up 
terrible through the night, three or four times. [Mr Matt: 
allocated to laser, no preference] 
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Hesitancy 
Hesitancy before urinating was also a problem for a number of men. This was 
sometimes associated with the effect their symptoms had on their social life: 
Frequency 
But the thing that really made me go to the doctor about it was 
the fact that I used to go to the toilet and then found you couldn't 
pass any water and then you went away and two minutes later 
you were back again and you know it got a bit embarrassing 
going back and forwards and that was when I thought well one of 
these days I'm going to go and it's not going to happen and it 
could be permanent. [Mr Taylor: allocated to and preference for 
TURP] 
I was having so much problems in trying to pee, standing over the 
toilet for so long and I dreaded going into the public toilets 
because you could stand there forever and it just wouldn't happen 
so you would have to be in the privacy of somewhere so you could 
stand there and wait before the water actually came away. [Mr 
Stone: allocated to laser, preferred TURP] 
A small number of these men mentioned frequency, that is, the need to urinate 
often during the day: 
Retention 
He said how many times do you go to the toilet, well fifteen times 
a day. Oh he said, well that's quite a bit. [Mr Murray: allocated 
to and preference for TURP] 
You know it started off going to the toilet a bit oftener that you 
used to [Mr Taylor: allocated to and preference for TURP1 
One participant experienced an episode of acute retention that required medical 
intervention: 
I went to pass water and I couldn't pass a raindrop, I said I can't 
believe this, nothing. Now of course you're talking about five 
pints of Guinness that wants to come out and I tried and tried 
and I was doubled up in the end. You just don't care, they just 
have to take you away to the hospital and they can do what they 
want, you just don't care, you've gone past caring. They 'were 
very quick, no hanging about and er they did this catheter or 
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whatever they call it and of course instant relief [Mr Hall: 
allocated to eM, no preference] 
Other symptoms 
One patient discussed terminal dribbling: 
I was getting up during the night, progressively like you know 
and there was other symptoms as well, will I be frank with you? 
well I was dribbling after I finished and I went to the doctors, I 
mean you hear so much about the prostate trouble now [Mr 
Watson: allocated to and preferred TURP] 
Affect on social life/normal daily activities 
A number of men described how their symptoms affected their social life and 
daily activities. They often described how they had to plan journeys and 
experienced anxiety finding public toilets. Such experiences were often 
I embarrassing' for these men: 
And it was getting embarrassing, you're standing there and 
everybody was away and new people are coming in and you're 
still there you know and as soon as you left the toilet you were 
wanting to go again. [Mr Pierce: allocated to and preferred laser] 
Embarrassing at times, when you are at the toilet and you stand 
there for hours and people are in and out you know, if you are 
going to the pub or what have you, but I found ... [Mr Formby: 
allocated to eM, preferred active treatment] 
The only thing that really embarrassed me was trying to go to the 
toilet and knowing that I couldn't that I would have to stand and 
wait was the most embarrassing part. [Mr Stone: allocated to 
laser, preferred TURP] 
One participant also mentioned that his symptoms had affected his sex life: 
But it has affected our lives sexually as well as far as the 
waterworks was concerned anyway, before the op. So anything 
was an improvement. [Mr Pierce: allocated to and preferred laser] 
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Knowledge of the treatments available within the trial 
Overall, these men displayed a high level of knowledge about the three 
treatments available within the trial: TURP, laser and conservative management. 
Their interpretations of what these treatments involved reflected the information 
contained within the trial patient information leaflets (see appendix 1). 
Knowledge of TURP 
Within the patient information leaflet, TURP was described as I the most common 
treatment'. Almost half (10) of these patients similarly described this treatment as 
the 'standard operation' (Mr Watson) or 'the conventional one' (Mr Murray). Some of 
these men appeared to believe that this indicated that TURP is 'better for most 
people' (Mr Murray): 
You know you think, oh I don't know, I think I'll have the 
conventional one. [Mr Murray: allocated to and preference for 
TURP] 
Wife: you had a preference didn't you, there were three ... 
The standard operation, yes. [Mr Watson: allocated to and 
preferred TURP] 
I think the common one must be the easiest, the one we had. [Mr 
Symonds: allocated to eM and preferred treatment- had TURP 
after the trial] 
The patient information leaflet also stated that this method involved I cutting' and 
involved 'some bleeding'. This was also mentioned by a number of patients: 
Wife: Well we looked at the things, I think it was in our mind that 
he'd had that many ops sort of thing he didn't really want the idea 
of cutting. [Mr Pierce: allocated to and preferred laser] 
That was always talked about of er just like taking the tissue 
away, that operation like. [Mr Mills: allocated to eM, preferred 
active treatment] 
Well he said to me the normal treatment, which they cut into the 
bladder and the penis is the most successful, [Mr Stone: allocated 
to laser, preferred TURP] 
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The other operation seemed as if, was it a knife or something and 
there could be a lot of bleeding. [Mr Bowler: allocated to and 
preference for laser] 
Knowledge of laser therapy 
Within the patient information leaflet, laser therapy was described as J a new 
treatment' that involved lasers. Eight of these patients similarly described laser 
as the new treatment: 
The laser was a new system that they had been using; they had 
been using it for about 12 months or something. The success rate 
he said was pretty good, [Mr Stone: allocated to laser, preferred 
TURP] 
I think I had already a belief in new technology. [Mr Bullock: 
allocated to and preferred laser] 
Well gone are the days that you get there, they cut and they delve 
in there with instruments and that the technology they've got 
now is absolutely brilliant, no visible scars, no pain actually. Oh 
great, great, the new technology, its getting better and better. [Mr 
Webster: allocated to TURP, preferred laser 1 
The use of a laser was thought to involve 'cauterising' (Mr Bullock) and 'burning' 
(Mr Taylor): 
Well it was principally that I knew that lasers in industry could 
be used to, very accurately and that possibly it cauterises as it 
cuts and I just thought that it would be the minimum amount 
would be removed, it sounded a better idea to me. I think I had 
already a belief in new technology. [Mr Bullock: allocated to and 
preferred laser] 
I'm a bit concerned about the laser, the idea of the burning 
through. [Mr Murray: allocated to and preference for TURP] 
I didn't to be honest like the idea of using burning or whatever 
they did. [Mr Taylor: allocated to and preference for TURP] 
This was also thought to involve less bleeding and possibly lead to a quicker 
recovery: 
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What they said was there was very little cutting because the laser 
sor~ of clos~s up as it's b~rning so you didn't have a lot of blood. 
So zt wasn t bad. [Mr Pzerce: allocated to and preferred laser] 
Because of the fact that the laser burnt it would heal quicker and 
it wouldn't be so much time healing, that was the main thing [. .. ] 
The fact that the laser was going to heal the wound if you like 
almost instantly, it sounded great. [Mr Grange: allocated to and 
preferred laser] 
Conservative management 
Conservative management was identified as an acceptible treatment option by 
one of these men: 
If they had said carry on for another six months, we'll monitor 
you that would have been OK. [Mr Murray: allocated to and 
preference for TURP] 
However, this tended to be described by these men as a treatment delay, similar 
to the waiting list, rather than a treatment option in its own right. These patients 
were aware that if allocated to this treatment, they could still receive surgery 
after the trial. 
Well it didn't bother us because I knew that eventually I would 
get the operation. Whether it would be six months, a year it didn't 
really bother us. [Mr Webster: allocated to TURP, preferred laser] 
Two participants felt (rightly) that if their symptoms worsened, they would 
receIve surgery: 
Well I would have accepted that [conservative management] as 
well providing that if I was going to need an operation I would 
have had one. I think obviously I would have done and it would 
have just been another six months until then presumably. [Mr 
Flint: allocated to laser, preference for TURP] 
But at the end of the day if you're really bad then I would imagine 
that, I don't know, they might bring the six months forward. [Mr 
Pierce: allocated to and preferred laser] 
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Perceptions of participation 
Patients talked about the concepts of I randomisation' and I trial' a number of 
times during the interview. However, they often expressed their understanding 
in different ways. 
An examination of the patient information leaflet for the trial (see appendix 1) 
shows that prospective participants were informed of the different treatment 
options available, what these treatments involved and the known effectiveness 
and potential side effects of these treatments based on the evidence so far. It also 
stated that the research project was a randomised controlled trial and that this 
study has been set up to find out which treatment has the best results. It went on 
to explain that this involved the comparison of treatments, that a sealed envelope 
would be opened to reveal their treatment, and (dependent on the severity of 
their symptoms) that they had a one in three or a one in two chance of receiving 
one of these treatments. 
Randomisation 
Based on the trial information, one could expect participants to know about 
randomisation in terms of six integral elements: the involvement of chance in 
their allocation, that envelopes were used to allocate treatments, that the 
treatment allocation was concealed, that treatments were being compared, that 
clinicians were uncertain about the most effective treatment, and that they were 
participating in an experiment. 
One participant (Mr Mott) professed no knowledge of the trial or randomisation. 
He believed that the clinician would choose which treatment he would receive. 
He was the only one who was not able to recall or report any details about the 
trial or his participation. 
136 
Table 12: Participants' knowledge of randomisation 
r····ii-i"ay·················-·····-........ --........ ~.-.-.............. -.-.... _ ... _ ... - .. -_. __ .. _;._---_. __ . _ ....... _ .............•............. _._ ..... --_ .. _._._---- ,---. Chance companson envelopes concealed - e-;p~ri;n~t clinical - ._-.., i ! 
I participant ! allocation uncertainty ! 
i ! 
1 Mr Murray ./ ./ ./ ! ./ ./ ./ 
, 
! i 
i MrTaylor ./ ./ ./ ./ i ./ 
Mr Pierce ./ ./ ./ ./ ./ 
, 
Mr ./ ./ ./ ./ ./ 
Houghton 
I MrHall 
./ ./ ./ ./ ./ 
I MrDaw ./ ./ ./ ./ j 
./ 
I Mr Cooper ./ ./ ./ I ./ ! 
i Mr Booth ./ ./ ./ ./ 
i 
• 
! Mr Flint ./ ./ ./ ./ : 
i MrCullum ./ ./ ./ ./ 
i Mr Bowler I ./ ./ ./ 
, 
I 
I MrFormby ./ ./ ./ 
I 
I Mr ./ ./ I ./ 
I Symonds 
I MrJamison ./ ./ 
MrGrange ./ ./ 
MrStone ./ ./ 
I MrBrown ./ 
./ 
Mr Mills ./ ./ 
I MrWatson ./ ./ 
I MrWebster ./ ./ 
Mr Bullock ./ I 
I Mr Mott 
I 
i 
L.._~~T A_: __ .... _ .. __ ... .... _.~~ .. ~~~~._ .. __ ._._~_~ .. (55 ~}_._._ .. 14(64%) 13 (59%) 11 (50%) 6 (27%) I • __ •• __ .M •• _. _______ •••• • -_ .. _-------_._.-_._- -----~ 
A tick signifies that the informant discussed that particular concept and that he 
demonstrated that he understood the concept in the way it was presented in the 
study information. 
It can be seen in table 12 that participants were most easily able to recall that the 
trial involved an element of chance, with about half or more having a good recall 
that the study involved a comparison of treatments, an experiment and allocation 
by concealment, usually by envelopes. Knowledge of clinical uncertainty was at a 
much lower level. 
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No relationship was found between understanding and any of the patient 
characteristics. For example, the six participants who could recall five or more of 
these concepts had been allocated to a range of treatments, represented both trial 
centres and had been interviewed between three and eight months after 
randomisation. Age and time after randomisation appeared to have had no 
influence on these men's recall and understanding of trial information. The 
influence of social class was also examined. The four 'middle class' men had 
varying levels of recall and understanding of these six elements, ranging from 
the highest (Mr Murray) to one of the lowest (Mr Bullock). 
Chance 
Two-thirds (15) of the participants recalled the involvement of chance in their 
treatment allocation. Of these, four (Mr Houghton, Mr Formby, Mr Hall and Mr 
Taylor) revealed a clear knowledge of this aspect of randomisation. 
What she said is it is a test you are going to have and we found 
you know, we opened one envelope and this is what you are going 
to have. But more than likely it could be that you were going to 
have one of the other tests, which I didn't mind you know. [. .. ] I 
think she said that there was that kind of survey thing and 
depending on what envelope you picked that is what you got you 
know. I thought that was fair enough yes. [Mr Formby: allocated 
to CM, preferred active treatment] 
There were those three things [ ... ] and he said oh yes you've got a 
swollen prostate, you'll probably have to have an operation but 
it's a chance you might take, which one of them you take, it comes 
out the hat, sort of thing you know. It's out of the hat you cannot 
pick. [Mr Symonds: allocated to CM and preferred active 
treatment] 
Well I'm prepared to go in and take my chance, see what they 
want to do. [Mr Hall: allocated to eM, no preference] 
Lay interpretation of randomisation was a common feature of such descriptions. 
Half of this group used terms such as 'lucky dip' (Mr Cooper), 'pot luck' (Mr Hall), 
'toss a coin' (Mr Webster), or 'out of the hat' (Mr Symonds and Mr Flint) to describe 
the involvement of chance in their treatment allocation: 
138 
Int: So you expected it to be tailored to your needs rather than ... 
Yes that's right, yes. Sort of toss a coin in the air and if it comes 
heads you get this or if it's tails you get the other. [Mr Webster: 
allocated to TURP, preferred laser j 
But anyway I agreed to have a go at it, a bit of a lucky dip. [Mr 
Cooper: allocated to and preference for TURPj 
It was just picked out of a hat as to which treatment you got. [Mr 
Flint: allocated to laser, preference for TURPj 
With the use of such terms as 'out of a hat' (Mr Jamison) and 'lottery' (Mr Pierce) 
this group demonstrated a further understanding of chance. For example, it was 
apparent within his account that Mr Jamison was aware that this method 
determined access to 'treatment': 
He walked away, came back with an envelope and said oh your 
not for surgery so I take it that they take it out of a hat and that's 
it, that's all I know. [ ... j The way it looks to me is they're taking 
it out of their hat and if it says yes you can get it sorted out, that's 
how I feel about it and that's all I can tell you, you know. [Mr 
Jamison: allocated to CM but preferred active treatment] 
However, although two participants (Mr Pierce and Mr Daw) were aware that 
chance was involved in their allocation, their rationalisation also incorporated a 
belief that fate and destiny were factors in their allocation (see also below). The 
use of the term 'lottery' by Mr Pierce implies that he believes that there will be a 
winner among the trial participants who receives the 'best' treatment. Mr Daw 
also believed that there was an envelope to pick containing the 'right' treatment. 
I thought it was very fair, very fair you know its pot luck what 
you get like. I just more or less thought well I just hope I pick the 
right one! You know not knowing what you are going in for sort 
of thing, just hope you pick the right one you know. [Mr Daw: 
allocated to CM, preferred active treatment j 
So I went, had a consultation with one of the doctors and then he 
said, well you've left it a long time, then he put us through to the 
clinic and then, that's when I came up against the lottery. 
Wife: The idea of a lottery, picking it out sort of thing, that was 
somebody else's choice sort of thing, even though you picked the 
envelope. [Mr Pierce: allocated to and preferred laser] 
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If you know someone who had been asked to take part, what would 
you say to them? 
Well go for it, because you've got nothing to lose you know. At 
the end of the day all you've got possibly is a six month if you pick 
the wrong ... [Mr Pierce: allocated to and preferred laser] 
The comparison of treatments 
Twelve participants were aware that the trial involved the comparison of 
treatments. For example, they were aware that participation involved testing 
treatments (Mr Murray and Mr Cullum) and comparing new interventions with 
the standard treatment (Mr Booth and Mr Pierce). 
But the scheme itself was I think they wanted to compare, they 
wanted to do all three and then make a comparison of what the 
end results were. So after six months or whatever they are going 
to do it for, they assess it and I suppose the replies that I'm giving 
will help to decide what was going to go on in the future. [Mr 
Murray: allocated to and preference for TURP] 
I was a little bit surprised that that's how they done it like you 
know. It was a bit er you know, but I've read different things 
about it, little snippets in the paper like you know about prostate 
things like you know. They don't know a lot about it even now I 
don't think, they're still sort of learning cos they're doing this 
study in America as well aren't they, the same sort of thing. 
They're linked up with Bristol, that's what they told me I think 
they're linked up with Bristol, Newcastle and somewhere in 
America as well and they are all, they're pooling all their 
information. I think he said America as well, yeah. [Mr Cullum: 
allocated to eM, no preference] 
I think it [the trial] was to help other people who were going to 
undergo that operation and she wanted to find out what 
differences there were between the, I can't remember the initials 
now .. . [Int: TURPs?] TURPs was the one I had and the laser one 
yes. [Mr Booth: allocated to TURP, no preference] 
But I think you've got to have surveys anyway to see how it 
compares. I mean it's not detrimental because you're still getting 
something done. [Mr Pierce: allocated to and preferred laser] 
But evidently this, the laser treatment on the prostate, I think it's 
still been, that's come from America and I think they're still sort 
of holding sort of to see what happens 'with that. I think it's, with 
a lot of these treatments they're long term ones. [Mr Watson: 
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allocated to and preferred TURP] 
As with chance, participants' acceptance of treatment comparison was often 
associated with a belief that this was helping the clinicians personally to improve 
their clinical skills and to help medical progress (see also below). 
Concealed allocation 
Thirteen participants knew that their allocation was concealed. This is associated 
with recalling that envelopes were used to allocate them to a treatment. Only two 
(Mr Symonds and Mr Daw) did not discuss concealment in the context of the use 
of envelopes. 
Did you see them opening the envelopes? 
Yes, well you picked one and they opened the envelope. Well they 
opened it in front of you. [Mr Pierce: allocated to and preferred 
laser] 
I think some of the staff drew an envelope and said next time you 
have an appointment well you've drawn this and this is it. [Mr 
Flint: allocated to laser, preference for TURF] 
Well, I think she said that there was that kind of survey thing and 
depending on what envelope you picked that is what you got you 
know. I thought that was fair enough yes. [Mr Formby: allocated 
to CM, preferred active treatment] 
They pick the - they have three envelopes or something - and they 
chose the envelope where they weren't going to do nothing and 
the specialist said that was sort of good really because we 
would've suggested that we done nothing anyway like you know. 
So it worked out quite all right really. [Mr Cullum: allocated to 
CM, no preference 1 
Two (Mr Hall and Mr Taylor), were also aware this involved concealment from 
the clinician: 
She told me there that what they would probably do is one of two 
things. I would either have the laser treatment or the operation 
and explained that if I had the operation, such and such would 
happen and if I had the laser treatment what the difference would 
be between the two and of course at the same time explained that 
neither she or the consultant himself knew which I would get 
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until they chose this famous envelope, one of two envelopes. [Mr 
Taylor: allocated to and preference for TURP] 
Yes, but when I go on the [date], he's not really decided. They're 
going to open the envelopes, it's not like they just decide. [Mr 
Hall: allocated to CM, no preference] 
The CLasP trial protocol and information sheets (see appendix 1) indicated that 
consecutive sealed envelopes were to be used for randomisation and indicated 
that the envelope should be opened in front of the participants. This was 
suggested by the trialists who assumed that seeing the envelopes being opened 
would help participants to believe that they had been randomly allocated to their 
treatment. Thirteen participants recalled hearing that consecutive opaque 
envelopes were involved in the trial treatment allocation and all but one was 
aware that this was concealed. 
Er if I wanted to go on a survey then you had a choice of 
treatment but you didn't know which one you were going to get. I 
think you got two cards or three cards, a choice of three and you 
picked one and then they opened it in front of you and that 
determined which treatment you got. [Mr Pierce: allocated to and 
preferred laser] 
I think she said there would be a choice of three envelopes you 
know, [Int: Yeah ... ] and depending on what envelope you have 
picked was the type of er .. .l think one was this type of thing that I 
have been on [Int: The watchful waiting?] yes [Int: conservative 
management?] and one was I think it was laser treatment and one 
was the old TURP thing you know (Int: Yes, the standard 
operation] that's right. So, this one came out as the waiting one 
you know. [Mr Formby: allocated to CM, preferred active 
treatment] 
Yes she did, well she did explain that yes. That there was the laser 
treatment and there was the TURPs, the ordinary, the normal one 
and she mentioned another one, a therapy, tablets. I couldn't see 
that one being much use, not if the prostate was enlarged [ ... ] she 
has them in envelopes, which operation you are going to get, or 
which method of treatment you are going to get. I drew the 
TURPs, which satisfied me, I was pretty pleased with that. [Mr 
Cooper: allocated to and preference for TURP] 
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Four participants (Mr Houghton, Mr Grange, Mr Mills and Mr Watson) had been 
informed that an envelope would be used to allocate them to their treatment and 
could recall this. However, when they did not actually see the envelope being 
opened, they found it difficult to believe that they had been randomised to their 
treatment. Their account of participation was a mixture of what actually 
happened to them and the information they had initially received about the trial. 
Any deviation from what they been told to expect should happen could be 
interpreted by them as an indication that they had not been randomised to their 
treatment, and that, for example, a clinician had decided: 
Well not really, no. Because I thought when I first went on it, 
when she first explained it, she said you'll be given an envelope 
and you take your pick apparently and that never happened. [Int: 
Oh really, you didn't see that?] No that never happened with me, 
I never got offered any envelope. I was just ... that was the 
treatment they more or less picked out for me. [Mr Mills: 
allocated to eM, preferred active treatment] 
She mentioned envelopes to me but I think she just wandered in 
one day and said you've plumped for the laser treatment and that 
was it you know. [Mr Haughton: allocated to and preferred laser] 
I've just been reading it all again Ere-read patient info sheet before 
the interview] there and I realise that [ ... ] there was envelopes 
and she would draw one out and open it. But as it happened, she 
brought it along and said oh I've opened it, sorry, you should've 
seen me open it. But I didn't mind, I wasn't worried about that 
because I was going to ask for laser. [Mr Bowler: allocated to and 
preference for laser] 
In recalling the use of envelopes, Mr Grange alludes to a kind of 'predestination' 
and this will be taken up further below. 
Fairly reasonable, I mean the fact that I said I'd go for the trial, I 
was quite happy that this was going to happen. I must say, that I 
was fairly convinced that I was going to get a laser operatIOn. I 
don't feel at all that those envelopes had anything to do with it. I 
never saw them drawn, that was done separately. [Mr Grange: 
allocated to and preferred laser J 
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Clinical equipoise 
The information sheet indicated that the evidence for the three treatments is 
equivocal and that the clinician has no treatment preference. Only six 
participants could recall this description of clinical equipoise or uncertainty: 
That I don't know. I mean I've got no evidence of preference 
expressed by the doctors and they tallred about the operation in 
detail and came to see me after the operation, which I thought, 
was very helpful. [Mr Booth: allocated to TURP, no preference] 
So I think it's just what you make your mind up when you hear 
people around you, but all the people, the doctors, the sisters 
whatever, they didn't say oh you should have this one, no. They 
were unbiased, didn't give you any impression that one was 
better than the other. [Mr Murray: allocated to and preference for 
TURP] 
Well ..... no because as they say, when they spoke about the two 
operations they explained to me then that the results should be the 
same all things being equal. Fair enough if that's the way They 
explained of course that if I had the laser treatment I would only 
be in for a couple of days, I would be sent home and then come 
back a week later. I can't say that really appealed to me, I'd rather 
get it all over and done with and then go home. But as I say, if I'd 
had to do that, then fair enough, it wouldn't have been any big 
problem. [Mr Taylor: allocated to and preference for TURP] 
A recollection that treatments were being compared implies an awareness of 
clinical uncertainty. 
Looking at it logically, they poked around inside, discovered what 
was wrong and then they put it right in one of two ways, I didn't 
really consider the wait and see business and that's it, they've 
done just that. [Mr Haughton: allocated to and preferred laser] 
Participation in an experiment 
Eleven participants knew they were involved in an experimental study of some 
sort: 
It was ideal, no problem, no problem. They have got to have these 
experiments and this sort of thing and I was quite prepared you 
know, they've got to learn somewhere, somewhere along the line 
you know. [Mr Daw: allocated to eM, preferred active treatment] 
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After my own doctor said would I like to go on this clinic and I 
sazd yes. I mean to say when you've got anything wrong with 
you, ~ou want to get it cleared up. I didn't mind sort of being 
experzmented on, no, no. [Mr Brown: allocated to and preferred 
TURP] 
Well initially my doctor obviously didn't know there was a 
scheme running. That only cropped up after, I don't know, either 
th~ fir~t or second visit to [hospital}. They said they were doing 
thls trzal and were there any objections and they were the people 
who explained the three different methods I think they were 
looking at. [Mr Flint: allocated to laser, preference for TURP] 
It didn't matter for me, I had plenty of time on my hands so I 
went in for the, you know in for the after results, before, during 
and after. She said it would help them in their research more than 
anything, so why not. [Mr Webster: allocated to TURP, preferred 
laser] 
Half of these participants used the term' guinea pig' (Mr Brown, Mr Symonds, Mr 
Hall and Mr Mills) to describe experimentation: 
I don't mind being a guinea pig [laughs]. [Mr Brown: allocated to 
and preferred TURP] 
She said, "would you mind being a sort of guinea pig you know 
for a test, for this clinical trial?" I said, "no, I don't mind" I says, 
"that's all right". [Mr Symonds: allocated to eM and preferred 
active treatment] 
Lay understandings of trial terms 
Within medical research the terms 'randomisation' and 'random allocation' have 
a specific meaning. This is not a haphazard method, but is a method of allocation 
whereby patients have an equal or known chance of being allocated to any of the 
trial interventions the systematic allocation of patients to treatments.18 However, 
for participants, this is often given a lay interpretation as being without purpose. 
The dictionary similarly defines random as 'without aim or purpose or 
principle'.267 
Well I suppose there's a random system, there isn't a better way 
really. I mean if it was just done randomly like that without 
anybody looking to see how certain results !zad gone and say oh 
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well we'll take t~at one for there, we'll do this one there. If it was 
do~e randomly lzke that then I suppose it's as good as any. [Mr 
Flznt: allocated to laser, preference for TURP] 
So judging by the tests and that I suppose you'd like to think I'd 
have this instead of that. Obviously the tests didn't show very 
much to bother him very much, so they just had a random. [Mr 
Hall: allocated to eM, no preference] 
A few patients (Mr Brown Mr Bowler and Mr Haughton) were aware that there 
was a systematic method of allocating patients to the various treatments, 
although they did not see this as 'randomisation' but by some other systematic 
method. 
Do you think they gave you enough information about the trial? 
Yes, like the first doctor I seen when I went out there, he said 
about it, different treatments and that and he said that they were 
like, trials and some would get one type of treatment and one the 
other. [Mr Brown: allocated to and preferred TURP] 
I was told you just got one every so often with the laser, whether 
they did half a dozen in a morning or so I don't know, but I don't 
suppose they would just do one. [Mr Bowler: allocated to and 
preference for laser] 
They explained that they were having this trial, that was the first 
I knew of it and laid out the three possibilities and said I nor her 
had any choice in the type. It came up on a rotation basis, so I 
agreed to that, fair enough. [Mr Houghton: Randomised to laser, 
had TURP, didn't want eM] 
The use of the word' trial' also has different meanings for trialists and patients. A 
trial sets out to measure and compare outcomes, that is, the events that are 
present or absent after participants have received an intervention allocated by 
randomisation.13 However, the lay definition of a 'trial' is to test or try something 
out: I a process or mode of testing qualities' or I a trying thing or experience'.267 
My trial didn't turn out to be one of the systems that they were, 
mine was two systems I would think because I had a laser and a 
catheter. [Mr Flint: allocated to laser, preference for TURP] 
For example, Mr Murray demonstrated high recall of the trial, but assumed that 
he might have had to endure the 'trial' of conservative management. This 
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participant believes he has to 'endure' observation for six months before he can 
receive' treatment', in this case the standard operation. 
What she said was that you help us by going through this, this 
trial or obseroation and then of the end of the day they decide 
what they should do with you. [Mr Murray: allocated to and 
preference for TURPJ 
Mr Bowler made a similar interpretation. He rationalised that the standard 
treatment could not be part of the trial because it was already in use: 
She said there was three options, which I had already read about. 
One was tablets, one was the ordinary operation and one was 
laser. I didn't really realise that it was this scheme whereby they 
were a trial you know. Because I didn't think the other one is a 
trial (TURP), it's long standing isn't it? [Mr Bowler: allocated to 
and preference for laser] 
Involvement in research 
Even when patients were aware that they were taking part in a trial, they often 
had only a partial understanding of what the trial actually involved. For 
example, Mr Hall and Mr Bullock assumed that this would merely entail 
additional/paper work', while Mr Pierce and Mr Formby saw the trial as a 'suroey' 
to assess the condition and supplement the standard treatment. 
When they said to you would you take part, was it how you 
expected? 
It wasn't an inconvenience it was just some, a little bit of extra 
work which was of no consequence .. f. .. J Well it didn't conjure up 
any additional treatment or anything, I just saw it as some paper 
work to back up the normal treatment. [Mr Bullock: allocated to 
and preferred laser] 
What did you think of that? 
Me? Well obviously what they find can help me and maybe mean 
I don't have to have an operation later on and also what they find 
may help them with their studies I assume. [Mr Hall: allocated to 
eM, no preference] 
Well I imagine that if they are going to do the suroey you know, 
like they were going to say that you are going to get the operation, 
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you know that's like a continual survey of things you know. [Mr 
Formby: allocated to eM, preferred active treatment] 
You got a lot ofextra tests, but you don't know whether other 
people were getting it as well, so it's, the only difference was that 
y~u were having surveys to fill in which is no hardship. [Mr 
Pzerce: allocated to and preferred laser] 
In contrast, Mr Stone accepted the tests, which he assumes, are part of the 
experiment, despite the pain involved: 
He tried to explain it to me but I think the worse experience was 
when he put the tubes up the penis into the bladder [ ... ] one of 
the tubes slipped out. I thought well how many bloody tubes have 
I got in me you know. [ ... ] He managed to get it back in again and 
he said fair enough, lets do it, so they did the rest of the 
experiment or whatever they were testing. As I say, that's another 
experieince I don't want to happen again. [Mr Stone: allocated to 
laser, preferred TURP] 
Alternative, non-randomised methods of allocation 
All but one (Mr Taylor) of the trial participants incorporated multiple accounts of 
how they might have been allocated to their treatment (although he was 
distrustful of this method of allocation). As previously indicated, many had a 
good or at least a partial recall of the major aspects of trial design and methods. 
However, they also believed variously that the treatments were being rationed, 
that treatment should have been individualised and that fate and destiny were 
also involved in their allocation to a treatment. Such beliefs were also associated 
with trust or distrust of their clinicians. 
As with these men's knowledge of the trial and randomisation, age, time since 
randomisation and social class appeared to have no influence on their beliefs 
about the existence of other non-randomised methods of allocation. For example, 
although Mr Murray (a teacher) had the highest level of knowledge about 
randomisation and the trial, he also used fate and destiny and trust to make 
sense of the trial. 
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Table 13: Non-randomised methods of allocation 
The 6 elements of Participant Rationing Individualised Fate! Trust Distrust 
randomisation destiny 
6 Mr Murray ./ ./ 
5 MrTaylor 
./ 
5 Mr Pierce ./ ./ ./ 
5 Mr ./ ./ ./ 
Houghton 
5 MrHall ./ ./ ./ ./ 
5 MrDaw ./ 
4 MrCooper ./ 
4 Mr Booth ./ ./ 
4 Mr Flint ./ ./ 
4 MrCullum ./ ./ 
3 MrBowler ./ ./ ./ 
3 MrFormby ./ ./ ./ 
3 MrSymonds ./ ./ ./ 
2 MrJamison ./ ./ ./ 
2 MrGrange ./ ./ ./ 
2 MrStone ./ ./ ./ 
2 MrBrown ./ ./ ./ 
2 MrMills ./ ./ 
2 MrWatson ./ ./ 
1 MrWebster ./ 
1 Mr Bullock ./ ./ ./ ./ 
0 Mr Mott 
TOTAL: 5 (23%) 12 (55%) 13 (59%) 10 (45%) 11 (50%) 
Rationing 
Five participants thought that the clinician might be rationing treatments using a 
quota system or based on patient characteristics. Almost all of this group could 
recall some aspects of randomisation in terms of chance (Mr Pierce, Mr Hall, Mr 
Bowler and Mr Symonds), that allocation was concealed (Mr Pierce, Mr Hall, Mr 
Bowler and Mr Symonds) and that sealed envelopes were used (Mr Pierce, Mr 
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Hall and Mr Bowler). Two were also aware that treatments were being compared 
(Mr Pierce and Mr Hall). 
Four believed that they had been allocated to a treatment in order to fill a quota 
for that procedure. For example, Mr Bullock implies that the rationale for 
allocating him to a treatment was because a patient was needed to fill the quota 
for the laser treatment at the time he attended the clinic: 
How about the method of treatment being decided for you? 
Well I think I was slightly cynical about it, I didn't really believe 
it. I thought that they, you know that...! really thought that they 
were just going to divide people up. I thought it was a bit of a con. 
[Mr Bullock: allocated to and preferred laser] 
These participants thought that randomisation was being used by the 
clinicians/ the NHS as a way of rationing scarce resources. This was believed to 
be related to waiting list size, the limited availability of one of the treatments or 
cost (laser required a shorter hospital stay and conservative management 
effectively no additional costs at all). For example, Mr Pierce is aware of the 
involvement of chance, comparison of treatments, concealed allocation and the 
use of envelopes, which indicates some understanding of the concept of 
experimentation. However randomisation is also seen as a way for the recruiting 
clinicians to restrict access to an innovative or popular treatment: 
Not really bearing in mind that I've had ops for the last four years 
so it wasn't something like ... how could I put it, fair comment you 
know getting the different treatments. Cos that's the only way 
they're going to say, cos everyone would probably go for one soon 
as they tell you there's not much cutting you're going to go for 
that one aren't' you so that means they're not going to get a 
realistic survey. [Mr Pierce: allocated to and preferred laser} 
Because I thought at the time that they were wanting customers 
for the laser, you know that they were running short, somethin~ 
new, although I didn't think it was new really, I'd heard about zt. 
[Mr Bowler: allocated to and preference for laser} 
Yes, but when I go on the [date}, he's not really decided. They're 
going to open the envelopes, it's not like they just decide. 
Are you surprised they do it that way? 
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Yes, yes, does that help them cut down on their operations as 
well? Is that their biggest time thing doing operation or not. [Mr 
Hall: allocated to eM, no preference] 
Such beliefs were often based on these patients' experience of receiving 
treatment. Within this trial, laser patients were grouped together to use the laser 
machine in one surgical session. Hence patients receiving either laser or TURP 
tended only to see other patients receiving the same treatment as them on the 
ward and so their interpretation of what was happening was consistent: 
Yes, that's the way I think, I may be wrong. Whether or not there 
is a chance of you getting a treatment in there I don't know. But 
I asked others afterwards and they all said the same, they all said 
the same as me. I never got any chance of getting laser. Cos I says 
to her, can I have the laser. [Mr Symonds: allocated to eM and 
preferred active treatment] 
How did they decide which was the best treatment for you? 
Well they done everybody in the ward you know. I suppose it was 
the operation. They put a thing in. [Mr Mott: allocated to laser, 
no preference] 
Individualised treatment 
Over half (12) of the participants felt that the clinician should have allocated 
them to a treatment based on their diagnosis and an assessment of their specific 
needs. 
I t was other doctors that I'd seen and they were very nice and you 
know they said like, they explained about the water test and all 
that and they said that I was definitely after they had examined 
me inside as well they said that I wanted the operation. [Mr 
Brown: allocated to and preferred TURP] 
Do you think there's any criterion, or do you think he asked 
everyone? 
Well no, unless the results show that I'm suitable for tests, the 
results from the x-rays, the blood tests and they measure the 
volume of water, these things, there's like a stethoscope. So I 
imagine he can put two and two together and decide who's most 
suitable for er, that's what I think ... [Mr Hall: allocated to eM, 
no preference] 
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What did they tell you about the trial? 
Well I wasn't concerned about the trial overall because it just 
seemed to be keyed in with the treatment and so the, I was told 
that they would decide the options. There were two options. The 
mechanical method of coring out the prostate and the laser and of 
course eventually it wasn't left to me and I received the laser 
treatment. [Mr Bullock: allocated to and preferred laser] 
I think it would be even better if they were to tell you what they 
prefer, that you're going to get. Because after all with, it's going 
to be the first time for everybody, you don't have this thing done 
twice. So therefore, after all if they tell you you still don't know 
what it's going to be so it makes no difference. [Mr Symonds: 
allocated to CM and preferred active treatment] 
This was often based on an assumption that this was how the various tests and 
examinations within the trial were utilised: 
I trusted them to give me the treatment that .. .! thought that they 
may've taken into consideration age and health in deciding which 
ones to try, which method to try. I wasn't really bothered one way 
or the other, not really. [Mr Bullock: allocated to and preferred 
laser] 
Before I had the operation, the last time I went out to [the clinic]I 
had to see the doctor, a gentleman aScot's chap I think and he 
was very nice and he said that, cos he was the one that examined 
me internally as well and he said that it was enlarged and he felt 
that it wanted an operation so that was that. [Mr Brown: 
allocated to and preferred TURP] 
Well what he did say was that they'll keep a check on me and then 
they'll play it, if things get worse then they might change their 
mind and decide that I do need treatment like you know. So I was 
quite happy with that so ... [Mr Cullum: allocated to CM, no 
preference] 
Almost all of these participants had some recall of randomisation. For example, 
despite being able to recall randomisation in terms of the involvement of chance, 
Mr Watson still believed his treatment had been individualised. Although such 
procedures are part of the trial, they apparently led this participant to believe 
that he was allocated on the basis of the test results: 
They took blood samples and they said OK and they would send 
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for me to have an operation on the prostate [ ... ] 
Int:How was your treatment chosen from the three different 
options? 
Yes well I think it was based on the tests that they gave me and it 
was one of the types. I think this was for a scan on my bladder to 
see if it was empty and everything and [the recruiting clinician] 
came back and she says to us reading the notes and everything 
and what had happened up to then as regards my case, in their 
opinion as well the middle operation was the best option they 
thought. [Mr Watson: allocated to and preferred TURP] 
Two participants (Mr Grange and Mr Symonds) believed that certain patient 
characteristics were the basis for their allocation. Mr Symonds concluded that 
patients who were retired would be allocated to conservative management 
because they would have the time to complete this option: 
But I thought they would probably they're only picking ones that 
are retired for doing that [conservative management]. I can't see 
them having fellas who are going to work because they wouldn't 
be able to do it. [Mr Symonds: allocated to eM and preferred 
active treatment] 
Mr Grange believed that his assignment to a treatment had been based on his 
youth and personality type. He felt that because he was the sort of person who 
would I accept new things' he was allocated to laser, the new technology. 
So how do you feel about being directed to a treatment like that? 
I felt that they had looked possibly at my previous medical history 
and saw that the fact that I wasn't a particularly old person, I was 
fairly young, fairly sturdy and what have you and if you like was 
prepared to accept new things maybe. I think possibly they had 
looked at that, that was my opinion anyway. I had recently been 
in hospital before that, in actual fact 1'd had a brain haemorrhage 
about twelve months previously, so they would've had plenty of 




Altruism and personal benefits 
A small number of participants cited altruism and personal benefits of 
participation as a motivation for taking part in the trial. Only seven men 
indicated that they agreed to participate in the trial for altruistic reasons, to help 
clinicians to improve their clinical skills and to contribute to medical progress. 
To help improve clinical skills: 
It was just a case of well if I can help somebody else then that's 
the main thing at least that's the way I go through life you know. 
As I said to you if you'd said I would have picked you up dO'lon 
there rather than you walk up. If I can help anybody as I go along. 
[Mr Daw: allocated to CM, preferred active treatment] 
They did in certain things which I'm sure, which doesn't worry 
me because everybody's got to learn, other people have to learn 
and unless you've got a willing person to be able to experiment on 
nobody will ever learn anything anyway. I've always looked at 
this all my life so it doesn't make any difference. [Mr Stone: 
allocated to laser, preferred TURP] 
To contribute to medical progress: 
Well not really, I don't know anything about it you see, but when 
it was explained to us verbally as well as in those [trial 
information sheets] I though well this is part of the medical 
progress you see. [Mr Watson: allocated to and preferred TURP] 
I suppose the replies that I'm giving will help to decide what was 
going to go on in the future. [Mr Murray: allocated to and 
preference for TURP 1 
Well that don't worry me neither. If I, you know, ifit's going to 
help research and that well, so be it, you kno~ it might not help 
me but it might help somebody else later on lzke you know 
(laughs). [Mr Cullum: allocated to CM, no preference] 
A similar number (7) expected to receive some personal benefits from trial 
participation, including quicker treatment within the trial: 
Yes when I went to the hospital, I felt that this would be one of 
tho~e things where you get seen and two years down tile line all 
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op.erati~n. When they.did men.tion the fact that they were doing 
trwls. I ve got to admIt that I Immediately thought oh this could 
m.ean that ~ would. be seen quicker and that definitely made a 
difference, It definItely made a difference. [Mr Grange: allocated 
to and preferred laser} 
A?a~n to be perfectly honest, I chose, I was quite happy to go the 
clInlc way and at the same time at the back of my mind was, well 
if I go that way I might get treated quicker than if I go the other 
way. [Mr Taylor: allocated to and preference for TURP} 
So I agreed to that, fair enough and the reason I really agreed was 
because I thought it would get us in quicker. She in fact said you 
know, if you don't do it you might wait six months [laughs} and I 
was in within six weeks [laughs}. [Mr Haughton: allocated to and 
preferred laser} 
For some, this expectation was based on information they had received from the 
recruiting clinician: 
1'd had the initial sort of interview if you like and someone came 
along and said would I be interested in doing a trial which 
involved possibly getting seen a bit quicker to start with. Which, 
that caught my interest to start with. So I said yes, fine. [Mr 
Grange: allocated to and preferred laser} 
He [recruiting clinician} says, all the time you are on it he said, it 
accounts for any waiting time if you have got to wait for the 
operation you see. He said, you will probably get it done quicker, 
so I says fair enough, so I went on this er ... programme. [Mr 
Mills: allocated to CM, preferred active treatment} 
The patient information sheet (see appendix 1) stated that a decision not to 
participate would not affect their treatment. However, it was sometimes thought 
that taking part must have an advantage. This is linked to distrust (see below). 
She say's even if you don't [volunteer}, it doesn't put you right to 
the back of the list. Don't think that because you're volunteering 
you're getting help, but indirectly I think you must do. That's 
another point. [Mr Symonds: allocated to CM and preferred 
active treatment} 
No, no there was no pressure, in fact she said bu t if you don't 
want to go onto it you know don't 'worry about it we'll just take 
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you i~ as normal. But she, didn't give me any indication of how 
long zt would be, so I don t know whether I would still have been 
in as quick or not, I couldn't say. I don't think I would. [Mr 
Cooper: allocated to and preference for TURP] 
Fate/destiny 
Almost two-thirds (13) of the participants held the belief that fate and destiny 
played a role in their treatment allocation. Such beliefs were commonly 
associated with acquiring their preferred treatment: 
What did the envelope have for you? 
It was the operation, which I thought all along I was going to get 
anyway. [Mr Webster: allocated to TURP, preferred laser] 
Yes I think as I say I would go for the laser again and 
disappointment didn't come into it, because I went with the idea 
that it was going to be the laser and it was. [Mr Bowler: allocated 
to and preference for laser] 
Were you surprised that they offered you an operation? 
No, no I think I expected it by then. I was looking forward to the 
operation, I thought that, my thoughts were that at 66 if I'm 
getting up three times through the night now but it's not life 
threatening, and I do this for another five years and it gets worse 
and then they say well you've got to have the operation, why 
don't I have it now and I'll have five years of trouble free I hope. 
[Mr Murray: allocated to and preference for TURP] 
So you didn't think they opened the envelopes? 
It definitely wasn't opened in my presence. It was just brought in 
and said this is the one you've got and I thought to myself, I knew 
that before it happened. That was pre-ordained, very much so. 
[Mr Grange: allocated to and preferred laser] 
There was also an indication that luck played a role in their allocation to their 
preferred treatment. 
But I've been lucky, or unlucky, I've had ops but I've been lucky 
because other patients have commented, have I been private and 
I've said no ... [Mr Pierce: allocated to and preferred laser] 
It just came out all right for me. [Mr Formby: allocated to CM, 
preferred active treatment] 
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Trust 
Well I'm not sure really, I preferred the one that I got, so I must 
have been lucky. I wasn't too keen on this laser idea of having the 
tube through the stomach into the bladder till it healed up. [Mr 
Cooper: allocated to and preference for TURP] 
Trusting the clinician involved in the men's treatment as well as trust in medicine 
and the wider medical profession was evident within many accounts (10) 
Typically, this trust was expressed in terms of the doctor being an expert: 
I don't think they can give you a choice really because you don't 
know do you. I mean they are the people who look at you and 
decide the best way, I mean there's no wayan individual can 
decide for themselves which way to have an operation, that's the 
way I look at it. I mean they are the professionals I mean so what 
else er ... [Mr Stone: allocated to laser, preferred TURP] 
You know I'm quite prepared to accept the fact that these guys 
have to learn their profession the same as everyone else. You know 
it didn't inconvenience me so I was happy to go along with it. 
[Mr Haughton: allocated to and preferred laser] 
This is associated with the altruistic desire to help others, particularly to help 
clinicians to improve their clinical skills, which is discussed earlier. 
Trust in doctors in general was also common: 
So you didn't have a preference when you went in, either TURP 
or the laser. The surgeon says this is what is going to happen to 
you and this is what he is going to do, you know. So I don't know 
what the laser one does you know, it just burns it out I think ha ... 
instead of cutting it out I think. [Mr Formby: allocated to eM, 
preferred active treatment] 
Did they talk about opening an envelope or anything? 
No, no a doctor came up to see me first thing in the morning and 
he said well, you'll have a whatever [TURP] and about an hour or 
so later another doctor came up and he said unfortunately 
something has happened and you're going to have the laser. He 
said so you won't be injected but you'll be brought down and 
you'll be put to sleep. I said well whatever I don't care you know, 
I'm here, lets get on with it. So as I say from then on it just 
progressed. [Mr Stone: allocated to laser, preferred TURP] 
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For others, trusting the doctor meant that they felt the treatment allocation 
should be based on the findings of examinations: 
Why don't they say we'd like you to do this, we'd I ike you to do 
that, or we'd like you to have the operation. Why don't they just 
tell me straight, why allocate it. [Mr Hall: allocated to eM no 
. I preference] 
Well, when he examined us, you know he um, I think he thought 
this was the best treatment for me because when he examined us, 
he said, well if the prostrate was too big, it would be ... I'm sure he 
said it would er ... If it was too big, he wouldn't be able to do 
micro surgery or something. [Mr Mills: allocated to eM, 
preferred active treatment] 
However, for some, trust in the clinician meant that they would accept whatever 
was suggested: 
You were told that you were allocated to laser, how did you feel 
about that? 
Well the decision had already been taken before I'm in the sense, if 
I was going to do it would I accept it and so forth really. So once a 
decision was taken I mean all right I'll accept it. [Mr Flint: 
allocated to laser, preference for TURP] 
When you, I look at it like this and the wife has found it the same, 
you want to get better so you go with it anyway, like. [Mr Brown: 
allocated to and preferred TURP] 
Well I don't know really, I thought well you know I don't suppose 
it worried me too much like you know, it didn't worry me too 
much. I thought they know what they're doing like, you know, so 
I sort of I'm in their hands like sort of thing, that's the attitude I 
took, they know more about it than what I know about it like you 
know. [Mr Cullum: allocated to eM, no preference] 
Because whatever they've asked me to I've done, you know, I'm all 
for it, if it's offered me I'll have it done, you know. [Mr Jamison: 
allocated to CM but preferred active treatment] 
This acceptance was also extended, for some, to participation in the trial itself: 
[the recruiting clinician] opened it [the envelope], I just accepted 
it, it was all right. I felt confident that they 'were doing what the 
thought they should do [. .. ] I don't know if that is the case, er I 
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fe~t that the.y did ;vhat was, what they thought was necessary. A 
friend of mIne he s had some tests that I didn't get, I don't know 
what it is but he, and he's not on any scheme, I forget what he 
said it was now but it was something, whether it was an insert in 
measuring something or other. But, so he had something which I 
didn't h~ve and he wasn't on the scheme, so I wouldn't say that I 
w~s gettIng more than other people. I was quite happy to go along 
WIth what they were doing, what they wanted me to do.[Mr 
Murray: allocated to and preference for TURP] 
I just hoped that all went well with me, you know. So it's 
something that you just have to hope goes well. [Mr Stone: 
allocated to laser, preferred TURP] 
It wouldn't worry me, wouldn't have worried me, I'm that sort of 
person, things like that don't worry me. You know I would've 
gone along with it, yeah. [Mr Cullum: allocated to CM, no 
preference] 
For example, two admitted that although they would not normally agree to 
volunteer for anything, in this situation they felt unable to refuse: 
So do you think there are any benefits to you in taking part? 
Oh no not really, no. There is a fair amount of inconvenience 
about that sort of test. I wouldn't volunteer, it's just I don't say 
no. [laughs] and I'm retired as well so I've got the time. [Mr 
Bullock: allocated to and preferred laser] 
It was, absolutely, I mean I was in the forces and you don't 
volunteer for anything, really. [laughs] I forgot about those rules. 
[Mr Bowler: allocated to and preference for laser] 
Three (Mr Jamison, Mr Brown and Mr Stone) felt that they did not have the skills 
or knowledge to make the decision to participate or not in the trial. They were 
dependent upon the expertise of the recruiting clinicians: 
Well he said to me the normal treatment which they cut into the 
bladder and the penis is the most successful, the laser one he said 
was more of an experimental one, how would I feel about it. I said 
whatever you think is best, you know. I mean I'm a layman, I 
don't know what goes on so I've got to leave it to them. So he said 
well I think we'll do it the other way we won't use the laser and it 
was at the last minute that they decided to llse the laser. [Mr 
Stone: allocated to laser, preferred TURP] 
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Distrust 
I said I can remember him saying when I sat down, would I be 
prepared to do something or another, but I can't remember what. 
But I went out, up the corridor, up the stairs, I'm sure I had a 
photo?raph ~aken, not what for I don't know and they asked a few 
questlOns mznd you know but I've been so many times that I can't 
remember what it's all about. [Mr Jamison: allocated to eM but 
preferred active treatment] 
A lack of trust in the clinicians was indicated by half (11). This was often caused 
by the difficulties participants had in making sense of randomisation. This often 
led to cynicism: 
Well I think I was slightly cynical about it, 1 didn't really believe 
it. 1 thought that they, you know that ... 1 really thought that they 
were just going to divide people up. 1 thought it was a bit of a can. 
[Mr Bullock: allocated to and preferred laser] 
Now that's a thing, cos she says 1 was free to choose from didn't 
she. Now, aye, yes she gave us three, she says pick one of them. 
But I think along the lines afterwards, I'll be honest here, I'm 
dubious whether they are all the same. You know, you'll know for 
a fact that they're giving you the choice of picking one but you're 
saying to yourself, no matter which one you pick, you're not 
getting onto the other one. [ ... ] Yes, 1 think that, 1 don't know 
mind. But 1 think it's obviously they decide on what, what they've 
found out on examining you 1 think they decide which is going to 
be best for you. That's only to keep you happy 1 think. [Mr 
Symonds: allocated to eM and preferred active treatment] 
When he said do 1 agree, or do 1 agree to take part in these tests, 
he looked at me as if, I said to myself, there's something you're not 
going to tell me, that I shouldn't do it or there's something funny 
about it, but he didn't say any more than that. So really 1 don't 
know what I've let myself in for, I know it's voluntary but it can 
only do good more than harm I suppose ... [Mr Hall: allocated to 
eM, no preference] 
Sister gave me, she handed me two envelopes and said pick 
your envelope. Unless they were both the same, I don't know! 
[laughs] But no, as I say I think that is the best way to do it, 
because 1 can see problems otherwise, saying well so and so got a 
choice, I want the same sort of choice. I appreciate as I say that 
you have to get a fifty fifty verdict on that I would imagine. [Mr 
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Taylor: allocated to and preference for TURP] 
For a small number (Mr Jamison, Mr Symonds, Mr Mills and Mr Bullock), a lack 
of trust was linked to the men's difficulty in reconciling aspects of the trial design 
with their own experience. For example, not seeing the envelopes was perceived 
by a small number to be an indication that the clinician selected their treatment: 
Int: Right. So you think they chose that? 
They must have chose that because I wasn't given er ... I know, 
people that have went on that course and have had the same thing 
and have done the ... they got to pick like, but I never got a pick of 
an envelope. Um, unless ... I know there was something in the 
form and I'm not sure, I know that I picked one of them but I 
don't think it was the laser thing you see, er and the 
questionnaire. [ ... ] But um, I, that was more or less picked for me 
through er the [hospital]. wasn't really, no I wouldn't say that I 
was offered erm, a choice like [Mr Mills: allocated to CM, 
preferred active treatment] 
They still let you do the three card trick and they just carry it on 
because from the very first start it's written in the pamphlets they 
give you. That's one of the things they'll do. You've got your 
three choices, your TURPs, your what do you call it, this one 
where you're under management, but I think it would be even 
better if they were to tell you that they prefer, that you're going to 
get. Because after all with, it's going to be the first time for 
everybody, you don't have this thing done twice. So therefore, 
after all if they tell you you still don't know what it's going to be 
so it makes no difference . .. [Mr Mills: allocated to CM, preferred 
active treatment] 
For the majority of those who expressed distrust, this is part of their struggle to 
understand and can be tempered by a successful outcome. For example, in 
contrast to Mr Symonds above, where the failure to obtain his preference led to 
distrust, the fact that Mr Grange received his preferred treatment seems to have 
outweighed any suspicion of how this actually occurred: 
I was convinced from the start that I was going to have a laser 
operation. I felt that that was what was going to be the result. I 
don't think the envelopes would've mattered. [Mr Grange: 
allocated to and preferred laser] 
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Three participants (Mr Bullock, Mr Cooper and Mr Symonds) were concerned 
that saying no to the trial could, they believe, affect their future treatment: 
It didn't enter my mind but I think I could've dropped out yes. I 
suppose at the back of your mind you are thinking, yes, but it may 
affect the treatment, the quality of the treatment. [Mr Bullock: 
allocated to and preferred laser] 
Taking part in the trial was also seen by some to be a 'trade off', a two way 
process whereby both parties benefited. For example, Mr Houghton and Mr 
Bullock believed that the clinicians had incorporated additional benefits for the 
patient into the trial as an inducement or 'carrot' to take part: 
Do you think it would have been easy for you to say no? 
Yes I think I could have said no, yes I think I could have done. I 
would've had to have been prepared to wait and I wasn't. There's 
always a carrot isn't there. I mean to be honest about it they've 
done that deliberately so you don't say no. Well all right I 
understand but it's still to my benefit, so you know you go along 
with it. [Mr Haughton: allocated to and preferred laser] 
Well you know if you are part of the scheme, you're playing ball 
with the hospital and so they play ball with you. I wouldn't have 
thought of dropping out. [Mr Bullock: allocated to and preferred 
laser] 
Treatment preferences 
All but four of the trial participants expressed a preference for one of the 
treatment options available as part of the trial. It is important to bear in mind that 
these are preferences described after the process of randomisation. It is not 
possible to know whether these preferences were present before randomisation 
as well as at the time of the interview. 
The preferences expressed by the men suggest that over half (10) were 
randomised to the treatment they preferred. This was associated with fate and 
destiny and an expectation of individualised treatment. 
What did you think of that? 
Fairly reasonable, I mean the fact that I said 1'd go for the trial, I 
was quite happy that this was going to happen. I must say that I 
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was fairly convinced that I was going to get a laser operation. I 
don't feel at all that those envelopes had anything to do with it. I 
never saw them drawn, that was done separately and I was 
convinced from the start that I was going to have a laser 
operation. I felt that that was what was going to be the result. I 
don't think the envelopes would've mattered. [Mr Grange: 
allocated to and preferred laser] 
Can we just go back to the envelopes again, what would you have 
done if i t wasn't the laser? 
I think I would have asked if I could change to the laser, I think I 
was set on the laser. [Mr Bowler: allocated to and preference for 
laser] 
Participants' beliefs about the trial and how they had been allocated sometimes 
appeared to be influenced by a preference for an alternative treatment. However, 
it is not known to what extent such preferences are independent of or had 
developed as a result of their subsequent allocation to that treatment. 
Eight participants appeared to have been randomised to a treatment that was not 
their original or rationalised preference: 
Well, I thought the standard operation. I wasn't too happy about 
the laser treatment because they reckoned the laser treatment 
would take a fortnight with a catheter in and this sort of thing 
which I wasn't too happy about and I thought the other one would 
be ideal which it was. It worked out ideal for me you know. [Mr 
Daw: allocated to CM, preferred active treatment] 
One (Mr Webster) preferred laser but received TURP: 
Brilliant, you know that's new technology. They're not going to 
use lasers if they're no good you know, quick, clean and efficient. 
So no I'd be happy with that. [Mr Webster: allocated to TURP, 
preferred laser] 
However, this group appeared to be satisfied with their allocation, perhaps 
because they received' treatment' . 
Five (Mr Formby, Mr Mills, Mr Symonds, Mr Daw and Mr Jamison) preferred 
TURP or laser, but had been allocated to conservative management. This group 
had been assured that they would receive 'treatment', the standard operation 
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TURP, (often their treatment preference) once they had completed the trial. This 
was often their reason for continuing to participate: 
You know once I put my mind to a thing I say to myselfI'm 
going to carry it out in any case. As long as, as long as I knew at 
the end it was going to be put right. Cos I told her, I said once I've 
gone through this I hope I'm put right. She said oh aye, no 
problem, you'll get put right. [Mr Symonds: allocated to CM and 
preferred active treatment] 
Well it didn't bother us because I knew that eventually I would 
get the operation. Whether it would be six months, a year it didn't 
really bother us. [Mr Webster: allocated to TURP, preferred laser] 
Well I think what normally happens - I think I don't know how 
long it was, was it 9 months, 10 months or something. I think 
really that 9 months span or 10 months span when you finished 
it, I think you automatically went to the front or near the front 
you know. [Mr Formby: allocated to CM, preferred active 
treatment] 
Well, I said of course I want the operation, I am not coming here 
for fun you see. At the finish of the last time I was there, they said 
I notice you've ticked that you want the operation because she 
said, well if you hadn't ticked it, I would advise you to have it you 
see, which is you are probably here within a fortnight when you 
are gonna .. and sure enough, within a fortnight I was given a 
date and went to go in. [Mr Mills: allocated to CM, preferred 
active treatment] 
The additional tests involved in conservative management were also thought to 
provide benefits, for example, by screening for cancer: 
Well just for peace of mind if you know what I mean. It would 
make my mind a lot easier to know that there was no, that I 
haven't got cancer, they're doing a thorough check. That's worth 
its weight in gold that having peace of mind isn't it. [Mr Webster: 
allocated to TURP, preferred laser] 
Or would be used to ensure that they received the most suitable treatment for 
them: 
Oh I was um, well I've ... it was either that or I would have just 
had to wait. At least I thought that something was getting done 
and at least they were finding something ou t because when I 
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finally went in for the operation on the night time when I saw Mr 
--, he said, well I've got some good information here, by 
being on the study, by monitoring different things he had to um 
er ... He had all the information there and he said this is good 
information for me er ... and there wasn't any problems really 
about the ... you know, about doing the operation like. [Mr Mills: 
allocated to eM, preferred active treatment] 
However, a few participants found their allocation to conservative management 
difficult to accept. Despite being able to recall the involvement of chance in their 
allocation, these participants also wanted and expected I treatment'. This was 
often interpreted as their exclusion from treatment and this was often upsetting 
for these pateints. 
You know at the moment, as I said like, the problem with this 
water trouble is you know four or five times every night and it's a 
bit annoying you know. I can go to the toilet, come downstairs 
and within a matter of minutes I've got to rush back upstairs. 
Well I think something ought to be done about it. [. .. ] It was, it 
was because it was like, I naturally thought that they were going 
to do something about it but as I said I had no tablets or nothing 
for it, so that's all I can tell you. [Mr Jamison: allocated to CM 
but preferred active treatment] 
I never got any chance of getting laser. Cos I says to her, can I 
have the laser [Mr Symonds: allocated to CM and preferred 
treatment] 
This is associated with rationing (see above) and this failure to receive their 
preference led some participants to recognise the implications of trial 
participation and randomisation (this is discussed in more detail in chapter 7). 
Outcome 
Most of the men interviewed felt that their symptoms had been improved after 
treatment: 
Well I was quite happy, because I mean there haven't been many 
side effects quite frankly. [Mr Watson: allocated to and preferred 
TURP] 
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Oh, ~hey've turned out er ... I think they've turned out champion, 
up till now anyway. [. .. ] I haven't had any problem. [Mr Mills: 
allocated to CM, preferred active treatment] 
No bother, no bother. You get a couple of days discomfort in 
hospital but that's all [Mr Haughton: allocated to and preferred 
laser] 
Oh yes, the problem has gone away, yes. I don't have a problem at 
all now. It was very successful. [Mr Bullock: allocated to and 
preferred laser] 
Some had such a good outcome, they would advise others to have it: 
Oh I think I would recommend anyone to have the treatment. I 
know it isn't successful in every case, but it certainly has been 
very successful for me. [Mr Bullock: allocated to and preferred 
laser] 
For one, the piece of mind that acute retention would not happen was an 
important outcome: 
But the bit that worried me about going and not being able, 
there's none of that touch wood, but that was the thing that 
worried me because I'd heard of people where that had happened, 
where they had been rushed into hospital, that was the one thing 
that worried me about it but as I say that's gone completely. [Mr 
Taylor: allocated to and preference for TURP] 
A small number, however, still experienced some symptoms following surgery. 
Two of these men (Mr Pierce and Mr Bowler) had received the laser treatment 
and this group were expected to improve more slowly: 
I'd still be getting up through the night but most gentlemen that I 
mention that to say's Oh aye, I get up at night. Well I never used 
to and during the day I go about half a dozen times, only passing 
about 100-150ml. but, I was talking to Sister __ yesterday, she 
say's that's OK, it's gradually getting better, six months is 
usually the time when you can, evidently, say right I should be 
better now [Mr Bowler: allocated to and preference for laser] 
Oh yes, it took a few weeks, after about 5 weeks I was beginning 
to despair, I thought this is not right but after seeing the doctor 
and him giving me this stuff to calm things down a bit, to get my 
balance, perfect. [Mr Cooper: allocated to and preference for 
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TURP] 
Some patients modified their behaviour after the operation: 
I think it's just training my bladder not to jump up if I feel and 
sort of just train it to put up with that little bit of pressure and it 
might just be accepted you know. [Mr Murray: allocated to and 
preference for TURP] 
It's helped, it's just getting confidence. You know I can go three 
to four hours now without going to the 100. But bear in mind 
prior to having any problems I used to go all day without going to 
the loa, you know. I might go in the morning when I went out 
and then late afternoon. So it's not back to that but then again it's 
been so long with running every two minutes. [Mr Pierce: 
allocated to and preferred laser] 
Complications following discharge from hospital 
A number of these patients experienced short term and occasionally long term 
problems following treatment. 
Laser 
Aftercare was sometimes a problem for those who had been allocated to laser 
and had been discharged from hospital with a catheter bag: 
I thought to myself this is great, but it wasn't great, I found out it 
wasn't great, wasn't as easy as you think. I didn't know what 
your experiences are with meeting different people like myself 
But I found out that the problem is just started then, after you've 
come out of hospital, when you think your fit but you're not. 
Did it take some time for you to recover? 
It took months actually. [Mr Symonds: allocated to eM and 
preferred active treatment] 
I came home, I had to get someone to take me home and I had that 
catheter in me for three weeks, I didn't expect it to be in for so 
long. [Mr Grange: allocated to and preferred laser] 
Well I think that, well not from experience of course but I got the 
impression that the recovery was longer and of course they put a 
catheter in through the stomach 'wall, yes in here which seemed to 
me to be a lot more elaborate than the other method and also 
although they said it would take a fortnight before that was away 
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I di~ have the ~ag for tu:ice as long as they said, it was in for four 
or five weeks, zt was quzte a long time. [Mr Bullock: allocated to 
and preferred laser] 
I did have quite a few problems, yes. I mean I ended up with a 
catheter for two weeks instead of the bag from the bladder. [Mr 
Flint: allocated to laser, preference for TURP] 
Support after they had been discharged from the hospital and reassurance about 
their progression was sometimes sought: 
TURF 
Once I had had the operation I had this yearning all the time to 
urinate and nobody ever mentioned that at all. For the first couple 
of days I'd gone home I actually phoned the hospital two or three 
times to find out was there something wrong. Now if somebody 
had said to me after you have this operation you are going to have 
this feeling all the time I would've been quite happy. Well not 
happy but I would have been aware of the fact, so they didn't 
make me aware of that. Eventually Sister after a week I 
phoned her and she said well possibly what's doing it it's the 
catheter is possibly touching something and if you tried pulling 
the catheter it might ease a little bit but that was after a week. 
Now if somebody had told me beforehand that sometimes the 
catheter can cause irritation and you can do this to alleviate this I 
would've done it. I was unaware of this and I had to find that out 
through frustration and through the telephone. [Mr Grange: 
allocated to and preferred laser] 
A small number of patients who had received TURP also experienced prolonged 
pain and bleeding after they had been discharged from hospital: 
I think if I had had, mind at the time, while, after this, when this 
pain was going on I thought I wish I'd never ever gone to the 
doctor about this. Now that it's over and now that it has settled 
down I can say yes, I'm glad that it's over. [Mr Murray: allocated 
to and preference for TURP] 
These men were also unsure about what to expect following treatment and who 
to contact for advice if they were having problems: 
For a long time, actually months every time I passed water I J~ad 
pain and I was, it was getting me dO'llm, the people I was talklng 
to, nobody's had this bother and I thought why is it that I'm 
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having so much pain and I phoned Sister __ a few times, she 
was helpful and then she made arrangements for me to see, come 
back up to the hospital and I saw this Dr and he didn't 
--
examine me he just told me- that was a bit annoying because if he 
had just said over the phone well it takes time but he let me get up 
to the hospital and then he said well it takes time and I thought 
well why bring me up and wait for me to see my turn for you to 
just tell me that, that's no help. Anyway, it did take time and I 
phoned, I spoke to Sister _ two or three times on the phone 
about this and what she said was I'll see Dr , there is a tablet, 
not the antibiotic, but the tablet which settles you down a bit 
[ .. }and eventually the pain did go away and since then I've been 
fine, I've been great. [Mr Murray: allocated to and preference for 
TURP} 
One of these men described a more serious complication following surgery: 
Well what went wrong was apparently there was a leakage from 
the tube into the bladder and they had to take it out and I think I 
must have had peritonitis. As far as I understand it, I obviously 
know nothing about it, I was in intensive care for 36 hours and 
they had to give me the electric treatment to get my heart going 
again and so forth. [Mr Flint: allocated to laser, preference for 
TURP} 
Sexual function 
Retrograde ejaculation was a side effect following surgery for four of these men. 
Although this is a known side effect of surgery for this condition, this was 
unexpected for a number of these men. 
Two of these men did not remember being told about this side effect until after 
this had happened to them: 
About the problem you were having [retrograde ejaculation}? 
Yes and he said that I should've been told. Well they never told 
me, they never told me at all.[ ... } I went to my own d?cto,r when 
it happened because when I first came out of the hospztalzt was all 
right but afterwards, well just a short while, after I went out of 
5 the last time, time before that it sort of happened all of a 
sudden. But I said to the wife, they never told me anything, 
whether it was just one of these things because at the time I went 
in to have the operation they were venJ very busy in there, they 
were coming in and out like a conveyor belt sort of business [Mr 
Brown: allocated to and preferred TURP} 
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I kn~w I might be wro~g, I probably am, cos you know they're 
cuttlng you and they Just slipped to one side and cut through the 
wall a bit and that's you, that part of it's finished. You are not 
going to ejaculate any more and you'll say that's it, that's finished 
and you just wonder if it's because they've using, because they 
tell you, _ told us that this does not, when I've been back I've 
mentioned this to the doctor, I've mentioned this I say, I can't 
understand this thing. He says were you not told, I says I was, 
but I didn't realise that it would happen and I says I didn't think 
that would happen. But, could you tell me does that happen all the 
time? Cos they told me it would just be normal you see and I 
found out that it wasn't so. That's the only thing that has made a 
difference. But otherwise everything is OK. [Mr Symonds: 
allocated to eM and preferred active treatment] 
One did recollect that he had been informed about this side effect before his 
operation, however, he did not feel that this had been clearly explained to him: 
There was, if you don't mind this is going to get on the sexual 
side. He did say to me that once you had the laser treatment 
through the penis it will effect you in the sexual side so I said well 
how. He said well er the sperm that comes through from the 
testicles won't come that way any more. So I said why not, he said 
welt he still didn't explain it to me properly he said you can still 
have intercourse or whatever but the sperm doesn't' come out it 
goes into the bladder. Well [. .. ] the way he spoke about it, it 
would be a definite side effect, but I couldn't understand why. 
[Mr Stone: allocated to laser, preferred TURP] 
One couple found that this had affected their sex life: 
I says well we're past the children age so it's not going to make 
any difference, it's just a case of getting used to a different way, 
you know. I think that affects the men more than the women 
because it's something they have to come to terms with. It's their 
body that's altering. I don't know, that's something you'd have to 
answer that. But I mean ... [Mr Pierce: allocated to and preferred 
laser] 
One patient was impotent. He had some symptoms prior to surgery, however, 
this got worse following treatment. He recalls that he tried to discuss this with 
the clinician on his follow-up visit, but did not feel that the clinican was 
interested in this problem: 
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I don't get erections any more. so it curtails, I've got a very good 
wife, don't take me wrong .......... 
Did they mention anything about impotence as a possible side 
effect? 
They did mention that as a possibility, but at my age I'm not 
worried about impotence but I would have liked to have full use of 
the penis sort of thing, you know. But unfortunately since the 
operation I've got worse. I've got to ..... since the operation 
erections are harder to get, so really there's no one I can talk to 
about it [. .. }all he [the clinician} was really interested in. 
Basically he just turned round and said are you all right, cos I 
didn't really gather that he wanted any more information [Mr 
Stone: allocated to laser, preferred TURF} 
These men's beliefs about the trial and randomisation were examined in the light 
of their outcomes. It is interesting to note that the men who stated that their 
symptoms had been improved after treatment also incorporated trust and 
distrust within their accounts which were similar to those who had experienced 
complications or side effects as a result of treatment. However, this distrust may 
be of the method of treatment allocation itself rather than the trial. 
Other findings 
Diagnostic tests 
A number of these patients found the tests involved in their diagnosis and the 
evaluation of their treatment painful and embarassing: 
The extra tests, for instance they took biopsies of my prostate, I 
can tell you now that if I thought I had a similar problem and 
would have to have that biopsy again I would lie to avoid having 
to go through that again. I really would lie, not pleasant at all. 
Something I would've thought they should've done under 
anaesthetic. Like I say if that had been described to me by someone 
who had it, no way I would go through that again. I would 
honestly I think I would lie, say I'd got no problems rather than 
go through that again. It was painful, but it wasn't so much that 
as it was totally undignified, painful, uncomfortable. No, never 
again, I don't even want to think about it [laughs]. [Mr Grange: 
allocated to and preferred laser} 
They put you through this test. I was watching it on the telly, 
where they, you could see it was turning in the inside and Jze was 
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taking pictures of your prostate and your bladder inside [. .. ] But 
that wasn't nice, that wasn't nice, the pipes and all that was all 
right but when you see that thing you think oh my God! [Mr 
Symonds: allocated to CM and preferred active treatment] 
The same with going out there to S to the clinic afterwards 
because they give you the water tests again and when they put the 
tube down through the penis like you always feel that with you 
afterwards. I still sort of feel sore there you know [Mr Brown: 
allocated to and preferred TURF] 
Well they're all right but I mean to say when they go up the front 
end and the back end with pipes and that and they do rather 
embarrass you and they leave you rather sore you know. But 
having said that if they tell you what they do you'd ... but 
hopefully as long as you'll be doing somebody some good. As long 
as it helps them for later on you know that's all that matters. [Mr 
Daw: allocated to CM, preferred active treatment] 
It [pain after tests] lasted for about 24 hours because the end of 
the penis is sore and it's just sore right the way through but you 
know I know these things have got to be done so I mean it never 
worries me [Mr Stone: allocated to laser, preferred TURF] 
Case studies 
Each individual's narrative about trial participation was also analysed as a case 
study. This showed that most participants engaged in a dialogue to try and make 
sense of the trial design, their lay beliefs and their actual experiences of 
participation. Three examples described below have been chosen because they 
indicate a number of the different ways in which these men struggled to make 
sense of their knowledge of the trial and their experience of participation. 
Similar recall of the trial and experiences of participation can produce different 
yet internally consistent accounts of participation. For example, this can lead to a 
belief that treatment should be individualised (Mr Watson) or that the clinicians 
were rationing treatments (Mr Symonds). Trust and distrust of the recruiting 
clinicians were common and Mr Haughton shows how participants incorporate 
trust into their accounts. 
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MrWatson 
Mr Watson, a 78 year old retired (retail) 'working class' man, was allocated to, 
and, indicated a preference for TURP, the I standard' treatment. He had some 
recall of randomisation, in that he knew about chance and the comparison of 
treatments: 
Yes, but what it was, they took biopsies as well which proved that 
there was no cancer there or anything. But to improve down there 
I could take the option one option of three, to have an operation 
and what it involved was going in and a tube up your urethra 
and scraping the prostate. [Mr Watson: allocated to and preferred 
TURP] 
However he was adamant that he had not been allocated a treatment by 'lottery', 
because he did not witness anything to indicate that this had happened to him: 
Int: So they didn't do that [randomisation/opening an envelope] 
with you? 
Oh no it wasn't a lottery sort of thing as far as I was concerned, 
no no. As I say it was in some of the information leaflets I got 
from the hospital saying that, but there was none of that. [Mr 
Watson: allocated to and preferred TURP] 
Because numerous tests were carried out, he believed that this had been used to 
inform his treatment allocation: 
How did you choose the treatment from the three different 
options? 
Yes well I think it was based on the tests that they gave me and it 
was one of the types, I think this was for a scan on my bladder to 
see if it was empty and everything and [the recruiting clinician] 
came back and she says to us reading the notes and everything 
and what had happened up to then as regards my case, in their 
opinion as well the middle operation was the best option t~ey . 
thought. I mean naturally if I hadn't been in agreement WIth It I 
would have said right, no I don't want it, that's that [Mr Watson: 
allocated to and preferred TURP] 
This was further reinforced by comments made by the clinician on allocation: 
Did they tell you much about the other options? 
Oh yes they were explained to us, but in their opinion this 
[TURP] was the better one for me, the other options was 
treatment 'with no operation, and the other operation was the 
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burni~g?f the prostate with laser and with that I think you came 
out wIthIn 24 hours with a bag and I think you had for about a 
week and then you went back. [Mr Watson: allocated to and 
preferred TURP] 
However, he received his treatment preference (TURP) and so was ultimately 
happy with the outcome, the treatment had proved successful. 
How did you choose the treatment from the three different 
options? 
Yes well I think it was based on the tests that they gave me and it 
was one of the types, I think this was for a scan on my bladder to 
see if it was empty and everything and [the recruiting clinician] 
came back and she says to us reading the notes and everything 
and what had happened up to then as regards my case, in their 
opinion as well the middle operation was the best option they 
thought. I mean naturally if I hadn't been in agreement with it I 
would have said right, no I don't want it, that's that [Mr Watson: 
allocated to and preferred TURP] 
MrSymonds 
This is in contrast to the experience of Mr Symonds, a 59 year old man who 
worked in the manufacturing industry. He had been allocated to conservative 
management and after completing the trial received 'the common one', TURP, his 
preference. Treatment was successful, however, it 'took months' for him to fully 
recover. He went through a long struggle to make sense of the trial design, 
culminating in cynicism. He was sceptical of the use of envelopes and believed 
that it was a sham and that there was a hidden quota system in operation. 
Now that's a thing, cos she says I was free to choose from didn't 
she. Now, eye, yes she gave us three, she says pick one of them. 
But I think along the lines afterwards, I'll be honest here, I'm 
dubious whether they are all the same. You know, you'll know for 
a fact that they're giving you the choice of picking one but you're 
saying to yourself, no matter which one you pick, you're not 
getting onto the other one. [Mr Symonds: allocated to eM and 
preferred active treatment] 
The information he had about randomisation proved problematic; he could not 
understand why envelopes were used. There was an element of suspicion within 
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this account, with the use of the envelope likened to a 'three card trick', which 
concealed a quota system: 
It might be too expensive, they probably have to keep that I don't 
know. But I seem to think that the three card trick as we call it it , 
is a three card trick like. It doesn't matter which one you pick, I 
think it will be all the same like. You know I think you know 
you're going to get it. [Mr Symonds: allocated to CM and 
preferred active treatment] 
Perhaps surprisingly this distrust was scepticism of the method of allocation 
itself rather than the motives of the clinician. This deception was thought to be 
for his benefit. Although this is not explicitly stated, it may be that he believed 
the clinician wanted him to believe there was a fair and equitable method of 
allocation, when in fact, there was a quota system that delayed his treatment. He 
concluded that the clinician allocated him with the envelope 'only to keep you 
happy I think'. 
Do you think they decided? 
Yes, I think that, I don't know mind. But I think it's obviously 
they decide on what, what they've found out on examining you I 
think they decide which is going to be best for you. That's only to 
keep you happy I think. 
Some people have told me that they expected the clinician to give 
you a treatment specifically for your condition ... 
Yes, I thought that, exactly, right. I thought they should tell you. 
That's why I think they do know by what they find out what is 
best for you, but they don't actually come out with that.. .... [Mr 
Symonds: allocated to CM and preferred active treatment] 
Perhaps the most crucial aspect was that Mr Symonds was not allocated to his 
preference. He expected active treatment and so individualised treatment 
allocation made the most sense to this participant. He did not understand why 
this did not happen: 
So why do you pick, they may as well tell you what it~s going t~ 
be. They may as well say well you're going to have thls don~ thls 
way and this is the process. You know, put i~ i,n a way that,lt's 
better for you in any case, it suits your condltzon then. I thlnk 
that would be better than they let you take your pick when I think 
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along the lines that you know you're being conned. [Mr 
Symonds: allocated to eM and preferred active treatment] 
MrHaughton 
Trust and a belief in the clinician as expert, was often the basis for others' 
participation. For example, Mr Haughton who was a 70 year old retired (betting 
shop) man, had been allocated to TURP and indicated a preference for 
'treatment', which was successful 'no bother'. He had a good recall of 
randomisation, although his acceptance of this approach was linked to trust, in 
that he would accept whatever the clinician suggested, such as the trial. 
I just wanted the thing over and done with. I didn't care too much 
how they did it as long as they did it. To be honest when you 
don't know what they are doing anyway, you are just quite 
prepared to take their word for it, certainly I am, happy to go 
along with whatever the expert recommends. That was it, we then 
went into the thing. [Mr Haughton: allocated to and preferred 
laser] 
It is interesting to consider whether this respondent would have felt differently if 
he had been allocated to conservative management, the treatment option he did 
not want. As it was, he was allocated to treatment and expressed an altruistic 
desire to participate. 
When __ asked you to take part, has it been how you 
expected? 
I think so yes. No looking at it logically, they poked around inside, 
discovered what was wrong and then they put it right in one of 
two ways, I didn't really consider the wait and see business and 
that's it, they've done just that. No, you know I'm quite prepared 
to accept the fact that these guys have to learn their profession the 
same as everyone else. You know it didn't inconvenience me so I 
was happy to go along with it. [Mr Haughton: allocated to and 
preferred laser] 
Conclusion 
Overall, most participants were able to recall some aspects of randomisation and 
what the trial involved. However, the majority also held other co-existing ideas 
about non-randomised methods of allocation such as rationing and 
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individualised treatment, which they used to understand and explain their 
treatment allocation. For a small number, altruism and an expectation of personal 
benefits were motivations for taking part. However, trust, distrust and their 
beliefs about fate and destiny developed as they tried to make sense of their 
treatment allocation in relation to their treatment preferences. The interview data 
and particularly the case studies illustrate the struggle that the participants 
engaged in to help them understand the experience of participation. Chapter 6 
goes on to examine the experience of non-participation. 
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The experience of those who are eligible but 
decide not to participate 
Introduction 
This chapter will examine what happened to those patients who were eligible to 
take part in the trial but decided not to participate, including their motivations 
for deciding not to take part and their perceptions of the trial. It will go on to 
explore their recall of what the trial involved and how they made sense of the 
treatment they received and non-participation. These men's symptoms and their 
knowledge of the treatment available within the trial are also examined. Their 
outcome will not be examined because they received treatment outside of the 
ClasP trial. As for the participants, a number of case studies are also described to 
demonstrate the dialogue that most participants engaged in a to try and make 
sense of the trial design, set within their lay beliefs and their actual experiences 
of participation. 
Characteristics of participants 
Patients (n=ll) were selected in order to reflect the main reasons for non-
participation within the ClasP trial and were identified by the recruiting 
clinicians. Data on non-participation was recorded - it is important that trials 
record such information about those who are eligible but decide not to 
participate in order to reduce selection bias. 
Thus those who according to the trial records decided not to participate because 
they had a treatment preference (5), did not want to be randomised to a 
treatment or take part in research (4), or did not want trial tests (1) were 
interviewed. One patient where no motive had been recorded was also selected. 
The labels used to link the quote to the non-participant include a brief 
description of their reason for this as recorded in the trial records. The sample 
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had similar characteristics to the participants. These men were aged 54-81 years 
old and were predominantly retired (Mr McCarthy and Mr Ladbroke were 
employed). The majority (8) attended clinic B and had not yet received treatment 
for their condition (7). Four had received the standard treatment (TURP) outside 
of the trial, one had received drug treatment and four were on the waiting list for 
surgery. 
Previous or present occupation and the area in which they lived were used to 
broadly indicate these mens' social class. The majority of these men were 
categorised as working class and two (Mr Ladbroke and Mr Frame) as middle 
class. 
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Table 14: Non-participants 
Name Age Occupation Reasonfor Status Location 
refusal within 
the trial records 
MrFlynn 81 Textile industry Preference Waiting for B 
treatment 
Mr Maynard 67 Mechanic Preference Waiting for B 
treatment 
MrMcCarthy 54 Environmental Preference Waiting for B 
Health treatment 
Mr Allgood 78 Water Board Randomisation TURP B 
MrYoung 74 Building Travel TURP B 
supplies 
MrLadbroke 61 Manager Randomisation No B 
treatment 
MrBecker 71 Catering Refused tests TURP B 
MrFrame 69 Aeronautical 'Refused', no Drug B 
engineer reason given treatment 
Mr Frost 66 Insurance Randomisation Waiting for B 
/research treatment 
MrGibbon 62 Coach driver Preference Waiting for A 
treatment 
Mr Williams 67 Bank Preference TURP A 
Reasons for attending the urology clinic 
Symptoms 
The majority of these men discussed the urinary symptoms they were currently 
or had previously experienced that had prompted them to seek treatment. The 
main symptoms were frequency, retention and nocturia. Many described how 
these symptoms had impacted on their lives. Only two (Mr Flynn and Mr 
Gibbon) gave no indication of the symptoms they had experienced. 
Table 15: Non-participants' reported symptoms 
Name Frequency Hesitancy Acute Affecting Affecting Other 




MrMaynard .(' .(' .(' 
MrMcCarthy .(' .(' .(' 
Mr Allgood .(' 
MrYoung .(' .(' .(' 
MrLadbroke .(' .(' .(' 
Mr Becker .(' .(' 
MrFrame .(' .(' .(' 
Mr Frost .(' .(' .(' 
MrGibbon 
MrWilliams .(' 
TOTAL: 4 (36 %) 2 (18%) 4 (36%) 2 (18 %) 5 (45%) 5 (45%) 
A tick signifies that these men discussed this symptom within the interview. 
Retention 
A small number of the men mentioned retention: 
I never put it to prostate or anything like that and I didn't worry 
about it and it went away and I never had it for many years after. 
But I have occasionally got it you know, [. .. ] you don't ever 
empty your bladder properly, so there's always some residue there 
so I suppose what happens is you've got this back pressure 
coming up. [Mr McCarthy: treatment preference] 
Two had experienced episodes of acute retention that required medical 
intervention: 
Nocturia 
But on the weekend on the Sunday it er just went into retention 
and there was er, I couldn't pass anything at all, it went on for 
about 10 hours and I thought well I'm getting a bit desperate 
here, so I phoned up in the morning and asked the doctor about it, 
if I could come over and see him and er he said the best thing to do 
is come straight over to the hospital. [Mr Young: travel] 
Had I been going over there like for months like some people they 
find it creeping up on them, unlike mine which come to an abrupt 
stop. [Mr Becker: refused trial tests] 
Nocturia, that is, the need to urinate often during the night, was a common 
symptom among these participants. 
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Yes I think it was, I can't remember how far back this was now, 
nearly six months ago perhaps I had been having some prostate 
problems for some while, not causing any great discomfort but the 
business of going to the toilet and not being able to do it that sort 
of thing and also getting up at all times during the night at one 
stage and not being able to go back to sleep again, so a lack of 
sleep. [Mr Ladbroke: a dislike of randomisation] 
Well I didn't mind the operation because you see I wanted to get 
it done because I was living on my own here and nights when I 
wanted to go to the toilet it was sometimes more than 5 minutes 
before I could start to go and it was terrible yeah, yeah the pain 
[Mr Allgood: a dislike of randomisation] 
Other symptoms 
One patient discussed terminal dribbling: 
Then the worst part of the lot which I did explain to them the 
worst thing really, the worst symptom I don't like is having gone 
to spend a penny you think you've finished and you're just 
walking away and you realise you haven't and you know that is 
embarrassing and that's the one symptom I would like to get rid 
of [Mr Maynard: treatment preference] 
A small number of the men mentioned frequency: 
Yes well prior to going to S , what happened, I knew I was 
having prostate, you know, knew it was going on first of all 
because of my age and then of course I kept going to the toilet 
and ... [Mr Young: travel] 
Two patients spoke of their reduced flow: 
It started about four or five years ago and what happened was I 
was having very slow flow of urine and not always emptying the 
bladder. [Mr Frame: no reason given] 
Incomplete emptying with frequency was also problematic for one: 
Well yes, I realise sometimes that the bladder doesn't empty but is 
that major? Is that a major problem, that's my point. I did say 
that the use of the bladder, just like last night, I didn't get up at 
all. Now I've been, had use of my bladder three times since seven 
o'clock. It's now halfpast 10. Maybe you could turn round and 
say that's excessive, I can't say. But it depends on, I mean this is 
my third cup of intake since then, so I don't know. It's what the 
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medical experts have to say not me. [Mr Frost: dislike of 
randomisation and research] 
Affect on social life/normal daily activities 
A number of men (5) described how their symptoms affected their social life and 
daily activities. They often described how they had to plan journeys and 
experienced anxiety finding public toilets: 
It was a bit unsocial [. .. ] Bit of a nuisance, yes you know I mean, 
if you went anywhere you'd think well first thing I've got to do 
before I go is go to the toilet and then when you get there you've 
got to make sure that there are toilets about like. It wasn't too bad 
but of course if you like a drink if you drink anything alcoholic 
that even makes it worse and that acts like a diuretic and makes it 
that little bit worse. [Mr Young: travel] 
I've not got to the stage where if I go on a coach journey I've got 
to make sure there are loos about and so on I do tend to get a bit 
concerned about that but there's people far worse than me, far 
worse than me. [ ... ] But I go on some coach trips with some 
retirement people that are a little bit older than me and they all, 
most of the men and so on you know they've got to stop for the 
toilet, comfort stops or whatever, [Mr McCarthy: treatment 
preference] 
I wouldn't have put up with it for long term, even if I' d have to 
pay to, you know, I did say I've put up with it for I think it was 
nearly three months probably, I lived a full life admitted but I was 
fed up to the back teeth of it. [Mr Becker: refused trial tests] 
I knew where and how long I was going to be out for and there 
would be no problem with toilets that sort of thing. [Mr Frame: 
no reason given] 
As for the participants, such experiences were often I embarrassing' for these 
men: 
I mean they may say it's not serious but to me it's quite 
embarrassing it does interfere with your life and I mean if I go out 
for an evening I've got to be very careful how much I drink and 
now if I go to a skittle match, where I would probably drunk two 
pints of shandy or something like that or a pint of beer and 
perhaps a shandy I now think I'll just have a half please and I tn) 
and make that halflast because if I don't then I'm in and out of 
bed all night you know. [Mr Maynard: treatment preference] 
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Well I've got nothing to compare with other than the symptoms I 
have I know are embarrassing to me, I've put up with them for a 
couple of years with tablets and the tablets didn't seem to be 
having any further effect then you know it got me to a stage and 
then I seemed to be static and I had problems which I explained 
and I was a bit disappointed that those problems are still going to 
be with me. You know I thought well I thought all this was going 
to put it right. [Mr Maynard: treatment preference] 
It gradually got uncomfortable in as much as it was embarrassing 
when I sometimes went into town with my wife to do some 
shopping and I've got to find a toilet quick, that sort of thing [Mr 
Frame: no reason given] 
Knowledge of the treatments available within the trial 
These men displayed a low level of knowledge about the three treatments 
available within the trial: TURP, laser and conservative management. The 
information levels within this group are probably comparable to ordinary men 
who receive 'normal' treatment for this condition. None of these men appeared 
to have any knowledge of what conservative management involved. 
Knowledge of TURP 
A small number of men (4) could recall that TURP was the standard treatment 
for this condition: 
Well I think me being me, if the TURPs is the standard one then 
I'm quite happy thank you because that's been proven with 
everyone else [ ... ] Well I suppose it's run of the mill treatment. 
[Mr Gibbon: treatment preference] 
A small number of these men also recalled that this method involved 'cutting': 
What had they told you about the operation? 
They told me what it ~ould entail, y~u know tha~ the¥ ,took ,this 
erm probe thing up wlth a cutter on It or somethIng, It s a lzght 
and a cutter I think something like that and they take off the 
prostate and er so in the end I went up and had it done and it 
worked out very well. He said, you know that there could be snags 
but it went very well. There was erm, no I don't suppose there 
was really any pain you know, not any excessive pain and only a 
little bit of discomfort anyway. [Mr Young: travel] 
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No he didn't say what they were going to do, he just said that 
they would,perform t~ remove, like coring an apple, my prostate 
gland, that s all he saId. [Mr Becker: refused trial tests] 
Knowledge of laser therapy 
Although eight of these men mentioned the laser therapy, only three (Mr 
Williams, Mr McCarthy and Mr Frost) were aware that this was a new treatment 
and only one (Mr Williams) knew that this involved a catheter bag: 
It's in its infancy [Mr McCarthy] 
The level of knowledge about all the treatments, particularly conservative 
management, is very much lower among these non-participants compared to the 
participants. Although it was likely that they were given the patient information 
leaflet, it would seem that they were not able to recall more than very basic 
matters. 
Recall of randomisation 
As for the participants, non-participants' recall of the trial can be broken down 
into six integral elements: an understanding of the involvement of chance, that 
their treatment allocation was concealed, that envelopes were used to allocate 
treatments, that treatments were being compared, the existence of clinical 
uncertainty and that they were being asked to participate in an experiment. 
As can be seen from table 16 below, all but two non-participants (Mr Flynn and 
Mr Allgood) could recall some aspects of trial design. As for the participants, 
their recall was often expressed in a number of different ways. Overall this group 
had a lower level of recall of randomisation than the participants, although 
surprisingly, almost all could recall the experimental nature of the trial, 
compared to only half of the participants. 
Age and time after they had been approached to participate appeared to have 
had no influence on these men's recall and understanding of trial information. 
The influence of social class was also examined. The two 'middle class' men had 
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varying levels of recall and understanding of these six elements, ranging from 
the second highest (Mr Ladbroke) to one within the middle range (Mr Frame). 
Table 16: Recall of randomisation 
participants allocation uncertainty 
Mr Becker ./ ./ ./ ./ ./ 
Mr Ladbroke ./ ./ ./ ./ 
Mr Maynard ./ ./ ./ 
MrMcCarthy ./ ./ ./ 
MrYoung ./ ./ 
MrFrame ./ 
Mr Frost ./ 
MrGibbon ./ 
Mr Williams ./ 
Mr Allgood 
Mr Flynn 
I TOTAL: 4 (36%) 4 (36%) 2 (18%) 3 (27%) 9 (82%) 4 (36%) I' 
•. _._ ..................... _ ..... __ ................... _ ....................... _.............................. .. ................................................................. _ .... _ .. _ ............ _ ...... _ ..... __ ................. _ .......... _ .. __ . __ ...... .. ............... _ .. __ ................... _ ....... L .......... __ .......... _. ___ ........... J 
As for the participants in the previous chapter, a tick in table 15 signifies that the 
informant discussed that particular concept and that he demonstrated that he 
understood the concept in the way it was presented in the study information. 
Chance 
Four non-participants (Mr McCarthy, Mr Ladbroke, Mr Becker and Mr Young) 
could recall that chance was involved in the way treatments would be allocated 
within the trial. 
Yes he did list for me, outline the various different methods, that's 
right, and explain to me that your particular case would be 
treated by lottery if you like, by picking up an envelope and that 
was to be it. [Mr Ladbroke: a dislike of randomisation1 
As for the participants, lay descriptions were also common within this group. For 
example, 'lottery' (Mr McCarthy and Mr Ladbroke), 'balls in a cup' (Mr McCarthy) 
and 'luck of the draw' (Mr Young and Mr Becker) was used to describe 
randomisation: 
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I mean I think you know they said you know, if the laser side of it 
is still in its infancy, it's not one hundred per cent then I would 
say no, well yes you can have this but we can't guarantee the 
results, OK, you know where you stand, not just to say well you 
know we'll just put balls in a cup and get whatever comes up. No, 
I'm not happy about that. I'd like to know what's, what I'm being 
offered, 100%, one way or another. [Mr McCarthy: treatment 
preference] 
However, such descriptions of chance, such as 'lottery' and 'luck of the draw' 
also integrated fate and destiny, comparable to the participants' accounts. For 
example, Mr Becker appears to believe that some participants will be 'lucky' and 
receive the 'right' treatment within the trial: 
It was the luck of the draw, which is why you had two envelopes, 
you've got to pick your choice. [Mr Becker: refused trial tests] 
Concealed allocation 
Three non-participants (Mr Ladbroke, Mr Maynard and Mr Becker) were aware 
that allocation to a treatment within the trial would be concealed. For both, this 
was linked to their awareness of the use of envelopes. 
You will be allowed to pick an envelope and one will say laser and 
one will say surgery. Whichever you pick you'll get. [Mr Becker: 
refused trial tests] 
Two were also aware that this also involved concealment from the clinician: 
He explained that there would be no specific method of treatment 
given, that they would be done by opening envelopes or something 
to decide' ah this is the method for you' or whatever and if it 
happened to be operation then you should bear in mind that 1 % 
die. [Mr Ladbroke: a dislike of randomisation] 
He said 'quite frankly I don't know which is the best way. [Mr 
Maynard: treatment preference] 
Comparison of treatments 
Four (Mr Maynard, Mr McCarthy, Mr Becker and Mr Frame) were aware that the 
trial involved the comparison of treatments: 
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Because they were running it to see which was the best result 
laser or surgery and you agreed to take part in it. [Mr Becker.~ 
refused trial tests] 
This also involved the testing of treatments: 
I can only imagine that it would mean going to the hospital with 
a group of people. Say there were ten people involved, if there 
were tw~ tests, five would do one, five would do the other. If there 
were a different number of tests, if it was three tests there 
would've been twelve people, four would've done one, four 
would've done ... something of that sort. It would've probably 
have meant keeping you in hospital for at least over one night. 
Though not necessarily, no I'm not sure about that, but you 
would have to go by whatever requirements they had about 
abstaining from certain foods for certain times if necessary and I 
don't really know more than that, I'm guessing. [Mr Frame: no 
reason given] 
Clinical equipoise 
The information sheets indicated that the clinicians did not have a treatment 
preference and that the three treatment options within the trial were equivocal. 
Four of the non-participants (Mr Maynard, Mr Becker, Mr Frame and Mr Young) 
could recall such uncertainty about the treatments within the trial. This is 
surprising, as less than a third (6) of the participants could recall this feature of 
the trial. 
This was often expressed as a belief that the treatments within the trial were 
equally effective: 
I think I would have thought well either have it cut out or have it 
lasered out. It wouldn't make no odds as long as it does the job. 
Yeah, I mean I wouldn't have, I don't think I would have minded 
either way there. [Mr Young: travel] 
Thinking back to when the nurse came to see you about the 
triaL.how did you feel about that? 
Well actually you get so brassed off with having the catheter up 
there you don't care what they did as long as they got you out of 
the predicament that you are in. Whether they did it by surgery or 
laser it doesn't matter. [Mr Becker: refused trial tests] 
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An acceptance of clinical equipoise is linked to trust. This will be discussed in 
more detail below: 
How would you feel about your treatment being chosen by 
randomisation rather than ... 
Well I wouldn't be worried about it because anything that the 
national health service is going to offer is obviously based on 
experience which is going to be satisfactory over the range of 
surgery requirements or types which are available. If something 
was quite unsuitable it would never have been included in the 
random method of tests. [Mr Frame: no reason given] 
The differing rationalisations of clinical equipoise were sometimes an element 
within their rationale for not participating. This will be discussed further below 
(pp. ). For example, Mr Frost does not believe that different treatments can be 
equivocal for all patients and that one treatment may be more likely to benefit a 
particular patient: 
You can't have a like for like because two patients can be 
altogether different [Mr Frost: dislike of randomisation and 
research] 
Participation in an experiment 
Almost all (9) were aware that the trial was some sort of experiment. This was 
often expressed in lay terms such as 'guinea pig' (Mr McCarthy, Mr Ladbroke, 
Mr Becker and Mr Frost): 
Going back to the trial for tablets, how do you feel about being 
part of a trial? 
Well in other words I was being used as a guinea pig. Yeah, I 
don't mind that no, no. [Mr McCarthy: treatment preference] 
Well all they were doing at that moment in time, they were doing 
so many with surgery and so many with laser and they 'l,vere 
using people like guinea pigs too. [Mr Becker: refused trzal tests] 
Well I suppose my initial reaction to that is that I n:i~ht be at risk 
a little bit in being a guinea pig. [Mr Ladbroke: a dlSlzke of 
randomisation] 
It may be that such knowledge was a factor in their non-participation. 
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Involvement in research 
These non-participants often held a partial knowledge of what a trial actually 
involved and these are similar to the descriptions given by participants. For 
example, two (Mr Young and Mr Becker) described the trial as a I survey': 
So when the nurse said there are these two options and these two 
envelopes, what did you think? 
I thought well, it was a survey. If you entered their survey then 
this is what they did when you were nearer the operation. [Mr 
Becker: refused trial tests] 
The trial was often believed to be tests (Mr Frame and Mr Williams): 
I would've agreed to say I'm perfectly happy to take part with any 
form of randomised treatment but whether it was going to be a 
trial test or whether it was to be the final test I wasn't aware. [Mr 
Frame: no reason given] 
Why did you prefer the operation? 
It just seemed quicker like. I mean they took us on a Thursday, 
done it on a Friday, took the catheter off on the Saturday, I 
could've come home on the Sunday but I couldn't get transport, 
so I came home on the Monday and it was finished. I just thought 
with the laser, getting it and carrying the bag. I wouldn't have 
minded the tests, it was just carrying the bag. [Mr Williams: 
treatment preference] 
It was also described as a questionnaire to assess symptoms. This is comparable 
to the beliefs of some participants that the trial would merely entail additional 
paperwork: 
Did they ever mention what being part of a trial would mean? 
Not a lot of detail no. I suppose the trial, the paper I was 
completing, was more or less self explanatory dealing with 
nothing else but symptoms. [Mr Maynard: treatment preference] 
I assumed from that that the degree of the symptoms that I'd had 
according to that paper would sort of indicate to somebody well 
perhaps this would be the best for you, whatever that's what I 
expected, but that really isn't what happened. [Mr Maynard: 
treatment preference] 
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Lay understanding of trial terms 
As with the participants, non-participants similarly gave a lay description of 
random as an event with no purpose: 
So anyone of those random things would therefore be successful 
and it wouldn't have worried me at all. [Mr Frame: no reason 
given] 
The trial was also believed to be the process of trying out a new treatment (Mr 
Maynard, Mr McCarthy, Mr Young and Mr Frost): 
I was referred to him for the prescription for the [tablets], which I 
thought was a trial, I don't know what they call it. They try you 
out on it and if it works OK and if it doesn't you know. [Mr 
McCarthy: treatment preference] 
So what were your expectations? 
Well I thought, I thought it might be a trial of tablets, drugs, 
because I've got a brother who's got it, he also has Parkinson's 
disease and he said they put him on drugs and I thought well it 
might be that you know. [Mr Young: travel] 
Three (Mr Maynard, Mr Gibbon and Mr Williams) non-participants rationalised 
that the standard treatment could not be part of the trial because it was already 
in use. This is similar to the interpretation of one participant (Mr Bowler). 
You filled out the questionnaire ... 
Well that's what I assumed, I thought well if you are of this 
opinion and you've looked at my records and you've spoken to the 
consultant, I thought well perhaps I have got wrong. I thought 
the laser was a standard treatment as well. [Mr Maynard: 
treatment preference] 
Well I think me being me, if the TURPs is the standard one then 
I'm quite happy thank you. [Mr Gibbon: treatment preference] 
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Pathways to refusal 
Despite the fact that the majority could recall being asked to take part in an 
experiment, these non-participants had distinct beliefs about the treatment they 
recedived. This is part of the process of making sense of their experience of being 
asked to participate and the treatment they received. Of the eleven non-
participants (based on information contained in the trial records), three believed 
that they had agreed to participate in the trial and only five believed that they 
had made an active decision not to take part in the trial. The remaining three had 
no recall of being asked to participate. 
Table 17: Pathways to refusal 
Knowledge of Name Reasonfor Active Believed No 
the elements of refusal within refusal they had knowledge 
randomisation the trial records agreed to of the 
participate ClasP 
trial 
6 Mr Becker Preference ./ 
(maximum) 
4 MrMaynard Preference ./ 
4 MrLadbroke Preference ./ 
3 MrYoung Randomisation ./ 
3 MrMcCarthy Travel ./ 
3 MrFrame Randomisation ./ 
1 Mr Frost Refused tests ./ 
1 MrGibbon 'Refused', no ./ 
reason given 
1 Mr Williams Randomisation ./ 
/ research 
0 Mr Allgood Preference ./ 
0 MrFlynn Preference ./ 
Active refusal 
Five non-participants (Mr Young, Mr Ladbroke, Mr Frost, Mr Gibbon and Mr 
Williams) appear to have made an active decision not to take part in the trial. 
This group all had a good recall of the trial in terms of experimentation, 
however, only two were aware of the involvement of chance (Mr Young and Mr 
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Ladbroke) and the additional presence of clinical uncertainty (Mr Young) and the 
use of concealed allocation (Mr Ladbroke). These men were 62-74 years old and 
had attended both trial centres. One (Mr Ladbroke) was categorised as middle 
class. 
According to the trial records these patients decided not to take part in the trial 
because they had a treatment preference (Mr Gibbon and Mr Williams), the 
travelling involved would be difficult (Mr Young), did not want to be 
randomised to a treatment (Mr Ladbroke) or take part in research (Mr Frost). 
This group also incorporated a number of additional reasons for not taking part 
in the trial within their accounts. They all additionally cited a dislike of 
randomisation and trial participation, three preferred to receive individualised 
treatment and two expressed high levels of anxiety about the trial and their 
treatment. 
Table 18: Reasons for active refusal 
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I Mr Williams ./ 
L ........ _ .. _ ....... _ ........ _ ................................................ __ ._ .......... _ .. 
Treatment preferences 
All five (Mr Young, Mr Ladbroke, Mr Frost, Mr Gibbon and Mr Williams) 
expressed a treatment preference. The majority (Mr Young, Mr Gibbon, Mr 
Williams) indicated that they wanted TURP because they believed this to be the 
standard and possibly the most effective treatment: 
Well I think me being me, if the TURPs is the standard ~ne then 
I'm quite happy thank you because that's been proven wzth 
everyone else. Having said that I appreciate someones got to do, 
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you've got to have someone for research and all that. But me 
worrying, no thank you, [Mr Gibbon: treatment preference] 
Just ~hat, they told us that the bladder wasn't quite empty after 
passIng water and asked us if I wanted laser treatment or the 
ordinary one, but I didn't like that. I just preferred the ordinary 
one she said you'd have to carry a bag [catheter] about, that sort 
of thing and I didn't fancy that. [Mr Williams: treatment 
preference] 
This decision was sometimes based on a preference for a less invasive treatment 
before having surgery: 
I was a little bit surprised when the gentleman said [about 
CLasP], gave me the information that it's self explanatory type of 
thing what was discussed. I don't particularly like the thought of 
having, if there is surgery involved because erm it's not always 
certain if there is a problem it will eradicate the problem. I mean 
this man said to me as I say about the tablets he said, I haven't 
been to the hospital, my GP has given me these tablets and if the 
tablets don't resolve any difficulty or problem there ... [Mr Frost: 
dislike of randomisation and research] 
If you had a free choice, what kind of treatment would you have 
wantedfrom them? 
Well I suppose what I, I would've wanted to be told, your 
condition is all right, you take these tablets and the tablets will 
improve your prostate gland trouble or at least try them before 
considering any of the other methods. I mean I think perhaps I 
wanted to try that course of action before considering anything 
else, that's what I thought, that's the way my mind thinks 
anyway, lets go for the soft option first and if that don't work, 
well we'll have to consider one of the other way of going about it. 
[Mr Ladbroke: a dislike of randomisation] 
This was associated only with wanting a 'successful' treatment: 
The thing is to my way of thinking erm it's either one form of 
treatment or the other on this and neither form of treatment are 
totally 100%. So there's no point in having something which isn't 
100% to my way of thinking. [Mr Frost: dislike of randomisation 
and research] 
Preference for individualised treatment 
The decision not to participate was often made because they received no 
direction from the clinician as to whether they should participate in the trial or 
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not. For example, Mr Young explicitly asked for advice and in response to 
receiving no direction from the clinician and he decided to have the option he 
knew most about, the standard treatment (TURP): 
When he said 'well its entirely up to you' he didn't seem to want 
to make any decisions or choices for me and so I said well I 
thought the easiest option, the thing is to go for the operation 
because I've been told about it before you know, I've been up there 
a couple of times to see Dr T . [Mr Young: travel] 
How did you feel about saying that you preferred the operation? 
They didn't put no pressure or owt on us. They just asked us, told 
us the alternative and what they were like and asked us which one 
do you prefer and I tell her like and she said well the laser one is, 
I'll go no further because they wanted tests and that but they 
didn't mention that at first. [Mr Williams: treatment preference] 
Mr Gibbon believed that his recruiting clinician had directed him towards one of 
the treatment options. This was seen in a positive light: sensing his uncertainty, 
the recruiting clinician had directed him away from trial participation: 
They did an ultrasound there and then and they give me this 
leaflet on various treatments for prostate problems and asked 
about the new laser treatment I think and this [recruiting 
clinician] explained with little diagrams and things and explained 
what this process would entail [ ... ] I really worry badly. So when 
[the recruiting clinician] tells me this I must have changed, I 
must have, because I was a bit taken aback by that, I wasn't 
expecting this to be honest. I thought it was 'here take these pills 
you'll be OK', so me face changed and she says what do you think 
about this laser you know and explained it and as I said I think 
my face must have changed and then [the recruiting clinician] 
said I don't think this is for you, I don't think it's in your best 
interest for you to, and I agreed and said no I don I t think it is. So 
then [the recruiting clinician] said Oh well you'll be referred onto 
Mr _ waiting list for, I forget, I think it's TURP's or 
something, which is the normal. [Mr Gibbon: treatment 
preference] 
I more or less went by guidance from [the recruiting clinician], 
[the recruiting clinician] said about this and I said yes that 
sounds lovely and as they explained it on [date] it was [th~ 
recruiting clinician] that noticed more or less the change zn me. 
[Mr Gibbon: treatment preference] 
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In contrast, Mr Ladbroke felt pressure to participate in the trial and infers from 
this that the clinician was having trouble recruiting patients, and thus rejected 
the trial: 
How about monitoring and no treatment? 
Well no he didn't mention that but that seems to be what's 
happening with me. But then, I found him a little bit pushy 
actually. 
So how did you feel about that? 
I said give us the pills, I thought I'll have the pills thank you very 
much! (Laughs) 
Why do you think he was so keen to have you on the trial? 
I've no idea, no idea. He was definitely, yes he gave me the 
impression, perhaps wrongly, that he was er having trouble 
getting anyone submitting themselves to the trial (laughs). I think 
he was determined to get somebody to volunteer, he gave me that 
impression (laughs). [Mr Ladbroke: a dislike of randomisation] 
Mr Frost found it hard to ask the recruiting clinician what the trial actually 
involved: 
I wondered whether it was an experiment to be funded by 
someone. Erm, it's was difficult to ask that man point blank, is it 
clinical research. [Mr Frost: dislike of randomisation and 
research] 
It is interesting to note that even when these patients had what appeared to be 
different levels of direction from their clinician, this can lead to a similar 
outcome, the rejection of the trial. 
The trial and randomisation 
All five of this group cited some aspect of the trial design in their reason not to 
participate. Almost all (Mr Young, Mr Frost, Mr Gibbon and Mr Williams) 
wanted the I right' treatment. This was often based on a misunderstanding of 
clinical equipoise and the belief that the standard treatment would be more 
effective: 
I mean in all forms, if it's going to be surgery, all right surgery 
has got to be positive, there's no point to my way of thinking to 
having some surgery if the problem isn't eradicated. [Mr Frost: 
dislike of randomisation and research] 
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But me worrying, no thank you, I'll stick with the one that's tried 
and tested if it's all the same you know. That is my way. [Mr 
Gibbon: treatment preference] 
A dislike of being part of an experiment was a factor for Mr Ladbroke and Mr 
Frost: 
How would you feel about that? 
A little bit uneasy 
In what way? 
Well, I shall I say, I don't want to be used for experimental 
purposes. If it's going to be, have to be surgery, I want the 
surgery to be successful. [Mr Frost: dislike of randomisation and 
research] 
I can see the reasoning behind it all, sensible enough, things that 
you know, we all want to learn and improve, I can understand 
that. But at the end of the day if the individual doesn't want to be 
forced down one particular route, he shouldn't be. But I can 
understand. [Mr Ladbroke: a dislike of randomisation] 
This was linked to not wanting to become a 'guinea pig' (Mr Ladbroke and Mr 
Frost): 
Obviously I think I was taken aback a bit about being offered to be 
a guinea pig, and to go into this trial and that threw me. So had I 
been, had I known about that before I went I might not of been 
thrown offbalance as much. But I was, but he did outline the 
alternatives to me, yes [ ... ] that smacks of smacks of possibly 
receiving some sort of treatment that hasn't been properly 
researched, that was it. [Mr Ladbroke: a dislike of randomisation] 
Well I felt the gentleman explained what he had written down, 
now my point about it is this. Is this [ CLasP patient info sheet], 
how shall I say, an experiment? Is this an experiment that is 
possibly funded by the University of B_ and the University of 
A or patients? Is this gentleman one of a team? Is it a 
research into prostate which the University of A and the 
University of B will fund on a patient basis? That wasn't 
explained and its a little bit difficult to come out and say right 
doctor, am I a guinea gig? [Mr Frost: dislike of randomisation 
and research] 
A dislike of the involvement of chance in their allocation to a treatment was also 
present: 
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What did you think of that? Instead of them saying 'this is the 
best treatment for you' they said 'we're going to open an envelope 
to decide'? 
No, I didn't like that I must confess, no I didn't like that (laughs). 
I wasn't in control of anything then was I, you're not in control 
(laughs). No I don't think so no, not being able to consider 
yourself consider the methods and design for yourself what you 
would like with the help of the doctor, er is yes out of control. [Mr 
Ladbroke: a dislike of randomisation] 
However, three (Mr Young, Mr Ladbroke, and Mr Williams) of these patients 
who appeared to be making an active decision not to participate in the trial 
because it involved experimentation and randomisation, also stated that this was 
not the main factor for this decision. For example, Mr Williams asserts that he 
was not concerned about the trial, he just did not want surgery, specifically 
because laser involved having a catheter bag: 
It wasn't the tests that I was worried about it was just the bag. I 
thought it was going to be a bit awkward and that like. [Mr 
Williams: treatment preference] 
Sometimes, the condition itself improved, so that treatment was no longer 
required: 
Did that pu t you off the operation? 
Yes, I suppose it did, I suppose it did er, but having said I mean if 
they can just, If I'm being serious and demanded an operation 
then obviously I would have to go along with that. But I mean the 
way its been described to me, that there were other, what I would 
call, harmless treatments that could rectify the condition and just 
thinking about it now, knowing that you were coming today 
Katie, I was thinking about it now, ever since, I don't know 
whether this is up here (points to head) or not, but ever since I'd 
been and had that examination by that consultant at S the 
situation would appear to be a little better. Aye, whether that's 
just me or not, no I don't seem to be bothered as much. I'n: not 
saying that the symptoms aren't there every now and agazn but 
certainly not as frequent as it was before. I would have th~u~ht on 
balance it's, the situation is better, yes. [Mr Ladbroke: a dzslzke of 
randomisation] 
198 
The practicalities of participation 
One non-participant (Mr Young), based his decision to refuse on a (valid) 
assumption that the trial would be more time consuming than the standard 
treatment: 
Anxiety 
They said somethin,g about a new treatment. He went all through 
the notes, and he sald well I am running a sort of a section of 
people wzth prostate to ... I don't know what the treatment was he 
didn't tell me anything about it. No he didn't tell me anything' 
about it, he said you know, you can come or whatsname ... but my 
trouble was not so much the, I wasn't worried about what the 
trea~ment was, I didn't know what it was. I thought to myself, 
comzng from C I had to arrange transport you see and so it 
means getting a car up, people waiting for me and so I didn't 
know if it was let's say a weekly treatment it would mean going 
up for probably a matter of months, weekly and he didn't sort of 
say too much about it and in the end he said well it's up to you 
entirely. [Mr Young: travel] 
For two non-participants (Mr Ladbroke and Mr Gibbon), their decision was 
linked to their anxiety about trial participation: 
Of course, I admit I'm a terrible worrier, I am, I really worry 
badly. [Mr Gibbon: treatment preference] 
What did you think of the operation after he had said that? 
I thought to myself well I'm not in any pain, I thought I'll have 
the pills I think. The coward's way out perhaps, I don't know, but 
that's the way. [Mr Ladbroke: a dislike of randomisation] 
Believed they had agreed to participate in the trial 
Surprisingly, a number of patients who according to their notes were non-
participants (Mr Maynard, Mr McCarthy and Mr Becker), believed they had 
agreed to take part in the trial. All of this group could recall experimentation (Mr 
Maynard, Mr McCarthy and Mr Becker), randomisation in terms of comparison 
(Mr Maynard, Mr McCarthy and Mr Becker) and clinical uncertainty (Mr 
Maynard, Mr McCarthy and Mr Becker). Fewer were also able to recall chance 
(Mr McCarthy and Mr Becker), concealed allocation and the use of envelopes (Mr 
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Becker). These men were 54-71 years old and had all attended clinic B. All three 
were categorised as working class. 
There was a disparity between these patients' interpretation of what had 
occurred during the consultation and what had been recorded in the patient trial 
records. Two (Mr Maynard and Mr Becker), were willing to participate but 
believed that the clinician had excluded them from the trial, while Mr McCarthy 
did not believe that he had' refused' . 
Table 19: Reasons for the belief that they agreed to participate 
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Directed by the clinician 
All three believed that they had been directed towards (or away from) one of the 
treatment options by the recruiting clinician: 
I never had a lot of choice. The same as she said that if it fails you 
have to have a catheter, but as you've already got one you've got 
no choice, you're going to go for it aren't you. I said oh yeah. [Mr 
Becker: refused trial tests 1 
So I brought this up with the consultant and the consultant I 
spoke to at the time he said 'we have been using it but we don't 
think a lot of it because its in it's infancy and its you know, 
there's a lot more work has to be done', research and so on. [Mr 
McCarthy: treatment preference 1 
The first thing that was offered was the laser, I said yes pl,ease and 
the next minute it was whipped away and then an operatlOn and I 
said yes again you know. What I'm looking for is something to 
put it right [ ... 1 Well he seemed to have his mind made up as I 
went in his room. [Mr Maynard: treatment preference] 
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Two (Mr Maynard and Mr Becker) had expected to participate, but believed that 
they had been excluded from the trial. This is similar to the participants' beliefs 
about rationing. 
Because when it said about I didn't, in your letter you said about 
the trials, I didn't have a chance. [Mr Becker: refused trial tests] 
I assumed that really, that was really what more or less I was 
doing with the tablets, that's what I assumed. The second one was 
straightforward laser and er I assumed that a laser would do er 
something similar to what they would do under an operation and 
I mean I'm not just, we didn't go into that sort of detail so I don't 
know but well I shall just have to wait and see I suppose now. But 
I did think that you were under the wrong impression when I 
received this (my letter) that I had not agreed to go through, take 
part in the ... [Mr Maynard: treatment preference] 
There is an element of distrust within their accounts, which will be discussed 
below. 
These two non-participants (Mr Maynard and Mr Becker) would appear to agree 
to receive any of the available treatments and appeared to be willing to accept 
trial participation. For example, Mr Maynard appears to agree to both laser and 
TURP as the recruiting clinician presents them to him: 
Then he went on to say to me that he expected it to be more 
serious perhaps than it was and that would I be interested in a 
laser job? I said that would suit me fine. So he went, he left the 
room and went out, spoke to someone, came back in and said 'well 
it appears that it's not bad enough for a laser job' So I said well 
OK. So then he surprised me again and said 'now I can still put 
you down for an operation' So I said 'well, OK' 
In the notes it stated that you would prefer the operation ... 
No that's not correct at all, I accepted what was offered to me. I 
was prepared to accept anything that was offered to me. [Mr 
Maynard: treatment preference] 
I think you get to the stage where you don't care what they do as 
long as you get one. [Mr Becker: refused trial tests] 
This is very similar to the experience of the participants (see previous chapter). 
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Understanding of the trial 
Non-participation within this group appeared to be unintentional. The belief that 
they had not refused may be associated with their lay interpretation of the trial. 
For example, to try something out: 
Wh~tever, I just sort of said oh there must be something they're 
tryIng out. [ ... J SO as regards to, I wasn't ever aware that I had 
refused to take part in a trial, I assumed that this investigation 
and the taking of this tablet F __ was part of some sort of trial 
that's all I can tell you really. [Mr McCarthy: treatment 
preference J 
He spent some time explaining the situation, that there are three, 
roughly three ways of dealing with the problem,[ ... Jand 'we will 
talk though your trial when you complete it [questionnaire], 
which was what I expected to happen. [Mr Maynard: treatment 
preference J 
The use of questionnaires also appears to be a factor. Both Mr Maynard and Mr 
Becker assumed that their completion of the initial symptom questionnaire was 
the first stage of trial participation: 
I thought I was participating in the trial. In fact, he went on to 
explain to me that the trial was nothing to do really with the 
hospital, it was something which was tied up with the University 
and he gave me the questionnaire. I brought it home- in fact it 
took me quite some time to complete it, and then having 
completed it, I went back and amended it a couple of times 
because I thought well there's more than one answer to these 
questions and erm I amended a couple. So I thought I has taken 
part in the trial. [Mr Maynard: treatment preference J 
She came and said would you like to fill this out so I said, it was a 
great big form and saying what, how it was affecting you. Well it 
was too late, I had a catheter in and it was all in the past. So she 
said would you fill it in what it was like, well I said, I was all 
right before you know, I just had[Mr Mills: allocated to CM, 
preferred active treatment] 
However, a few participants found their allocation to conservative management 
difficult to accept. Despite being able to recall the involvement of chance in their 
allocation, these participants also wanted and expected' treatment'. This was 
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often interpreted as their exclusion from treatment and this was often upsetting 
for these pateints. 
You know at the moment, as I said like, the problem with this 
w.ater tro~ble is you know four or five times every night and it's a 
bIt annoYlng you know. I can go to the toilet, come downstairs 
and within a matter of minutes I've got to rush back upstairs. 
Well I think something ought to be done about it. [ ... ] It was, it 
was because it was like, I naturally thought that they were going 
to d? somethi:zg about it but as I said I had no tablets or nothing 
for It, so that s all I can tell you. [Mr Jamison: allocated to eM 
but preferred active treatment] 
a sudden chomp it was stopped, so she said fill it out what you 
can. So I filled it out and then they sent for me for the interview to 
go and see the specialist and I took it with me and he said well 
that's a bit late isn't it and promptly threw it away. [Mr Becker: 
refused trial tests] 
For one (Mr Becker), the use of envelopes was an important factor. He believed 
that he had been excluded from the trial because he had an expectation of, but 
did not see, an envelope being used to allocate him to a treatment: 
Well what they did, when that [recruiting clinician] was there 
[ ... J said if you partake of this, this survey you will fill this out 
and then come and see us and then you will be given an envelope. 
[ ... ] Well it never happened. [Mr Becker: refused trial tests] 
This is very similar to the rationalisations of those who actually participated. The 
absence or occurrence of certain anticipated trial events led some participants to 
conclude that they had not been randomised to their treatment. However, for 
non-participants, this may have led them to believe that they had actually 
participated in the trial. 
N on-randomised methods of allocation 
Despite their knowledge of the trial and randomisation, this entire group also 
believed that non-random methods of allocation were not inconsistent with trial 
participation. This may have led to their exclusion from the trial. 
Mr Maynard had an expectation that the clinician could individually allocate him 
to a treatment within the trial: 
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The surgeon did say, I take it he was a surgeon anyway, he did 
say that ~ll three methods really are quite OK and they are quite 
happy wzth all three methods but er you know what suits some 
may not suit n~cessarily suit someone else. So and the impression 
I got was that zt would be as a result of talking to me about it 
before it was decided. [Mr Maynard: treatment preference] 
There was also an expectation that they could decide which of the treatment 
options to receive: 
Well I self allocated to the watch and wait. Of course they did 
mention the main side effects, well of course the main side effects 
is that you can become sterile. Well that doesn't worry me because 
I'm not married now and I'm not particularly thinking about a 
family or anything, I've not got any family, it's just something I 
accept in the same way as I can't understand IVF, why people 
can't accept it, there are more important things that can go 
wrong. But that's the position with me, watching and waiting, 
sort of putting it off I suppose, I don't know. [Mr McCarthy: 
treatment preference] 
Mr Becker appears to believe that he is still eligible to participate in the trial even 
though he had refused to consent to a diagnostic test for cancer. This would not 
have excluded him from the trial: 
So all in all, I didn't refuse to partake of anything. The only thing 
I did refuse, when I saw him he did say would you like to come in 
for a biopsy so we can see what we are going to do or if you want 
to go straight in. I said I want to go straight in said, I'd have it 
done now if I could. [Mr Becker: refused trial tests] 
Such beliefs that individualised treatment allocation is not inconsistent with trial 
participation are similar to the beliefs of some participants. 
Acceptance 
Willingness to accept trial participation can also be seen in their expectation of 
receiving personal and altruistic benefits. However, only Mr McCarthy, who 
believed he had agreed to participate in the trial, did so for altruistic reasons: 
But I like to know you know and I can manage the problem better, 
but also I think this research is a very good thing to help the 
medical side of things, it helps other people. But I just manage it I 
do the right things. [Mr McCarthy: treatment preference] 
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No knowledge of the ClasP trial 
Three patients (Mr Flynn, Mr Allgood and Mr Frame) had no knowledge of this 
particular trial and could not recall being asked to participate. It is interesting to 
note that these patients have very different levels of recall of experimentation 
and randomisation. Although both Mr Flynn and Mr Allgood have none, Mr 
Frame (an aeronautical engineer) has a clear understanding of experimentation 
and randomisation in terms of chance, comparison of treatments and concealed 
allocation. Given his level of knowledge, one might expect him to recall being 
asked to participate in this specific trial. These men were 69-81 years old and had 
all attended clinic B. One, (Mr Frame) was categorised as middle class. 
Table 20: Reasons for non-participation 
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Directed by the recruiting clinician 
All three believed that they had been directed by the clinician towards one 
treatment: 
They didn't think it was severe enough or .. ? 
Well it was about right I think but erm he said that I think it 
would be best if you didn't go in for it, so I left it like that. Now 
I've got to go again in September so I don't know what that's 
for ... and I had a scan about a month ago. [Mr Flynn: treatment 
preference] 
Was that (trial treatments) ever mentioned by anyone else? 
No, no that's all he told me, he said that's what we got to do ye~h 
that's how your operation will be. The other way we cannot do zt 
so he said 'that's what you'll have to have done'. [Mr Allgood: a 
dislike of randomisation] 
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This may be associated with having a treatment preference. For example, Mr 
Allgood appears to have a preference for laser treatment: 
All I said, I know is the young oldish man by me had it done with 
the laser beam see. So I said I'd like it done with the laser beam. So 
when I went down again I seen Mr Wand he said 'you 
wanted it done with the laser beam didn't you' and I said yes. 
Well he said you can count that out. He said if I do you with a 
laser beam he said it would damage your kidneys and he said you 
will have a bag (catheter) all your life. That's what he said, so he 
said 'what we've got to do is we got to take the tissue out and 
that's what they done. [Mr Allgood: a dislike of randomisation] 
Interestingly, one non-participant sees his treatment allocation as a form of 
rationing (a rationalisation among participants): 
Well it didn't come to the point where I needed a choice. They 
seemed to say that your condition is not so bad as to need surgery, 
therefore we recommend you have tablets and that's really how it 
was presented to me. [ ... ] and of course would be a lot cheaper 
over the period of time, although it would take longer to effect, I 
was quite happy with that. [Mr Frame: no reason given] 
Two (Mr Flynn and Mr Frame) indicated that they were willing to participate in 
future trials. 
It rests with them, I'm willing to do whatever they want to do, 
and if they said come in and we'll do it then I'll do it. [Mr Flynn: 
treatment preference] 
One (Mr Flynn) would agree to whatever the clinician suggests: 
Well I don't mind what they say, you know, wait till what they 
dec .. suggest, go from there. Not really looking forward to 
operation if they can clear it up with medication. [Mr Flynn: 
treatment preference] 
Similarly, Mr Frame has no recall of being asked to participate. However, his 
career as an engineer meant that he had a clear understanding of 
experimentation. He believes he would agree to participate if asked: 
I don't remember being asked at all [to take part in the trial]. Now 
he may have said these things but I certainly don't remember. The 
reason I would have responded in the way that I would have 
agreed for trials was because all my life at British Aerospace I was 
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involved with engineering which involved a great deal of testing 
and I know the benefits of going through stringent testing and 
weighing this method against that method, length of times, 
temperatures and all sorts of things like that so had he asked me I 
would have approved. [Mr Frame: no reason given] 
Acceptance 
As previously indicated there appeared to be three pathways to refusal: those 
who made an active decision not to take part, those who believed that they had 
agreed to participate and those who had no recall of being invited to participate. 
The majority seemed to have a good or at least a partial recall of being asked to 
participate in an experiment, with some also able to recall aspects of trial design 
and methods. However, as with the participants, many of these patients also 
believed variously that they had been directed towards a treatment by the 
recruiting clinician (individualised treatment) and that the treatments were being 
rationed. 
Such beliefs were also associated with trust and distrust and this is similar to the 
experience of the participants. A number of these patients expressed anxiety 
about their condition and their treatment and this may be one reason they 
became non-participants. 

















As with the participants, a number of these men (Mr Allgood, Mr Frame, Mr 
McCarthy, Mr Maynard and Mr Young) felt that as laymen, they did not have the 
expertise or experience to make such decisions about their treatment and were 
dependent upon the clinician to guide them. 
What did you think about the information they gave you about 
the different treatments? 
Well what he told me? Well I could only go with what he said you 
see what I mean. I couldn't go against him because I told him I 
says I don't know nothing about it I said you're the person I said I 
don't know nothing about it. But they treated me all right and it 
is a wonderful ward yeah it is I like it yeah it was a wonderful 
ward they're really good. [Mr Allgood: a dislike of randomisation] 
So the last couple of times you've been to see the consultant did he 
ever mention a laser treatment? 
Yes, well I'm not a medically trained person so I can't comment 
on it but I've read about it in the newspaper about two or three 
years ago and they were doing some trials in 5 using it. 
[Mr McCarthy: treatment preference] 
Such trust was also typically expressed as a belief in the clinicians as experts: 
They are the experts not me. I mean all I know is the problems 
I've got. My problems seem to be the same sort of problems that 
everybody else has had before they had their operations. So ... you 
know all I can say is that I've got problems of prostate trouble and 
it seems to be quite common with everyone I've spoken to and 
everybody I've spoken to said in the end they are OK. Which is 
what I hoped I would've been OK. [Mr Maynard: treatment 
preference] 
Did you have any expectations when you were referred about 
what they could do for you? 
Well the image I've got in my mind is that when you go to your 
GP and he says yes you've got this, that, oh I'll refer you to the 
experts, that's what I would say you know. So down to the 
hospital you go and they examine you and it's over to them, you 
know, the GP doesn't seen, not that he's not interested, he Just 
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gets feedback I suppose oh yeah, you're cured or you're not cured 
you know. [Mr McCarthy: treatment preference] 
Would you've been happy to leave it to them? 
Yes I think so, yes cos I think with treatments of any sort I mean 
you don't know enough about it yourself You've got to trust the 
professionals haven't you, it's like getting the plumber in (laughs) 
you know. I mean you trust him to do the job properly and that's 
that. Quite happy normally. [Mr Young: travel] 
They sometimes appeared to be willing to accept whatever the clinician 
suggested. They trusted the clinician to direct them to the 'best' treatment: 
Well what I should do is went where the doctor told me, yes, if he 
said laser beam I should have it done with a laser beam but I think 
they would've known. Yeah, yeah, the man I spoke to they 
would've known, yeah, yeah. He told me out straight, he said 'you 
cannot have it done'. Well I said this gentleman's all right he's 
living in the flats over there he said 'you cannot have it done'. 
[Mr Allgood: a dislike of randomisation] 
This acceptance was extended to participation in the trial itself in some cases: 
How about the fact that by doing the trial the doctors are saying 
we don't know which is the best treatment? 
I'm not sure what to say about that.. ..... Well I wouldn't be 
worried about that because I would recognise immediately that if 
there was something they were uncertain about the fact they were 
carrying out that test, first of all they would recognise that it 
wasn't dangerous and I would recognise that the results would be 
such that it would go some way to satisfying their uncertainty in 
the future. [Mr Frame: no reason given] 
For Mr McCarthy, his willingness to accept the trial was linked to the rapport 
and thus the trust he has in the recruiting clinician. 
As long as they don't treat you as a sort of, like a, didn't have the 
attitude that you're just a patient and you're, you don't sort of 
have any rapport from it. In other words they're not telling you 
what they're doing or anything about it if you are interested. I 
mean a lot of people probably are not interested you know, but I 
would be you know. [Mr McCarthy: treatment preference] 
However, Mr Gibbon believes that he has no choice but to trust the clinician: 
How do you feel about that? 
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Distrust 
Well there's not a lot I can do about it is there? You know I'd 
rather they'd said there the actual doctor approved because well 
that's why '!f0u~re going in, isn't it. You know I don't want to go 
through thIS thIng and then sayah well I'm sorry but you're back 
to square one. What happens then? [Mr Gibbon: treatment 
preference] 
A few non-participants were distrustful of some aspects of their experience. 
There was a general suspicion (Mr Flynn, Mr McCarthy, Mr Young, Mr Frost and 
Mr Gibbon) that the clinicians were holding back some information about the 
trial or their treatment: 
What happened? 
Well they won't tell you will they. [Mr Flynn: treatment 
preference] 
How did you feel abou t that? 
I don't know, I don't really know because they said oh no it won't 
be drugs and I thought well if it isn't enlarged, why won't it be 
drugs, this is the way my mind was working you see. If it was 
enlarged, they'll say oh we'll have to cut it, but if it isn't, why not 
drugs. Because ifit's not enlarged, why are they cutting it? 
Obviously there must be something but they haven't told me, not 
in as many words. [Mr Gibbon: treatment preference] 
When he said that he wouldn't try to persuade you one way or 
another do you think he was ... 
I don't think he seemed to be offering any advice at all, probably 
thought he couldn't you know you have to be very careful these 
days. You know they are in a very difficult position I think these 
doctors these days, very difficult. I mean everybody's suing 
everybody now aren't they (laughs), you know they've got to be a 
little careful I suppose. [Mr Young: travel] 
This is associated with the belief that the clinicians are rationing treatments (Mr 
Maynard, Mr Becker and Mr Frame). For example, when Mr Maynard did not 
receive treatment, he became cynical about the trial, believing he had been 
excluded: 
If you had taken part in the trial you would've had an equal 
chance of getting the operation, laser or waiting. 
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What I still find confusing is if it's not so serious as he thought 
and therefore they weren't going to do the trial, how come he 
offers the operation? It seems a bit well strange to me. I would've 
thought if it wasn't serious enough to go into the trial, how come 
it's s~rious.e~ough t~ offer. me a~ ope~ation? It's not very 
consIstent IS It? So I m a lzttle bIt up In the air about it. I'm not 
entirely satisfied that everything has gone as it should've done 
but somehow or other it's come off the line somewhere so I'm not 
terribly happy about it. But if there is to be something done 
eventually then you I am quite happy with whatever is on offer 
it's as simple as that really. [Mr Maynard: treatment preference] 
Looking back, Mr Gibbon believed he might have gained quicker access to 
treatment: 
Having said that, I wonder if it has, because the bottom line in my 
mind is that had I said yes I might of had this done now you 
know. So that did cross my mind to be honest. I thought well if I'd 
said yes, oh yes I'll go on this laser thing, would they have said 
right come on it we'll do it. Rather than say well, you refused the 
laser you're on the list. So that did cross my mind if I'm honest, 
yes and I don't know if that is the case or not. [Mr Gibbon: 
treatment preference] 
This is similar to the way some participants made sense of their treatment 
allocation (see previous chapter). 
Anxiety 
For half of these patients (Mr McCarthy, Mr Frost, Mr Ladbroke, Mr Williams, 
Mr Flynn and Mr Gibbon), the decision to participate or not in the trial was not 
their only concern. Four (Mr McCarthy, Mr Ladbroke, Mr Frost and Mr Williams) 
were apprehensive about having surgery and what that involved and two were 
concerned that their symptoms may indicate cancer (Mr Flynn and Mr Gibbon). 
These are sensible reasons for not wanting to be involved in the trial and may be 
why they are 'refusers'. 
I've had excellent treatment and evenjthing else but it's me, I'm a 
coward. Why I asked about this laser treatment is because within 
the laser treatment procedure they said that they use a general 
anaesthetic and that's one of my biggest fears. I just, that's a big 
barrier for me you know so I must admit I'm a coward you know 
that's that. I can go to the dentist, I can do anything else you 
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know most other things anyway but it's just that's the big barrier. 
[Mr McCarthy: treatment preference] 
So what did you think it would be? 
Not really, I was more terrified of what it would it be. You know 
you hear all these .... 
Were you worried about cancer? 
Naturally, yes and he said no the prostate isn't enlarged that he 
could discover but I will send for you again and you'll come and 
have various tests and flow tests that and then I was referred to 
this [clinic]. [Mr Gibbon: treatment preference] 
Case studies 
As for the participants, each individual non-participant's narrative was also 
analysed as a case study. This helped to elucidate the different pathways to non-
participation. 
The two examples described below have been chosen because they show a 
number of the different ways in which these men struggled to make sense of 
their recall of the trial and their experience of non-participation. Mr Gibbon is an 
example of a clear non-participant and in contrast, Mr Frame is a non-participant 
who believes that he would have agreed to take part if approached. 
Similar levels of knowledge of experimentation appear to produce different yet 
internally consistent accounts of being asked to participate. Their rationalisation 
of non-participation also appears to be similar to those of participants. 
MrGibbon 
According to the trial records Mr Gibbon, a 62-year-old former coach driver (he 
took early retirement) was eligible to participate in the trial but made the 
decision not to participate. He confirms that he made an active decision not to 
take part in the trial. The information he had about randomisation proves 
problematic; he does not comprehend why they cannot tell him which treatment 
he will receive. There was an element of suspicion within this account: 
What did you think of the idea of being randomised ....... ? 
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Er, I hadn't really thought about it but yeah, it seemed a bit vague 
th~t. If t~ey want to have you, if they say will you take part in 
thIS I thInk wel~ they shoul~ say well yes you are going to do it 
rather than sayIng oh yes I II take part and them saying no we 
don't. wan.t you. I think if you said yes, you are willing to take 
part In thIS, then they should do. [Mr Gibbon: treatment 
preference] 
This leads him to reject the trial in favour of the standard treatment, which he 
believes to be the most effective treatment: 
Well I think me being me, if the TURP's is the standard one then 
I'm quite happy thank you because that's been proven with 
everyone else. Having said that I appreciate someone's got to do, 
you've got to have someone for research and all that. But me 
worrying, no thank you, I'll stick with the one that's tried and 
tested if it's all the same you know. That is my way. [Mr Gibbon: 
treatment preference] 
He appears to be influenced by the recruiting clinician, who, after introducing 
the option of trial participation, also offers the alternative of the standard 
treatment: 
She said I don't really think this is in your best interests, I think 
you are far better off sticking with the normal treatment and I 
said yeah, I think you could well be right. [Mr Gibbon: treatment 
preference 
This patient stated that he would have agreed to whatever treatment option the 
clinician directed him towards: 
No because I more or less went by guidance from [the recruiting 
clinician], [he] said about this and I said yes that sounds lovely 
and as they explained it on [date] it was [the recruiting clinician] 
that noticed more or less the change in me. [Mr Gibbon: 
treatment preference] 
There are a number of possible interpretations of this exchange. The clinician 
may have intervened as a sensitive response to the patient's anxiety, attempting 
to make it easier for him to say no. Alternatively, this may be an example of the 
clinician actively directing a patient away from the trial because he/ she believed 
in was not in his best interests or that the standard treatment was the most 
suitable for his particular symptoms/ condition. 
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It is interesting to consider the outcome if this patient had been recruited by a 
different clinician who might not have had such an awareness of this patient's 
anxiety and so continued with the process of recruiting him onto the trial. 
MrFrame 
Mr Frame, a 69-year-old former aeronautical engineer, was able to recall 
experimentation, in that he knew about clinical uncertainty and the comparison 
of treatments. Yet he had no recall of being asked to participate in this specific 
trial. Given this amount of knowledge, one might expect him to recollect being 
asked to take part in this specific trial. 
Now he may have said these things but I certainly don't 
remember. [Mr Frame: no reason given] 
He believed he was directed by the clinician, who informed him that treatment 
was not necessary: 
As a result of that flow test I met the consultant, that was on 
[date] of this year and he told me the flow test was such that it 
wasn't too bad. I was middle of the way, I can't remember what he 
described as the middle of what, at the borderline for tablet 
treatment and wasn't really necessary for me to have surgery. 
Now I went on from there and I've got another appointment there 
on [date] of next year to find out how the tablets are working. [Mr 
Frame: no reason given] 
Yet he was willing to accept whatever the clinician suggested, including trial 
participation. He had trust in the recruiting clinician who appeared to treat him 
with drug treatment: 
The consultant at the last occasion when I saw him on [date] he 
did say that sometimes the surgery wasn't always as successful as 
has hoped it would be so the tablet form in my case was probably 
just as well to do that and er I accepted his word for it. [Mr 
Frame: no reason given 1 
He believes he would have agreed to participate if approached. Based on his 
career as an engineer, he acknowledges the importance of experimentation and 
the testing and comparison of treatments: 
I would've agreed to say I'm perfectly happy to take part with any 
form of randomised treatment. But whether it was g~ing to b~ a 
trial test or whether it 'was to be the final test I wasn t aware zn 
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the slightest because of the nature of my previous work I recognise 
the necessity of carrying out tests for the benefit of anybody and 
everybody concerned so I just would have agreed. [Mr Frame: no 
reason given] 
He accepted the option provided by the recruiting clinician: 
They didn't leave me with a choice. In fact I recognise that they 
were saying that your condition was not as bad as many people 
that we've met. [Mr Frame: no reason given] 
The trial records indicate only that he 'refused'. It is surprising that this patient 
has no knowledge of the trial when he has such a clear understanding of 
experimentation and has such a strong belief in the importance of 
experimentation. Although it may be that this patient has forgotten being asked 
to participate, he does appear to be strongly altruistic. Although there is no other 
information available on the clinician's experience of this consultation, one 
possible explanation is that the clinician may have directed the patient to a 
treatment or did not actually attempt to recruit this patient onto the trial. 
Conclusion 
Thus the majority of these non-participants appeared to have at least a partial 
recall of being asked to participate in an experiment, with some also able to recall 
aspects of trial design and methods. However, their recall was at a lower level 
than that of the participants. There appeared to be three pathways to refusal, 
those who made an active decision not to take part, those who believed that they 
had agreed to participate or had no recall of being invited to participate. Trust 
and distrust were strongly associated with how these men made sense of their 
treatment allocation and of being asked to participate. A number also expressed 
anxiety about their condition and their treatment and this may be one reason 
they became non-participants. There are, therefore, some clear similarities but 
also some specific differences between participants and refusers. These issues are 
considered further in the next chapter. 
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Discussion 
Within this chapter, I will discuss the empirical findings contained within 
chapters 5 and 6 and examine participants' and non-participants' struggles to 
understand their participation in the ReT. These findings will also be examined 
within the context of their implications for trialists and within the current ethical 
and methodological debates and the literature examining trial participation. 
Introduction 
Historically, the literature examining the ReT has emphasised the ethical and 
methodological issues that should be taken into account in the design and 
implementation of an ReT. Debate about the ethics involved in the ReT (see 
chapter 1) have examined issues of equipoise; the appropriateness of 
randomisation, blinding and placebos; and the dilemma of which groups should 
be included or excluded from trials. Attention has often focussed on the 
importance of the informed consent procedure. These debates have influenced 
the design of the ReT, although these developments have been primarily from 
the perspective of trialists, hence there is little consideration of the perspective of 
participation in RCTs.35 
Textbooks and reports in journals focus on the design, methods and results of 
trials,15, 106, 176 suggesting that each decision in the planning and design of a trial, 
from selecting the intervention, the population, and the aims of the trial, occurs 
in isolation and according to standard rules. However, there is an increasing 
awareness of the problems of attaining the required level of precision, validity, 
and the feasibility of this approach (see chapter 2). Such decisions may influence 
the behavioural dynamics of participation and affect the internal and external 
validity of a trial.129 Thus the role of the trial participant has predominantly been 
viewed as a source of data and as a potential source of bias, with the possible 
impact of these design issues on patients often ignored. 
However, studies examining the public's and patients' perspectives of being 
involved in RCTs have primarily been undertaken from the perspective of 
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trialists, often using hypothetical trial scenarios with a variety of lay or potential 
trial populations with the ultimate aim of improving accrual within future trials. 
The reliance of such studies on hypothetical vignettes is problematic and 
possibly misleading; those who have taken part in a trial may have a real and 
distinct difference of opinion compared to those whose responses are based on 
speculation.178,182 Studies that explore the experience of actual participation have 
predominantly used structured questionnaires to examine motivation, 
satisfaction and barriers to recruitment. Their focus on informed consent, often 
evaluating effectiveness using recall and recruitment rates as opposed to 
patients' views has also tended to reflect the perspective of trialists. Only recently 
and in a few studies42,173 has there been an assessment of the perspective of 
actual participants: their attitudes towards, their experience of, and motivation 
for, taking part in a clinical trial. 
Hence this study carried out in-depth interviews with participants and non-
participants in an actual randomised controlled trial comparing surgical and 
conservative treatments for a common disorder in older men: lower urinary tract 
symptoms related to benign prostatic disease. 
In the previous two chapters, participants' (22) and non-participants' (11) recall 
and understanding of what the ClasP trial involved were examined. It was found 
that the majority of the participants were aware of some aspects of 
randomisation and most (15/22) acknowledged the involvement of chance in 
their allocation. As with the participants, a large number of the non-participants 
were also aware of some aspects of randomisation. Almost all (9) could recall 
that the trial was some sort of experiment. However, only a small number (4/11) 
were aware of the involvement of chance. 
All but one (Mr Taylor) of the trial participants incorporated multiple accounts of 
how they might have been allocated to their treatment. As previously indicated, 
many had a good or at least a partial recall of the major aspects of trial design 
and methods. However, the majority also held other co-existing ideas about non-
randomised methods of allocation such as rationing and individualised 
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treatment, which they used to understand and explain their treatment allocation. 
For a small number, altruism (7) and an expectation of personal benefits (7) were 
motivations for taking part. However, trust (10), distrust (11) and beliefs about 
fate and destiny (13) were evident as they tried to make sense of their treatment 
allocation in relation to their treatment preferences. The interview data and 
particularly the case studies illustrate the struggle that the participants engaged 
in to help them understand the experience of participation. 
The majority of the non-participants appeared to have at least a partial recall of 
being asked to participate in an experiment, with some also able to recall aspects 
of trial design and methods. However, their recall was at a lower level than that 
of the participants. Three main types of refusal were identified: those who made 
an active decision not to take part in the trial (5), those who believed that they 
had agreed to participate (3), and those having no recall of being invited to 
participate in the trial (3). Surprisingly a small number of non-participants also 
appeared willing to participate in the trial, citing trust (7), personal benefits (4) 
and altruism (2) as motivations to take part. 
Among those who made an active decision not to take part, wanting 
individualised treatment and having a treatment preference both appear to be 
important motivations. A dislike of the trial design and randomisation were also 
important among this group. Those who believed that they had agreed to 
participate or had no recall of being invited to participate all believed that they 
had been directed towards a treatment by the recruiting clinician. They appeared 
willing to accept whatever treatment the clinician suggested and sometimes 
believed that the clinician had guided them towards a particular treatment. Non-
participation for some was associated with their lay beliefs about what trial 
participation involved and was seemingly unintentional. However, a number of 
these men (6/11) expressed anxiety about their condition and their treatment and 
this may be one reason they did not take part in the trial. 
The participants and non-participants appeared to be very similar in terms of 
how they made sense of the trial. Only around half of the non-participants 
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actively opted out of the trial, and as with the participants, this group produced 
multiple accounts of how they had been allocated to their treatment. Trust and 
distrust were strongly associated with how these patients made sense of their 
treatment allocation and of being asked to participate. Thus there are some clear 
similarities but some specific differences between participants and refusers and 
these issues are considered further within this chapter. 
A large amount of information was also gathered about these patients' 
symptoms, outcome, and knowledge of the treatments available within the trial. 
However, this chapter will focus particularly on ReT participation, using this 
material as context where appropriate. 
Reasons for willingness to participate 
The personal motivations for trial participation, both hypothetical49, 58, 99, 124, 143-148, 
150,177-186 and actual,68, 83, 97, lOS, 181, 187-199,201 have been well documented within the 
literature. These have been reported to be altruism, an expectation of receiving 
personal benefits from taking part in the trial and trusting the recruiting 
clinicians. 
Altruism 
In examining the reasons why these patients were willing to participate it is clear 
that a small number had altruistic reasons for participation: to help clinicians to 
improve their clinical skills and to contribute to medical progress. Surprisingly, 
two non-participants also stated that they would agree to participate for altruistic 
reasons: 
I recognise the necessity of carrying out tests for the benefit of 
anybody and everybody concerned so I just would have agreed. 
[Mr Frame: no reason given] 
Within the literature, there are no studies that reported the altruistic desire to 
help clinicians to improve their clinical skills. The hypothetical studies and those 
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examining trial participants have found that altruism was mainly expressed as a 
desire to help 'others' and future patients.49, 58, 97, lOS, 124, 146, 148, ISO, 177, 179, 181, 183, 190, 192, 
196,201-203 The progress of science was also an important motivation within the 
studies examining participants.68, 83,97, 148, 150, 177, 179, 181, 183, 189 However, many of 
these studies examined Phase 1 trials where such high levels of altruism may be 
associated with both the nature of the trials and the seriousness of their 
condition. 
The desire to help future patients and to contribute to medical progress was 
mentioned by fewer than expected within this study given its prevalence within 
the literature where altruism is commonly found to be a motivation ranging from 
26% to all participants within a trial. However the role of altruism as a 
motivation to participate is variable and a small number of studies have also 
questioned its importance.143, 178, 188, 191 
Such differing levels of altruism may be associated with the different 
methodologies employed by these studies. Surveys and structured schedules 
used to examine both actual and hypothetical participation found high levels of 
altruism ranging from over half (56%) up to 100%. Hypothetical studies using 
qualitative methods also found high levels of altruism. However, such 
motivations are perhaps to be expected from predominantly lay groups where 
responses are based on speculation. In contrast, altruism was a weak motivation 
within the small number of studies examining actual participation using 
qualitative methodologies to examine the experience of participation.83, 193,196,201 
Personal benefits 
A similar number of these men had an expectation of personal benefits such as 
obtaining faster and possibly superior treatment within the trial. Participants (7) 
often thought that taking part must have an advantage of obtaining quicker 
treatment: 
Again to be perfectly honest, I chose, I was quite happy to go the 
clinic way and at the same time at the back of my mind was, well 
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if I go that way I might get treated quicker than if I go the other 
way. [Mr Taylor: allocated to and preference for TURP] 
Within the literature, obtaining the best care has been reported to be an 
important motivation for some patient groupS.49 However, such benefits within 
many trials were often unrealistically high, especially within Phase I trials where 
the actual chances of receiving any personal medical benefits from such trials 
was small. 
Among the non-participants here, four focussed on the belief that they had been 
excluded from receiving the 'new' and more advanced treatment, and with the 
idea that the function of the trial was to ration this treatment. Within this 
particular trial, this belief often appeared to be triggered by the recruiting 
clinicians, who informed the men that the laser treatment was only available 
within this trial. These patients believed that this new treatment had been 
incorporated into the trial by the recruiting clinicians as an inducement or 
'carrot' to take part: 
He read the back page [of the questionnaire] and then he closed it 
again, put it down and said 'well what about a laser' and I said 
'yes fine' and he said to me 'I'll just check' and out he went and 
came back in and said no to the laser. It was like a carrot like 'here 
it is but we can't give it to you now' and then out of the blue I 
thought then he was going to say well nothing just stay on the 
tablets well then he said to me 'what about an operation' and I 
thought well OK. [Mr Maynard: treatment preference] 
A few participants similarly found their allocation to conservative management 
difficult to accept. Despite being able to recall the involvement of chance in their 
allocation, these participants also wanted and expected' treatment'. This was 
often interpreted as their exclusion from treatment and this was often upsetting 
for these patients. 
I never got any chance of getting laser. Cos I says to her, can I 
have the laser [Mr Symonds: allocated to CM and preferred 
treatment] 
Thus the hope of obtaining the 'new' or 'experimental' treatment was an 
important motivation for many of these participants and non-participants. 
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Within the literature, this has also been cited by many willing, hypothetically, to 
participate as their main motivation.143,145, 148, 179, 183 For example, 72% of UK 
oncology patients welcomed the' greater chance of receiving new treatments', 
although many (27%) also indicated that the least appealing aspect of 
participation was the 'chance of obtaining experimental treatments'.150 Similarly, a 
small number of the non-participants within this study also cited a dislike of the 
trial design and randomisation within their rationale for not taking part in the 
trial. 
Trust 
A number of previous studies have indicated that trust in the clinician often 
constitutes an integral part of participants' decision making,l90, 191, 193, 194, 196 with a 
large number believing that their clinician always acted in their best interest. 97,188, 
189,198,201 Trust in their clinician or clinicians generally was an important factor for 
many who were willing (hypothetically) to participate.143, 148, 178, 179, 182, 183 The 
literature also indicates that the perceived expertise of the recruiting clinicians 
may also play an important role in recruitment.150, 177, 178, 182 However this finding 
was principally within trials of patients who had a life threatening condition. ISO, 
190,191,193,194,196,198,201 
Trust was also important within the accounts within this study. Trusting the 
clinician involved in the men's treatment as well as trust in medicine was evident 
within many of the accounts of both participants (10) and non-participants (7). 
Typically, among both these groups, this trust was expressed in terms of the 
doctor being an expert and among participants this extended to doctors the 
wider medical profession. This trust also included trial participation itself among 
participants and surprisingly also among some non-participants. A small 
number of these participants and non-participants felt that, as laymen, they did 
not have the expertise or experience to make such decisions about their treatment 
and were dependant upon the clinician to guide them. 
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An association between socio-economic status and willingness to trust the 
recruiting clinician has been identified. A large scale survey of a UK lay 
population found that those who were older (60-70years) and from lower socio-
economic groups were more (hypothetically) likely to agree.178 However, this 
was not reflected within this study. The majority of the men within this trial were 
categorised as 'working class' and four (Mr Bowler, Mr Murray, Mr Grange and 
Mr Bullock) as 'middle class'. The four 'middle class' men had varying levels of 
recall and understanding of the trial and randomisation and the majority (3) 
appeared equally to incorporate trust into their accounts of participation as the 
'working class' men. For example, although Mr Murray (a teacher) had the 
highest level of knowledge about randomisation and the trial, he also used fate, 
destiny and trust to make sense of the trial. The two 'middle class' men who 
were non-participants in this study had varying levels of recall. Although one of 
these men had made an active decision not to take part (Mr Ladbroke), Mr Frame 
(a former aeronautical engineer) had a clear understanding of experimentation 
and randomisation and expressed a strong willingness to participate, but had no 
recall of being asked to participate in this specific trial. 
Thus, although on one level trust was an important motivation to participate, it 
was also an important element within the men's struggle to make sense of the 
trial and participation. This will be discussed in more detail below. 
Non-participation 
Few studies have examined non-participation. Those that have examined why 
people refuse to take part in clinical trials are primarily set within the context of 
how to improve the response rate for future studies. The main focus has been an 
examination of non-participation within trials that present trialists with specific 
accrual or ethical problems such as HIVl44-147, 183-185 and oncology.49, 142, ISO, 186 
Among the non-participants here there appeared to be three pathways to refusal: 
those who made an active decision not to take part, those who believed that they 
had agreed to participate and those who had no recall of the trial. 
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Within the literature there is often an expectation that trial design issues such as 
randomisation, experimentation and research methods would be an important 
rationale for refusal. However, only a small number of participants within a few 
studies actually cited such reasons. 50, 126, 148,209,210 Trial design was problematic 
for a number of those asked to participate in hypothetical HIV vaccine trials. 
However, the aim of these studies was to assess the acceptability of the design of 
such trials. Similarly, a study specifically examining patients' and clinicians' 
views of trial design found that randomisation (39%) was the main reason for 
non-participation among breast cancer clinicians and their patients (58% ).49 
Among the men who made an active decision not to participate in this study (5), 
all cited some aspect of the trial design and randomisation. The decision not to 
participate was sometimes made because these men received no direction from 
the clinician as to whether they should participate in the trial or not: 
I said what do you think is best, well he said well, I won't advise 
you he said, it's up to you. Well I said I'll have the operation and I 
went and had the operation and that was very good. [Mr Young: 
travel] 
All five of these' true refusers' also expressed a treatment preference, with the 
majority wanting TURP because they believed it to be the standard and most 
effective treatment. These men wanted the 'right' treatment. This was based on 
their inability to accept clinical equipoise and the belief that the standard 
treatment would be more effective: 
I mean in all forms, if it's going to be surgery, all right surgery 
has got to be positive, there's no point to my way of thinking to 
having some surgery if the problem isn't eradicated. [Mr Frost: 
dislike of randomisation and research] 
Half of the non-participants (6) expressed anxiety about their treatment and were 
apprehensive about having surgery and what that involved. Two were 
concerned that their symptoms may indicate cancer. These are sensible reasons 
for not wanting to be involved in the trial and may be why they are 'refusers'. 
Concerns about safety were also prevalent among those asked hypothetically to 
participate in a range of trials.148, 180, 181 One non-participant based his decision to 
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refuse on a (valid) assumption that the trial would be more time consuming than 
the standard treatment. Logistical problems such as transportation and 
inconvenience were also mentioned by a small number of patients as reasons for 
non-participation in other published trials.97, 126, 181, 209, 210 
A distrust of modern medicine (52%) and the hospital (19%) was cited by non-
participants in a small number of studies.50, 58, 97, 141 However, the issue of 
mistrust, mainly arose amongst those who would refuse to participate in HIV 
vaccine trials.145-147, 183, 184 Such beliefs were also associated with trust and distrust 
and this is similar to the experience of the participants here and will be discussed 
in more detail below. 
This rationalisation of the trial appears to be similar to those of participants. It is 
interesting to speculate how these non-participants, who are in many ways very 
similar to the participants, came to be non-participants. The interaction between 
the clinician and the patient does appear to influence the direction these men 
take to participate or not in the trial. This will be discussed in more detail below. 
Recall and comprehension of the trial 
Within the literature, the majority of studies have focussed on patient recall 
rather than comprehension, often based on partiCipants' own rating of their 
understanding of the trial (see chapter 3). Participation rates, both hypothetical 
and actual have also been used to indicate the effectiveness of the informed 
consent procedure. A smaller number of studies have used the informed consent 
procedure or international guidelines to evaluate participants' understanding. 
These studies appear to be attempting to examine understanding against some 
objective criteria, however, such criteria are not defined by these studies and are 
predominantly used to inform the questionnaire design. These studies still fail to 
unpack the meaning of trial concepts, although a number do demonstrate that 
patient recall does not reflect understanding.lOl, 103, 105, 217 
Only a small number of studies have examined trial participants' understanding 
of what a trial involves and have asked them to describe the trial in their own 
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terms.42, 173, 200 However, the majority of these studies fail to examine participants' 
recall or to define how participants, clinicians and researchers understand these 
trial concepts. The main criticism of such studies is that they" only give a weak 
clue as to what patients had understood of the questions and hence what they 
meant by their responses" (p.1210).72 
Randomisation is a complex concept and this study considered recall and 
understanding as six integral elements: the involvement of chance in their 
allocation, that envelopes were to be used to allocate treatments, that the 
treatment allocation was concealed, that treatments were being compared, that 
clinicians were uncertain about the most effective treatment, and that they were 
participating in an experiment. These aspects were included in the trial patient 
information leaflet (see Appendix 1). 
As chapter 5 showed, most participants were able to describe some aspects of the 
concept of randomisation, particularly in terms of the involvement of chance: 
Well I'm prepared to go in and take my chance. [Mr Hall: 
allocated to CM, no preference]. 
Well it's a bit like the lottery isn't it really, I'm not very happy. 
[Mr McCarthy: treatment preference] 
Some had a more detailed understanding of treatment comparison, concealed 
allocation and experimental design. In chapter 6, it was shown that levels of 
recall and understanding were lower for non-participants, with only a small 
number (4) having an awareness of the involvement of chance. The majority of 
those who, according to the trial records were eligible but decided not to 
participate, were able to describe the experimental nature of the trial: 
Well I suppose my initial reaction to that is that I might be at risk 
a little bit in being a guinea pig. [Mr Ladbroke: a dislike of 
randomisation] 
If this study had utilised a structured questionnaire to assess knowledge of the 
trial, the majority of these participants and non-participants would probably 
226 
have been shown to understand the concept of randomisation in basic terms and 
would have indicated an awareness that they were taking part (or had been 
approached to participate) in a trial. The use of qualitative research methods, 
however, showed that these participants and non-participants also held a 
number of other apparently contradictory beliefs about the treatment they 
received. They believed variously that the treatments were being rationed and 
that their therapy should have been individualised. Such beliefs were associated 
with trust and distrust in their clinicians. Over half (13) of the participants 
additionally believed that fate and destiny were also involved in their allocation 
to a treatment. 
The struggle to understand 
The previous two chapters have assessed patients' recall of the trial and beyond 
that, an investigation of their understanding of the underlying concepts. The key 
to understanding peoples' experiences of RCTs lies in the basic inconsistencies of 
trial design, as shown in these men's struggle to piece together what 
participation means. Each individual's narrative about trial participation was 
analysed as a case study and this showed that most engaged in a dialogue to try 
and make sense of the trial design, using their lay beliefs and their actual 
experiences of the trial and to construct an explanation. 
Participants adopted several approaches to making sense of the trial. Some 
cynically interpreted this as rationing and had a distrust of the clinicians (see Mr 
Pierce); others put their trust in their clinician and their beliefs about fate and 
destiny (see Mr Watson), while others just keep struggling with the perceived 
inconsistencies (see Mr Symonds). 
Surprisingly, the non-participants made sense of their experience of being asked 
to participate in similar ways. Some placed their trust in the clinician, believing 
they received the best treatment by individualised care (see Mr Young). For 
others, the best treatment was thought to be within the trial and thus they 
believed that they had been excluded from the trial and that the most effective 
treatment was being rationed and denied them (see Mr McCarthy). 
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Many patients could recall the trial and randomisation, but the trial did not 
easily make sense to them in their own terms. Such a method of treatment 
allocation seems too haphazard and does not appear to be based on clinical 
evidence. 
Thus, in attempting to make sense of their participation (or not) in this trial, these 
men produced narratives which on the one hand described their understanding 
of elements of randomisation, but on the other hand challenged these 
understandings with, for example, the desire to trust the clinicians to make 
treatment allocations based on individual clinical characteristics. Both the 
participants and non-participants made sense of their experience using these 
similar rationalisations. For example, participants sometimes believed that 
randomisation was being used to ration limited resources (5), and some non-
participants (5) similarly believed that they had been excluded from the trial and 
thus denied access to a treatment they might have preferred. 
Many participants characterised their struggle to understand participation by 
their questioning of this method of allocating them to a treatment. They recalled 
the mechanics (chance, the use of envelopes etc) but not the theoretical rationale 
for its use. For example, Mr Symonds searching for an explanation for why there 
were three treatments, found it hard to believe that they were equivalent: 
Do you think they had a preference. Do you think they thought 
one treatment was better than another? 
I think they do, obviously they must, I mean, what would they 
have three treatments for? You know they don't tell you why 
they've got the three treatments, especially ..... they didn't say 
we're going to do this one for that if you're this way inclined or 
that one for that way inclined or the other one because you've got 
to take the, you know the other one. You know they didn't give 
you any reasons why there's three. If they gave you reasons you'd 
be able to choose. [Mr Symonds: allocated to eM and preferred 
active treatment] 
Mr Hall also had a good recall of the trial and randomisation in terms of chance, 
comparison, concealed allocation and the use of envelopes. However, although 
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he knew that envelopes were used to allocate him to a treatment, he was none 
the less confused as to why this method was being employed. 
So it's shared out more or less, whichever envelope they open 
then. so why don't they say which one they want really to suit 
them. Why don't they say we'd like you to do this, we'd like you 
~o do that, or we,' d like you to have the operation. Why don't they 
Just tell me strazght, why allocate it? [Mr Hall: allocated to eM, 
no preference] 
The existence of such different accounts about treatment allocation could be 
indicative of confusion or distortion, as suggested elsewhere.42,67, 173 The men in 
this trial acknowledged that randomisation was confusing (see Mr Webster and 
Mr Maynard above). Closer examination, however, suggests that these 
apparently contradictory accounts are consistent in their own terms. For 
example, the number and complexity of tests and questionnaires participants 
completed during the trial reinforced the men's view that treatment should be 
determined by clinical and personal characteristics (symptoms/ age). In contrast, 
some non-participants believed that the initial questionnaires they were asked to 
fill out confirmed that they were actually participating in the trial. 
Similar recall of the trial and experiences of participation can produce different 
yet internally consistent accounts of participation. For example, this can lead to a 
belief that treatment should be individualised (Mr Watson) or that the clinicians 
were rationing treatments (Mr Symonds). Any confusion that arises comes from 
their attempts to make sense of their experience by trying to piece together 
apparently contradictory accounts - not confusion relating to a lack of 
understanding of randomisation per se. 
The patient perspective: implications for trial design 
While the incorporation of multiple accounts could indicate that these men were 
confused about randomisation,42,173 an alternative explanation would suggest 
that their views are internally consistent and a reasonable reaction to a difficult 
situation: participating (or not) in an RCT. The practicalities of being in the trial, 
the role of the clinician and how these men incorporate these events into their 
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accounts all appeared to contribute to this. These findings have implications for 
trial design and for trialists as such beliefs may affect the internal and external 
validity of a trial. 
Trial terminology, treatment preferences, the role of the clinician and the impact 
of the practicalities of the trial design can all influence participants in terms of 
both their willingness to participate and their beliefs about how they had been 
allocated to the treatment they received. 
The participants' understanding of trial terminology, treatment preferences and 
their trust and distrust in the recruiting clinician all appeared to influence their 
interpretation of what the trial involved and its implications for them. 
Lay understanding of trial terminology 
The terminology used in trials can have different meanings to participants and 
trialists. As Altman points out, randomisation does not mean that allocation is 
"haphazard" (p.86), but that patients have an equal (or known) chance of being 
allocated to any of the trial interventions.18 In contrast, the lay definition of 
randomisation is of a 'random event' with no purpose to it and thus participants 
unsurprisingly believed randomisation to be an indiscriminate, haphazard and 
unplanned method of allocating them to a treatment. 
These participants and non-participants also held various other interpretations. 
For example, the use of lay interpretations of randomisation such as 'luck' (Mr 
Hall) and 'lottery' (Mr McCarthy) implies that they believe that there is a winner 
who receives the 'best' treatment. For those who took part in the trial, their actual 
allocation was also believed to be due to fate and destiny and for some was 'pre-
ordained' (Mr Grange). Hope was also present within these accounts: 'So it's 
something that you just have to hope goes well' (Mr Stone). Such beliefs were linked 
to a failure to understand clinical equipoise, the belief that one of the treatments 
is more effective: 'I just hope I pick the right one' (Mr Daw). 
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Many patients had difficulty resolving the apparent differences between their lay 
understanding of randomisation and their beliefs about how they would want to 
be allocated to a treatment. Such lay perceptions of 'random' frequently 
interfered with participants' understanding or acceptance that this was how they 
had been allocated to their treatment. For example, although Mr Webster 
acknowledges that chance is involved in his allocation, this does not reduce his 
difficulty accepting such an occurrence. He interprets randomisation to be an 
indiscriminate method for deciding which treatment to give him: 
What did you think about being randomised? 
Well that was a bit confusing, it was like they know what's wrong 
with us. I thought it would be just one operation and that was it. 
If it was an operation, if they could have cured it by medication 
they would have decided there and then, the other consultant 
would've decided. You know this lad need medication, or yes this 
lad needs the operation. [Mr Webster: allocated to TURP, 
preferred laser] 
Randomisation is perceived to lack the direction or purpose expected from 
clinicians and he acknowledges that he finds it hard to accept that treatment 
would not be allocated in response to his symptoms: 
I could understand it but I couldn't realise, cope with the idea 
that whatever the symptoms were that was the envelope we were 
going to get. [Mr Webster: allocated to TURP, preferred laser] 
Similarly, Mr Flint holds a lay definition of random as a 'random event' with no 
purpose to it. His recall of experimentation and randomisation, in terms of 
chance, the use of envelopes and concealed allocation, clashes with his 
expectation of individualised treatment. He rationalises this by accepting that 
randomisation is in some way necessary: 
Well I would have thought that [individualised treatment] was 
the normal way, yes. I would have thought that anyone looking at 
a patient would say well I think you'd be better of!havin,g this o~ 
you would be better of! doing that. But I suppose on a tnal as thzs 
was, they didn't want to make the decisions, they wanted to see 
how it came out randomly. Whether or not my problem and what 
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ha~pened to me gave them a lot of information I don't know. [Mr 
Flznt: allocated to laser, preference for TURP] 
Similarly, the term "trial' tended to be interpreted as something being "tried and 
tested' (see Mr Bowler). For example, Mr Bowler is able to believe that laser 
therapy is 'on trial', but has difficulty with the idea that the standard operation, 
TURP, is still 'on trial'. A number of non-participants (5) also believed that the 
trial was a process of trying out a new treatment. Similar lay definitions of trial 
have been found elsewhere. 58, 173 
A small number of both participants and non-participants held a partial 
knowledge of what the trial actually involved. For example, some saw the trial as 
a 'survey' to assess their condition and supplement the standard treatment. 
Others assumed that this would merely entail additional paper work or tests. 
However, only one participant (Mr Mott) and three non-participants (Mr Flynn, 
Mr Allgood and Mr Frame) professed to have no knowledge of the trial at all. 
Such lay interpretations of trial terminology may have been a factor in some of 
the non-participants receiving a treatment outside of the trial. All of the non-
participants who thought they were taking part in the trial believed that 
individualised treatment was not inconsistent with trial participation and that 
they could obtain their preference, which was 'on trial', and still participate: 
The surgeon did say, I take it he was a surgeon anyway, he did 
say that all three methods really are quite OK and they are quite 
happy with all three methods but er you know what suits some 
may not suit necessarily suit someone else. So and the impression 
I got was that it would be as a result of talking to me about it 
before it was decided [Mr Maynard: treatment preference 1 
Such findings have clear implications for future trials. Recruiting clinicians 
should not assume a shared understanding of trial terms with their patients. 
Trialists should discuss with recruiting clinicians the potential problems their 
eligible patients may have with such terms. However, providing explicit 
information to patients may be problematic for clinicians and can affect the 
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development and uptake of trials.49 Clear definitions of trial terms such as 
'randomisation' and 'trial' could perhaps also be incorporate within the patient 
information forms. 
Treatment preferences 
Few classically designed trials have attempted to take patients' preferences or 
views into account. However, many eligible patients have a preference for, or do 
not want to receive one of the treatment options available within a trial. Some 
refuse to participate in trials for this reason, while others may take part despite 
such preferences. The outcomes of these groups of patients are rarely examined, 
even though such perceptions can affect the internal and external validity of an 
RCT.159 The importance of patient preferences varies with the condition, but may 
be particularly important for conditions such as benign hyperplasia of the 
prostate, where there is not only a choice between treatments, but a decision 
about whether treatment is necessary.22 
All but four of the trial participants expressed a preference for one of the 
treatment options available as part of the trial. However, it is important to bear in 
mind that these are preferences described after the process of randomisation. It is 
not possible to know whether these preferences were present before 
randomisation as well as at the time of the interview within this study. Among 
participants, over half (10) were randomised to the treatment they appeared to 
prefer. Several believed that fate and destiny were involved. Others related the 
allocation to an expectation of receiving individualised treatment. All five of the 
'true refusers' expressed a treatment preference. The majority (3) indicated that 
they wanted TURP because they believed this to be the standard and possibly the 
most effective treatment. 
Preferences did seem to influence some participants' understanding of the trial in 
that they may have been less likely to question the method of allocation when 
they obtained a treatment they preferred or were not averse to. For example, Mr 
Bowler was determined to obtain laser and received this treatment anyway: 
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Can we just go back to the envelopes again, what would you have 
done if it wasn't the laser? 
I think I would have asked if I could change to the laser, I think I 
was set on the laser. [Mr Bowler: allocated to and preference for 
laser] 
It is interesting to consider what would have happened if he had been allocated 
to TURP. He would not have been able to obtain laser outside of the trial and this 
may have led him to question how he had been allocated to his treatment. 
Participants' beliefs about the trial and how they had been allocated sometimes 
appeared to be influenced by a preference for an alternative treatment. However, 
it is not known to what extent such preferences are independent of or had 
developed as a result of their subsequent allocation to that treatment. 
Eight participants appeared to have been randomised to a treatment that was not 
their original or rationalised preference. Two preferred TURP but were allocated 
to laser and five wanted either TURP or laser, but had been allocated to 
conservative management. This latter group had been assured that they would 
receive TURP (often their treatment preference) if they still both needed and 
desired it once they had completed the trial. This was often their reason for 
continuing to participate. However, two participants found their allocation to 
conservative management difficult to accept. Despite being able to recall the 
involvement of chance in their allocation, these men also wanted and expected 
'treatment'. They often interpreted randomisation as an exclusion from treatment 
and this was often upsetting for these men: 
You know at the moment, as I said like, the problem with this 
water trouble is you know four or five times every night and it's a 
bit annoying you know. I can go to the toilet, come downstairs 
and within a matter of minutes I've got to rush back upstairs. 
Well I think something ought to be done about it. [. .. ] It was, it 
was because it was like, I naturally thought that they were going 
to do something about it but as I said I had no tablets or nothing 
for it, so that's all I can tell you. [Mr Jamison: allocated to CM 
but preferred 'treatment'] 
Thus, even when patients agree to participate they may still have strong 
preferences, agreeing to take part only because there is a chance they will be 
234 
allocated to their preference or because it is their only chance of receiving the 
experimental treatment. The potential influences of treatment preferences on 
patients' understanding of the trial and motivation to participate needs to be 
examined by recruiting clinicians. It has been suggested that when such patients 
are not allocated to their preference, this may reduce their motivation and lead to 
biased estimates of treatment effectiveness.lo9 This may have introduced bias into 
this trial, where the treatments options are very different. For example, a small 
number of these men who were allocated to conservative management became 
cynical and believed that treatments were being rationed. This may have 
increased their determination to receive the standard treatment (TURP) after they 
had completed the trial, which may in turn have led to an underestimation of the 
efficacy of that intervention. For example, Mr Mills, appears to endure the delay 
of conservative management in order to receive I treatment': 
Well, I said of course I want the operation, I am not coming here 
for fun you see. At the finish of the last time I was there, they said 
I notice you've ticked that you want the operation because she 
said, well if you hadn't ticked it, I would advise you to have it you 
see, which is you are probably here within a fortnight when you 
are gonna .. and sure enough, within a fortnight I was given a 
date and went to go in. [Mr Mills: allocated to eM, preferred 
active treatment] 
All five of the patients who made an active decision not to participate expressed 
a treatment preference. The majority wanted TURP because they believed it to be 
the standard and most effective. This was associated with wanting a I successful' 
treatment. For the others their decision was based on a preference for a less 
invasive treatment (i.e. conservative management) before surgery. 
Although preferences may be based on a belief that a treatment will be the most 
effective, quality of life is also an important factor in patients' decision making24 
and may be important for trials where the treatment options have different 
degrees of impact on patients' lives. This may be the case within this trial where 
patients could be randomised to three very different treatments. 
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However, from this study, it is important to concede that we cannot identify the 
role of preferences. It is not known to what extent preferences are independent 
of, or developed as a result of, subsequent allocation to that treatment. These 
patients' treatment allocations may have reinforced a weak preference or 
introduced such a preference. The clinicians' confirmation that their allocation 
was' good' could also have influenced this. For example, in one case the clinician 
appeared to have indicated that TURP was the more effective treatment: 
Trust 
Well he said to me the normal treatment which they cut into the 
bladder and the penis is the most successful, the laser one he said 
was more of an experimental one, how would I feel about it. [Mr 
Stone: allocated to laser, preferred TURP] 
Trust in the clinician was found to be an overarching theme within the accounts 
of both participants and non-participants that appeared to exceed its current role 
within the literature. It had an important role in terms of both their willingness to 
participate and in terms of how they made sense of the trial. 
The importance of trust within these accounts was often based on the patients' 
belief that as a 'layman' (Mr Stone), they did not have the skills or knowledge to 
make an independent decision about their treatment or about trial participation, 
which could have repercussions for their future health. They were dependant 
upon the recruiting clinicians who were 'the professionals' (Mr Stone) and as such 
had to be trusted. Although some had a good knowledge of randomisation, this 
was particularly important within the accounts of patients with low-level recall. 
For example, Mr Allgood's acceptance of his treatment allocation was linked to 
trust: 
When you first went to see your GP did you have any 
expectations about what they could do for you at the hospital? 
No I seen one doctor and he said 'how would you like it done' you 
see well I said 'I'm not the doctor am I ' I said 'you are the person' 
I said 'I don't know anything about it . [Mr Allgood: a dislike of 
randomisation] 
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This acceptance extended to participation in the trial itself. This was viewed by a 
number of participants in a positive way; they believed that the clinicians were 
acting in their best interests. By agreeing to participate in the trial, patients must 
take a leap of faith that the clinicians actually believe that the three treatments 
are equal and have no preference between the treatments being compared 
(equipoise). Only a small number of these patients could recall clinical equipoise 
and among those that did, trust was incorporated within their struggle to 
understand. For example, three men (Mr Jamison, Mr Brown and Mr Stone) felt 
that they did not have the skills or knowledge to make the decision to participate 
or not in the trial, they were dependant upon the expertise of the recruiting 
clinicians. Trust in the clinician meant that these men would accept whatever 
was suggested: in this case trial participation. Two men (Mr Bowler and Mr 
Bullock) admitted that although they would not normally agree to volunteer for 
anything, in this situation they felt unable to refuse. 
A small number of non-participants also appeared willing to accept whatever the 
clinician suggested. They trusted the clinician to direct them to the 'best' 
treatment and this acceptance was, for a small number (4), similarly extended to 
a willingness to participate in the trial itself. 
Oh yeah I would've gone through with it yeah I would've gone 
through with it, yeah, yeah, quite happy, yeah I don't, that's their 
job isn't it, they know what they're doing, that's the way I look at 
it, like, you know you've got to trust them really, you know to a 
certain extent I suppose. I've had a couple of hernia operations but 
I've always had good treatment so it's never worried me like you 
know so, I would've been quite happy to go in and have it done 
whatever they said, whether it would've been any good I don't 
know (laughs) [Mr Cullum: allocated to CM, no preference] 
Trust also has implications for how these men understand the trial. The concepts 
of randomisation and clinical equipoise may not make sense to patients who 
have implicit trust in doctors. This may lead them to re-interpret their experience 
of being recruited and in the case of participants, the experience of taking part, to 
incorporate this fundamental belief about their clinician. This may be significant 
within the context of the struggle to make sense of what happened to them or 
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what participation involved. With trust as their frame of reference, patients may 
be more likely to doubt that randomisation or clinical equipoise was involved 
and that they had been given the treatment by some other non-random means, 
possibly according to which was the best treatment for them. 
The importance of trust in terms of participants' understanding and its influence 
on their willingness to agree to take part in the trial must be taken into account 
by trialists. To try to mitigate its effect, trust must be taken into account during 
the informed consent procedure. Trialists should discuss with recruiting 
clinicians the potential influence trust may have on eligible patients' willingness 
to participate in the trial. It may be that someone other than the patients' 
clinician, who is primarily the focus of such trust, should carry out recruitment. 
This also indicates that informed consent must ensure that participants have a 
clear understanding of clinical equipoise (this will be discussed in more detail 
below). 
Distrust 
A lack of trust in the clinicians was indicated by half (11) of the participants and 
this was often caused by the difficulties they had in making sense of 
randomisation. Surprisingly this distrust was sometimes scepticism of the 
method of allocation itself rather than the motives of the clinician. In some cases, 
randomisation was thought to be for the participant's benefit. For example, Mr 
Symonds believed that the clinician was giving him the best treatment in the end, 
even though this is not explicitly stated: 
Yes, I thought that, exactly, right. I thought they should tell you. 
That's why I think they do know by what they find out what is 
best for you, but they don't actually come out with that.. .... [Mr 
Symonds: allocated to eM and preferred active treatment] 
He concluded that the clinician allocated him, with the envelope used 'to keep 
him happy': 
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I think it.' s .obviously they decide on what, what they've found out 
on examl~lng you I think they decide which is going to be best for 
you. That s [the envelope] only to keep you happy I think. [Mr 
Symonds: allocated to eM and preferred active treatment] 
He was sceptical of the use of envelopes and believed that it was a sham and that 
there was a hidden quota system in operation. It may be that although the 
envelopes led to a delay in him receiving 'treatment', this allocation did mean 
that he obtained his preferred treatment (TURP) at the end of the trial, rather 
than laser. 
For the majority of those who expressed distrust, this could be tempered by a 
successful outcome. For example, in contrast to Mr Symonds above, where the 
failure to obtain his preference led to distrust, the fact that Mr Grange received 
his preferred treatment seems to have outweighed any suspicion of how this 
actually occurred: 
I was convinced from the start that I was going to have a laser 
operation. I felt that that was what was going to be the result. I 
don't think the envelopes would've mattered. [Mr Grange: 
allocated to and preferred laser] 
For a small number, a lack of trust was linked to the men's difficulty in 
reconciling aspects of the trial design with their own experience. For example, 
not seeing the envelopes was perceived to be an indication that the clinician 
selected their treatment. Three participants were also concerned that saying no to 
the trial could, they believed, affect their future treatment. A few non-
participants were also distrustful of some aspects of their experience. There was a 
general suspicion (5) that the clinicians were holding back some information 
about the trial or their treatment. 
Being denied access to the trial (non-participants) or access to one of the 
treatments within the trial (participants), was often seen as a form of rationing. 
These patients believed they had been denied laser, the 'new' and more 
advanced treatment (or treatment itself if they had been allocated to conservative 
management). This was linked to the men's difficulty in reconciling aspects of 
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the trial design with their own experience. For example, when Mr Maynard did 
not receive treatment, he became cynical about the trial, believing he has been 
excluded: 
How do you feel about the way things have turned out? 
Well I'm not very happy with the way things have turned out so 
far in as much as I am a little bit up in the air about what is going 
to happen if anything is going to happen. I came out of [clinic] 
assuming that all right I'm on the list for the operation so bang 
goes the laser, bang goes the tablets, that's the way it appears I 
can go now. [Mr Maynard: treatment preference] 
Cynicism is brought about by a sophisticated narrative of rationing which does 
follow the original rationalisation for the first use of randomisation within the 
MRC streptomycin trial of pulmonary tuberculosisl . Randomisation was initially 
used within this trial as an answer to the pressure faced by the MRC to distribute 
equitably the limited supplies of streptomycin as well as for the methodological 
benefits of randomisation.2 In this trial, some of the men concluded that the 'new' 
more advanced technology (laser) was being rationed by the NHS, with 
randomisation used to achieve this equitably: 
Do you think they had any preferences? 
The doctors? Not really, I think at the end of the day if the laser is 
going to free a bed a day quicker, I think it was a day quicker but 
you had longer at home with a catheter, that was it. If it's going to 
free a bed it's better for them because they can get more people in. 
Over the week they could get another two patients in you know 
which is fair comment. But it's the only way they are going to 
find out which treatments are the same cos I would imagine there 
would be a follow-up in years to come. [Mr Pierce: allocated to 
and preferred laser] 
These men believed that there was a quota of operations to be carried out, with 
each patient receiving a treatment because he attended the clinic at either the 
'right' or 'wrong' time. Such beliefs were often based on these patients' 
experience of receiving treatment. Within this trial, laser patients were grouped 
together to use the machine in one surgical session, and similarly, TURP patients 
were also treated together. 
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In the design of a trial, trialists must take into account the effect simple 
organisational issues can have on participants' understanding of how they have 
been allocated to a treatment. For example, the surgery schedules here led some 
participants to believe that one of the treatments was being rationed in some 
way. 
The practicalities of being in a trial 
The practicalities of being in a trial in terms of the absence or occurrence of 
certain anticipated trial events led some participants to believe that they had not 
been randomised to treatment. For some, not seeing the envelopes, for example, 
indicated that their treatment could have been determined by the clinicians. For 
Mr Symonds, this was a source of distrust about the study: 
You know, you'll know for a fact that they're giving you the 
choice of picking one but you're saying to yourself, no matter 
which one you pick, you're not getting onto the other one. [ ... J 
Yes, I think that, I don't know mind. But I think it's obviously 
they decide on what, what they've found out on examining you I 
think they decide which is going to be best for you. That's only to 
keep you happy I think. [Mr Symonds: allocated to eM and 
preferred active treatment J 
The experience of a small number of non-participants was similar. Not seeing the 
envelopes being used confirmed that they were not participating in the trial. 
However, for this group, the envelopes were often believed to provide access to 
the most effective or experimental treatment. For example, Mr Becker believed 
that he had agreed to take part, but the absence of the envelope was confirmation 
for him, that he had been excluded: 
Well what they did, when that [recruiting clinician] was 
there [ ... ] said if you partake of this, this survey you will fill this 
ou t and then come and see us and then you will be given an 
envelope and on one, you will be allowed to pick an envelope and 
one will say laser and one will say surgery. Whichever you pick 
you'll get. Well it never happened. [[Mr Becker: refused trial 
tests] 
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Hence, consistency between the information given to participants and actual 
practice is important. In CLasP, patient information indicated that clinicians 
would open treatment allocation envelopes in front of patients. This happened 
during most of the participants' allocations and did help to confirm their method 
of allocation. However, in practice, this was not always possible and for patients 
who did not see the envelope, distrust could develop. 
Trial protocols clearly have an impact on patients' experiences of participation. If 
recruiting clinicians and the trial protocol maintain that a procedure will occur, 
then it is important that this actually happens. What may seem an unimportant 
change in protocol procedure to the clinician has the potential to have a large 
impact on a participant's beliefs about what has happened to him. 
The apparent failure of some recruiting clinicians to follow the trial protocol and 
open the sealed envelopes in front of participants highlights the additional issue 
of whether the use of envelopes to randomise patients within this trial ensured 
that allocation was adequately concealed. There is anecdotal evidence that some 
of these methods, for example, the use of envelopes, may still be open to 
subversion.112 It may be that telephone randomisation would be a more 
satisfactory method, however, this may introduce problems of its own. 
Concealed random allocation is important to avoid bias.116 Kunz and Oxman, in 
their review, found that failure to conceal adequately can lead to the distortion of 
the treatment effects in either direction, leading to either larger or smaller effects 
than is actually the case.113 For example, Schulz et al found that inadequately 
concealed randomisation led to estimates of effect which were 30-40% larger than 
trials which were believed to have adequately concealed allocation.117 Schulz 
points out that although sequentially numbered, opaque, sealed envelopes, 
pharmacy allocation, centralised or telephone randomisation methods are 
generally seen to represent the minimal standards required for concealed 
randomisation, they are met by only a quarter of current trials.117 The description 
of randomisation and the methods employed are often poorly reported in 
published trials, even within principal journals, making it difficult to establish 
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whether these studies have employed a truly random method of allocation.13, 118 
Kunz and Oxman conclude that the adequacy of concealment may be a more 
sensitive measure of bias within a trial than current quality assessment scales.113 
The role of the recruiting clinician 
The information patients received from their clinician often appeared to have an 
important influence on their interpretation of how they had been assigned to a 
treatment. This is indicated by the information participants reported they had 
received from the recruiting clinicians, the way in which these men reflected on 
the events of the trial and the apparent 'lottery' of participation that was 
observed among participants and non-participants. 
Information provision 
In some cases the clinician appeared to provide positive information about the 
allocated treatment after randomisation. This was used by participants to fill in 
the gaps in their understanding of why they had been allocated to that treatment. 
Based on the positive information they received about this treatment, these 
patients concluded that the clinician had provided them with the best treatment 
for them. To them, individualised allocation seemed a plausible theory for 
receiving a treatment, despite the conflicting components that this narrative 
contained. It was likely that the clinicians were attempting to reassure patients 
about their treatment rather than indicating a preference, although it could also 
be a way of dealing with their own unease with the process of randomisation 
and clinical equipoise. 
He went away and got the envelope and opened it up yeah. No no 
I wasn't (laughs) I just sort of sat there and he went away and 
said 'I'm going to get this envelope' and brought it out and 
opened it in front of me and he says 'I'm happy to say that you'll 
be having no treatment' which he said he would have 
recommended anyway you know, so he said not to say that you 
won't you know when we check you, keep a check on you that you 
won't later on. So I was quite happy with that, said I'll live with 
that, so [Mr Cullum: allocated to CM, no preference] 
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Similarly, a number of non-participants believed that they had been directed by 
the clinician towards one treatment. In this case, it is possible that the clinicians 
were merely presenting different treatment options to these patients as 
alternatives to the trial. We do not know whether the clinicians found this group 
difficult to recruit and if this was the case they may have placed more emphasis 
on the standard treatment. 
So I brought this up with the consultant and the consultant I 
spoke to at the time he said Iwe have been using it but we don't 
think a lot of it because it's in it's infancy and it's you know, 
there's a lot more work has to be done', research and so on. [Mr 
McCarthy: treatment preference] 
The majority of these patients wanted to be directed towards a treatment. For 
participants, this direction was often inferred from the clinician's descriptions of 
the various treatments. For a number of these men, this search for direction 
extended to trial participation itself: 
When you, I look at it like this and the wife has found it the same, 
you want to get better so you go with it anyway, like. [Mr Brown: 
allocated to and preferred TURP] 
Similarly, the decision not to participate was frequently made because they 
received no direction from the clinician indicating that they should participate in 
the trial. For example, Mr Young explicitly asked for advice and in response to 
receiving no direction from the clinician he decided to have the option he knew 
most about, the standard treatment (TURP): 
When he said 'well its entirely up to you' he didn't seem to want 
to make any decisions or choices for me and so I said well I 
thought the easiest option, the thing is to go for the operation 
because I've been told about it before you know, I've been up there 
a couple of times to see Dr T . [Mr Young: travel] 
This indicates that recruiting clinicians must discuss with potential participants 
the ways in which the trial differs from individualised treatment. Descriptions of 
the key abstract concepts of the ReT such as randomisation and clinical 
equipoise should be included within the patient information leaflet. They must 
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also be clear that the clinician has no treatment preference. This will be discussed 
in more detail below. 
Reflecting on events 
A few participants only realised what randomisation actually involved after they 
had agreed to participate. For example, Mr Formby only understood 
randomisation when he observed the envelope being used to allocate him to a 
treatment. He expected to receive the standard operation (TURP) and was 
surprised when this did not happen and he was allocated to laser. He makes 
sense of this by placing his trust in his clinician and by concluding that the 
clinician still has a role in deciding which treatment he receives: 
Well, when I went there I ... I only thought that there is one 
thing, I thought there was just one operation, yeah. I didn't 
realise that you could get the laser, or you could get this er 
waiting thing, I thought there was just this TURP thing you 
know? ( Yeah.) I thought that was it, you know cause I went in 
and she said, oh - pull such and such envelope open and I said, 
fair enough - that's it. [Mr Formby: allocated to eM, preferred 
active treatment] 
Mr Bowler admitted that he only realised that he had been randomly allocated to 
the treatment after he had taken part and had re-examined the patient 
information leaflet prior to the interview. However, this realisation may have less 
significance for him because he had been allocated to his preferred treatment: 
I didn't realise it was going to be a lucky dip, these envelopes, 
picking one out and opening it in front of you and say it's the 
laser. [Mr Bowler: allocated to and preference for laser] 
I mean I probably just read that [patient information leaflet] sort 
of light heartedly. But when I read it now it does state th,at there 
may be bleeding and sometimes it ends up that the man 1S a lot 
better; where he's no different; and sometimes even worse than 
when he started. It tells you that now that I read it properly. [Mr 
Bowler: allocated to and preference for laser] 
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In contrast, a number of non-participants were surprised to discover that they 
were not in the trial and were often adamant that they did not' refuse'. Two non-
participants appeared to agree to receive any of the available treatments and to 
be willing to accept trial participation. 
Then he went on to say to me that he expected it to be more 
serious perhaps than it was and that would I be interested in a 
laser job? I said that would suit me fine. So he went, he left the 
room and went out, spoke to someone, came back in and said 'well 
it appears that it's not bad enough for a laser job' So I said well 
OK. So then he surprised me again and said 'now I can still put 
you down for an operation' So I said 'well, OK' 
In the notes it stated that you would prefer the operation ... 
No that's not correct at all, I accepted what was offered to me. I 
was prepared to accept anything that was offered to me. [Mr 
Maynard: treatment preference] 
This indicates that a number of practical policies could be implemented within 
trials that could have helped these men to understand what the trial involved. 
The clinicians recruiting patients onto trials must be consistent and their 
behavior must reflect the information they provide to participants. For example, 
within this trial, the trialists expected that the protocol requirement that 
participants witness the use of envelopes would enhance their understanding of 
randomisation because they could actually see this happening in front of them. 
However the inability of the trialists to ensure that this happened caused 
confusion among many of the respondents. 
The 'lottery' of participation 
It is surprising that there appear to be similar levels of willingness to participate 
among the participants and non-participants interviewed. For example, a small 
number of both participants and non-participants stated that they were willing to 
accept whatever treatment the clinician suggested and this often extended to trial 
participation itself. 
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Although we cannot say from these data, it may be that key exchanges within the 
recruitment consultation may have different meanings for patients and the 
recruiting clinicians. Some participants confirmed that they only realised they 
were in a trial and what this meant once they were enrolled in the trial. In 
contrast, many non-participants were surprised to discover that they were not in 
the trial and were often adamant that they did not' refuse'. It would be 
interesting to consider whether they would have ended up as participants or 
non-participants with a different clinician recruiting them onto the trial. 
The language used to describe the treatments within the trials may have been 
significant. For example, the terms 'standard' and 'new' were commonly used by 
patients to describe their treatment. Such labels may have been obtained from 
their recruiting clinicians. Similarly, after allocation, some clinicians were 
reported to have referred to the treatment patients received as 'good' or 'best'. 
For patients searching for meaning and often willing to agree to any treatment 
the clinician suggested, this might reinforce the belief that this is the preferred 
treatment. 
This may be associated with key questions or topics covered during the 
consultation. Patients often recalled that the recruiting clinician had asked which 
treatment they preferred. Although we do not know what actually went on 
during these consultations, this may have been used by the clinicians to provide 
patients with a way to opt out of the trial. More cynically, some clinicians may 
not have held personal equipoise and such key questions may have been used to 
direct some patients away from the trial. 
There is an assumption of shared decision making within trial recruitment, but 
within this study we do not actually know what went on during these 
consultations or whether these patients made an active decision to participate or 
not in the trial. There may be miscommunication or it may be that the recruiting 
clinicians are directing some patients. 
This raises an important issue about the theoretical requirement of clinical 
equipoise and current practice. It is important to consider how far this obligation 
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must extend both within the trial and more widely within clinical practice in the 
trial setting. It may be argued that clinical equipoise is only necessary at the point 
of recruitment and any reassurance the clinician provides about the treatment 
allocation is a good thing, although this may have an effect on outcome.22 
However, trials must only be carried out when the evidence for treatments is 
balanced, and the clinician has no treatment preference. If recruiting clinicians, 
based on their previous experience or patient history, suspect that one treatment 
may be more likely to benefit a particular patient, the use of randomisation 
within trials represents a compromise in individual care.42 Personal equipoise, 
when an individual clinician has no treatment preferences, is also an important 
element of patient-centred ethics within medicine. Clinicians have a duty to 
recommend what they believe to be the most beneficial treatment for a patient.44 
However, as Freedman points out, such theoretical equipoise is 
"overwhelmingly fragile" (p.143) and can be disturbed by any slight change in 
the evidence which can be obtained from "the literature, uncontrolled 
experience, considerations of basic science and fundamental physiologic 
processes, and perhaps a 'gut feeling' or 'instinct'" (p.143).43 Levine similarly 
argues that perfect equipoise rarely exists and that when it does, this state cannot 
be maintained for long.44 As Fried notes, "is it ever likely to be the case that in a 
complex medical situation, the balance of harms and benefits discounted by their 
appropriate probabilities really does appear on the then available evidence to be 
in equipoise?" (p.52).40 For a trial to be ethical, then, the research hypothesis must 
be simple enough to allow such a balance to exist. 
The practical aspect of the dilemma of equipoise means that clinicians often have 
difficulty recruiting patients. A number of studies indicate that the requirement 
of an open discussion of clinical equipoise with patients is an obstacle for many 
recruiting clinicians.43,45-48 Many clinicians appear to prefer to trust their own 
experience, even if this is in conflict with the available evidence.45, 50 
In this study, we can only suggest what went on in these consultations from the 
patient's perspective. However, the experience of these men and the literature 
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suggests that many recruiting clinicians do not enter all their eligible patients 
onto trials and this has implications for the realistic estimation of accrual rates 
and the representativeness and generalisability of trial findings. 
There are a number of reasons for this. It has been suggested that the inherent 
conflict of taking on the dual role of investigator and physician committed to an 
individual patient's health is a barrier for many.46-48, 136-138 Clinicians may fall into 
two groups: 'experimenters', who are primarily interested in contributing to 
scientific information, and therapists, for whom the patient is the main focus.45 
Recruiting oncologists have often been found to have such a 'therapist' 
orientation to their practice45, 46,75 and appeared to be deterred because they 
believed helping individual patients was more important than contributing to 
research.46, 75 This ethical dilemma may be one of the main reasons for such 
difficulties50 (see further in chapter 1). 
Such findings suggest that trialists should engage in an open discussion of the 
issue of equipoise with recruiting clinicians. This should perhaps extend to all 
clinical staff likely to encounter or care for trial participants such as the research 
nurses working on the trial. Such members of staff may be in the position to 
discuss the effectiveness of treatments with patients. Thus even if trialists hold 
equipoise themselves they must not assume this extends to other members of the 
team. 
Equipoise is often a barrier for recruitment and open discussion of the difficulties 
this requirement involves may help to minimise this problem. Before 
commencing the trial the issue of equipoise should be discussed with recruiting 
clinicians and a decision should be made as to whether individual or community 
equipoise is required. Trialists must also be aware that equipoise may change 
during the course of the trial and acknowledge that clinicians may not hold 
equipoise consistently; even if they hold equipoise for the patient group 
generally, they may not hold this for a particular patient. Even though from the 
clinician's perspective, a trial may have achieved equipoise, a patient's personal 
circumstances may mean that they have a preference for one of the treatments. 34 
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Trial design may also be a barrier and it is important to incorporate the recruiting 
clinician's perspective when designing trials. For example, the design of some 
oncology trials were often believed to be too rigid for many recruiters within one 
US centre, and this was their rationale for excluding patients,73 Many breast 
cancer clinicians have also been found to have objections to trial design,45,49 
believing that they would enter more of their patients if trial participation were 
closer to normal practice.45 Surprisingly, only a small number were deterred by 
the practical barriers to recruitment such as difficulty collecting data,50, 73, 74,78 the 
time involved,73,74 staff shortages,74 cost,73 traveF8 and side effects,78 However, 
the majority of these studies have examined those recruiting patients onto 
oncology trials and it is not known to what extent these barriers are present 
within trials for non-life threatening conditions. 
The informed consent procedure 
The findings from this study indicate that the majority of these trial participants 
did not achieve fully informed consent. A fundamental ethical requirement of the 
randomised controlled trial is that patients must give their informed consent to 
participate. The clinicians who obtain informed consent are expected to ensure 
that patients receive all relevant information to make that decision.36 When 
patients do not understand the implications of what they have consented to 
participate in, then this does not constitute truly informed consent. 
There are a number of aspects of the information about the trial contained within 
the patient information leaflet and participant's experiences during the trial that 
appeared to introduce difficulties for patients in terms of their understanding of 
the implications for them of trial participation. For example, it appears that 
patients must be made aware that the treatments within the trial are equivalent-
the terms 'standard' and 'new' were used to describe the treatments within the 
patient information leaflet and by the recruiting clinicians and thus patients often 
believed that the treatments were of differing effectiveness. 
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The majority had a treatment preference. Snowdon et al similarly found that the 
majority of parents preferred the' new' experimental treatment. Most did not 
believe that there was uncertainty about this treatment and few were concerned 
about the possible risks. They were aware that the 'new' treatment was being 
used in other countries and thus assumed that this treatment had been proven 
and was safe. Treatment preferences were often based on information from the 
recruiting clinician, who sometimes 'inadvertently promoted a preference' 
(p.1349) for the 'new' treatment.173 
This does have implications for the ethics of the trial. Patients must not agree to 
take part in a trial because they have false hopes or expectations of an 
intervention achieving a favourable outcome which is "less than reasonably 
likely" (p.261)36 to happen. Such false expectations may be the result of receiving 
inaccurate information about a treatment's possible benefits and associated risks. 
This may not be deliberate, as recruiting clinicians may believe that some 
information is not necessary and this can occur particularly if there are cultural 
or socio-economic differences between the recruiting clinicians and 
participants.36 Similarly, many men in this study believed that the questionnaires 
and tests they completed were used to establish which treatment would suit their 
condition and be best for them. It should be explained to patients that such 
examinations are used to establish that their condition is eligible for all of the 
treatments within the trial. 
Much of the literature concludes that patients just need better or more 
information to help them understand participation. However, more information 
itself appears to be unlikely to be the entire solution because trial participation is 
not part of normal experience and thus does not make sense to patients. The 
concepts involved, such as randomisation, appear to be nonsensical to patients. 
The majority of the men found the concepts of the trial design and randomisation 
difficult to accept and developed other accounts to make sense of their 
experiences. 
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It is often stated that obtaining informed consent to participate in a trial from 
poorly educated patients is a "sham'.66 However, the data examining inequalities 
in the comprehension of informed consent is contradictory and as this study 
shows, the" middle class' men within this trial also had differing levels of 
knowledge of the trial and incorporated other co-existing beliefs such as 
rationing, individualised treatment and fate and destiny within their rationale of 
how they had been allocated to their treatment. 
Research examining informed consent has found that even when trials adhere to 
strict informed consent procedures and ensure that" simple language' is used, 
this does not guarantee subjects will fully understand the implications of 
participation and may still have unrealistic treatment expectations.69 A number 
of trials have incorporated checklists into their informed consent procedure in 
order to confirm recall at recruitment. However, as can be seen from these 
results, recall is very different from understanding. 
Clearer information would be beneficial; it appeared to help some of these 
participants to make sense of their experience. While this study confirms the 
importance of providing clear and accurate patient information, it also shows 
that this in itself is unlikely to ensure consistent interpretation of concepts such 
as randomisation by participants. The patient information in this study was well 
received and largely accurately recalled, but patients still struggled with the 
concepts underlying the design and developed sometimes competing accounts. It 
is also not clear what impact such beliefs may have on outcome, although some 
found the difficulty of reconciling their views upsetting. In some cases, patients 
doubted the veracity of the trial. 
It may be that participants need to discuss the reasons for particular methods of 
trial design (such as randomisation) with researchers and reflect on these in 
order to understand them fully enough to give true informed consent. Having 
the chance to discuss before making the decision to participate or not may help 
patients to make sense of the trial. This should be someone other than the 
clinicians, who were often seen as the gatekeeper to the 'best' treatment, 
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although it is not clear who is suitable for this role and this may only be a partial 
solution. 
Potential trial participants should be informed specifically about the components 
of research that constitutes a change from the standard doctor-patient 
relationship. These central differences are randomisation and blinding, plus any 
additional clinical examinations and therapies.66 Edwards et al conclude in their 
review that abstract concepts such as randomisation should receive particular 
attention, "since it is the conceptual scientific basis of trials rather than details of 
the treatments themselves which patients find hard to grasp" (p.53). It is also 
important that participants understand equipoise and thus have realistic 
expectations of the benefits of trial participation. 67 
From this study we do not know the perspective of the recruiting clinicians, 
however the experience of these participants and non-participants does indicate 
that recruitment was problematic for them. This is reflected within much of the 
literature where obtaining informed consent is commonly a barrier to 
recruitment among clinicians.45, 47,48,73,74 For many this is based on a 
dissatisfaction with the rigid format of the consent form48,73 or because it 
highlights their dual role as physician and investigator.48 Such barriers can affect 
the development and uptake of trials. For example, the introduction of explicit 
regulations for a clearly defined process of informed consent describing both the 
risks and benefits to potential participants, led to a subsequent drop in the 
number of breast cancer trials being carried out.49 Alderson concluded that 
providing such explicit information to patients may be problematic for 
clinicians.49 
The apparent lottery as to which patients became participants in the trial 
indicated that these clinicians may have attempted to screen patients by trying to 
predict who would have difficulty with the informed consent process and thus 
enrol only some of their eligible patients onto trials. This is reflected in the 
literature47, 75, 76 and Kee suggests that this may be because paternalism is still 
prevalent within medicine, with clinicians still believing that they can make the 
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best therapeutic decisions for their patients. However, it is highly questionable as 
to whether clinicians are better able to interpret medical evidence than patients 
themselves.77 Given the importance of the clinician in recruiting patients onto 
trials, it is surprising that little research has investigated their role.78 
Edwards et aF2 in a recent (1998) systematic review of the ethics of the ReT from 
the perspective of patients, the public, and healthcare professionals concluded 
that a surprising number of recruiting clinicians were aware that their patients 
did not fully understand what trial participation involved, "For many, informed 
consent seemed little more than a ritual" (p1212). Edwards et al conclude that 
there may be significant differences between trialists and ethicists as to what is 
ethically acceptable and suggest that there should be a greater public debate 
about ethics and medical research. Zwitter and Tobias similarly acknowledge 
that there may be a wide gap between the investigator's beliefs about informed 
consent and patients' actual understanding of the trial.79 
Methodology 
Understanding 
Qualitative research is a collection of interpretive methods, within which no 
single methodology is held as superior. The overall aim is to make sense of 
phenomena from the perspective of the individuals within the social world, 
emphasising the importance of the socially constructed nature of reality by 
examining the social world from an interpretivist, naturalistic perspective using a 
variety of empirical approaches such as observation, interviews, and case 
studies.223 Ethnographic methods were influential within this study. The aim was 
to provide a detailed description within one trial rather than attempt to generate 
universal principles. Thus the less structured methods of ethnography, in this 
case using interviews as the main method for gathering data, were most suitable 
for the exploratory nature of this study. 
Within the present study, the theoretical approach of phenomenology advocates 
an exploration of trial participants' own interpretation of their experience, their 
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search for meaning and the importance of context in understanding their 
perspective. For example this allowed an examination of these men's 
understanding of randomisation that looked beyond the standard definition to 
explore their perspective and their process of rationalisation after they had had 
time to reflect on the actual events of the trial. 
Qualitative research has shown that individuals routinely attempt to make sense 
of events by interpreting them in the context of their existing beliefs. Schutz 
introduced the idea that experience can only be accessed reflectively, not when it 
actually occurs. The meanings of our actions are reconstructed retrospectively on 
the basis of memory, they are not given in an immediate way.228 This has 
important implications for interpretation, because it suggests that social scientists 
cannot access directly the experiences of others, but only through the 
interpretation of their reasons and motives. 
The aim of this research strategy was to elicit participants' experiences, therefore 
in-depth interviews using a semi-structured checklist of topics were 
employed.219,227,238,239 This approach attempts to look beneath the surface of a 
subject in order to examine in detail what people say and explore trial 
participants' own interpretation of their experience and their search for meaning. 
Rather than using survey methods or structured interviews which rely upon 
assumptions about people's behaviour, this has the additional potential of 
revealing new areas that may not initially be anticipated.240 Within the context of 
this study, this allowed me to uncover participants' actual understanding of trial 
terminology rather than assume such comprehension. 
Reflexivity 
Within qualitative research, it is important to reflect on how we present 
ourselves to respondents and how this may affect the interview.227,240 The 
researcher may embody a number of different identities within the interview268 
and hence a number of personal characteristics may have had an impact on the 
research. As a I personable young woman'269 interviewing men aged 55-81 years 
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old who were predominantly working class, I am aware that this may have 
introduced age, gender and social class issues into the interviews. 
The age difference does appear to have had some impact on the interviews. 
Participants often stated that they were happy to help a student and I believe that 
this sympathy with my position often helped me to obtain interviews. Although I 
explained my status within the letter and before the interview, many also 
assumed I was a medical student and often saw the interviews as a way for me to 
learn from their experiences. Hammersley and Atkinson27o discuss age in 
fieldwork relations, although the consensus is that it should not be overestimated 
as a factor. Robert Dingwall (personal correspondence) suggests that age has 
often been confused with gender and that it is important to consider whether 
these effects exist separately. 
At the start of the interviewing process I was aware from the literature that the 
majority of studies were from the perspective of clinicians recruiting patients 
onto trials. I felt that such an approach had led to a focus onto certain areas such 
as gathering information to improve future recruitment rates. In addition, this 
work tended to utilise research methods (structured questionnaire surveys) that 
may have led participants to produce socially acceptable responses. For example 
a number of these studies used closed questions asking participants if they 
'understood' what trial participation involved (see chapter 3). In response to this, 
I tried to distance myself from the trial and hoped that my status as 'student' 
would allow these men to explain what trial participation had involved for them 
with less anxiety about producing the 'wrong' response. Yet, as Dingwall points 
out, interview data are inevitably a social construct, /I the respondent is still 
concerned to bring the occasion off in a way that demonstrates his or her 
competence as a member of whatever community is invoked by the interview 
topic" (p.59).242 Although these men predominantly gave multiple accounts of 
how they had been allocated to their treatment (see chapters 5 and 6), some of the 
men did seek confirmation that they had' got it right', implying that they were 
attempting to piece together the 'right' account of their experience. 
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In this way I often became a platform for them to make sense of their 
experiences. Although Becker is referring to those experiencing a serious illness, 
she argues that those undergoing' disrupted lives' produce meaning through 
storytelling. When such accounts are verbalised they are shared and thus 
coherence and order is established from apparent chaos.271 These men similarly 
appeared to be attempting to produce meaning from the 'unnatural' experience 
of trial participation. 
Gender was also an issue. Before carrying out the interviews I did expect the men 
to be less willing to talk to me about their condition (benign prostatic 
hyperplasia). Although such issues would be part of any discussion of the trial, I 
felt that the focus on trial participation would mean that any reluctance to talk 
about their condition would not hinder the interviews. In practice, however, I 
found all the men eager to discuss their condition, their symptoms and how 
these had affected their daily life, the treatment they received and outcome. 
Some spoke about (unprompted) the side effects they experienced as a result of 
treatment, which varied from the expected (retrograde ejaculation) to more 
serious (impotence). I was surprised by the readiness with which these men were 
willing to talk to me about such issues. Many of the men remarked during the 
interviews that although this was a common condition that affected many of 
their peers, few friends were willing to discuss their experience or the treatment 
they had received: 
Really that is the final, because as far as he's {clinician 1 concerned 
now I'm OK and nothing else to be done. I hope you don't mind 
me talking like this because there's nobody else I can talk to, to be 
honest with you.{Mr Stone1 
Limitations 
There are clear limitations to this study because of its reliance on interview data 
collected after the recruitment consultation for the trial and because it examined 
only a small number of middle aged and elderly men asked to participate within 
one trial. 
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Although textbooks and reports of trials in journals focus on issues concerned 
with design, methods and results,lS, 106, 176 the patient's perspective is relatively 
neglected. The medical model of the clinical trial tends to assume that such 
experiences are not relevant to trial outcome; as Oakley points out 1/ the doctor's 
task is repair by physical or chemical means, and the theory underpinning this 
sees the body as cellular or molecular biology, not inhabiting the same frame as 
the psyche, an identity, a social being intimately connected to the social and 
material world" (p.17).272 
As a result there has been little work looking at patients' actual experiences of 
taking part in a clinical trial. However, it has been increasingly recognised that 
participants' perceptions of the condition, treatment and the trial can affect the 
internal and external validity of an RCT.1S9 As Silverman and Altman 
acknowledge, the placebo effect suggests that other possible psychosocial 
influences such as preferences should be examined.160 Thus far, little research has 
been undertaken to explore the views of participants and non-participants. The 
majority of studies within the literature have used structured, closed questions to 
examine the motivation for, and satisfaction with, trial participation.218 As 
Edwards et al in a recent (1998) systematic review point out, the methods 
employed in accessing participants' motivation vary greatly between studies. 
Some only provide closed, forced choice questions, few allow open responses, 
whilst others fail to outline their rationale and hence these studies may not be 
comparable.72 
The literature has predominantly examined participation to establish satisfaction 
with and motivation to take part in trials. Although actual participation has been 
examined, a fundamental problem with many of these studies is their reliance on 
attitudes to hypothetical trial participation. Those who have taken part in a trial 
may have a real and distinct difference of opinion compared to those whose 
responses are based on speculation.149, 178, 182 The trials examined previously have 
been predominantly those that present trialists with specific ethical or 
recruitment issues. For example, phase I trials; trials where consent is through a 
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third party or trials that recruit patients with a life threatening condition such as 
oncology or HIV; or trials that recruit vulnerable populations such as paediatric 
and psychiatric trials. 
At the outset of this study, the experience of participation within a pragmatic 
trial for a common condition had not been examined. The study reported here 
used qualitative research methods to elicit the perspectives of 'ordinary' middle 
aged and elderly men who require elective treatment for a common condition 
and had themselves agreed or decided not to participate in a pragmatic 
randomised controlled trial. 
Only a small number of studies have examined the experience of trial 
participation and have asked participants to describe the trial in their own 
terms.42, 173. This study builds on this approach. These studies failed to 
adequately define recall or their assessment of understanding. Appelbaum et al 
give no indication as to how they defined such understanding,42 while Snowdon 
et al divided parents into two main categories, those who did or did not believe 
that their treatment allocation was based on chance.173 Only within this study 
was patient knowledge of trial design and randomisation broken down into six 
integral elements: the involvement of chance in their allocation, that envelopes 
were used to allocate treatments, that the treatment allocation was concealed, 
that treatments were being compared, that clinicians were uncertain about the 
most effective treatment, and that they were participating in an experiment. In 
the light of this assessment of recall, the men's subsequent understanding of the 
randomised controlled trial was examined. 
Snowdon et al found that the recognition of the involvement of chance did not 
mean that these participants held a coherent model of the trial or 
randomisation.173 Snowdon et a1173 and Appelbaum et al42 argued that although 
participants' descriptions of the trial seemed correct, I distortions' of the aims of 
randomisation were often present. I concur with this, as the men in this study 
similarly incorporated other non-random accounts of how they had been 
allocated to the treatment they received. 
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However, Snowdon concluded from these I distortions' that most parents were 
'confused' (p.1348) and only two parents totally accepted the use of 
randomisation.173 This conclusion is common with much of the literature 
examining informed consent. For example, a recent systematic review of 
informed consent similarly suggests that the literature indicates that "patients do 
not always grasp what information is disclosed to them" (p.44), resulting in 
"defects in reasoning" (p.44).67 However, this is a simplification of how patients 
make sense of their experiences of recruitment and participation in a randomised 
controlled trial. 
In contrast, I showed that these men were striving to make sense of this 
confusion and sometimes developed coexisting contradictory accounts. Any 
confusion that arose came from their attempts to make sense of the experience by 
trying to piece together contradictory accounts; not from a lack of understanding 
of randomisation per se. Even though their narratives would not make sense to 
trialists, these patients made a coherent attempt to make sense of their experience 
of taking part (or not) in the trial. The patients' view of equipoise is also rarely 
examined49 and this study shows how patients recall and struggle to make sense 
of this concept. 
Few studies have examined the experience of non-participation. Those that do 
have been from the perspective of trialists in order to examine ways to improve 
accrual. These often examine hypothetical non-participation for trials that 
present ethical problems such as HIV vaccine, oncology or paediatric trials. This 
study uses qualitative methods to examine these non-participants' recall and 
understanding of what the trial involved, additionally exploring their pathways 
to non-participation. 
The widespread use of the open-ended interview within qualitative research has 
been called into question.242 Interview data are not just a series of objective facts, 
but active social interactions.243 Thus interview data are social constructs 
developed through the participants' self-presentation and the cues the 
interviewer has transferred within this interaction.242 It has been argued that 
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observational data, by their focus on naturally occurring events, enable the 
researcher to record individuals accounting to each other within their natural 
environment.242 However, the aim of this study was to explore these men's 
accounts of their experience and understanding of trial participation and how 
they make sense of that verbally, rather than to reveal how people react within a 
specific environment. An observational approach also assumes that participants 
will respond to the setting in a similar way and within this study it was 
important to examine the distinction between what people say and what they 
actually do. 
However, the sample of participants (22) and non-participants (11) was small. 
This was due to a combination of the constraints of the trial and the development 
of the analysis of these men's accounts, which required a number of different 
approaches. The interpretive strategy employed within this study was grounded 
theory and thus purposive sampling and an iterative, cyclical approach to the 
analysis of these data was carried out. This strategy did impose some constraints 
on the data collection. The timetable of the trial and recruitment within the trial 
was fixed and once I had reached the stage in the analysis of these data when 
more interviews would have been appropriate, the recruitment within the trial 
had been completed. 
The analysis of these data was a laborious process. The men produced very 
complex and often contradictory accounts of what the trial involved and the 
process of participation and non-participation. There was a stage during the 
analysis of these accounts where on one level 'confusion' was strongly indicated, 
as in previous studies. However, I did not feel that this did justice to the men's 
accounts and it took a number of different approaches within the analysis of this 
data to untangle and uncover their 'struggle' to understand the trial. The analysis 
of these data required a detailed interrogation of the interviews, a search for 
negative cases and the development of detailed case histories for each of these 
men. At each stage these data were also independently examined by my 
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supervisor (JD) and followed by a detailed discussion of conflicting 
interpretations. 
At the start of this study, published research has mainly used structured 
questionnaires to examine attitudes and barriers to participation in order to 
improve accrual. There was little detailed information on patients' 
understanding of key concepts such as randomisation. This qualitative study 
does provide insights into the complex process of recruitment and participation 
among a small number of men within one trial. 
This study used retrospective interviews with trial participants and non-
participants at different time points after they had been approached to 
participate in the trial. Thus within this study patients were not followed 
through the process of participation and the interactions between patients and 
the recruiting clinician were not observed. We do not know whether these 
patients had an actual preference or whether this was a post-facto rationalisation 
of their allocation. For example, some participants believed that their allocation 
was predestined and luckily received their preference (or rationalisation). We do 
not really know what would happen if these participants received a different 
treatment from the one they were expecting. 
Observations were not carried out within this study, but future studies might 
benefit from examining the interaction between the recruiting clinicians and 
eligible patients being asked to participate in a trial. For example, we do not 
know what would have happened if different events had occurred during their 
recruitment or treatment, for example, by seeing the envelope being opened. 
Interviews with recruiting clinicians were not carried out within this study and 
few studies have examined their experience of recruiting patients onto trials and 
their understanding of and the practical implementation of the ethics and 
methods of the randomised controlled trial. For example, given its importance to 
the ethics of trials, no studies have carried out an in-depth examination of the 
requirement of clinical equipoise, investigating the practicalities of how 
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recruiting clinicians define and implement this or how equipoise may change 
over time. 
This exploratory study raises issues that might be answered by such approaches 
and these limitations can be rectified in future studies. Comparative studies of 
those who take part, drop out or refuse to participate in trials have also been 
suggested but have not yet been undertaken.180, 187, 196 
Future research 
Further research is required to investigate whether these interpretations are 
found more widely. Although this study examines a specific population, middle-
aged and elderly men who had agreed to participate in a trial for a common 
condition, a number of these findings appear to achieve plausibility. Snowdon et 
al demonstrate similar findings with a population of men and women in their 
20' sand 30's. Although this study concluded that the majority of their sample 
were I confused', they found similar patterns of trust, distrust and alternative 
interpretations of how they had been allocated to the treatment they received 
such as predestination, despite their understanding of the involvement of chance 
in their allocation. They also found lay interpretations of trial terms. 
The methodologies employed within this study could also be used to ensure that 
participants receive truly informed consent and to ensure that the uncertainties 
regarding treatments are communicated effectively, not just meeting the official 
guidelines for disclosure of such riskS.151 It is not clear, however, whether greater 
understanding would lead to higher or lower levels of accrual to trials, but such 
an investigation could be linked with research attempting to incorporate patient 
preferences into RCTs.160, 163,204 
It would also be interesting to explore the influence of preferences further. 
Silverman and Altman suggest that misconceptions about probability may be an 
important aspect of preferences and thus patients must be protected from 
exaggerated claims about new treatments.160 Patients may also prefer different 
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outcomes from those imposed by trialists.56 However, so far trialists have been 
reluctant to involve patient groups in the design of trials. An investigation of the 
role of preferences could be achieved using longitudinal methods. Patients' 
views about the various treatment options could be examined prior to 
recruitment and after their subsequent allocation to a treatment, through to the 
subsequent completion of the trial. 
In addition, this study indicates that the experience of recruiting clinicians and 
their understanding of the ethics and methods of the randomised controlled trial 
should be examined. This under-researched area has important implications for 
the external and internal validity of a trial. 
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APPENDIX 1 
General Information for patients 
Doctors and researchers in [Centre A] and [Centre B], supported by the NHS 
Research Directorate, are carrying out a research project to find out the best way 
to treat men with urinary problems. These problems are caused by an 
enlargement of the prostate gland which obstructs or blocks the tube (your 
urethra) that carries urine from your bladder. You will be asked to take part in 
this study if you are unable to pass urine (this often involves admission to 
hospital and is called acute urinary retention), or if you have urinary symptoms 
which are considered by yourself and the doctor to need treatment. These can 
be treated in hospital in a number of ways, and the aim of this research project is 
to find out the best method of treatment. 
At the moment, two main treatments are offered to men with urinary symptoms: 
conservative management or an operation. Men with acute retention are usually 
offered an operation. New treatments are being discovered all the time, and the 
most promising of these is laser therapy. At the moment, doctors are not sure 
which of these treatments is best. Each of them has advantages and 
disadvantages. The CLasP study has been set up to find out which treatment 
has the best results and is most preferred by patients. 
Conservative management. There is no surgery involved. You will be given a 
thorough check-up. If you wish, you can obtain information and advice about the 
symptoms that bother you and your fluid intake from the researcher. The latest 
evidence from America shows that nearly one half of men having conservative 
management felt better or the same after one year, and felt that they did not need 
surgery. All patients having conservative management will have a full review in 6 
months' time. At this time, you will be able to discuss with the doctor the 
treatment that you need. This may be a further period of conservative 
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management, or surgery, depending on your symptoms and clinical need. 
TURP. This is the most common treatment and involves an operation. A probe 
is passed into your urethra, and the inside of the prostate gland is removed by 
electric cutting. There is usually some bleeding. On average, you will have a 
catheter for 2-3 days, and be in hospital for 3-4 days. After the operation, most 
men find that their symptoms are considerably improved straight away, but about 
a quarter find that some of their symptoms are the same afterwards. A small 
number may find that their symptoms are worse, or experience problems 
following the operation - such as an infection, heavy bleeding, sexual 
complications. 
Laser therapy. This is a new treatment and involves an operation. A probe is 
passed into the urethra, and the inside of the prostate gland is removed by 
lasers. On average, you will have to be in hospital for only 1-2 days, and you will 
be sent home with a catheter for about one week. Then you will need to come 
back to the ward for a few hours to have the catheter removed and to be 
checked. Men who have had this treatment so far have found that most of their 
symptoms are improved, not straight away but after about one month. As this is 
a new treatment, it is not known whether symptoms will return in the future, nor if 
there are any other complications. 
The research 
In order to compare these treatments, it is necessary to carry out a research 
project called a randomised controlled trial. If you agree to be involved in the 
study, the doctor or researcher will open a sealed envelope in front of you which 
will contain the name of one of the treatments. If you have urinary symptoms, 
you will have a one in three chance of being given conservative management, 
laser therapy or TURP. If you have urinary retention, you will have a one in two 
chance of being given laser therapy or TURP. 
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So that we can find out how effective the treatments are, we will ask you to 
complete a questionnaire about your symptoms, answer some questions, and 
have measurements of your flow rate and pressure in your bladder 
(urodynamics). Some patients will be asked if they would be willing to be 
interviewed about their symptoms and treatment. Approximately six months after 
your treatment started, you will have a full review and we will ask you to fill in 
another questionnaire, and to have these measurements again. 
All the information you give in this study will be kept completely 
confidential. 
You can withdraw from the study at any time without having to give any 
reason and your treatment will not be affected by this action. Participation 
in this trial is purely voluntary, and refusal to take part will not affect your 
future treatment in any way. 
If you decide you do not wish to join the study, you will be given the 
standard treatment for your symptoms. 
If you are willing to be included in this important s~udy, please .sig~ the atta?hed 
Consent Form. If you have any questions or wornes about being Involved In the 
study, please contact ___ _ 
Thank you very much for helping with this research. 
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APPENDIX 2 
Patient Expectations and Experiences of Clinical 
Research 
General Information 
My name is Katie Featherstone and I'm a PhD student funded by the Medical 
Research Council, based at the Department of Social Medicine, University of 
Bristol. 
I am carrying out a study looking at people's views of clinical trials. I am 
particularly interested in finding out why people choose not to take part in a 
clinical trial. My research is separate from the prostate trial. I will not pass 
anything you tell me on to staff involved in this or any other study in the Urology 
Unit, and nothing you tell me will affect your treatment in any way. 
I understand that you are one of the many people who did not take part in a 
recent trial of treatments for prostate problems. Your name has been chosen at 
random from those people attending the Urology Institute who did not want to 
take part. Your consultant has given me permission to approach you. 
I hope that you will be able to take part in my study. I do not want to persuade 
you to change your mind about taking part, I would just like to ask you some 
questions. There are very few studies looking at why people choose not to take 
part in clinical trials, and your views and feelings will give me an insight into how 
people view clinical research. 
The interview will take approximately half an hour of your time and the 
information you give will not be used in any way that could identify you 
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personally. The South mead Medical Research Ethics Committee has approved 
this study. 
All the information you give in this study will be kept completely 
confidential. 
You can withdraw from this study at any time without having to give any 
reason and your treatment will not be affected by this action. 
Participation in my study is purely voluntary, and refusal to take part will 
not affect your future treatment in any way. 
I will contact you in the next few days to see if you are willing to take part. 
If you have any questions or worries about taking part, please contact me, Katie 
Featherstone (tel: 0117 928 7395) or my supervisor Dr Jenny Donovan (tel: 0117 
928 7214) at the Department of Social Medicine, Canynge Hall, Whiteladies 
Road, Clifton, Bristol BS8 2PR. 




Patients Expectations and Experiences of Clinical Trials 
Patient interview schedule 
How did you find out about your prostate condition / urinary symptoms? 
What has happened since you started attending the clinic 
Did you have any initial expectations of what the treatment would involve/ the 
success of the available treatments? 
Did you have any ideas about which treatment you wanted? 
What kind of choices did you think you would be given? 
What happened when you attended the clinic? 
Were you asked if you wanted to take part in research / study/ of treatments for 
prostate problems: Can you remember/tell me anything about that? 
What did you think about this option? 
Looking back, what did taking part in this would involve? 
What were your initial expectations? 
Were you able to ask questions about this/the research 
Did you speak to /ask for advice from anyone before you made a decision 
Were you given any written information explaining what taking part would involve-
what did that say 
How did taking part in this research compare with the other treatment options 
Did you have any worries about taking part [in the research] 
What were you told about the different treatments [offered as part of the 
research]? 
Who decided which treatment you should receive? 
How was the doctor going to decide which treatment to give you? 
If you had a free choice, which treatment would you have chosen? 
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how did you come to that decision / why was that 
How do you think that treatment compared to the other options [that were part of 
the research study] 
had you heard anything about that treatment 
Why did you decide not to take part in the research? 
can you tell me more about that 
Did you have any concerns about taking part? 
Who decided which treatment you should receive 
How was this decided? 
Were you able to choose which treatment to 
How did you decide which treatment 
Why do you think this clinic does these sorts of studies? 
Who do you think benefits the most from these research studies? 
Why did you think the doctor asked...YQ.Y? 
What do you know about medical research in general? 
Looking back, how do you feel about the way things have turned out? 
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